id	sid	tid	token	lemma	pos
aji-40	1	1	_	_	PUNCT
aji-40	2	1	_	_	PUNCT
aji-40	3	1	_	_	PUNCT
aji-40	4	1	_	_	PUNCT
aji-40	5	1	_	_	PUNCT
aji-40	6	1	_	_	PUNCT
aji-40	7	1	_	_	PUNCT
aji-40	8	1	_	_	PUNCT
aji-40	9	1	_	_	PUNCT
aji-40	10	1	_	_	PUNCT
aji-40	11	1	_	_	PUNCT
aji-40	12	1	_	_	PUNCT
aji-40	13	1	_	_	PUNCT
aji-40	14	1	_	_	PUNCT
aji-40	15	1	_	_	PUNCT
aji-40	16	1	_	_	PUNCT
aji-40	17	1	_	_	PUNCT
aji-40	18	1	_	_	PUNCT
aji-40	19	1	_	_	PUNCT
aji-40	20	1	_	_	PUNCT
aji-40	21	1	_	_	PUNCT
aji-40	22	1	_	_	PUNCT
aji-40	23	1	_	_	PUNCT
aji-40	24	1	_	_	PUNCT
aji-40	25	1	_	_	PUNCT
aji-40	26	1	_	_	PUNCT
aji-40	27	1	_	_	PUNCT
aji-40	28	1	_	_	PUNCT
aji-40	29	1	_	_	PUNCT
aji-40	30	1	_	_	PUNCT
aji-40	31	1	_	_	PUNCT
aji-40	32	1	_	_	PUNCT
aji-40	33	1	_	_	PUNCT
aji-40	34	1	_	_	PUNCT
aji-40	35	1	_	_	PUNCT
aji-40	36	1	_	_	PUNCT
aji-40	37	1	_	_	PUNCT
aji-40	38	1	_	_	PUNCT
aji-40	39	1	_	_	PUNCT
aji-40	40	1	_	_	PUNCT
aji-40	41	1	_	_	PUNCT
aji-40	42	1	_	_	PUNCT
aji-40	43	1	_	_	PUNCT
aji-40	44	1	_	_	PUNCT
aji-40	45	1	_	_	PUNCT
aji-40	46	1	_	_	PUNCT
aji-40	47	1	_	_	PUNCT
aji-40	48	1	_	_	PUNCT
aji-40	49	1	_	_	PUNCT
aji-40	50	1	_	_	PUNCT
aji-40	51	1	_	_	PUNCT
aji-40	52	1	_	_	PUNCT
aji-40	53	1	_	_	PUNCT
aji-40	54	1	_	_	PUNCT
aji-40	55	1	_	_	PUNCT
aji-40	56	1	_	_	PUNCT
aji-40	57	1	_	_	PUNCT
aji-40	58	1	_	_	PUNCT
aji-40	59	1	_	_	PUNCT
aji-40	60	1	_	_	PUNCT
aji-40	61	1	_	_	PUNCT
aji-40	62	1	_	_	PUNCT
aji-40	63	1	_	_	PUNCT
aji-40	64	1	_	_	PUNCT
aji-40	65	1	_	_	PUNCT
aji-40	66	1	_	_	PUNCT
aji-40	67	1	_	_	PUNCT
aji-40	68	1	_	_	PUNCT
aji-40	69	1	_	_	PUNCT
aji-40	70	1	_	_	PUNCT
aji-40	71	1	_	_	PUNCT
aji-40	72	1	_	_	PUNCT
aji-40	73	1	_	_	PUNCT
aji-40	74	1	_	_	PUNCT
aji-40	75	1	_	_	PUNCT
aji-40	76	1	_	_	PUNCT
aji-40	77	1	_	_	PUNCT
aji-40	78	1	_	_	PUNCT
aji-40	79	1	_	_	PUNCT
aji-40	80	1	_	_	PUNCT
aji-40	81	1	_	_	PUNCT
aji-40	82	1	_	_	PUNCT
aji-40	83	1	_	_	PUNCT
aji-40	84	1	_	_	PUNCT
aji-40	85	1	_	_	PUNCT
aji-40	86	1	_	_	PUNCT
aji-40	87	1	_	_	PUNCT
aji-40	88	1	_	_	PUNCT
aji-40	89	1	_	_	PUNCT
aji-40	90	1	_	_	PUNCT
aji-40	91	1	_	_	PUNCT
aji-40	92	1	_	_	PUNCT
aji-40	93	1	_	_	PUNCT
aji-40	94	1	_	_	PUNCT
aji-40	95	1	_	_	PUNCT
aji-40	96	1	_	_	PUNCT
aji-40	97	1	_	_	PUNCT
aji-40	98	1	_	_	PUNCT
aji-40	99	1	_	_	PUNCT
aji-40	100	1	_	_	PUNCT
aji-40	101	1	_	_	PUNCT
aji-40	102	1	*	*	PUNCT
aji-40	102	2	corresponding	correspond	VERB
aji-40	102	3	author	author	NOUN
aji-40	102	4	:	:	PUNCT
aji-40	102	5	e	e	NOUN
aji-40	102	6	-	-	NOUN
aji-40	102	7	mail	mail	NOUN
aji-40	102	8	:	:	PUNCT
aji-40	102	9	brianmarkc7@gmail.com	brianmarkc7@gmail.com	X
aji-40	102	10	;	;	PUNCT
aji-40	102	11	brian.churchill@iqvia.com	brian.churchill@iqvia.com	NUM
aji-40	102	12	;	;	PUNCT
aji-40	102	13	asian	asian	ADJ
aji-40	102	14	journal	journal	NOUN
aji-40	102	15	of	of	ADP
aji-40	102	16	immunology	immunology	NOUN
aji-40	102	17	3(1	3(1	NUM
aji-40	102	18	):	):	PUNCT
aji-40	102	19	208	208	NUM
aji-40	102	20	-	-	SYM
aji-40	102	21	222	222	NUM
aji-40	102	22	,	,	PUNCT
aji-40	102	23	2020	2020	NUM
aji-40	102	24	;	;	PUNCT
aji-40	102	25	article	article	NOUN
aji-40	102	26	no.aji.57464	no.aji.57464	PROPN
aji-40	102	27	tnf	tnf	PROPN
aji-40	102	28	-	-	PUNCT
aji-40	102	29	α	α	PROPN
aji-40	102	30	,	,	PUNCT
aji-40	102	31	tnf	tnf	PROPN
aji-40	102	32	receptors	receptor	NOUN
aji-40	102	33	and	and	CCONJ
aji-40	102	34	their	their	PRON
aji-40	102	35	complex	complex	ADJ
aji-40	102	36	implications	implication	NOUN
aji-40	102	37	in	in	ADP
aji-40	102	38	therapy	therapy	PROPN
aji-40	102	39	brian	brian	PROPN
aji-40	102	40	mark	mark	PROPN
aji-40	102	41	churchill1	churchill1	PROPN
aji-40	102	42	*	*	PROPN
aji-40	102	43	,	,	PUNCT
aji-40	102	44	pallavi	pallavi	PROPN
aji-40	102	45	patri2,3	patri2,3	PROPN
aji-40	102	46	,	,	PUNCT
aji-40	102	47	rashna	rashna	NOUN
aji-40	102	48	cama4	cama4	NOUN
aji-40	102	49	and	and	CCONJ
aji-40	102	50	jula	jula	PROPN
aji-40	102	51	k.	k.	PROPN
aji-40	103	1	inrig5,6	inrig5,6	PROPN
aji-40	103	2	1	1	NUM
aji-40	103	3	department	department	NOUN
aji-40	103	4	of	of	ADP
aji-40	103	5	medical	medical	ADJ
aji-40	103	6	science	science	NOUN
aji-40	103	7	and	and	CCONJ
aji-40	103	8	strategy	strategy	NOUN
aji-40	103	9	(	(	PUNCT
aji-40	103	10	asia	asia	PROPN
aji-40	103	11	)	)	PUNCT
aji-40	103	12	,	,	PUNCT
aji-40	103	13	iqvia	iqvia	PROPN
aji-40	103	14	,	,	PUNCT
aji-40	103	15	etamin	etamin	PROPN
aji-40	103	16	block	block	NOUN
aji-40	103	17	,	,	PUNCT
aji-40	103	18	prestige	prestige	NOUN
aji-40	103	19	tech	tech	NOUN
aji-40	103	20	park	park	NOUN
aji-40	103	21	,	,	PUNCT
aji-40	103	22	kadubeesanahalli	kadubeesanahalli	PROPN
aji-40	103	23	,	,	PUNCT
aji-40	103	24	bengaluru	bengaluru	PROPN
aji-40	103	25	,	,	PUNCT
aji-40	103	26	karnataka	karnataka	PROPN
aji-40	103	27	,	,	PUNCT
aji-40	103	28	560103	560103	NUM
aji-40	103	29	,	,	PUNCT
aji-40	103	30	india	india	PROPN
aji-40	103	31	.	.	PROPN
aji-40	103	32	2	2	NUM
aji-40	103	33	department	department	NOUN
aji-40	103	34	of	of	ADP
aji-40	103	35	nephrology	nephrology	NOUN
aji-40	103	36	,	,	PUNCT
aji-40	103	37	columbia	columbia	PROPN
aji-40	103	38	asia	asia	PROPN
aji-40	103	39	hospital	hospital	PROPN
aji-40	103	40	–	–	PUNCT
aji-40	103	41	sarjapur	sarjapur	NOUN
aji-40	103	42	road	road	NOUN
aji-40	103	43	,	,	PUNCT
aji-40	103	44	ambalipura	ambalipura	NOUN
aji-40	103	45	,	,	PUNCT
aji-40	103	46	bengaluru	bengaluru	PROPN
aji-40	103	47	,	,	PUNCT
aji-40	103	48	karnataka	karnataka	PROPN
aji-40	103	49	,	,	PUNCT
aji-40	103	50	india	india	PROPN
aji-40	103	51	.	.	PROPN
aji-40	103	52	3	3	NUM
aji-40	103	53	weill	weill	PROPN
aji-40	103	54	cornell	cornell	PROPN
aji-40	103	55	medical	medical	PROPN
aji-40	103	56	college	college	PROPN
aji-40	103	57	,	,	PUNCT
aji-40	103	58	new	new	PROPN
aji-40	103	59	york	york	PROPN
aji-40	103	60	,	,	PUNCT
aji-40	103	61	usa	usa	PROPN
aji-40	103	62	.	.	PROPN
aji-40	103	63	4	4	NUM
aji-40	103	64	department	department	NOUN
aji-40	103	65	of	of	ADP
aji-40	103	66	medical	medical	ADJ
aji-40	103	67	sciences	science	NOUN
aji-40	103	68	and	and	CCONJ
aji-40	103	69	strategy	strategy	NOUN
aji-40	103	70	(	(	PUNCT
aji-40	103	71	asia	asia	PROPN
aji-40	103	72	)	)	PUNCT
aji-40	103	73	,	,	PUNCT
aji-40	103	74	iqvia	iqvia	NOUN
aji-40	103	75	,	,	PUNCT
aji-40	103	76	natraj	natraj	VERB
aji-40	103	77	by	by	ADP
aji-40	103	78	rustomjee	rustomjee	NOUN
aji-40	103	79	,	,	PUNCT
aji-40	103	80	702	702	NUM
aji-40	103	81	western	western	ADJ
aji-40	103	82	express	express	ADJ
aji-40	103	83	highway	highway	NOUN
aji-40	103	84	,	,	PUNCT
aji-40	103	85	sir	sir	PROPN
aji-40	103	86	mathuradas	mathuradas	PROPN
aji-40	103	87	vasanji	vasanji	PROPN
aji-40	103	88	road	road	NOUN
aji-40	103	89	junction	junction	NOUN
aji-40	103	90	,	,	PUNCT
aji-40	103	91	mumbai	mumbai	PROPN
aji-40	103	92	,	,	PUNCT
aji-40	103	93	maharashtra	maharashtra	PROPN
aji-40	103	94	,	,	PUNCT
aji-40	103	95	400069	400069	NUM
aji-40	103	96	,	,	PUNCT
aji-40	103	97	india	india	PROPN
aji-40	103	98	.	.	PROPN
aji-40	104	1	5	5	NUM
aji-40	104	2	global	global	ADJ
aji-40	104	3	head	head	NOUN
aji-40	104	4	renal	renal	ADJ
aji-40	104	5	center	center	NOUN
aji-40	104	6	of	of	ADP
aji-40	104	7	excellence	excellence	NOUN
aji-40	104	8	,	,	PUNCT
aji-40	104	9	therapeutic	therapeutic	ADJ
aji-40	104	10	science	science	NOUN
aji-40	104	11	and	and	CCONJ
aji-40	104	12	strategy	strategy	NOUN
aji-40	104	13	unit	unit	NOUN
aji-40	104	14	,	,	PUNCT
aji-40	104	15	iqvia	iqvia	NOUN
aji-40	104	16	,	,	PUNCT
aji-40	104	17	10188	10188	NUM
aji-40	104	18	telesis	telesis	PROPN
aji-40	104	19	ct	ct	PROPN
aji-40	104	20	suite	suite	PROPN
aji-40	104	21	400	400	NUM
aji-40	104	22	,	,	PUNCT
aji-40	104	23	san	san	PROPN
aji-40	104	24	diego	diego	PROPN
aji-40	104	25	,	,	PUNCT
aji-40	104	26	ca	ca	NOUN
aji-40	104	27	92121	92121	NUM
aji-40	104	28	,	,	PUNCT
aji-40	104	29	usa	usa	PROPN
aji-40	104	30	.	.	PROPN
aji-40	104	31	6	6	NUM
aji-40	104	32	department	department	NOUN
aji-40	104	33	of	of	ADP
aji-40	104	34	medicine	medicine	NOUN
aji-40	104	35	,	,	PUNCT
aji-40	104	36	uc	uc	PROPN
aji-40	104	37	irvine	irvine	PROPN
aji-40	104	38	and	and	CCONJ
aji-40	104	39	duke	duke	PROPN
aji-40	104	40	university	university	PROPN
aji-40	104	41	,	,	PUNCT
aji-40	104	42	usa	usa	PROPN
aji-40	104	43	.	.	PROPN
aji-40	104	44	authors	author	NOUN
aji-40	104	45	’	’	PART
aji-40	104	46	contributions	contribution	NOUN
aji-40	104	47	this	this	DET
aji-40	104	48	work	work	NOUN
aji-40	104	49	was	be	AUX
aji-40	104	50	carried	carry	VERB
aji-40	104	51	out	out	ADP
aji-40	104	52	in	in	ADP
aji-40	104	53	collaboration	collaboration	NOUN
aji-40	104	54	among	among	ADP
aji-40	104	55	all	all	DET
aji-40	104	56	authors	author	NOUN
aji-40	104	57	.	.	PUNCT
aji-40	105	1	author	author	NOUN
aji-40	105	2	bmc	bmc	PROPN
aji-40	105	3	conceptualized	conceptualize	VERB
aji-40	105	4	and	and	CCONJ
aji-40	105	5	designed	design	VERB
aji-40	105	6	the	the	DET
aji-40	105	7	review	review	NOUN
aji-40	105	8	paper	paper	NOUN
aji-40	105	9	,	,	PUNCT
aji-40	105	10	performed	perform	VERB
aji-40	105	11	the	the	DET
aji-40	105	12	literature	literature	NOUN
aji-40	105	13	search	search	NOUN
aji-40	105	14	,	,	PUNCT
aji-40	105	15	wrote	write	VERB
aji-40	105	16	the	the	DET
aji-40	105	17	paper	paper	NOUN
aji-40	105	18	and	and	CCONJ
aji-40	105	19	wrote	write	VERB
aji-40	105	20	the	the	DET
aji-40	105	21	first	first	ADJ
aji-40	105	22	draft	draft	NOUN
aji-40	105	23	of	of	ADP
aji-40	105	24	the	the	DET
aji-40	105	25	manuscript	manuscript	NOUN
aji-40	105	26	,	,	PUNCT
aji-40	105	27	collected	collect	VERB
aji-40	105	28	feedback	feedback	NOUN
aji-40	105	29	,	,	PUNCT
aji-40	105	30	incorporated	incorporate	VERB
aji-40	105	31	the	the	DET
aji-40	105	32	changes	change	NOUN
aji-40	105	33	,	,	PUNCT
aji-40	105	34	prepared	prepare	VERB
aji-40	105	35	subsequent	subsequent	ADJ
aji-40	105	36	drafts	draft	NOUN
aji-40	105	37	and	and	CCONJ
aji-40	105	38	then	then	ADV
aji-40	105	39	the	the	DET
aji-40	105	40	final	final	ADJ
aji-40	105	41	manuscript	manuscript	NOUN
aji-40	105	42	.	.	PUNCT
aji-40	106	1	authors	author	NOUN
aji-40	106	2	pp	pp	ADP
aji-40	106	3	,	,	PUNCT
aji-40	106	4	rc	rc	PROPN
aji-40	106	5	and	and	CCONJ
aji-40	106	6	jki	jki	ADP
aji-40	106	7	reviewed	review	VERB
aji-40	106	8	the	the	DET
aji-40	106	9	manuscript	manuscript	NOUN
aji-40	106	10	and	and	CCONJ
aji-40	106	11	helped	help	VERB
aji-40	106	12	in	in	ADP
aji-40	106	13	shaping	shape	VERB
aji-40	106	14	it	it	PRON
aji-40	106	15	.	.	PUNCT
aji-40	107	1	all	all	DET
aji-40	107	2	authors	author	NOUN
aji-40	107	3	read	read	VERB
aji-40	107	4	and	and	CCONJ
aji-40	107	5	approved	approve	VERB
aji-40	107	6	the	the	DET
aji-40	107	7	final	final	ADJ
aji-40	107	8	manuscript	manuscript	NOUN
aji-40	107	9	.	.	PUNCT
aji-40	108	1	article	article	NOUN
aji-40	108	2	information	information	PROPN
aji-40	108	3	editor(s	editor(s	PROPN
aji-40	108	4	):	):	PUNCT
aji-40	108	5	(	(	PUNCT
aji-40	108	6	1	1	X
aji-40	108	7	)	)	PUNCT
aji-40	108	8	dr	dr	PROPN
aji-40	108	9	.	.	PROPN
aji-40	108	10	cynthia	cynthia	PROPN
aji-40	108	11	aracely	aracely	ADV
aji-40	108	12	alvizo	alvizo	VERB
aji-40	108	13	báez	báez	ADJ
aji-40	108	14	,	,	PUNCT
aji-40	108	15	autonomous	autonomous	ADJ
aji-40	108	16	university	university	PROPN
aji-40	108	17	of	of	ADP
aji-40	108	18	nuevo	nuevo	PROPN
aji-40	108	19	leon	leon	PROPN
aji-40	108	20	,	,	PUNCT
aji-40	108	21	mexico	mexico	PROPN
aji-40	108	22	.	.	PUNCT
aji-40	109	1	reviewers	reviewer	NOUN
aji-40	109	2	:	:	PUNCT
aji-40	109	3	(	(	PUNCT
aji-40	109	4	1	1	X
aji-40	109	5	)	)	PUNCT
aji-40	109	6	joseli	joseli	PROPN
aji-40	109	7	lannes	lannes	PROPN
aji-40	109	8	vieira	vieira	PROPN
aji-40	109	9	,	,	PUNCT
aji-40	109	10	brazil	brazil	PROPN
aji-40	109	11	.	.	PUNCT
aji-40	110	1	(	(	PUNCT
aji-40	110	2	2	2	X
aji-40	110	3	)	)	PUNCT
aji-40	110	4	juei	juei	PROPN
aji-40	110	5	-	-	PUNCT
aji-40	110	6	tang	tang	PROPN
aji-40	110	7	cheng	cheng	PROPN
aji-40	110	8	,	,	PUNCT
aji-40	110	9	christian	christian	PROPN
aji-40	110	10	university	university	PROPN
aji-40	110	11	,	,	PUNCT
aji-40	110	12	taiwan	taiwan	PROPN
aji-40	110	13	.	.	PUNCT
aji-40	111	1	complete	complete	ADJ
aji-40	111	2	peer	peer	NOUN
aji-40	111	3	review	review	NOUN
aji-40	111	4	history	history	NOUN
aji-40	111	5	:	:	PUNCT
aji-40	111	6	http://www.sdiarticle4.com/review-history/57464	http://www.sdiarticle4.com/review-history/57464	PRON
aji-40	111	7	received	receive	VERB
aji-40	111	8	10	10	NUM
aji-40	111	9	may	may	NOUN
aji-40	111	10	2020	2020	NUM
aji-40	111	11	accepted	accept	VERB
aji-40	111	12	02	02	NUM
aji-40	111	13	june	june	PROPN
aji-40	111	14	2020	2020	NUM
aji-40	111	15	published	publish	VERB
aji-40	111	16	10	10	NUM
aji-40	111	17	june	june	PROPN
aji-40	111	18	2020	2020	NUM
aji-40	111	19	abstract	abstract	ADJ
aji-40	111	20	tumor	tumor	NOUN
aji-40	111	21	necrosis	necrosis	NOUN
aji-40	111	22	factor	factor	NOUN
aji-40	111	23	alpha	alpha	NOUN
aji-40	111	24	(	(	PUNCT
aji-40	111	25	tnf	tnf	PROPN
aji-40	111	26	-	-	PUNCT
aji-40	111	27	α	α	NOUN
aji-40	111	28	)	)	PUNCT
aji-40	111	29	,	,	PUNCT
aji-40	111	30	also	also	ADV
aji-40	111	31	called	call	VERB
aji-40	111	32	cachectin	cachectin	NOUN
aji-40	111	33	or	or	CCONJ
aji-40	111	34	cachexin	cachexin	NOUN
aji-40	111	35	,	,	PUNCT
aji-40	111	36	is	be	AUX
aji-40	111	37	a	a	DET
aji-40	111	38	naturally	naturally	ADV
aji-40	111	39	occurring	occur	VERB
aji-40	111	40	cytokine	cytokine	NOUN
aji-40	111	41	produced	produce	VERB
aji-40	111	42	by	by	ADP
aji-40	111	43	activated	activate	VERB
aji-40	111	44	macrophages	macrophage	NOUN
aji-40	111	45	and	and	CCONJ
aji-40	111	46	monocytes	monocyte	NOUN
aji-40	111	47	,	,	PUNCT
aji-40	111	48	and	and	CCONJ
aji-40	111	49	to	to	ADP
aji-40	111	50	a	a	DET
aji-40	111	51	smaller	small	ADJ
aji-40	111	52	scale	scale	NOUN
aji-40	111	53	by	by	ADP
aji-40	111	54	tlymphocytes	tlymphocyte	NOUN
aji-40	111	55	,	,	PUNCT
aji-40	111	56	b	b	X
aji-40	111	57	-	-	PUNCT
aji-40	111	58	lymphocytes	lymphocyte	NOUN
aji-40	111	59	,	,	PUNCT
aji-40	111	60	fibroblasts	fibroblast	NOUN
aji-40	111	61	and	and	CCONJ
aji-40	111	62	astrocytes	astrocyte	NOUN
aji-40	111	63	.	.	PUNCT
aji-40	112	1	it	it	PRON
aji-40	112	2	has	have	VERB
aji-40	112	3	both	both	CCONJ
aji-40	112	4	inflammatory	inflammatory	ADJ
aji-40	112	5	and	and	CCONJ
aji-40	112	6	immunomodulatory	immunomodulatory	ADJ
aji-40	112	7	roles	role	NOUN
aji-40	112	8	effectuated	effectuate	VERB
aji-40	112	9	through	through	ADP
aji-40	112	10	its	its	PRON
aji-40	112	11	action	action	NOUN
aji-40	112	12	on	on	ADP
aji-40	112	13	tumor	tumor	NOUN
aji-40	112	14	necrosis	necrosis	NOUN
aji-40	112	15	factor	factor	NOUN
aji-40	112	16	receptor-1	receptor-1	NUM
aji-40	112	17	(	(	PUNCT
aji-40	112	18	tnfr1	tnfr1	NOUN
aji-40	112	19	)	)	PUNCT
aji-40	112	20	and	and	CCONJ
aji-40	112	21	tumor	tumor	NOUN
aji-40	112	22	necrosis	necrosis	NOUN
aji-40	112	23	factor	factor	NOUN
aji-40	112	24	receptor-2	receptor-2	NUM
aji-40	112	25	(	(	PUNCT
aji-40	112	26	tnfr2	tnfr2	NOUN
aji-40	112	27	)	)	PUNCT
aji-40	112	28	.	.	PUNCT
aji-40	113	1	tnf	tnf	PROPN
aji-40	113	2	-	-	PUNCT
aji-40	113	3	α	α	PROPN
aji-40	113	4	overexpression	overexpression	NOUN
aji-40	113	5	(	(	PUNCT
aji-40	113	6	especially	especially	ADV
aji-40	113	7	of	of	ADP
aji-40	113	8	tnfr1	tnfr1	NOUN
aji-40	113	9	mediated	mediate	VERB
aji-40	113	10	actions	action	NOUN
aji-40	113	11	)	)	PUNCT
aji-40	113	12	or	or	CCONJ
aji-40	113	13	under	under	ADP
aji-40	113	14	expression	expression	NOUN
aji-40	113	15	(	(	PUNCT
aji-40	113	16	especially	especially	ADV
aji-40	113	17	of	of	ADP
aji-40	113	18	tnfr2	tnfr2	NOUN
aji-40	113	19	mediated	mediate	VERB
aji-40	113	20	actions	action	NOUN
aji-40	113	21	)	)	PUNCT
aji-40	113	22	may	may	AUX
aji-40	113	23	review	review	VERB
aji-40	113	24	article	article	PROPN
aji-40	113	25	churchill	churchill	PROPN
aji-40	113	26	et	et	PROPN
aji-40	113	27	al	al	PROPN
aji-40	113	28	.	.	PROPN
aji-40	113	29	;	;	PUNCT
aji-40	113	30	aji	aji	PROPN
aji-40	113	31	,	,	PUNCT
aji-40	113	32	3(1	3(1	NUM
aji-40	113	33	):	):	PUNCT
aji-40	113	34	208	208	NUM
aji-40	113	35	-	-	SYM
aji-40	113	36	222	222	NUM
aji-40	113	37	,	,	PUNCT
aji-40	113	38	2020	2020	NUM
aji-40	113	39	;	;	PUNCT
aji-40	113	40	article	article	NOUN
aji-40	113	41	no.aji.57464	no.aji.57464	PRON
aji-40	113	42	209	209	NUM
aji-40	113	43	contribute	contribute	VERB
aji-40	113	44	to	to	ADP
aji-40	113	45	several	several	ADJ
aji-40	113	46	diseases	disease	NOUN
aji-40	113	47	including	include	VERB
aji-40	113	48	rheumatoid	rheumatoid	NOUN
aji-40	113	49	arthritis	arthritis	NOUN
aji-40	113	50	,	,	PUNCT
aji-40	113	51	psoriatic	psoriatic	ADJ
aji-40	113	52	arthritis	arthritis	NOUN
aji-40	113	53	,	,	PUNCT
aji-40	113	54	ankylosing	ankylose	VERB
aji-40	113	55	spondylitis	spondylitis	NOUN
aji-40	113	56	,	,	PUNCT
aji-40	113	57	crohn	crohn	PROPN
aji-40	113	58	’s	’s	PART
aji-40	113	59	disease	disease	NOUN
aji-40	113	60	,	,	PUNCT
aji-40	113	61	ulcerative	ulcerative	ADJ
aji-40	113	62	colitis	colitis	NOUN
aji-40	113	63	,	,	PUNCT
aji-40	113	64	and	and	CCONJ
aji-40	113	65	juvenile	juvenile	ADJ
aji-40	113	66	inflammatory	inflammatory	ADJ
aji-40	113	67	arthritis	arthritis	NOUN
aji-40	113	68	.	.	PUNCT
aji-40	114	1	several	several	ADJ
aji-40	114	2	anti	anti	ADJ
aji-40	114	3	-	-	ADJ
aji-40	114	4	tnf	tnf	ADJ
aji-40	114	5	therapies	therapy	NOUN
aji-40	114	6	are	be	AUX
aji-40	114	7	proven	prove	VERB
aji-40	114	8	to	to	PART
aji-40	114	9	be	be	AUX
aji-40	114	10	beneficial	beneficial	ADJ
aji-40	114	11	in	in	ADP
aji-40	114	12	these	these	DET
aji-40	114	13	diseases	disease	NOUN
aji-40	114	14	,	,	PUNCT
aji-40	114	15	including	include	VERB
aji-40	114	16	etanercept	etanercept	NOUN
aji-40	114	17	,	,	PUNCT
aji-40	114	18	infliximab	infliximab	NOUN
aji-40	114	19	,	,	PUNCT
aji-40	114	20	adalimumab	adalimumab	NOUN
aji-40	114	21	,	,	PUNCT
aji-40	114	22	certolizumab	certolizumab	NOUN
aji-40	114	23	and	and	CCONJ
aji-40	114	24	golimumab	golimumab	NOUN
aji-40	114	25	.	.	PUNCT
aji-40	115	1	biological	biological	ADJ
aji-40	115	2	responses	response	NOUN
aji-40	115	3	of	of	ADP
aji-40	115	4	tnf	tnf	PROPN
aji-40	115	5	-	-	PUNCT
aji-40	115	6	α	α	PROPN
aji-40	115	7	include	include	VERB
aji-40	115	8	inflammation	inflammation	NOUN
aji-40	115	9	,	,	PUNCT
aji-40	115	10	apoptosis	apoptosis	NOUN
aji-40	115	11	,	,	PUNCT
aji-40	115	12	immunomodulation	immunomodulation	NOUN
aji-40	115	13	,	,	PUNCT
aji-40	115	14	tissue	tissue	NOUN
aji-40	115	15	repair	repair	NOUN
aji-40	115	16	,	,	PUNCT
aji-40	115	17	antiviral	antiviral	NOUN
aji-40	115	18	and	and	CCONJ
aji-40	115	19	antitumor	antitumor	PROPN
aji-40	115	20	activity	activity	NOUN
aji-40	115	21	and	and	CCONJ
aji-40	115	22	mediation	mediation	NOUN
aji-40	115	23	of	of	ADP
aji-40	115	24	endotoxin	endotoxin	NOUN
aji-40	115	25	-	-	PUNCT
aji-40	115	26	induced	induce	VERB
aji-40	115	27	septic	septic	ADJ
aji-40	115	28	shock	shock	NOUN
aji-40	115	29	,	,	PUNCT
aji-40	115	30	recruitment	recruitment	NOUN
aji-40	115	31	of	of	ADP
aji-40	115	32	inflammatory	inflammatory	ADJ
aji-40	115	33	cells	cell	NOUN
aji-40	115	34	including	include	VERB
aji-40	115	35	neutrophils	neutrophil	NOUN
aji-40	115	36	,	,	PUNCT
aji-40	115	37	monocytes	monocyte	NOUN
aji-40	115	38	and	and	CCONJ
aji-40	115	39	lymphocytes	lymphocyte	VERB
aji-40	115	40	to	to	ADP
aji-40	115	41	sites	site	NOUN
aji-40	115	42	of	of	ADP
aji-40	115	43	infection	infection	NOUN
aji-40	115	44	;	;	PUNCT
aji-40	115	45	and	and	CCONJ
aji-40	115	46	cell	cell	NOUN
aji-40	115	47	activation	activation	NOUN
aji-40	115	48	through	through	ADP
aji-40	115	49	action	action	NOUN
aji-40	115	50	on	on	ADP
aji-40	115	51	different	different	ADJ
aji-40	115	52	receptors	receptor	NOUN
aji-40	115	53	(	(	PUNCT
aji-40	115	54	tnfr1	tnfr1	NOUN
aji-40	115	55	and	and	CCONJ
aji-40	115	56	tnfr2	tnfr2	NOUN
aji-40	115	57	)	)	PUNCT
aji-40	115	58	.	.	PUNCT
aji-40	116	1	low	low	ADJ
aji-40	116	2	grade	grade	PROPN
aji-40	116	3	chronic	chronic	ADJ
aji-40	116	4	inflammation	inflammation	NOUN
aji-40	116	5	occurs	occur	VERB
aji-40	116	6	in	in	ADP
aji-40	116	7	several	several	ADJ
aji-40	116	8	other	other	ADJ
aji-40	116	9	diseases	disease	NOUN
aji-40	116	10	including	include	VERB
aji-40	116	11	atherosclerosis	atherosclerosis	NOUN
aji-40	116	12	,	,	PUNCT
aji-40	116	13	hypertension	hypertension	NOUN
aji-40	116	14	,	,	PUNCT
aji-40	116	15	chronic	chronic	ADJ
aji-40	116	16	kidney	kidney	NOUN
aji-40	116	17	disease	disease	NOUN
aji-40	116	18	,	,	PUNCT
aji-40	116	19	alzheimer	alzheimer	PROPN
aji-40	116	20	’s	’s	PART
aji-40	116	21	disease	disease	NOUN
aji-40	116	22	,	,	PUNCT
aji-40	116	23	parkinson	parkinson	NOUN
aji-40	116	24	’s	’s	PART
aji-40	116	25	disease	disease	NOUN
aji-40	116	26	and	and	CCONJ
aji-40	116	27	multiple	multiple	ADJ
aji-40	116	28	sclerosis	sclerosis	NOUN
aji-40	116	29	.	.	PUNCT
aji-40	117	1	researchers	researcher	NOUN
aji-40	117	2	have	have	AUX
aji-40	117	3	explored	explore	VERB
aji-40	117	4	whether	whether	SCONJ
aji-40	117	5	anti	anti	ADJ
aji-40	117	6	-	-	ADJ
aji-40	117	7	tnf	tnf	ADJ
aji-40	117	8	therapies	therapy	NOUN
aji-40	117	9	can	can	AUX
aji-40	117	10	be	be	AUX
aji-40	117	11	helpful	helpful	ADJ
aji-40	117	12	in	in	ADP
aji-40	117	13	these	these	DET
aji-40	117	14	diseases	disease	NOUN
aji-40	117	15	too	too	ADV
aji-40	117	16	.	.	PUNCT
aji-40	118	1	both	both	DET
aji-40	118	2	positive	positive	ADJ
aji-40	118	3	and	and	CCONJ
aji-40	118	4	negative	negative	ADJ
aji-40	118	5	effects	effect	NOUN
aji-40	118	6	of	of	ADP
aji-40	118	7	anti	anti	ADJ
aji-40	118	8	-	-	ADJ
aji-40	118	9	tnf	tnf	ADJ
aji-40	118	10	therapies	therapy	NOUN
aji-40	118	11	have	have	AUX
aji-40	118	12	been	be	AUX
aji-40	118	13	observed	observe	VERB
aji-40	118	14	in	in	ADP
aji-40	118	15	these	these	DET
aji-40	118	16	diseases	disease	NOUN
aji-40	118	17	.	.	PUNCT
aji-40	119	1	these	these	DET
aji-40	119	2	observations	observation	NOUN
aji-40	119	3	suggest	suggest	VERB
aji-40	119	4	that	that	SCONJ
aji-40	119	5	tnf	tnf	PROPN
aji-40	119	6	-	-	PUNCT
aji-40	119	7	α	α	PROPN
aji-40	119	8	and	and	CCONJ
aji-40	119	9	tnf	tnf	PROPN
aji-40	119	10	receptors	receptor	NOUN
aji-40	119	11	system	system	NOUN
aji-40	119	12	have	have	VERB
aji-40	119	13	an	an	DET
aji-40	119	14	incredibly	incredibly	ADV
aji-40	119	15	complex	complex	ADJ
aji-40	119	16	pathophysiologic	pathophysiologic	ADJ
aji-40	119	17	role	role	NOUN
aji-40	119	18	,	,	PUNCT
aji-40	119	19	and	and	CCONJ
aji-40	119	20	hence	hence	ADV
aji-40	119	21	blockade	blockade	NOUN
aji-40	119	22	of	of	ADP
aji-40	119	23	this	this	DET
aji-40	119	24	pathway	pathway	NOUN
aji-40	119	25	results	result	NOUN
aji-40	119	26	in	in	ADP
aji-40	119	27	complex	complex	ADJ
aji-40	119	28	effects	effect	NOUN
aji-40	119	29	on	on	ADP
aji-40	119	30	different	different	ADJ
aji-40	119	31	organ	organ	NOUN
aji-40	119	32	systems	system	NOUN
aji-40	119	33	.	.	PUNCT
aji-40	120	1	in	in	ADP
aji-40	120	2	this	this	DET
aji-40	120	3	review	review	NOUN
aji-40	120	4	we	we	PRON
aji-40	120	5	have	have	AUX
aji-40	120	6	explored	explore	VERB
aji-40	120	7	the	the	DET
aji-40	120	8	myriad	myriad	ADJ
aji-40	120	9	effects	effect	NOUN
aji-40	120	10	on	on	ADP
aji-40	120	11	various	various	ADJ
aji-40	120	12	organ	organ	NOUN
aji-40	120	13	systems	system	NOUN
aji-40	120	14	due	due	ADJ
aji-40	120	15	to	to	ADP
aji-40	120	16	tnf	tnf	PROPN
aji-40	120	17	blockade	blockade	NOUN
aji-40	120	18	,	,	PUNCT
aji-40	120	19	including	include	VERB
aji-40	120	20	covid-19	covid-19	PROPN
aji-40	120	21	.	.	PUNCT
aji-40	121	1	keywords	keyword	NOUN
aji-40	121	2	:	:	PUNCT
aji-40	121	3	tumor	tumor	NOUN
aji-40	121	4	necrosis	necrosis	NOUN
aji-40	121	5	factor	factor	NOUN
aji-40	121	6	alpha	alpha	NOUN
aji-40	121	7	(	(	PUNCT
aji-40	121	8	tnf	tnf	PROPN
aji-40	121	9	-	-	PUNCT
aji-40	121	10	α	α	NOUN
aji-40	121	11	)	)	PUNCT
aji-40	121	12	;	;	PUNCT
aji-40	121	13	rheumatoid	rheumatoid	NOUN
aji-40	121	14	arthritis	arthritis	NOUN
aji-40	121	15	;	;	PUNCT
aji-40	121	16	covid-19	covid-19	PROPN
aji-40	121	17	;	;	PUNCT
aji-40	121	18	tnfr1	tnfr1	PROPN
aji-40	121	19	;	;	PUNCT
aji-40	121	20	tnfr2	tnfr2	NOUN
aji-40	121	21	.	.	NOUN
aji-40	122	1	1	1	X
aji-40	122	2	.	.	X
aji-40	122	3	introduction	introduction	NOUN
aji-40	122	4	tumor	tumor	NOUN
aji-40	122	5	necrosis	necrosis	NOUN
aji-40	122	6	factor	factor	NOUN
aji-40	122	7	(	(	PUNCT
aji-40	122	8	tnf	tnf	PROPN
aji-40	122	9	)	)	PUNCT
aji-40	122	10	is	be	AUX
aji-40	122	11	a	a	DET
aji-40	122	12	naturally	naturally	ADV
aji-40	122	13	occurring	occur	VERB
aji-40	122	14	inflammatory	inflammatory	ADJ
aji-40	122	15	cytokine	cytokine	VERB
aji-40	122	16	the	the	DET
aji-40	122	17	tnf	tnf	PROPN
aji-40	122	18	superfamily	superfamily	NOUN
aji-40	122	19	that	that	PRON
aji-40	122	20	consists	consist	VERB
aji-40	122	21	of	of	ADP
aji-40	122	22	19	19	NUM
aji-40	122	23	members	member	NOUN
aji-40	122	24	(	(	PUNCT
aji-40	122	25	ligands	ligand	NOUN
aji-40	122	26	)	)	PUNCT
aji-40	123	1	[	[	X
aji-40	123	2	1	1	NUM
aji-40	123	3	]	]	PUNCT
aji-40	123	4	.	.	PUNCT
aji-40	124	1	they	they	PRON
aji-40	124	2	are	be	AUX
aji-40	124	3	type	type	NOUN
aji-40	124	4	ii	ii	NOUN
aji-40	124	5	transmembrane	transmembrane	NOUN
aji-40	124	6	proteins	protein	NOUN
aji-40	124	7	that	that	PRON
aji-40	124	8	can	can	AUX
aji-40	124	9	bind	bind	VERB
aji-40	124	10	to	to	ADP
aji-40	124	11	29	29	NUM
aji-40	124	12	receptors	receptor	NOUN
aji-40	124	13	of	of	ADP
aji-40	124	14	the	the	DET
aji-40	124	15	tnf	tnf	PROPN
aji-40	124	16	receptor	receptor	NOUN
aji-40	124	17	superfamily	superfamily	ADV
aji-40	124	18	including	include	VERB
aji-40	124	19	fas	fas	NOUN
aji-40	124	20	,	,	PUNCT
aji-40	124	21	cd40	cd40	PROPN
aji-40	124	22	,	,	PUNCT
aji-40	124	23	cd27	cd27	PROPN
aji-40	124	24	and	and	CCONJ
aji-40	124	25	rank	rank	VERB
aji-40	124	26	[	[	X
aji-40	124	27	2	2	NUM
aji-40	124	28	]	]	PUNCT
aji-40	124	29	.	.	PUNCT
aji-40	125	1	tnf	tnf	PROPN
aji-40	125	2	-	-	PUNCT
aji-40	125	3	α	α	PROPN
aji-40	125	4	,	,	PUNCT
aji-40	125	5	also	also	ADV
aji-40	125	6	called	call	VERB
aji-40	125	7	cachectin	cachectin	NOUN
aji-40	125	8	or	or	CCONJ
aji-40	125	9	cachexin	cachexin	NOUN
aji-40	125	10	,	,	PUNCT
aji-40	125	11	is	be	AUX
aji-40	125	12	produced	produce	VERB
aji-40	125	13	by	by	ADP
aji-40	125	14	activated	activate	VERB
aji-40	125	15	macrophages	macrophage	NOUN
aji-40	125	16	and	and	CCONJ
aji-40	125	17	monocytes	monocyte	NOUN
aji-40	125	18	,	,	PUNCT
aji-40	125	19	and	and	CCONJ
aji-40	125	20	to	to	ADP
aji-40	125	21	a	a	DET
aji-40	125	22	smaller	small	ADJ
aji-40	125	23	scale	scale	NOUN
aji-40	125	24	by	by	ADP
aji-40	125	25	tlymphocytes	tlymphocyte	NOUN
aji-40	125	26	,	,	PUNCT
aji-40	125	27	b	b	X
aji-40	125	28	-	-	PUNCT
aji-40	125	29	lymphocytes	lymphocyte	NOUN
aji-40	125	30	,	,	PUNCT
aji-40	125	31	fibroblasts	fibroblast	NOUN
aji-40	125	32	,	,	PUNCT
aji-40	125	33	and	and	CCONJ
aji-40	125	34	astrocytes	astrocyte	NOUN
aji-40	125	35	[	[	X
aji-40	125	36	3	3	NUM
aji-40	125	37	]	]	PUNCT
aji-40	125	38	.	.	PUNCT
aji-40	126	1	it	it	PRON
aji-40	126	2	can	can	AUX
aji-40	126	3	bind	bind	VERB
aji-40	126	4	to	to	ADP
aji-40	126	5	tnfr1	tnfr1	NOUN
aji-40	126	6	(	(	PUNCT
aji-40	126	7	tumor	tumor	NOUN
aji-40	126	8	necrosis	necrosis	NOUN
aji-40	126	9	factor	factor	NOUN
aji-40	126	10	receptor-1	receptor-1	NUM
aji-40	126	11	)	)	PUNCT
aji-40	126	12	and	and	CCONJ
aji-40	126	13	tnfr2	tnfr2	NOUN
aji-40	126	14	(	(	PUNCT
aji-40	126	15	tumor	tumor	NOUN
aji-40	126	16	necrosis	necrosis	NOUN
aji-40	126	17	factor	factor	NOUN
aji-40	126	18	receptor-2	receptor-2	NUM
aji-40	126	19	)	)	PUNCT
aji-40	126	20	,	,	PUNCT
aji-40	126	21	and	and	CCONJ
aji-40	126	22	has	have	VERB
aji-40	126	23	both	both	CCONJ
aji-40	126	24	inflammatory	inflammatory	ADJ
aji-40	126	25	and	and	CCONJ
aji-40	126	26	immunomodulatory	immunomodulatory	ADJ
aji-40	126	27	roles	role	NOUN
aji-40	126	28	[	[	X
aji-40	126	29	4	4	NUM
aji-40	126	30	]	]	PUNCT
aji-40	126	31	.	.	PUNCT
aji-40	127	1	it	it	PRON
aji-40	127	2	has	have	AUX
aji-40	127	3	been	be	AUX
aji-40	127	4	implicated	implicate	VERB
aji-40	127	5	in	in	ADP
aji-40	127	6	pathogenesis	pathogenesis	NOUN
aji-40	127	7	of	of	ADP
aji-40	127	8	several	several	ADJ
aji-40	127	9	diseases	disease	NOUN
aji-40	127	10	including	include	VERB
aji-40	127	11	rheumatoid	rheumatoid	NOUN
aji-40	127	12	arthritis	arthritis	NOUN
aji-40	127	13	,	,	PUNCT
aji-40	127	14	systemic	systemic	ADJ
aji-40	127	15	lupus	lupus	PROPN
aji-40	127	16	erythematosus	erythematosus	NOUN
aji-40	127	17	,	,	PUNCT
aji-40	127	18	ulcerative	ulcerative	ADJ
aji-40	127	19	colitis	colitis	NOUN
aji-40	127	20	and	and	CCONJ
aji-40	127	21	crohn	crohn	PROPN
aji-40	127	22	’s	’s	PART
aji-40	127	23	disease	disease	NOUN
aji-40	127	24	[	[	X
aji-40	127	25	1,3	1,3	NUM
aji-40	127	26	]	]	PUNCT
aji-40	127	27	.	.	PUNCT
aji-40	128	1	tnf	tnf	PROPN
aji-40	128	2	-	-	PUNCT
aji-40	128	3	α	α	PROPN
aji-40	128	4	and	and	CCONJ
aji-40	128	5	tnf	tnf	PROPN
aji-40	128	6	receptors	receptor	NOUN
aji-40	128	7	system	system	NOUN
aji-40	128	8	is	be	AUX
aji-40	128	9	complex	complex	ADJ
aji-40	128	10	and	and	CCONJ
aji-40	128	11	has	have	VERB
aji-40	128	12	complicated	complicate	VERB
aji-40	128	13	implications	implication	NOUN
aji-40	128	14	in	in	ADP
aji-40	128	15	therapy	therapy	NOUN
aji-40	128	16	[	[	X
aji-40	128	17	5	5	NUM
aji-40	128	18	]	]	PUNCT
aji-40	128	19	.	.	PUNCT
aji-40	129	1	anti	anti	ADJ
aji-40	129	2	-	-	ADJ
aji-40	129	3	tnf	tnf	ADJ
aji-40	129	4	agents	agent	NOUN
aji-40	129	5	including	include	VERB
aji-40	129	6	etanercept	etanercept	NOUN
aji-40	129	7	,	,	PUNCT
aji-40	129	8	infliximab	infliximab	NOUN
aji-40	129	9	and	and	CCONJ
aji-40	129	10	adalimumab	adalimumab	NOUN
aji-40	129	11	are	be	AUX
aji-40	129	12	helpful	helpful	ADJ
aji-40	129	13	in	in	ADP
aji-40	129	14	treatment	treatment	NOUN
aji-40	129	15	of	of	ADP
aji-40	129	16	many	many	ADJ
aji-40	129	17	diseases	disease	NOUN
aji-40	129	18	where	where	SCONJ
aji-40	129	19	chronic	chronic	ADJ
aji-40	129	20	inflammation	inflammation	NOUN
aji-40	129	21	is	be	AUX
aji-40	129	22	involved	involve	VERB
aji-40	129	23	for	for	ADP
aji-40	129	24	example	example	NOUN
aji-40	129	25	,	,	PUNCT
aji-40	129	26	rheumatoid	rheumatoid	NOUN
aji-40	129	27	arthritis	arthritis	NOUN
aji-40	129	28	,	,	PUNCT
aji-40	129	29	psoriatic	psoriatic	ADJ
aji-40	129	30	arthritis	arthritis	NOUN
aji-40	129	31	,	,	PUNCT
aji-40	129	32	ulcerative	ulcerative	ADJ
aji-40	129	33	colitis	colitis	NOUN
aji-40	129	34	,	,	PUNCT
aji-40	129	35	and	and	CCONJ
aji-40	129	36	crohn	crohn	PROPN
aji-40	129	37	’s	’s	PART
aji-40	129	38	disease	disease	NOUN
aji-40	129	39	[	[	X
aji-40	129	40	5	5	NUM
aji-40	129	41	-	-	SYM
aji-40	129	42	8	8	NUM
aji-40	129	43	]	]	PUNCT
aji-40	129	44	.	.	PUNCT
aji-40	130	1	these	these	DET
aji-40	130	2	therapies	therapy	NOUN
aji-40	130	3	may	may	AUX
aji-40	130	4	predispose	predispose	VERB
aji-40	130	5	patients	patient	NOUN
aji-40	130	6	to	to	ADP
aji-40	130	7	increased	increase	VERB
aji-40	130	8	risk	risk	NOUN
aji-40	130	9	of	of	ADP
aji-40	130	10	infections	infection	NOUN
aji-40	130	11	(	(	PUNCT
aji-40	130	12	including	include	VERB
aji-40	130	13	reactivation	reactivation	NOUN
aji-40	130	14	of	of	ADP
aji-40	130	15	tuberculosis	tuberculosis	NOUN
aji-40	130	16	)	)	PUNCT
aji-40	130	17	,	,	PUNCT
aji-40	130	18	cardiovascular	cardiovascular	ADJ
aji-40	130	19	events	event	NOUN
aji-40	130	20	,	,	PUNCT
aji-40	130	21	autoimmune	autoimmune	ADJ
aji-40	130	22	diseases	disease	NOUN
aji-40	130	23	,	,	PUNCT
aji-40	130	24	malignancy	malignancy	NOUN
aji-40	130	25	,	,	PUNCT
aji-40	130	26	hepatitis	hepatitis	NOUN
aji-40	130	27	,	,	PUNCT
aji-40	130	28	nephritis	nephritis	NOUN
aji-40	130	29	and	and	CCONJ
aji-40	130	30	tubulointerstitial	tubulointerstitial	ADJ
aji-40	130	31	diseases	disease	NOUN
aji-40	130	32	,	,	PUNCT
aji-40	130	33	as	as	SCONJ
aji-40	130	34	has	have	AUX
aji-40	130	35	been	be	AUX
aji-40	130	36	discussed	discuss	VERB
aji-40	130	37	later	later	ADV
aji-40	130	38	in	in	ADP
aji-40	130	39	this	this	DET
aji-40	130	40	paper	paper	NOUN
aji-40	130	41	.	.	PUNCT
aji-40	131	1	several	several	ADJ
aji-40	131	2	other	other	ADJ
aji-40	131	3	diseases	disease	NOUN
aji-40	131	4	including	include	VERB
aji-40	131	5	atherosclerosis	atherosclerosis	NOUN
aji-40	131	6	,	,	PUNCT
aji-40	131	7	hypertension	hypertension	NOUN
aji-40	131	8	,	,	PUNCT
aji-40	131	9	chronic	chronic	ADJ
aji-40	131	10	kidney	kidney	NOUN
aji-40	131	11	disease	disease	NOUN
aji-40	131	12	,	,	PUNCT
aji-40	131	13	alzheimer	alzheimer	PROPN
aji-40	131	14	’s	’s	PART
aji-40	131	15	disease	disease	NOUN
aji-40	131	16	,	,	PUNCT
aji-40	131	17	parkinson	parkinson	NOUN
aji-40	131	18	’s	’s	PART
aji-40	131	19	disease	disease	NOUN
aji-40	131	20	and	and	CCONJ
aji-40	131	21	multiple	multiple	ADJ
aji-40	131	22	sclerosis	sclerosis	NOUN
aji-40	131	23	also	also	ADV
aji-40	131	24	show	show	VERB
aji-40	131	25	evidence	evidence	NOUN
aji-40	131	26	of	of	ADP
aji-40	131	27	lowgrade	lowgrade	NOUN
aji-40	131	28	chronic	chronic	ADJ
aji-40	131	29	inflammation	inflammation	NOUN
aji-40	131	30	.	.	PUNCT
aji-40	132	1	researchers	researcher	NOUN
aji-40	132	2	have	have	AUX
aji-40	132	3	explored	explore	VERB
aji-40	132	4	whether	whether	SCONJ
aji-40	132	5	anti	anti	ADJ
aji-40	132	6	-	-	ADJ
aji-40	132	7	tnf	tnf	ADJ
aji-40	132	8	therapies	therapy	NOUN
aji-40	132	9	can	can	AUX
aji-40	132	10	be	be	AUX
aji-40	132	11	helpful	helpful	ADJ
aji-40	132	12	in	in	ADP
aji-40	132	13	these	these	DET
aji-40	132	14	diseases	disease	NOUN
aji-40	132	15	too	too	ADV
aji-40	132	16	.	.	PUNCT
aji-40	133	1	both	both	DET
aji-40	133	2	positive	positive	ADJ
aji-40	133	3	and	and	CCONJ
aji-40	133	4	negative	negative	ADJ
aji-40	133	5	effects	effect	NOUN
aji-40	133	6	of	of	ADP
aji-40	133	7	anti	anti	ADJ
aji-40	133	8	-	-	ADJ
aji-40	133	9	tnf	tnf	ADJ
aji-40	133	10	therapies	therapy	NOUN
aji-40	133	11	have	have	AUX
aji-40	133	12	been	be	AUX
aji-40	133	13	observed	observe	VERB
aji-40	133	14	in	in	ADP
aji-40	133	15	these	these	DET
aji-40	133	16	diseases	disease	NOUN
aji-40	133	17	.	.	PUNCT
aji-40	134	1	these	these	DET
aji-40	134	2	observations	observation	NOUN
aji-40	134	3	suggest	suggest	VERB
aji-40	134	4	that	that	SCONJ
aji-40	134	5	tnf	tnf	PROPN
aji-40	134	6	-	-	PUNCT
aji-40	134	7	α	α	PROPN
aji-40	134	8	and	and	CCONJ
aji-40	134	9	tnf	tnf	PROPN
aji-40	134	10	receptors	receptor	NOUN
aji-40	134	11	system	system	NOUN
aji-40	134	12	have	have	VERB
aji-40	134	13	a	a	DET
aji-40	134	14	complex	complex	ADJ
aji-40	134	15	pathophysiologic	pathophysiologic	ADJ
aji-40	134	16	role	role	NOUN
aji-40	134	17	,	,	PUNCT
aji-40	134	18	and	and	CCONJ
aji-40	134	19	hence	hence	ADV
aji-40	134	20	blockade	blockade	NOUN
aji-40	134	21	of	of	ADP
aji-40	134	22	this	this	DET
aji-40	134	23	pathway	pathway	NOUN
aji-40	134	24	results	result	NOUN
aji-40	134	25	in	in	ADP
aji-40	134	26	complex	complex	ADJ
aji-40	134	27	effects	effect	NOUN
aji-40	134	28	on	on	ADP
aji-40	134	29	different	different	ADJ
aji-40	134	30	organ	organ	NOUN
aji-40	134	31	systems	system	NOUN
aji-40	134	32	.	.	PUNCT
aji-40	135	1	in	in	ADP
aji-40	135	2	this	this	DET
aji-40	135	3	review	review	NOUN
aji-40	135	4	we	we	PRON
aji-40	135	5	have	have	AUX
aji-40	135	6	explored	explore	VERB
aji-40	135	7	the	the	DET
aji-40	135	8	effects	effect	NOUN
aji-40	135	9	of	of	ADP
aji-40	135	10	tnf	tnf	PROPN
aji-40	135	11	blockade	blockade	NOUN
aji-40	135	12	on	on	ADP
aji-40	135	13	various	various	ADJ
aji-40	135	14	organ	organ	NOUN
aji-40	135	15	systems	system	NOUN
aji-40	135	16	.	.	PUNCT
aji-40	136	1	2	2	X
aji-40	136	2	.	.	X
aji-40	136	3	biological	biological	ADJ
aji-40	136	4	properties	property	NOUN
aji-40	136	5	of	of	ADP
aji-40	136	6	tnf	tnf	PROPN
aji-40	136	7	-	-	PUNCT
aji-40	136	8	α	α	PROPN
aji-40	136	9	and	and	CCONJ
aji-40	136	10	tnf	tnf	PROPN
aji-40	136	11	receptors	receptor	NOUN
aji-40	136	12	2.1	2.1	NUM
aji-40	136	13	tumor	tumor	NOUN
aji-40	136	14	necrosis	necrosis	NOUN
aji-40	136	15	factor	factor	NOUN
aji-40	136	16	-	-	PUNCT
aji-40	136	17	α	α	NOUN
aji-40	136	18	tumor	tumor	NOUN
aji-40	136	19	necrosis	necrosis	NOUN
aji-40	136	20	factor	factor	NOUN
aji-40	136	21	-	-	PUNCT
aji-40	136	22	α	α	X
aji-40	136	23	(	(	PUNCT
aji-40	136	24	tnf	tnf	PROPN
aji-40	136	25	-	-	PUNCT
aji-40	136	26	α	α	NOUN
aji-40	136	27	)	)	PUNCT
aji-40	136	28	was	be	AUX
aji-40	136	29	discovered	discover	VERB
aji-40	136	30	by	by	ADP
aji-40	136	31	lloyd	lloyd	PROPN
aji-40	136	32	j	j	PROPN
aji-40	136	33	old	old	ADJ
aji-40	136	34	together	together	ADV
aji-40	136	35	with	with	ADP
aji-40	136	36	elizabeth	elizabeth	PROPN
aji-40	136	37	carswell	carswell	PROPN
aji-40	136	38	in	in	ADP
aji-40	136	39	1975	1975	NUM
aji-40	136	40	[	[	X
aji-40	136	41	6,9	6,9	NUM
aji-40	136	42	]	]	PUNCT
aji-40	136	43	.	.	PUNCT
aji-40	137	1	they	they	PRON
aji-40	137	2	discovered	discover	VERB
aji-40	137	3	that	that	SCONJ
aji-40	137	4	tnf	tnf	PROPN
aji-40	137	5	-	-	PUNCT
aji-40	137	6	α	α	PROPN
aji-40	137	7	is	be	AUX
aji-40	137	8	produced	produce	VERB
aji-40	137	9	by	by	ADP
aji-40	137	10	lymphocytes	lymphocyte	NOUN
aji-40	137	11	and	and	CCONJ
aji-40	137	12	macrophages	macrophage	NOUN
aji-40	137	13	that	that	PRON
aji-40	137	14	cause	cause	VERB
aji-40	137	15	lysis	lysis	NOUN
aji-40	137	16	of	of	ADP
aji-40	137	17	specific	specific	ADJ
aji-40	137	18	type	type	NOUN
aji-40	137	19	of	of	ADP
aji-40	137	20	cells	cell	NOUN
aji-40	137	21	like	like	ADP
aji-40	137	22	tumor	tumor	NOUN
aji-40	137	23	cells	cell	NOUN
aji-40	137	24	[	[	X
aji-40	137	25	6	6	NUM
aji-40	137	26	]	]	PUNCT
aji-40	137	27	.	.	PUNCT
aji-40	138	1	this	this	DET
aji-40	138	2	discovery	discovery	NOUN
aji-40	138	3	led	lead	VERB
aji-40	138	4	to	to	ADP
aji-40	138	5	the	the	DET
aji-40	138	6	discovery	discovery	NOUN
aji-40	138	7	of	of	ADP
aji-40	138	8	a	a	DET
aji-40	138	9	number	number	NOUN
aji-40	138	10	of	of	ADP
aji-40	138	11	other	other	ADJ
aji-40	138	12	cytokines	cytokine	NOUN
aji-40	138	13	including	include	VERB
aji-40	138	14	lymphotoxin	lymphotoxin	NOUN
aji-40	138	15	alpha	alpha	NOUN
aji-40	138	16	(	(	PUNCT
aji-40	138	17	tnf	tnf	PROPN
aji-40	138	18	-	-	PUNCT
aji-40	138	19	β	β	NOUN
aji-40	138	20	)	)	PUNCT
aji-40	138	21	,	,	PUNCT
aji-40	138	22	cd40l	cd40l	NOUN
aji-40	138	23	,	,	PUNCT
aji-40	138	24	cd27l	cd27l	X
aji-40	138	25	,	,	PUNCT
aji-40	138	26	and	and	CCONJ
aji-40	138	27	fasl	fasl	NOUN
aji-40	139	1	[	[	X
aji-40	139	2	6,9	6,9	NUM
aji-40	139	3	]	]	PUNCT
aji-40	139	4	.	.	PUNCT
aji-40	140	1	biological	biological	ADJ
aji-40	140	2	responses	response	NOUN
aji-40	140	3	of	of	ADP
aji-40	140	4	tnf	tnf	PROPN
aji-40	140	5	-	-	PUNCT
aji-40	140	6	α	α	PROPN
aji-40	140	7	include	include	VERB
aji-40	140	8	inflammation	inflammation	NOUN
aji-40	140	9	,	,	PUNCT
aji-40	140	10	apoptosis	apoptosis	NOUN
aji-40	140	11	,	,	PUNCT
aji-40	140	12	immunomodulation	immunomodulation	NOUN
aji-40	140	13	,	,	PUNCT
aji-40	140	14	tissue	tissue	NOUN
aji-40	140	15	repair	repair	NOUN
aji-40	140	16	,	,	PUNCT
aji-40	140	17	antiviral	antiviral	NOUN
aji-40	140	18	and	and	CCONJ
aji-40	140	19	antitumor	antitumor	PROPN
aji-40	140	20	activity	activity	NOUN
aji-40	140	21	and	and	CCONJ
aji-40	140	22	mediation	mediation	NOUN
aji-40	140	23	of	of	ADP
aji-40	140	24	endotoxin	endotoxin	NOUN
aji-40	140	25	-	-	PUNCT
aji-40	140	26	induced	induce	VERB
aji-40	140	27	septic	septic	ADJ
aji-40	140	28	shock	shock	NOUN
aji-40	140	29	.	.	PUNCT
aji-40	141	1	it	it	PRON
aji-40	141	2	is	be	AUX
aji-40	141	3	involved	involve	VERB
aji-40	141	4	in	in	ADP
aji-40	141	5	recruitment	recruitment	NOUN
aji-40	141	6	of	of	ADP
aji-40	141	7	inflammatory	inflammatory	ADJ
aji-40	141	8	cells	cell	NOUN
aji-40	141	9	including	include	VERB
aji-40	141	10	neutrophils	neutrophil	NOUN
aji-40	141	11	,	,	PUNCT
aji-40	141	12	monocytes	monocyte	NOUN
aji-40	141	13	and	and	CCONJ
aji-40	141	14	churchill	churchill	PROPN
aji-40	141	15	et	et	PROPN
aji-40	141	16	al	al	PROPN
aji-40	141	17	.	.	PROPN
aji-40	141	18	;	;	PUNCT
aji-40	141	19	aji	aji	PROPN
aji-40	141	20	,	,	PUNCT
aji-40	141	21	3(1	3(1	NUM
aji-40	141	22	):	):	PUNCT
aji-40	141	23	208	208	NUM
aji-40	141	24	-	-	SYM
aji-40	141	25	222	222	NUM
aji-40	141	26	,	,	PUNCT
aji-40	141	27	2020	2020	NUM
aji-40	141	28	;	;	PUNCT
aji-40	141	29	article	article	NOUN
aji-40	141	30	no.aji.57464	no.aji.57464	ADP
aji-40	141	31	210	210	NUM
aji-40	141	32	lymphocytes	lymphocyte	NOUN
aji-40	141	33	to	to	ADP
aji-40	141	34	sites	site	NOUN
aji-40	141	35	of	of	ADP
aji-40	141	36	infection	infection	NOUN
aji-40	141	37	;	;	PUNCT
aji-40	141	38	and	and	CCONJ
aji-40	141	39	cell	cell	NOUN
aji-40	141	40	activation	activation	NOUN
aji-40	141	41	through	through	ADP
aji-40	141	42	its	its	PRON
aji-40	141	43	action	action	NOUN
aji-40	141	44	on	on	ADP
aji-40	141	45	different	different	ADJ
aji-40	141	46	receptors	receptor	NOUN
aji-40	141	47	(	(	PUNCT
aji-40	141	48	tnfr1	tnfr1	NOUN
aji-40	141	49	and	and	CCONJ
aji-40	141	50	tnfr2	tnfr2	NOUN
aji-40	141	51	)	)	PUNCT
aji-40	142	1	[	[	X
aji-40	142	2	3,4,10	3,4,10	NUM
aji-40	142	3	]	]	PUNCT
aji-40	142	4	.	.	PUNCT
aji-40	143	1	tnf	tnf	PROPN
aji-40	143	2	-	-	PUNCT
aji-40	143	3	α	α	PROPN
aji-40	143	4	exhibits	exhibit	VERB
aji-40	143	5	both	both	DET
aji-40	143	6	pro	pro	ADJ
aji-40	143	7	-	-	ADJ
aji-40	143	8	inflammatory	inflammatory	ADJ
aji-40	143	9	and	and	CCONJ
aji-40	143	10	immunoregulatory	immunoregulatory	ADJ
aji-40	143	11	properties	property	NOUN
aji-40	143	12	.	.	PUNCT
aji-40	144	1	in	in	ADP
aji-40	144	2	addition	addition	NOUN
aji-40	144	3	to	to	ADP
aji-40	144	4	its	its	PRON
aji-40	144	5	function	function	NOUN
aji-40	144	6	as	as	ADP
aji-40	144	7	an	an	DET
aji-40	144	8	endogenous	endogenous	ADJ
aji-40	144	9	pyrogen	pyrogen	NOUN
aji-40	144	10	,	,	PUNCT
aji-40	144	11	tnf	tnf	PROPN
aji-40	144	12	-	-	PUNCT
aji-40	144	13	α	α	PROPN
aji-40	144	14	has	have	AUX
aji-40	144	15	been	be	AUX
aji-40	144	16	shown	show	VERB
aji-40	144	17	to	to	PART
aji-40	144	18	initiate	initiate	VERB
aji-40	144	19	a	a	DET
aji-40	144	20	powerful	powerful	ADJ
aji-40	144	21	inflammatory	inflammatory	ADJ
aji-40	144	22	response	response	NOUN
aji-40	144	23	by	by	ADP
aji-40	144	24	stimulating	stimulate	VERB
aji-40	144	25	the	the	DET
aji-40	144	26	generation	generation	NOUN
aji-40	144	27	of	of	ADP
aji-40	144	28	other	other	ADJ
aji-40	144	29	inflammatory	inflammatory	ADJ
aji-40	144	30	cytokines	cytokine	NOUN
aji-40	144	31	such	such	ADJ
aji-40	144	32	as	as	ADP
aji-40	144	33	interleukin-6	interleukin-6	PROPN
aji-40	144	34	(	(	PUNCT
aji-40	144	35	il6	il6	NOUN
aji-40	144	36	)	)	PUNCT
aji-40	144	37	,	,	PUNCT
aji-40	144	38	interleukin-8	interleukin-8	NUM
aji-40	144	39	(	(	PUNCT
aji-40	144	40	il-8	il-8	NOUN
aji-40	144	41	)	)	PUNCT
aji-40	144	42	,	,	PUNCT
aji-40	144	43	interleukin-10	interleukin-10	PROPN
aji-40	144	44	,	,	PUNCT
aji-40	144	45	corticosteroids	corticosteroid	NOUN
aji-40	144	46	,	,	PUNCT
aji-40	144	47	and	and	CCONJ
aji-40	144	48	metalloproteinases	metalloproteinase	NOUN
aji-40	144	49	[	[	X
aji-40	144	50	3,10	3,10	NUM
aji-40	144	51	]	]	PUNCT
aji-40	144	52	.	.	PUNCT
aji-40	145	1	once	once	SCONJ
aji-40	145	2	the	the	DET
aji-40	145	3	triggering	trigger	VERB
aji-40	145	4	factor	factor	NOUN
aji-40	145	5	for	for	ADP
aji-40	145	6	the	the	DET
aji-40	145	7	immune	immune	ADJ
aji-40	145	8	system	system	NOUN
aji-40	145	9	activation	activation	NOUN
aji-40	145	10	is	be	AUX
aji-40	145	11	eliminated	eliminate	VERB
aji-40	145	12	,	,	PUNCT
aji-40	145	13	tnf	tnf	PROPN
aji-40	145	14	-	-	PUNCT
aji-40	145	15	α	α	PROPN
aji-40	145	16	steps	step	NOUN
aji-40	145	17	in	in	ADP
aji-40	145	18	again	again	ADV
aji-40	145	19	to	to	PART
aji-40	145	20	control	control	VERB
aji-40	145	21	and	and	CCONJ
aji-40	145	22	resolve	resolve	VERB
aji-40	145	23	the	the	DET
aji-40	145	24	inflammatory	inflammatory	ADJ
aji-40	145	25	process	process	NOUN
aji-40	145	26	[	[	X
aji-40	145	27	3	3	NUM
aji-40	145	28	]	]	PUNCT
aji-40	145	29	.	.	PUNCT
aji-40	146	1	the	the	DET
aji-40	146	2	gene	gene	NOUN
aji-40	146	3	that	that	PRON
aji-40	146	4	codes	code	VERB
aji-40	146	5	for	for	ADP
aji-40	146	6	human	human	PROPN
aji-40	146	7	tnf	tnf	PROPN
aji-40	146	8	-	-	PUNCT
aji-40	146	9	α	α	PROPN
aji-40	146	10	is	be	AUX
aji-40	146	11	located	locate	VERB
aji-40	146	12	on	on	ADP
aji-40	146	13	short	short	ADJ
aji-40	146	14	arm	arm	NOUN
aji-40	146	15	of	of	ADP
aji-40	146	16	chromosome	chromosome	NOUN
aji-40	146	17	6	6	NUM
aji-40	146	18	,	,	PUNCT
aji-40	146	19	linked	link	VERB
aji-40	146	20	to	to	ADP
aji-40	146	21	human	human	ADJ
aji-40	146	22	leucocyte	leucocyte	PROPN
aji-40	146	23	antigen	antigen	NOUN
aji-40	146	24	(	(	PUNCT
aji-40	146	25	hla	hla	NOUN
aji-40	146	26	)	)	PUNCT
aji-40	146	27	b	b	NOUN
aji-40	147	1	[	[	X
aji-40	147	2	11	11	NUM
aji-40	147	3	-	-	SYM
aji-40	147	4	13	13	NUM
aji-40	147	5	]	]	PUNCT
aji-40	147	6	.	.	PUNCT
aji-40	148	1	there	there	PRON
aji-40	148	2	are	be	VERB
aji-40	148	3	two	two	NUM
aji-40	148	4	forms	form	NOUN
aji-40	148	5	of	of	ADP
aji-40	148	6	tnf	tnf	PROPN
aji-40	148	7	-	-	PUNCT
aji-40	148	8	α	α	PROPN
aji-40	148	9	:	:	PUNCT
aji-40	148	10	transmembrane	transmembrane	PROPN
aji-40	148	11	tnf	tnf	PROPN
aji-40	148	12	-	-	PUNCT
aji-40	148	13	α	α	PROPN
aji-40	148	14	or	or	CCONJ
aji-40	148	15	membrane	membrane	NOUN
aji-40	148	16	-	-	PUNCT
aji-40	148	17	associated	associate	VERB
aji-40	148	18	tnf	tnf	PROPN
aji-40	148	19	-	-	PUNCT
aji-40	148	20	α	α	PROPN
aji-40	148	21	(	(	PUNCT
aji-40	148	22	mtnf	mtnf	PROPN
aji-40	148	23	-	-	PUNCT
aji-40	148	24	α	α	NOUN
aji-40	148	25	)	)	PUNCT
aji-40	148	26	and	and	CCONJ
aji-40	148	27	soluble	soluble	ADJ
aji-40	148	28	tnf	tnf	PROPN
aji-40	148	29	-	-	PUNCT
aji-40	148	30	α	α	PROPN
aji-40	148	31	(	(	PUNCT
aji-40	148	32	stnf	stnf	PROPN
aji-40	148	33	-	-	PUNCT
aji-40	148	34	α	α	NOUN
aji-40	148	35	)	)	PUNCT
aji-40	148	36	.	.	PUNCT
aji-40	149	1	membrane	membrane	NOUN
aji-40	149	2	-	-	PUNCT
aji-40	149	3	associated	associate	VERB
aji-40	149	4	tnf	tnf	PROPN
aji-40	149	5	-	-	PUNCT
aji-40	149	6	α	α	PROPN
aji-40	149	7	(	(	PUNCT
aji-40	149	8	mtnf	mtnf	PROPN
aji-40	149	9	-	-	PUNCT
aji-40	149	10	α	α	NOUN
aji-40	149	11	)	)	PUNCT
aji-40	149	12	is	be	AUX
aji-40	149	13	cleaved	cleave	VERB
aji-40	149	14	by	by	ADP
aji-40	149	15	metalloproteinases	metalloproteinase	NOUN
aji-40	149	16	adam-17[tnf	adam-17[tnf	PROPN
aji-40	149	17	-	-	PUNCT
aji-40	149	18	α	α	ADJ
aji-40	149	19	converting	convert	VERB
aji-40	149	20	enzyme	enzyme	NOUN
aji-40	149	21	(	(	PUNCT
aji-40	149	22	tace	tace	NOUN
aji-40	149	23	)	)	PUNCT
aji-40	149	24	]	]	PUNCT
aji-40	149	25	to	to	AUX
aji-40	149	26	soluble	soluble	VERB
aji-40	149	27	tnf	tnf	PROPN
aji-40	149	28	-	-	PUNCT
aji-40	149	29	α	α	PROPN
aji-40	149	30	[	[	X
aji-40	149	31	stnf	stnf	PROPN
aji-40	149	32	-	-	PUNCT
aji-40	149	33	α	α	PROPN
aji-40	149	34	]	]	X
aji-40	149	35	that	that	PRON
aji-40	149	36	can	can	AUX
aji-40	149	37	subsequently	subsequently	ADV
aji-40	149	38	be	be	AUX
aji-40	149	39	detected	detect	VERB
aji-40	149	40	in	in	ADP
aji-40	149	41	blood	blood	NOUN
aji-40	149	42	plasma	plasma	NOUN
aji-40	150	1	[	[	X
aji-40	150	2	4,6,11,14	4,6,11,14	X
aji-40	150	3	]	]	X
aji-40	150	4	.	.	PUNCT
aji-40	151	1	please	please	INTJ
aji-40	151	2	refer	refer	VERB
aji-40	151	3	to	to	ADP
aji-40	151	4	table	table	NOUN
aji-40	151	5	1	1	NUM
aji-40	151	6	for	for	ADP
aji-40	151	7	an	an	DET
aji-40	151	8	overview	overview	NOUN
aji-40	151	9	[	[	X
aji-40	151	10	4,6,11	4,6,11	NUM
aji-40	151	11	-	-	SYM
aji-40	151	12	14	14	NUM
aji-40	151	13	]	]	PUNCT
aji-40	151	14	.	.	PUNCT
aji-40	152	1	2.2	2.2	NUM
aji-40	152	2	tnf	tnf	PROPN
aji-40	152	3	receptors	receptor	NOUN
aji-40	152	4	tnf	tnf	PROPN
aji-40	152	5	-	-	PUNCT
aji-40	152	6	α	α	PROPN
aji-40	152	7	acts	act	VERB
aji-40	152	8	through	through	ADP
aji-40	152	9	two	two	NUM
aji-40	152	10	cell	cell	NOUN
aji-40	152	11	-	-	PUNCT
aji-40	152	12	surface	surface	NOUN
aji-40	152	13	receptors	receptor	NOUN
aji-40	152	14	tumor	tumor	NOUN
aji-40	152	15	necrosis	necrosis	NOUN
aji-40	152	16	factor	factor	NOUN
aji-40	152	17	receptor	receptor	NOUN
aji-40	152	18	1	1	NUM
aji-40	152	19	(	(	PUNCT
aji-40	152	20	tnfr1	tnfr1	NOUN
aji-40	152	21	)	)	PUNCT
aji-40	152	22	,	,	PUNCT
aji-40	152	23	also	also	ADV
aji-40	152	24	known	know	VERB
aji-40	152	25	as	as	ADP
aji-40	152	26	p55	p55	NOUN
aji-40	152	27	,	,	PUNCT
aji-40	152	28	tnfrsf1a	tnfrsf1a	NOUN
aji-40	152	29	,	,	PUNCT
aji-40	152	30	cd120a	cd120a	NOUN
aji-40	152	31	;	;	PUNCT
aji-40	152	32	and	and	CCONJ
aji-40	152	33	tumor	tumor	NOUN
aji-40	152	34	necrosis	necrosis	NOUN
aji-40	152	35	factor	factor	NOUN
aji-40	152	36	receptor	receptor	NOUN
aji-40	152	37	2	2	NUM
aji-40	152	38	(	(	PUNCT
aji-40	152	39	tnfr2	tnfr2	NOUN
aji-40	152	40	)	)	PUNCT
aji-40	152	41	also	also	ADV
aji-40	152	42	known	know	VERB
aji-40	152	43	as	as	ADP
aji-40	152	44	p75	p75	ADJ
aji-40	152	45	,	,	PUNCT
aji-40	152	46	tnfrsf1b	tnfrsf1b	PROPN
aji-40	152	47	,	,	PUNCT
aji-40	152	48	cd120b	cd120b	PROPN
aji-40	153	1	[	[	X
aji-40	153	2	15	15	NUM
aji-40	153	3	-	-	SYM
aji-40	153	4	17	17	NUM
aji-40	153	5	]	]	PUNCT
aji-40	153	6	.	.	PUNCT
aji-40	154	1	although	although	SCONJ
aji-40	154	2	both	both	DET
aji-40	154	3	tnfr1	tnfr1	NOUN
aji-40	154	4	and	and	CCONJ
aji-40	154	5	tnfr2	tnfr2	NOUN
aji-40	154	6	can	can	AUX
aji-40	154	7	bind	bind	VERB
aji-40	154	8	with	with	ADP
aji-40	154	9	the	the	DET
aji-40	154	10	soluble	soluble	ADJ
aji-40	154	11	and	and	CCONJ
aji-40	154	12	transmembrane	transmembrane	ADJ
aji-40	154	13	forms	form	NOUN
aji-40	154	14	of	of	ADP
aji-40	154	15	tnf	tnf	PROPN
aji-40	154	16	-	-	PUNCT
aji-40	154	17	α	α	PROPN
aji-40	154	18	,	,	PUNCT
aji-40	154	19	tnfr2	tnfr2	NOUN
aji-40	154	20	has	have	VERB
aji-40	154	21	high	high	ADJ
aji-40	154	22	affinity	affinity	NOUN
aji-40	154	23	for	for	ADP
aji-40	154	24	the	the	DET
aji-40	154	25	transmembrane	transmembrane	ADJ
aji-40	154	26	form	form	NOUN
aji-40	154	27	of	of	ADP
aji-40	154	28	tnf	tnf	PROPN
aji-40	154	29	-	-	PUNCT
aji-40	154	30	α	α	PROPN
aji-40	155	1	[	[	X
aji-40	155	2	16	16	NUM
aji-40	155	3	]	]	PUNCT
aji-40	155	4	.	.	PUNCT
aji-40	156	1	jonathan	jonathan	PROPN
aji-40	156	2	holbrook	holbrook	PROPN
aji-40	156	3	et	et	PROPN
aji-40	156	4	al	al	PROPN
aji-40	156	5	have	have	AUX
aji-40	156	6	described	describe	VERB
aji-40	156	7	tnf	tnf	PROPN
aji-40	156	8	-	-	PUNCT
aji-40	156	9	α	α	PROPN
aji-40	156	10	and	and	CCONJ
aji-40	156	11	tnf	tnf	PROPN
aji-40	156	12	receptors	receptor	NOUN
aji-40	156	13	in	in	ADP
aji-40	156	14	detail	detail	NOUN
aji-40	156	15	[	[	X
aji-40	156	16	14	14	NUM
aji-40	156	17	]	]	PUNCT
aji-40	156	18	.	.	PUNCT
aji-40	157	1	tnfr1	tnfr1	PROPN
aji-40	157	2	is	be	AUX
aji-40	157	3	expressed	express	VERB
aji-40	157	4	on	on	ADP
aji-40	157	5	almost	almost	ADV
aji-40	157	6	all	all	PRON
aji-40	157	7	cells	cell	NOUN
aji-40	157	8	[	[	X
aji-40	157	9	14	14	NUM
aji-40	157	10	]	]	PUNCT
aji-40	157	11	.	.	PUNCT
aji-40	158	1	it	it	PRON
aji-40	158	2	has	have	VERB
aji-40	158	3	‘	'	PUNCT
aji-40	158	4	death	death	NOUN
aji-40	158	5	domain	domain	NOUN
aji-40	158	6	or	or	CCONJ
aji-40	158	7	dd	dd	VERB
aji-40	158	8	’	'	PUNCT
aji-40	158	9	in	in	ADP
aji-40	158	10	its	its	PRON
aji-40	158	11	intracellular	intracellular	ADJ
aji-40	158	12	region	region	NOUN
aji-40	158	13	.	.	PUNCT
aji-40	159	1	when	when	SCONJ
aji-40	159	2	tnf	tnf	PROPN
aji-40	159	3	-	-	PUNCT
aji-40	159	4	α	α	PROPN
aji-40	159	5	binds	bind	VERB
aji-40	159	6	with	with	ADP
aji-40	159	7	tnfr1	tnfr1	PROPN
aji-40	159	8	,	,	PUNCT
aji-40	159	9	it	it	PRON
aji-40	159	10	leads	lead	VERB
aji-40	159	11	to	to	ADP
aji-40	159	12	recruitment	recruitment	NOUN
aji-40	159	13	of	of	ADP
aji-40	159	14	tnfr1	tnfr1	NOUN
aji-40	159	15	-	-	PUNCT
aji-40	159	16	associated	associate	VERB
aji-40	159	17	dd	dd	NOUN
aji-40	159	18	(	(	PUNCT
aji-40	159	19	tradd	tradd	NOUN
aji-40	159	20	)	)	PUNCT
aji-40	160	1	[	[	X
aji-40	160	2	14	14	NUM
aji-40	160	3	]	]	PUNCT
aji-40	160	4	.	.	PUNCT
aji-40	161	1	this	this	PRON
aji-40	161	2	triggers	trigger	VERB
aji-40	161	3	an	an	DET
aji-40	161	4	inflammatory	inflammatory	ADJ
aji-40	161	5	response	response	NOUN
aji-40	161	6	or	or	CCONJ
aji-40	161	7	cell	cell	NOUN
aji-40	161	8	survival	survival	NOUN
aji-40	161	9	response	response	NOUN
aji-40	161	10	through	through	ADP
aji-40	161	11	activation	activation	NOUN
aji-40	161	12	of	of	ADP
aji-40	161	13	nf	nf	NOUN
aji-40	161	14	-	-	PUNCT
aji-40	161	15	kb	kb	NOUN
aji-40	161	16	(	(	PUNCT
aji-40	161	17	nuclear	nuclear	ADJ
aji-40	161	18	factor	factor	NOUN
aji-40	161	19	kappa	kappa	ADJ
aji-40	161	20	-	-	ADJ
aji-40	161	21	light	light	ADJ
aji-40	161	22	-	-	PUNCT
aji-40	161	23	chain	chain	NOUN
aji-40	161	24	-	-	PUNCT
aji-40	161	25	enhancer	enhancer	NOUN
aji-40	161	26	of	of	ADP
aji-40	161	27	activated	activated	ADJ
aji-40	161	28	b	b	NOUN
aji-40	161	29	cells	cell	NOUN
aji-40	161	30	)	)	PUNCT
aji-40	161	31	,	,	PUNCT
aji-40	161	32	or	or	CCONJ
aji-40	161	33	cell	cell	NOUN
aji-40	161	34	death	death	NOUN
aji-40	161	35	response	response	NOUN
aji-40	161	36	depending	depend	VERB
aji-40	161	37	on	on	ADP
aji-40	161	38	the	the	DET
aji-40	161	39	physiological	physiological	ADJ
aji-40	161	40	state	state	NOUN
aji-40	161	41	of	of	ADP
aji-40	161	42	the	the	DET
aji-40	161	43	cell	cell	NOUN
aji-40	161	44	[	[	X
aji-40	161	45	3,14,17	3,14,17	NUM
aji-40	161	46	]	]	PUNCT
aji-40	161	47	.	.	PUNCT
aji-40	162	1	tnfr2	tnfr2	NOUN
aji-40	162	2	is	be	AUX
aji-40	162	3	expressed	express	VERB
aji-40	162	4	in	in	ADP
aji-40	162	5	immune	immune	ADJ
aji-40	162	6	cells	cell	NOUN
aji-40	162	7	[	[	X
aji-40	162	8	predominantly	predominantly	ADV
aji-40	162	9	in	in	ADP
aji-40	162	10	t	t	PROPN
aji-40	162	11	regulatory	regulatory	ADJ
aji-40	162	12	cells	cell	NOUN
aji-40	162	13	(	(	PUNCT
aji-40	162	14	tregs	treg	NOUN
aji-40	162	15	)	)	PUNCT
aji-40	162	16	]	]	PUNCT
aji-40	162	17	,	,	PUNCT
aji-40	162	18	neurons	neuron	NOUN
aji-40	162	19	and	and	CCONJ
aji-40	162	20	endothelial	endothelial	NOUN
aji-40	162	21	cells	cell	NOUN
aji-40	163	1	[	[	X
aji-40	163	2	3,14	3,14	NUM
aji-40	163	3	]	]	X
aji-40	163	4	.	.	PUNCT
aji-40	164	1	besidesleading	besidesleade	VERB
aji-40	164	2	to	to	ADP
aji-40	164	3	direct	direct	ADJ
aji-40	164	4	actions	action	NOUN
aji-40	164	5	after	after	SCONJ
aji-40	164	6	tnf	tnf	PROPN
aji-40	164	7	-	-	PUNCT
aji-40	164	8	α	α	PROPN
aji-40	164	9	binding	bind	VERB
aji-40	164	10	occurs	occur	VERB
aji-40	164	11	,	,	PUNCT
aji-40	164	12	tnfr2	tnfr2	NOUN
aji-40	164	13	may	may	AUX
aji-40	164	14	have	have	VERB
aji-40	164	15	a	a	DET
aji-40	164	16	‘	'	PUNCT
aji-40	164	17	ligandpassing	ligandpasse	VERB
aji-40	164	18	’	'	PUNCT
aji-40	164	19	role	role	NOUN
aji-40	164	20	as	as	ADV
aji-40	164	21	well	well	ADV
aji-40	164	22	:	:	PUNCT
aji-40	164	23	soluble	soluble	ADJ
aji-40	164	24	tnf	tnf	PROPN
aji-40	164	25	-	-	PUNCT
aji-40	164	26	α	α	PROPN
aji-40	164	27	may	may	AUX
aji-40	164	28	dissociate	dissociate	VERB
aji-40	164	29	from	from	ADP
aji-40	164	30	tnfr2	tnfr2	NOUN
aji-40	164	31	rapidly	rapidly	ADV
aji-40	164	32	and	and	CCONJ
aji-40	164	33	then	then	ADV
aji-40	164	34	bind	bind	VERB
aji-40	164	35	with	with	ADP
aji-40	164	36	tnfr1	tnfr1	NOUN
aji-40	165	1	[	[	X
aji-40	165	2	16,17	16,17	NUM
aji-40	165	3	]	]	PUNCT
aji-40	165	4	.	.	PUNCT
aji-40	166	1	there	there	PRON
aji-40	166	2	is	be	VERB
aji-40	166	3	no	no	DET
aji-40	166	4	death	death	NOUN
aji-40	166	5	domain	domain	NOUN
aji-40	166	6	(	(	PUNCT
aji-40	166	7	dd	dd	NOUN
aji-40	166	8	)	)	PUNCT
aji-40	166	9	in	in	ADP
aji-40	166	10	tnfr2	tnfr2	NOUN
aji-40	166	11	.	.	PUNCT
aji-40	167	1	after	after	ADP
aji-40	167	2	interacting	interact	VERB
aji-40	167	3	with	with	ADP
aji-40	167	4	tnf	tnf	PROPN
aji-40	167	5	-	-	PUNCT
aji-40	167	6	α	α	PROPN
aji-40	167	7	,	,	PUNCT
aji-40	167	8	tnfr2	tnfr2	NOUN
aji-40	167	9	binds	bind	VERB
aji-40	167	10	with	with	ADP
aji-40	167	11	the	the	DET
aji-40	167	12	proteins	protein	NOUN
aji-40	167	13	tnfr	tnfr	NOUN
aji-40	167	14	-	-	PUNCT
aji-40	167	15	associated	associate	VERB
aji-40	167	16	factors	factor	NOUN
aji-40	167	17	1	1	NUM
aji-40	167	18	and	and	CCONJ
aji-40	167	19	2	2	NUM
aji-40	167	20	(	(	PUNCT
aji-40	167	21	traf1	traf1	ADJ
aji-40	167	22	and	and	CCONJ
aji-40	167	23	traf2	traf2	NUM
aji-40	167	24	)	)	PUNCT
aji-40	167	25	activating	activate	VERB
aji-40	167	26	nf	nf	NOUN
aji-40	167	27	-	-	PUNCT
aji-40	167	28	kb	kb	PROPN
aji-40	167	29	.	.	PUNCT
aji-40	167	30	nf	nf	PROPN
aji-40	167	31	-	-	PUNCT
aji-40	167	32	kb	kb	PROPN
aji-40	167	33	then	then	ADV
aji-40	167	34	triggers	trigger	VERB
aji-40	167	35	a	a	DET
aji-40	167	36	cell	cell	NOUN
aji-40	167	37	survival	survival	NOUN
aji-40	167	38	response	response	NOUN
aji-40	167	39	including	include	VERB
aji-40	167	40	immune	immune	ADJ
aji-40	167	41	modulation	modulation	NOUN
aji-40	167	42	,	,	PUNCT
aji-40	167	43	inflammation	inflammation	NOUN
aji-40	167	44	and	and	CCONJ
aji-40	167	45	tissue	tissue	NOUN
aji-40	167	46	regeneration	regeneration	NOUN
aji-40	167	47	depending	depend	VERB
aji-40	167	48	on	on	ADP
aji-40	167	49	the	the	DET
aji-40	167	50	conditions	condition	NOUN
aji-40	167	51	[	[	X
aji-40	167	52	3,14,17	3,14,17	NUM
aji-40	167	53	]	]	PUNCT
aji-40	167	54	.	.	PUNCT
aji-40	168	1	tnfr2	tnfr2	NOUN
aji-40	168	2	has	have	VERB
aji-40	168	3	an	an	DET
aji-40	168	4	important	important	ADJ
aji-40	168	5	role	role	NOUN
aji-40	168	6	in	in	ADP
aji-40	168	7	pancreatic	pancreatic	ADJ
aji-40	168	8	regeneration	regeneration	NOUN
aji-40	168	9	,	,	PUNCT
aji-40	168	10	protection	protection	NOUN
aji-40	168	11	of	of	ADP
aji-40	168	12	cardiomyocytes	cardiomyocyte	NOUN
aji-40	168	13	,	,	PUNCT
aji-40	168	14	remyelination	remyelination	NOUN
aji-40	168	15	,	,	PUNCT
aji-40	168	16	survival	survival	NOUN
aji-40	168	17	of	of	ADP
aji-40	168	18	some	some	DET
aji-40	168	19	neuronal	neuronal	ADJ
aji-40	168	20	cells	cell	NOUN
aji-40	168	21	and	and	CCONJ
aji-40	168	22	in	in	ADP
aji-40	168	23	stem	stem	NOUN
aji-40	168	24	cell	cell	NOUN
aji-40	168	25	proliferation	proliferation	NOUN
aji-40	168	26	too	too	ADV
aji-40	169	1	[	[	X
aji-40	169	2	3	3	NUM
aji-40	169	3	]	]	PUNCT
aji-40	169	4	.	.	PUNCT
aji-40	170	1	since	since	SCONJ
aji-40	170	2	tnfr2	tnfr2	NOUN
aji-40	170	3	does	do	AUX
aji-40	170	4	not	not	PART
aji-40	170	5	bind	bind	VERB
aji-40	170	6	with	with	ADP
aji-40	170	7	tradd	tradd	NOUN
aji-40	170	8	,	,	PUNCT
aji-40	170	9	it	it	PRON
aji-40	170	10	does	do	AUX
aji-40	170	11	not	not	PART
aji-40	170	12	lead	lead	VERB
aji-40	170	13	to	to	ADP
aji-40	170	14	cell	cell	NOUN
aji-40	170	15	death	death	NOUN
aji-40	170	16	response	response	NOUN
aji-40	170	17	.	.	PUNCT
aji-40	171	1	please	please	INTJ
aji-40	171	2	refer	refer	VERB
aji-40	171	3	to	to	ADP
aji-40	171	4	fig	fig	NOUN
aji-40	171	5	.	.	PUNCT
aji-40	172	1	1	1	X
aji-40	172	2	.	.	X
aji-40	172	3	please	please	INTJ
aji-40	172	4	note	note	VERB
aji-40	172	5	that	that	SCONJ
aji-40	172	6	the	the	DET
aji-40	172	7	figure	figure	NOUN
aji-40	172	8	is	be	AUX
aji-40	172	9	symbolic	symbolic	ADJ
aji-40	172	10	for	for	ADP
aji-40	172	11	easy	easy	ADJ
aji-40	172	12	understanding	understanding	NOUN
aji-40	172	13	.	.	PUNCT
aji-40	173	1	it	it	PRON
aji-40	173	2	is	be	AUX
aji-40	173	3	not	not	PART
aji-40	173	4	representative	representative	ADJ
aji-40	173	5	of	of	ADP
aji-40	173	6	true	true	ADJ
aji-40	173	7	molecular	molecular	ADJ
aji-40	173	8	structure	structure	NOUN
aji-40	173	9	of	of	ADP
aji-40	173	10	tnf	tnf	PROPN
aji-40	173	11	or	or	CCONJ
aji-40	173	12	its	its	PRON
aji-40	173	13	receptors	receptor	NOUN
aji-40	173	14	.	.	PUNCT
aji-40	174	1	3	3	X
aji-40	174	2	.	.	X
aji-40	174	3	tnf	tnf	PROPN
aji-40	174	4	-	-	PUNCT
aji-40	174	5	α	α	PROPN
aji-40	174	6	polymorphism	polymorphism	NOUN
aji-40	174	7	and	and	CCONJ
aji-40	174	8	diseases	disease	NOUN
aji-40	174	9	tnf	tnf	PROPN
aji-40	174	10	-	-	PUNCT
aji-40	174	11	α	α	PROPN
aji-40	174	12	polymorphisms	polymorphism	NOUN
aji-40	174	13	may	may	AUX
aji-40	174	14	have	have	VERB
aji-40	174	15	an	an	DET
aji-40	174	16	influence	influence	NOUN
aji-40	174	17	on	on	ADP
aji-40	174	18	susceptibility	susceptibility	NOUN
aji-40	174	19	of	of	ADP
aji-40	174	20	diseases	disease	NOUN
aji-40	174	21	.	.	PUNCT
aji-40	175	1	a	a	DET
aji-40	175	2	few	few	ADJ
aji-40	175	3	examples	example	NOUN
aji-40	175	4	are	be	AUX
aji-40	175	5	given	give	VERB
aji-40	175	6	below	below	ADV
aji-40	175	7	.	.	PUNCT
aji-40	176	1	3.1	3.1	NUM
aji-40	176	2	rheumatoid	rheumatoid	NOUN
aji-40	176	3	arthritis	arthritis	NOUN
aji-40	176	4	role	role	NOUN
aji-40	176	5	of	of	ADP
aji-40	176	6	tnf	tnf	PROPN
aji-40	176	7	-	-	PUNCT
aji-40	176	8	α	α	PROPN
aji-40	176	9	-308g	-308g	NOUN
aji-40	176	10	/	/	SYM
aji-40	176	11	a	a	DET
aji-40	176	12	polymorphism	polymorphism	NOUN
aji-40	176	13	and	and	CCONJ
aji-40	176	14	differential	differential	ADJ
aji-40	176	15	expression	expression	NOUN
aji-40	176	16	of	of	ADP
aji-40	176	17	tnf	tnf	PROPN
aji-40	176	18	-	-	PUNCT
aji-40	176	19	α	α	PROPN
aji-40	176	20	in	in	ADP
aji-40	176	21	pathogenesis	pathogenesis	NOUN
aji-40	176	22	table	table	NOUN
aji-40	176	23	1	1	NUM
aji-40	176	24	.	.	PUNCT
aji-40	177	1	the	the	DET
aji-40	177	2	two	two	NUM
aji-40	177	3	forms	form	NOUN
aji-40	177	4	of	of	ADP
aji-40	177	5	tnf	tnf	PROPN
aji-40	177	6	-	-	PUNCT
aji-40	177	7	α	α	PROPN
aji-40	177	8	soluble	soluble	ADJ
aji-40	177	9	tnf	tnf	PROPN
aji-40	177	10	-	-	PUNCT
aji-40	177	11	α	α	PROPN
aji-40	177	12	transmembrane	transmembrane	PROPN
aji-40	177	13	tnf	tnf	PROPN
aji-40	177	14	-	-	PUNCT
aji-40	177	15	α	α	PROPN
aji-40	177	16	amino	amino	ADJ
aji-40	177	17	acids	acid	NOUN
aji-40	177	18	157	157	NUM
aji-40	177	19	amino	amino	NOUN
aji-40	177	20	acid	acid	NOUN
aji-40	177	21	residues	residue	NOUN
aji-40	177	22	233	233	NUM
aji-40	177	23	amino	amino	NOUN
aji-40	177	24	acid	acid	NOUN
aji-40	177	25	residues	residue	NOUN
aji-40	177	26	molecular	molecular	ADJ
aji-40	177	27	weight	weight	NOUN
aji-40	177	28	17	17	NUM
aji-40	177	29	kda	kda	NOUN
aji-40	177	30	26	26	NUM
aji-40	177	31	kda	kda	NOUN
aji-40	177	32	receptor	receptor	NOUN
aji-40	177	33	interaction	interaction	NOUN
aji-40	177	34	attaches	attach	VERB
aji-40	177	35	to	to	PART
aji-40	177	36	type	type	VERB
aji-40	177	37	1	1	NUM
aji-40	177	38	and	and	CCONJ
aji-40	177	39	type	type	NOUN
aji-40	177	40	2	2	NUM
aji-40	177	41	tnf	tnf	NOUN
aji-40	177	42	receptors	receptor	NOUN
aji-40	177	43	(	(	PUNCT
aji-40	177	44	tnf	tnf	PROPN
aji-40	177	45	-	-	PUNCT
aji-40	177	46	r1	r1	PROPN
aji-40	177	47	and	and	CCONJ
aji-40	177	48	tnf	tnf	PROPN
aji-40	177	49	-	-	PUNCT
aji-40	177	50	r2	r2	PROPN
aji-40	177	51	)	)	PUNCT
aji-40	177	52	;	;	PUNCT
aji-40	177	53	cellular	cellular	ADJ
aji-40	177	54	actions	action	NOUN
aji-40	177	55	mainly	mainly	ADV
aji-40	177	56	mediated	mediate	VERB
aji-40	177	57	through	through	ADP
aji-40	177	58	tnf	tnf	PROPN
aji-40	177	59	-	-	PUNCT
aji-40	177	60	r1	r1	PROPN
aji-40	177	61	.	.	PUNCT
aji-40	178	1	attaches	attach	VERB
aji-40	178	2	to	to	ADP
aji-40	178	3	tnf	tnf	PROPN
aji-40	178	4	-	-	PUNCT
aji-40	178	5	r1	r1	PROPN
aji-40	178	6	and	and	CCONJ
aji-40	178	7	tnf	tnf	PROPN
aji-40	178	8	-	-	PUNCT
aji-40	178	9	r2	r2	PROPN
aji-40	178	10	;	;	PUNCT
aji-40	178	11	actions	action	NOUN
aji-40	178	12	mainly	mainly	ADV
aji-40	178	13	mediated	mediate	VERB
aji-40	178	14	through	through	ADP
aji-40	178	15	tnf	tnf	PROPN
aji-40	178	16	-	-	PUNCT
aji-40	178	17	r2	r2	PROPN
aji-40	178	18	.	.	PUNCT
aji-40	179	1	sites	site	NOUN
aji-40	179	2	of	of	ADP
aji-40	179	3	action	action	NOUN
aji-40	179	4	acts	act	VERB
aji-40	179	5	at	at	ADP
aji-40	179	6	sites	site	NOUN
aji-40	179	7	distant	distant	ADJ
aji-40	179	8	from	from	ADP
aji-40	179	9	tnf	tnf	PROPN
aji-40	179	10	-	-	PUNCT
aji-40	179	11	α	α	NOUN
aji-40	179	12	producing	produce	VERB
aji-40	179	13	cells	cell	NOUN
aji-40	179	14	.	.	PUNCT
aji-40	180	1	acts	act	NOUN
aji-40	180	2	locally	locally	ADV
aji-40	180	3	churchill	churchill	PROPN
aji-40	180	4	et	et	PROPN
aji-40	180	5	al	al	PROPN
aji-40	180	6	.	.	PROPN
aji-40	180	7	;	;	PUNCT
aji-40	181	1	aji	aji	PROPN
aji-40	181	2	,	,	PUNCT
aji-40	181	3	3(1	3(1	NUM
aji-40	181	4	):	):	PUNCT
aji-40	181	5	208	208	NUM
aji-40	181	6	-	-	SYM
aji-40	181	7	222	222	NUM
aji-40	181	8	,	,	PUNCT
aji-40	181	9	2020	2020	NUM
aji-40	181	10	;	;	PUNCT
aji-40	181	11	article	article	NOUN
aji-40	181	12	no.aji.57464	no.aji.57464	ADP
aji-40	181	13	211	211	NUM
aji-40	181	14	fig	fig	NOUN
aji-40	181	15	.	.	PUNCT
aji-40	182	1	1	1	X
aji-40	182	2	.	.	X
aji-40	182	3	an	an	DET
aji-40	182	4	overview	overview	NOUN
aji-40	182	5	of	of	ADP
aji-40	182	6	tnf	tnf	PROPN
aji-40	182	7	-	-	PUNCT
aji-40	182	8	α	α	PROPN
aji-40	182	9	signaling	signal	VERB
aji-40	182	10	pathway	pathway	NOUN
aji-40	182	11	of	of	ADP
aji-40	182	12	rheumatoid	rheumatoid	NOUN
aji-40	182	13	arthritis	arthritis	NOUN
aji-40	182	14	was	be	AUX
aji-40	182	15	evaluated	evaluate	VERB
aji-40	182	16	by	by	ADP
aji-40	182	17	somdatta	somdatta	NOUN
aji-40	182	18	das	das	PROPN
aji-40	182	19	,	,	PUNCT
aji-40	182	20	et	et	PROPN
aji-40	182	21	al	al	PROPN
aji-40	182	22	.	.	PUNCT
aji-40	183	1	[	[	X
aji-40	183	2	18	18	NUM
aji-40	183	3	]	]	PUNCT
aji-40	183	4	.	.	PUNCT
aji-40	184	1	they	they	PRON
aji-40	184	2	conducted	conduct	VERB
aji-40	184	3	a	a	DET
aji-40	184	4	case	case	NOUN
aji-40	184	5	-	-	PUNCT
aji-40	184	6	control	control	NOUN
aji-40	184	7	study	study	NOUN
aji-40	184	8	,	,	PUNCT
aji-40	184	9	including	include	VERB
aji-40	184	10	126	126	NUM
aji-40	184	11	rheumatoid	rheumatoid	NOUN
aji-40	184	12	arthritis	arthritis	NOUN
aji-40	184	13	patients	patient	NOUN
aji-40	184	14	and160	and160	PROPN
aji-40	184	15	community	community	NOUN
aji-40	184	16	matched	match	VERB
aji-40	184	17	age	age	NOUN
aji-40	184	18	and	and	CCONJ
aji-40	184	19	sex	sex	NOUN
aji-40	184	20	controls	control	NOUN
aji-40	184	21	.	.	PUNCT
aji-40	185	1	the	the	DET
aji-40	185	2	study	study	NOUN
aji-40	185	3	duration	duration	NOUN
aji-40	185	4	was	be	AUX
aji-40	185	5	3	3	NUM
aji-40	185	6	years	year	NOUN
aji-40	185	7	.	.	PUNCT
aji-40	186	1	they	they	PRON
aji-40	186	2	found	find	VERB
aji-40	186	3	that	that	DET
aji-40	186	4	presence	presence	NOUN
aji-40	186	5	of	of	ADP
aji-40	186	6	tnf	tnf	PROPN
aji-40	186	7	-	-	PUNCT
aji-40	186	8	α	α	PROPN
aji-40	186	9	-308a	-308a	PROPN
aji-40	186	10	allele	allele	NOUN
aji-40	186	11	and	and	CCONJ
aji-40	186	12	differential	differential	PROPN
aji-40	186	13	tnf	tnf	PROPN
aji-40	186	14	-	-	PUNCT
aji-40	186	15	α	α	NOUN
aji-40	186	16	expression	expression	NOUN
aji-40	186	17	are	be	AUX
aji-40	186	18	associated	associate	VERB
aji-40	186	19	with	with	ADP
aji-40	186	20	increased	increase	VERB
aji-40	186	21	risk	risk	NOUN
aji-40	186	22	susceptibility	susceptibility	NOUN
aji-40	186	23	for	for	ADP
aji-40	186	24	rheumatoid	rheumatoid	NOUN
aji-40	186	25	arthritis	arthritis	NOUN
aji-40	186	26	[	[	X
aji-40	186	27	18	18	NUM
aji-40	186	28	]	]	PUNCT
aji-40	186	29	.	.	PUNCT
aji-40	187	1	this	this	DET
aji-40	187	2	study	study	NOUN
aji-40	187	3	suggests	suggest	VERB
aji-40	187	4	that	that	SCONJ
aji-40	187	5	polymorphism	polymorphism	NOUN
aji-40	187	6	of	of	ADP
aji-40	187	7	tnf	tnf	PROPN
aji-40	187	8	-	-	PUNCT
aji-40	187	9	α	α	PROPN
aji-40	187	10	has	have	VERB
aji-40	187	11	a	a	DET
aji-40	187	12	role	role	NOUN
aji-40	187	13	in	in	ADP
aji-40	187	14	pathogenesis	pathogenesis	NOUN
aji-40	187	15	of	of	ADP
aji-40	187	16	rheumatoid	rheumatoid	NOUN
aji-40	187	17	arthritis	arthritis	NOUN
aji-40	187	18	.	.	PUNCT
aji-40	188	1	3.2	3.2	NUM
aji-40	188	2	systemic	systemic	ADJ
aji-40	188	3	lupus	lupus	PROPN
aji-40	188	4	erythematosus	erythematosus	PROPN
aji-40	188	5	y	y	PROPN
aji-40	188	6	-	-	PROPN
aji-40	188	7	j	j	PROPN
aji-40	188	8	lin	lin	PROPN
aji-40	188	9	,	,	PUNCT
aji-40	188	10	et	et	PROPN
aji-40	188	11	al	al	PROPN
aji-40	188	12	investigated	investigate	VERB
aji-40	188	13	the	the	DET
aji-40	188	14	association	association	NOUN
aji-40	188	15	of	of	ADP
aji-40	188	16	tnfalpha	tnfalpha	ADJ
aji-40	188	17	genetic	genetic	ADJ
aji-40	188	18	polymorphisms	polymorphism	NOUN
aji-40	188	19	(	(	PUNCT
aji-40	188	20	-1031t	-1031t	NOUN
aji-40	188	21	/	/	SYM
aji-40	188	22	c	c	NOUN
aji-40	188	23	,	,	PUNCT
aji-40	188	24	863c	863c	PROPN
aji-40	188	25	/	/	SYM
aji-40	188	26	a	a	PRON
aji-40	188	27	,	,	PUNCT
aji-40	188	28	-857t	-857t	PROPN
aji-40	188	29	/	/	SYM
aji-40	188	30	c	c	PROPN
aji-40	188	31	,	,	PUNCT
aji-40	188	32	-308a	-308a	PROPN
aji-40	188	33	/	/	SYM
aji-40	188	34	g	g	PROPN
aji-40	188	35	and	and	CCONJ
aji-40	188	36	+489a	+489a	PROPN
aji-40	188	37	/	/	SYM
aji-40	188	38	g	g	NOUN
aji-40	188	39	)	)	PUNCT
aji-40	188	40	in	in	ADP
aji-40	188	41	sle	sle	PROPN
aji-40	188	42	patients	patient	NOUN
aji-40	188	43	and	and	CCONJ
aji-40	188	44	controls	control	NOUN
aji-40	188	45	in	in	ADP
aji-40	188	46	taiwanese	taiwanese	ADJ
aji-40	188	47	population	population	NOUN
aji-40	188	48	[	[	X
aji-40	188	49	19	19	NUM
aji-40	188	50	]	]	PUNCT
aji-40	188	51	.	.	PUNCT
aji-40	189	1	their	their	PRON
aji-40	189	2	observations	observation	NOUN
aji-40	189	3	included	include	VERB
aji-40	189	4	[	[	X
aji-40	189	5	19	19	NUM
aji-40	189	6	]	]	NUM
aji-40	189	7	:	:	PUNCT
aji-40	189	8			X
aji-40	189	9	the	the	DET
aji-40	189	10	frequency	frequency	NOUN
aji-40	189	11	of	of	ADP
aji-40	189	12	the	the	DET
aji-40	189	13	polymorphisms	polymorphism	NOUN
aji-40	189	14	at	at	ADP
aji-40	189	15	1031	1031	NUM
aji-40	189	16	and	and	CCONJ
aji-40	189	17	-857	-857	PROPN
aji-40	189	18	were	be	AUX
aji-40	189	19	significantly	significantly	ADV
aji-40	189	20	different	different	ADJ
aji-40	189	21	in	in	ADP
aji-40	189	22	patients	patient	NOUN
aji-40	189	23	with	with	ADP
aji-40	189	24	antinuclear	antinuclear	ADJ
aji-40	189	25	antibodies	antibody	NOUN
aji-40	189	26	and	and	CCONJ
aji-40	189	27	hematological	hematological	ADJ
aji-40	189	28	disorders	disorder	NOUN
aji-40	189	29	respectively	respectively	ADV
aji-40	189	30	.	.	PUNCT
aji-40	189	31			PUNCT
aji-40	190	1	the	the	DET
aji-40	190	2	frequency	frequency	NOUN
aji-40	190	3	of	of	ADP
aji-40	190	4	a	a	DET
aji-40	190	5	allele	allele	NOUN
aji-40	190	6	of	of	ADP
aji-40	190	7	the	the	DET
aji-40	190	8	polymorphisms	polymorphism	NOUN
aji-40	190	9	at	at	ADP
aji-40	190	10	-308	-308	PROPN
aji-40	190	11	was	be	AUX
aji-40	190	12	significantly	significantly	ADV
aji-40	190	13	increased	increase	VERB
aji-40	190	14	in	in	ADP
aji-40	190	15	patients	patient	NOUN
aji-40	190	16	with	with	ADP
aji-40	190	17	malar	malar	ADJ
aji-40	190	18	rash	rash	NOUN
aji-40	190	19	,	,	PUNCT
aji-40	190	20	discoid	discoid	NOUN
aji-40	190	21	rash	rash	NOUN
aji-40	190	22	,	,	PUNCT
aji-40	190	23	photosensitivity	photosensitivity	NOUN
aji-40	190	24	,	,	PUNCT
aji-40	190	25	oral	oral	ADJ
aji-40	190	26	ulcers	ulcer	NOUN
aji-40	190	27	and	and	CCONJ
aji-40	190	28	serositis	serositis	NOUN
aji-40	190	29	.	.	PUNCT
aji-40	191	1			X
aji-40	192	1	the	the	DET
aji-40	192	2	frequency	frequency	NOUN
aji-40	192	3	of	of	ADP
aji-40	192	4	the	the	DET
aji-40	192	5	polymorphisms	polymorphism	NOUN
aji-40	192	6	at	at	ADP
aji-40	192	7	+489	+489	ADV
aji-40	192	8	was	be	AUX
aji-40	192	9	significantly	significantly	ADV
aji-40	192	10	different	different	ADJ
aji-40	192	11	in	in	ADP
aji-40	192	12	patients	patient	NOUN
aji-40	192	13	with	with	ADP
aji-40	192	14	discoid	discoid	ADJ
aji-40	192	15	rash	rash	NOUN
aji-40	192	16	and	and	CCONJ
aji-40	192	17	photosensitivity	photosensitivity	NOUN
aji-40	192	18	.	.	PUNCT
aji-40	193	1	churchill	churchill	PROPN
aji-40	193	2	et	et	PROPN
aji-40	193	3	al	al	PROPN
aji-40	193	4	.	.	PROPN
aji-40	193	5	;	;	PUNCT
aji-40	193	6	aji	aji	PROPN
aji-40	193	7	,	,	PUNCT
aji-40	193	8	3(1	3(1	NUM
aji-40	193	9	):	):	PUNCT
aji-40	193	10	208	208	NUM
aji-40	193	11	-	-	SYM
aji-40	193	12	222	222	NUM
aji-40	193	13	,	,	PUNCT
aji-40	193	14	2020	2020	NUM
aji-40	193	15	;	;	PUNCT
aji-40	193	16	article	article	NOUN
aji-40	193	17	no.aji.57464	no.aji.57464	ADP
aji-40	193	18	212	212	NUM
aji-40	193	19	julian	julian	PROPN
aji-40	193	20	ramírez	ramírez	PROPN
aji-40	193	21	-	-	PUNCT
aji-40	193	22	bello	bello	PROPN
aji-40	193	23	,	,	PUNCT
aji-40	193	24	et	et	PROPN
aji-40	193	25	al	al	PROPN
aji-40	193	26	investigated	investigate	VERB
aji-40	193	27	whether	whether	SCONJ
aji-40	193	28	the	the	DET
aji-40	193	29	tnf	tnf	PROPN
aji-40	193	30	-238g	-238g	PROPN
aji-40	193	31	/	/	SYM
aji-40	193	32	a	a	DET
aji-40	193	33	,	,	PUNCT
aji-40	193	34	-308g	-308g	PROPN
aji-40	193	35	/	/	SYM
aji-40	193	36	a	a	NOUN
aji-40	193	37	,	,	PUNCT
aji-40	193	38	-376g	-376g	ADP
aji-40	193	39	/	/	SYM
aji-40	193	40	a	a	PRON
aji-40	193	41	(	(	PUNCT
aji-40	193	42	rs1800750	rs1800750	NOUN
aji-40	193	43	)	)	PUNCT
aji-40	193	44	,	,	PUNCT
aji-40	193	45	and	and	CCONJ
aji-40	193	46	-1031t	-1031t	PROPN
aji-40	193	47	/	/	SYM
aji-40	193	48	c	c	PROPN
aji-40	193	49	(	(	PUNCT
aji-40	193	50	rs1799964	rs1799964	PROPN
aji-40	193	51	)	)	PUNCT
aji-40	193	52	polymorphisms	polymorphism	NOUN
aji-40	193	53	are	be	AUX
aji-40	193	54	associated	associate	VERB
aji-40	193	55	with	with	ADP
aji-40	193	56	sle	sle	PROPN
aji-40	193	57	or	or	CCONJ
aji-40	193	58	lupus	lupus	ADJ
aji-40	193	59	nephritis	nephritis	NOUN
aji-40	193	60	susceptibility	susceptibility	NOUN
aji-40	193	61	in	in	ADP
aji-40	193	62	a	a	DET
aji-40	193	63	mexican	mexican	ADJ
aji-40	193	64	population	population	NOUN
aji-40	194	1	[	[	X
aji-40	194	2	20	20	NUM
aji-40	194	3	]	]	PUNCT
aji-40	194	4	.	.	PUNCT
aji-40	195	1	the	the	DET
aji-40	195	2	study	study	NOUN
aji-40	195	3	included	include	VERB
aji-40	195	4	442	442	NUM
aji-40	195	5	patients	patient	NOUN
aji-40	195	6	with	with	ADP
aji-40	195	7	sle	sle	PROPN
aji-40	195	8	and	and	CCONJ
aji-40	195	9	495	495	NUM
aji-40	195	10	controls	control	NOUN
aji-40	195	11	.	.	PUNCT
aji-40	196	1	the	the	DET
aji-40	196	2	investigators	investigator	NOUN
aji-40	196	3	found	find	VERB
aji-40	196	4	that	that	SCONJ
aji-40	196	5	tnf	tnf	PROPN
aji-40	196	6	-238g	-238g	PROPN
aji-40	196	7	/	/	SYM
aji-40	196	8	a	a	PRON
aji-40	196	9	and	and	CCONJ
aji-40	196	10	-1031t	-1031t	NOUN
aji-40	196	11	/	/	SYM
aji-40	196	12	c	c	NOUN
aji-40	196	13	polymorphisms	polymorphism	NOUN
aji-40	196	14	were	be	AUX
aji-40	196	15	associated	associate	VERB
aji-40	196	16	with	with	ADP
aji-40	196	17	sle	sle	PROPN
aji-40	196	18	susceptibility	susceptibility	NOUN
aji-40	196	19	[	[	X
aji-40	196	20	20	20	NUM
aji-40	196	21	]	]	PUNCT
aji-40	196	22	.	.	PUNCT
aji-40	197	1	these	these	DET
aji-40	197	2	observations	observation	NOUN
aji-40	197	3	of	of	ADP
aji-40	197	4	different	different	ADJ
aji-40	197	5	investigators	investigator	NOUN
aji-40	197	6	suggest	suggest	VERB
aji-40	197	7	that	that	SCONJ
aji-40	197	8	tnf	tnf	PROPN
aji-40	197	9	-	-	PUNCT
aji-40	197	10	alpha	alpha	NOUN
aji-40	197	11	genetic	genetic	ADJ
aji-40	197	12	polymorphisms	polymorphism	NOUN
aji-40	197	13	contribute	contribute	VERB
aji-40	197	14	to	to	ADP
aji-40	197	15	increased	increase	VERB
aji-40	197	16	sle	sle	PROPN
aji-40	197	17	susceptibility	susceptibility	NOUN
aji-40	197	18	.	.	PUNCT
aji-40	198	1	3.3	3.3	NUM
aji-40	198	2	crohn	crohn	PROPN
aji-40	198	3	’s	’s	PART
aji-40	198	4	disease	disease	NOUN
aji-40	198	5	genoile	genoile	VERB
aji-40	198	6	santana	santana	PROPN
aji-40	198	7	,	,	PUNCT
aji-40	198	8	et	et	PROPN
aji-40	198	9	al	al	PROPN
aji-40	198	10	conducted	conduct	VERB
aji-40	198	11	a	a	DET
aji-40	198	12	case	case	NOUN
aji-40	198	13	-	-	PUNCT
aji-40	198	14	control	control	NOUN
aji-40	198	15	and	and	CCONJ
aji-40	198	16	cross	cross	ADJ
aji-40	198	17	-	-	ADJ
aji-40	198	18	sectional	sectional	ADJ
aji-40	198	19	study	study	NOUN
aji-40	198	20	to	to	PART
aji-40	198	21	analyze	analyze	VERB
aji-40	198	22	whether	whether	SCONJ
aji-40	198	23	tnf	tnf	PROPN
aji-40	198	24	-	-	PUNCT
aji-40	198	25	α	α	NOUN
aji-40	198	26	-308	-308	NOUN
aji-40	198	27	polymorphism	polymorphism	NOUN
aji-40	198	28	is	be	AUX
aji-40	198	29	associated	associate	VERB
aji-40	198	30	with	with	ADP
aji-40	198	31	crohn	crohn	PROPN
aji-40	198	32	's	's	PART
aji-40	198	33	disease	disease	NOUN
aji-40	198	34	and	and	CCONJ
aji-40	198	35	its	its	PRON
aji-40	198	36	clinical	clinical	ADJ
aji-40	198	37	features	feature	NOUN
aji-40	198	38	[	[	X
aji-40	198	39	21	21	NUM
aji-40	198	40	]	]	PUNCT
aji-40	198	41	.	.	PUNCT
aji-40	199	1	they	they	PRON
aji-40	199	2	enrolled	enrol	VERB
aji-40	199	3	91	91	NUM
aji-40	199	4	patients	patient	NOUN
aji-40	199	5	with	with	ADP
aji-40	199	6	crohn	crohn	PROPN
aji-40	199	7	's	's	PART
aji-40	199	8	disease	disease	NOUN
aji-40	199	9	and	and	CCONJ
aji-40	199	10	91	91	NUM
aji-40	199	11	controls	control	NOUN
aji-40	199	12	(	(	PUNCT
aji-40	199	13	either	either	CCONJ
aji-40	199	14	with	with	ADP
aji-40	199	15	gastroesophageal	gastroesophageal	NOUN
aji-40	199	16	reflux	reflux	NOUN
aji-40	199	17	disease	disease	NOUN
aji-40	199	18	or	or	CCONJ
aji-40	199	19	functional	functional	ADJ
aji-40	199	20	dyspepsia	dyspepsia	NOUN
aji-40	199	21	)	)	PUNCT
aji-40	199	22	in	in	ADP
aji-40	199	23	salvador	salvador	PROPN
aji-40	199	24	[	[	X
aji-40	199	25	21	21	NUM
aji-40	199	26	]	]	PUNCT
aji-40	199	27	.	.	PUNCT
aji-40	200	1	the	the	DET
aji-40	200	2	investigators	investigator	NOUN
aji-40	200	3	observed	observe	VERB
aji-40	200	4	that	that	SCONJ
aji-40	200	5	high	high	ADJ
aji-40	200	6	tnf	tnf	PROPN
aji-40	200	7	-	-	PUNCT
aji-40	200	8	α	α	NOUN
aji-40	200	9	producing	produce	VERB
aji-40	200	10	predicted	predict	VERB
aji-40	200	11	phenotype	phenotype	NOUN
aji-40	200	12	was	be	AUX
aji-40	200	13	associated	associate	VERB
aji-40	200	14	with	with	ADP
aji-40	200	15	the	the	DET
aji-40	200	16	penetrating	penetrate	VERB
aji-40	200	17	form	form	NOUN
aji-40	200	18	of	of	ADP
aji-40	200	19	crohn	crohn	PROPN
aji-40	200	20	’s	’s	PART
aji-40	200	21	disease	disease	NOUN
aji-40	200	22	and	and	CCONJ
aji-40	200	23	colectomy	colectomy	NOUN
aji-40	200	24	.	.	PUNCT
aji-40	201	1	they	they	PRON
aji-40	201	2	found	find	VERB
aji-40	201	3	that	that	SCONJ
aji-40	201	4	the	the	DET
aji-40	201	5	tnf	tnf	PROPN
aji-40	201	6	-	-	PUNCT
aji-40	201	7	α	α	NOUN
aji-40	201	8	-308	-308	NOUN
aji-40	201	9	polymorphism	polymorphism	NOUN
aji-40	201	10	was	be	AUX
aji-40	201	11	not	not	PART
aji-40	201	12	associated	associate	VERB
aji-40	201	13	with	with	ADP
aji-40	201	14	the	the	DET
aji-40	201	15	perianal	perianal	ADJ
aji-40	201	16	disease	disease	NOUN
aji-40	201	17	[	[	X
aji-40	201	18	21	21	NUM
aji-40	201	19	]	]	PUNCT
aji-40	201	20	.	.	PUNCT
aji-40	202	1	4	4	X
aji-40	202	2	.	.	X
aji-40	202	3	tnfr1	tnfr1	NOUN
aji-40	202	4	gene	gene	NOUN
aji-40	202	5	polymorphism	polymorphism	NOUN
aji-40	202	6	and	and	CCONJ
aji-40	202	7	diseases	disease	NOUN
aji-40	202	8	4.1	4.1	NUM
aji-40	202	9	tumor	tumor	NOUN
aji-40	202	10	necrosis	necrosis	NOUN
aji-40	202	11	factor	factor	NOUN
aji-40	202	12	receptorassociated	receptorassociate	VERB
aji-40	202	13	periodic	periodic	ADJ
aji-40	202	14	syndrome	syndrome	NOUN
aji-40	202	15	(	(	PUNCT
aji-40	202	16	traps	trap	NOUN
aji-40	202	17	)	)	PUNCT
aji-40	202	18	missense	missense	NOUN
aji-40	202	19	mutations	mutation	NOUN
aji-40	202	20	of	of	ADP
aji-40	202	21	tnfr1	tnfr1	NOUN
aji-40	202	22	gene	gene	NOUN
aji-40	202	23	results	result	NOUN
aji-40	202	24	in	in	ADP
aji-40	202	25	development	development	NOUN
aji-40	202	26	of	of	ADP
aji-40	202	27	tumor	tumor	NOUN
aji-40	202	28	necrosis	necrosis	NOUN
aji-40	202	29	factor	factor	NOUN
aji-40	202	30	receptorassociated	receptorassociate	VERB
aji-40	202	31	periodic	periodic	ADJ
aji-40	202	32	syndrome	syndrome	NOUN
aji-40	202	33	(	(	PUNCT
aji-40	202	34	traps	trap	NOUN
aji-40	202	35	)	)	PUNCT
aji-40	202	36	,	,	PUNCT
aji-40	202	37	an	an	DET
aji-40	202	38	autosomal	autosomal	ADJ
aji-40	202	39	dominant	dominant	ADJ
aji-40	202	40	disease	disease	NOUN
aji-40	202	41	[	[	X
aji-40	202	42	22	22	NUM
aji-40	202	43	]	]	PUNCT
aji-40	202	44	.	.	PUNCT
aji-40	203	1	the	the	DET
aji-40	203	2	gene	gene	NOUN
aji-40	203	3	mutation	mutation	NOUN
aji-40	203	4	results	result	VERB
aji-40	203	5	in	in	ADP
aji-40	203	6	structural	structural	ADJ
aji-40	203	7	alteration	alteration	NOUN
aji-40	203	8	of	of	ADP
aji-40	203	9	tnfr1	tnfr1	NOUN
aji-40	203	10	receptor	receptor	NOUN
aji-40	203	11	rendering	render	VERB
aji-40	203	12	it	it	PRON
aji-40	203	13	nonfunctional	nonfunctional	ADJ
aji-40	203	14	and	and	CCONJ
aji-40	203	15	its	its	PRON
aji-40	203	16	retention	retention	NOUN
aji-40	203	17	in	in	ADP
aji-40	203	18	endoplasmic	endoplasmic	ADJ
aji-40	203	19	reticulum	reticulum	NOUN
aji-40	203	20	[	[	X
aji-40	203	21	23	23	NUM
aji-40	203	22	]	]	PUNCT
aji-40	203	23	.	.	PUNCT
aji-40	204	1	the	the	DET
aji-40	204	2	disease	disease	NOUN
aji-40	204	3	is	be	AUX
aji-40	204	4	associated	associate	VERB
aji-40	204	5	with	with	ADP
aji-40	204	6	unprovoked	unprovoked	ADJ
aji-40	204	7	prolonged	prolonged	ADJ
aji-40	204	8	periodic	periodic	ADJ
aji-40	204	9	or	or	CCONJ
aji-40	204	10	episodic	episodic	ADJ
aji-40	204	11	fever	fever	NOUN
aji-40	204	12	(	(	PUNCT
aji-40	204	13	fever	fever	NOUN
aji-40	204	14	lasting	last	VERB
aji-40	204	15	from	from	ADP
aji-40	204	16	a	a	DET
aji-40	204	17	few	few	ADJ
aji-40	204	18	days	day	NOUN
aji-40	204	19	to	to	ADP
aji-40	204	20	months	month	NOUN
aji-40	204	21	,	,	PUNCT
aji-40	204	22	average	average	ADJ
aji-40	204	23	duration	duration	NOUN
aji-40	204	24	21	21	NUM
aji-40	204	25	days	day	NOUN
aji-40	204	26	)	)	PUNCT
aji-40	204	27	,	,	PUNCT
aji-40	204	28	severe	severe	ADJ
aji-40	204	29	abdominal	abdominal	ADJ
aji-40	204	30	pain	pain	NOUN
aji-40	204	31	,	,	PUNCT
aji-40	204	32	localized	localized	ADJ
aji-40	204	33	inflammation	inflammation	NOUN
aji-40	204	34	affecting	affect	VERB
aji-40	204	35	multiple	multiple	ADJ
aji-40	204	36	organs	organ	NOUN
aji-40	204	37	,	,	PUNCT
aji-40	204	38	and	and	CCONJ
aji-40	204	39	migrating	migrate	VERB
aji-40	204	40	rash	rash	NOUN
aji-40	204	41	on	on	ADP
aji-40	204	42	the	the	DET
aji-40	204	43	limbs	limb	NOUN
aji-40	204	44	[	[	X
aji-40	204	45	23	23	NUM
aji-40	204	46	]	]	PUNCT
aji-40	204	47	.	.	PUNCT
aji-40	205	1	since	since	SCONJ
aji-40	205	2	these	these	DET
aji-40	205	3	inflammatory	inflammatory	ADJ
aji-40	205	4	episodes	episode	NOUN
aji-40	205	5	are	be	AUX
aji-40	205	6	unprovoked	unprovoked	ADJ
aji-40	205	7	,	,	PUNCT
aji-40	205	8	they	they	PRON
aji-40	205	9	are	be	AUX
aji-40	205	10	described	describe	VERB
aji-40	205	11	as	as	ADP
aji-40	205	12	‘	'	PUNCT
aji-40	205	13	autoinflammation	autoinflammation	NOUN
aji-40	205	14	’	'	PUNCT
aji-40	206	1	[	[	X
aji-40	206	2	14	14	NUM
aji-40	206	3	]	]	PUNCT
aji-40	206	4	.	.	PUNCT
aji-40	207	1	there	there	PRON
aji-40	207	2	is	be	VERB
aji-40	207	3	an	an	DET
aji-40	207	4	elevation	elevation	NOUN
aji-40	207	5	of	of	ADP
aji-40	207	6	cytokines	cytokine	NOUN
aji-40	207	7	il-6	il-6	PRON
aji-40	207	8	and	and	CCONJ
aji-40	207	9	tnf	tnf	PROPN
aji-40	207	10	-	-	PUNCT
aji-40	207	11	α	α	PROPN
aji-40	207	12	in	in	ADP
aji-40	207	13	this	this	DET
aji-40	207	14	disease	disease	NOUN
aji-40	207	15	[	[	X
aji-40	207	16	23	23	NUM
aji-40	207	17	]	]	PUNCT
aji-40	207	18	.	.	PUNCT
aji-40	208	1	there	there	PRON
aji-40	208	2	is	be	VERB
aji-40	208	3	a	a	DET
aji-40	208	4	paradox	paradox	NOUN
aji-40	208	5	in	in	ADP
aji-40	208	6	the	the	DET
aji-40	208	7	pathogenesis	pathogenesis	NOUN
aji-40	208	8	of	of	ADP
aji-40	208	9	traps	trap	NOUN
aji-40	208	10	:	:	PUNCT
aji-40	208	11	as	as	SCONJ
aji-40	208	12	tnfr1	tnfr1	PROPN
aji-40	208	13	is	be	AUX
aji-40	208	14	associated	associate	VERB
aji-40	208	15	with	with	ADP
aji-40	208	16	inflammation	inflammation	NOUN
aji-40	208	17	,	,	PUNCT
aji-40	208	18	nonfunctional	nonfunctional	ADJ
aji-40	208	19	tnfr1	tnfr1	PROPN
aji-40	208	20	should	should	AUX
aji-40	208	21	not	not	PART
aji-40	208	22	lead	lead	VERB
aji-40	208	23	to	to	ADP
aji-40	208	24	inflammation	inflammation	NOUN
aji-40	208	25	,	,	PUNCT
aji-40	208	26	contrary	contrary	ADV
aji-40	208	27	to	to	ADP
aji-40	208	28	the	the	DET
aji-40	208	29	observation	observation	NOUN
aji-40	208	30	of	of	ADP
aji-40	208	31	inflammation	inflammation	NOUN
aji-40	208	32	affecting	affect	VERB
aji-40	208	33	multiple	multiple	ADJ
aji-40	208	34	organs	organ	NOUN
aji-40	208	35	in	in	ADP
aji-40	208	36	this	this	DET
aji-40	208	37	disease	disease	NOUN
aji-40	208	38	[	[	X
aji-40	208	39	23	23	NUM
aji-40	208	40	]	]	PUNCT
aji-40	208	41	.	.	PUNCT
aji-40	209	1	this	this	PRON
aji-40	209	2	suggests	suggest	VERB
aji-40	209	3	that	that	SCONJ
aji-40	209	4	mechanism	mechanism	NOUN
aji-40	209	5	of	of	ADP
aji-40	209	6	action	action	NOUN
aji-40	209	7	of	of	ADP
aji-40	209	8	the	the	DET
aji-40	209	9	tnf	tnf	PROPN
aji-40	209	10	-	-	PUNCT
aji-40	209	11	α	α	PROPN
aji-40	209	12	and	and	CCONJ
aji-40	209	13	tnf	tnf	PROPN
aji-40	209	14	receptors	receptor	NOUN
aji-40	209	15	is	be	AUX
aji-40	209	16	complex	complex	ADJ
aji-40	209	17	,	,	PUNCT
aji-40	209	18	and	and	CCONJ
aji-40	209	19	further	further	ADJ
aji-40	209	20	studies	study	NOUN
aji-40	209	21	are	be	AUX
aji-40	209	22	needed	need	VERB
aji-40	209	23	to	to	PART
aji-40	209	24	elucidate	elucidate	VERB
aji-40	209	25	these	these	DET
aji-40	209	26	mechanisms	mechanism	NOUN
aji-40	209	27	.	.	PUNCT
aji-40	210	1	treatment	treatment	NOUN
aji-40	210	2	modalities	modality	NOUN
aji-40	210	3	include	include	VERB
aji-40	210	4	high	high	ADJ
aji-40	210	5	doses	dose	NOUN
aji-40	210	6	of	of	ADP
aji-40	210	7	prednisolone	prednisolone	PROPN
aji-40	210	8	,	,	PUNCT
aji-40	210	9	high	high	PROPN
aji-40	210	10	dose	dose	ADJ
aji-40	210	11	non	non	ADJ
aji-40	210	12	-	-	ADJ
aji-40	210	13	steroidal	steroidal	ADJ
aji-40	210	14	antiinflammatory	antiinflammatory	NOUN
aji-40	210	15	drugs	drug	NOUN
aji-40	210	16	,	,	PUNCT
aji-40	210	17	colchicine	colchicine	PROPN
aji-40	210	18	,	,	PUNCT
aji-40	210	19	etanercept	etanercept	NOUN
aji-40	210	20	,	,	PUNCT
aji-40	210	21	anakinra	anakinra	VERB
aji-40	210	22	(	(	PUNCT
aji-40	210	23	il-1	il-1	ADP
aji-40	210	24	receptor	receptor	NOUN
aji-40	210	25	antagonist	antagonist	NOUN
aji-40	210	26	)	)	PUNCT
aji-40	210	27	,	,	PUNCT
aji-40	210	28	canakinumab	canakinumab	NOUN
aji-40	210	29	(	(	PUNCT
aji-40	210	30	anti	anti	ADJ
aji-40	210	31	-	-	ADJ
aji-40	210	32	il-1β	il-1β	ADJ
aji-40	210	33	)	)	PUNCT
aji-40	210	34	,	,	PUNCT
aji-40	210	35	and	and	CCONJ
aji-40	210	36	tocilizumab	tocilizumab	NOUN
aji-40	210	37	(	(	PUNCT
aji-40	210	38	anti	anti	NOUN
aji-40	210	39	-	-	NOUN
aji-40	210	40	il-6	il-6	NOUN
aji-40	210	41	)	)	PUNCT
aji-40	210	42	but	but	CCONJ
aji-40	210	43	each	each	PRON
aji-40	210	44	have	have	VERB
aji-40	210	45	variable	variable	ADJ
aji-40	210	46	success	success	NOUN
aji-40	211	1	[	[	X
aji-40	211	2	14,23	14,23	NOUN
aji-40	211	3	]	]	PUNCT
aji-40	211	4	.	.	PUNCT
aji-40	212	1	presently	presently	ADV
aji-40	212	2	,	,	PUNCT
aji-40	212	3	antiinterleukin1β	antiinterleukin1β	NOUN
aji-40	212	4	therapy	therapy	NOUN
aji-40	212	5	is	be	AUX
aji-40	212	6	the	the	DET
aji-40	212	7	standard	standard	NOUN
aji-40	212	8	to	to	PART
aji-40	212	9	treat	treat	VERB
aji-40	212	10	more	more	ADV
aji-40	212	11	severe	severe	ADJ
aji-40	212	12	cases	case	NOUN
aji-40	212	13	of	of	ADP
aji-40	212	14	traps	trap	NOUN
aji-40	212	15	[	[	X
aji-40	212	16	14	14	NUM
aji-40	212	17	]	]	SYM
aji-40	212	18	.	.	PUNCT
aji-40	213	1	4.2	4.2	NUM
aji-40	213	2	susceptibility	susceptibility	NOUN
aji-40	213	3	to	to	PART
aji-40	213	4	develop	develop	VERB
aji-40	213	5	invasive	invasive	ADJ
aji-40	213	6	pulmonary	pulmonary	ADJ
aji-40	213	7	aspergillosis	aspergillosis	NOUN
aji-40	213	8	investigators	investigator	NOUN
aji-40	213	9	have	have	AUX
aji-40	213	10	found	find	VERB
aji-40	213	11	that	that	DET
aji-40	213	12	polymorphism	polymorphism	NOUN
aji-40	213	13	of	of	ADP
aji-40	213	14	both	both	DET
aji-40	213	15	tnfr1	tnfr1	NOUN
aji-40	213	16	and	and	CCONJ
aji-40	213	17	tnfr2	tnfr2	NOUN
aji-40	213	18	is	be	AUX
aji-40	213	19	associated	associate	VERB
aji-40	213	20	with	with	ADP
aji-40	213	21	increased	increase	VERB
aji-40	213	22	susceptibility	susceptibility	NOUN
aji-40	213	23	to	to	ADP
aji-40	213	24	invasive	invasive	ADJ
aji-40	213	25	pulmonary	pulmonary	ADJ
aji-40	213	26	aspergillosis	aspergillosis	NOUN
aji-40	213	27	.	.	PUNCT
aji-40	214	1	sainz	sainz	PROPN
aji-40	214	2	et	et	PROPN
aji-40	214	3	al	al	PROPN
aji-40	214	4	found	find	VERB
aji-40	214	5	that	that	SCONJ
aji-40	214	6	tnfr1	tnfr1	NOUN
aji-40	214	7	gene	gene	NOUN
aji-40	214	8	polymorphism	polymorphism	NOUN
aji-40	214	9	results	result	VERB
aji-40	214	10	in	in	ADP
aji-40	214	11	greater	great	ADJ
aji-40	214	12	susceptibility	susceptibility	NOUN
aji-40	214	13	to	to	ADP
aji-40	214	14	invasive	invasive	ADJ
aji-40	214	15	pulmonary	pulmonary	ADJ
aji-40	214	16	aspergillosis	aspergillosis	NOUN
aji-40	215	1	[	[	X
aji-40	215	2	24	24	NUM
aji-40	215	3	]	]	PUNCT
aji-40	215	4	.	.	PUNCT
aji-40	216	1	the	the	DET
aji-40	216	2	group	group	NOUN
aji-40	216	3	had	have	AUX
aji-40	216	4	found	find	VERB
aji-40	216	5	in	in	ADP
aji-40	216	6	an	an	DET
aji-40	216	7	earlier	early	ADJ
aji-40	216	8	study	study	NOUN
aji-40	216	9	that	that	SCONJ
aji-40	216	10	tnf	tnf	PROPN
aji-40	216	11	-	-	PUNCT
aji-40	216	12	α	α	PROPN
aji-40	216	13	gene	gene	NOUN
aji-40	216	14	polymorphism	polymorphism	NOUN
aji-40	216	15	or	or	CCONJ
aji-40	216	16	tnf	tnf	PROPN
aji-40	216	17	-	-	PUNCT
aji-40	216	18	α	α	PROPN
aji-40	216	19	levels	level	NOUN
aji-40	216	20	had	have	AUX
aji-40	216	21	no	no	DET
aji-40	216	22	correlation	correlation	NOUN
aji-40	216	23	with	with	ADP
aji-40	216	24	susceptibility	susceptibility	NOUN
aji-40	216	25	to	to	ADP
aji-40	216	26	invasive	invasive	ADJ
aji-40	216	27	pulmonary	pulmonary	ADJ
aji-40	216	28	aspergillosis	aspergillosis	NOUN
aji-40	216	29	,	,	PUNCT
aji-40	216	30	while	while	SCONJ
aji-40	216	31	polymorphism	polymorphism	NOUN
aji-40	216	32	in	in	ADP
aji-40	216	33	tnfr2	tnfr2	NOUN
aji-40	216	34	gene	gene	NOUN
aji-40	216	35	was	be	AUX
aji-40	216	36	strongly	strongly	ADV
aji-40	216	37	associated	associate	VERB
aji-40	216	38	with	with	ADP
aji-40	216	39	susceptibility	susceptibility	NOUN
aji-40	216	40	to	to	ADP
aji-40	216	41	the	the	DET
aji-40	216	42	infection	infection	NOUN
aji-40	216	43	[	[	X
aji-40	216	44	25	25	NUM
aji-40	216	45	]	]	PUNCT
aji-40	216	46	.	.	PUNCT
aji-40	217	1	5	5	X
aji-40	217	2	.	.	X
aji-40	217	3	tnfr2	tnfr2	ADJ
aji-40	217	4	gene	gene	NOUN
aji-40	217	5	polymorphism	polymorphism	NOUN
aji-40	217	6	and	and	CCONJ
aji-40	217	7	diseases	disease	NOUN
aji-40	217	8	tnfr2	tnfr2	NOUN
aji-40	217	9	gene	gene	NOUN
aji-40	217	10	polymorphism	polymorphism	NOUN
aji-40	217	11	may	may	AUX
aji-40	217	12	affect	affect	VERB
aji-40	217	13	susceptibility	susceptibility	NOUN
aji-40	217	14	and/or	and/or	CCONJ
aji-40	217	15	severity	severity	NOUN
aji-40	217	16	of	of	ADP
aji-40	217	17	some	some	DET
aji-40	217	18	diseases	disease	NOUN
aji-40	217	19	.	.	PUNCT
aji-40	218	1	a	a	DET
aji-40	218	2	few	few	ADJ
aji-40	218	3	examples	example	NOUN
aji-40	218	4	are	be	AUX
aji-40	218	5	given	give	VERB
aji-40	218	6	below	below	ADP
aji-40	218	7	.	.	PUNCT
aji-40	219	1	in	in	ADP
aji-40	219	2	all	all	DET
aji-40	219	3	these	these	DET
aji-40	219	4	examples	example	NOUN
aji-40	219	5	,	,	PUNCT
aji-40	219	6	the	the	DET
aji-40	219	7	sample	sample	NOUN
aji-40	219	8	size	size	NOUN
aji-40	219	9	is	be	AUX
aji-40	219	10	small	small	ADJ
aji-40	219	11	.	.	PUNCT
aji-40	220	1	more	more	ADJ
aji-40	220	2	studies	study	NOUN
aji-40	220	3	are	be	AUX
aji-40	220	4	needed	need	VERB
aji-40	220	5	to	to	PART
aji-40	220	6	evaluate	evaluate	VERB
aji-40	220	7	this	this	DET
aji-40	220	8	area	area	NOUN
aji-40	220	9	.	.	PUNCT
aji-40	221	1	5.1	5.1	NUM
aji-40	221	2	schizophrenia	schizophrenia	NOUN
aji-40	221	3	renata	renata	NOUN
aji-40	221	4	suchanek	suchanek	NOUN
aji-40	221	5	-	-	PUNCT
aji-40	221	6	raif	raif	NOUN
aji-40	221	7	,	,	PUNCT
aji-40	221	8	et	et	PROPN
aji-40	221	9	al	al	PROPN
aji-40	221	10	conducted	conduct	VERB
aji-40	221	11	a	a	DET
aji-40	221	12	case	case	NOUN
aji-40	221	13	control	control	NOUN
aji-40	221	14	study	study	NOUN
aji-40	221	15	involving	involve	VERB
aji-40	221	16	401	401	NUM
aji-40	221	17	patients	patient	NOUN
aji-40	221	18	and	and	CCONJ
aji-40	221	19	657	657	NUM
aji-40	221	20	controls	control	NOUN
aji-40	221	21	to	to	PART
aji-40	221	22	study	study	VERB
aji-40	221	23	whether	whether	SCONJ
aji-40	221	24	the	the	DET
aji-40	221	25	three	three	NUM
aji-40	221	26	single	single	ADJ
aji-40	221	27	nucleotide	nucleotide	ADJ
aji-40	221	28	polymorphisms	polymorphism	NOUN
aji-40	221	29	(	(	PUNCT
aji-40	221	30	rs3397	rs3397	ADJ
aji-40	221	31	,	,	PUNCT
aji-40	221	32	rs1061622	rs1061622	PROPN
aji-40	221	33	,	,	PUNCT
aji-40	221	34	and	and	CCONJ
aji-40	221	35	rs1061624	rs1061624	NOUN
aji-40	221	36	)	)	PUNCT
aji-40	221	37	in	in	ADP
aji-40	221	38	tnfr2	tnfr2	ADJ
aji-40	221	39	gene	gene	NOUN
aji-40	221	40	were	be	AUX
aji-40	221	41	associated	associate	VERB
aji-40	221	42	with	with	ADP
aji-40	221	43	a	a	DET
aji-40	221	44	predisposition	predisposition	NOUN
aji-40	221	45	to	to	ADP
aji-40	221	46	paranoid	paranoid	ADJ
aji-40	221	47	schizophrenia	schizophrenia	NOUN
aji-40	221	48	in	in	ADP
aji-40	221	49	caucasian	caucasian	ADJ
aji-40	221	50	population	population	NOUN
aji-40	222	1	[	[	X
aji-40	222	2	26	26	NUM
aji-40	222	3	]	]	PUNCT
aji-40	222	4	.	.	PUNCT
aji-40	223	1	they	they	PRON
aji-40	223	2	observed	observe	VERB
aji-40	223	3	that	that	SCONJ
aji-40	223	4	tnfr2	tnfr2	NOUN
aji-40	223	5	gene	gene	NOUN
aji-40	223	6	polymorphism	polymorphism	NOUN
aji-40	223	7	of	of	ADP
aji-40	223	8	rs3397	rs3397	PROPN
aji-40	223	9	,	,	PUNCT
aji-40	223	10	rs1061622	rs1061622	PROPN
aji-40	223	11	,	,	PUNCT
aji-40	223	12	and	and	CCONJ
aji-40	223	13	rs1061624	rs1061624	NOUN
aji-40	223	14	are	be	AUX
aji-40	223	15	associated	associate	VERB
aji-40	223	16	with	with	ADP
aji-40	223	17	a	a	DET
aji-40	223	18	higher	high	ADJ
aji-40	223	19	risk	risk	NOUN
aji-40	223	20	of	of	ADP
aji-40	223	21	developing	develop	VERB
aji-40	223	22	schizophrenia	schizophrenia	NOUN
aji-40	223	23	and	and	CCONJ
aji-40	223	24	a	a	DET
aji-40	223	25	more	more	ADV
aji-40	223	26	severe	severe	ADJ
aji-40	223	27	course	course	NOUN
aji-40	223	28	of	of	ADP
aji-40	223	29	progression	progression	NOUN
aji-40	223	30	in	in	ADP
aji-40	223	31	males	male	NOUN
aji-40	223	32	[	[	X
aji-40	223	33	26	26	NUM
aji-40	223	34	]	]	PUNCT
aji-40	223	35	.	.	PUNCT
aji-40	224	1	in	in	ADP
aji-40	224	2	this	this	DET
aji-40	224	3	study	study	NOUN
aji-40	224	4	,	,	PUNCT
aji-40	224	5	the	the	DET
aji-40	224	6	rs3397	rs3397	ADJ
aji-40	224	7	single	single	ADJ
aji-40	224	8	nucleotide	nucleotide	NOUN
aji-40	224	9	polymorphisms	polymorphism	NOUN
aji-40	224	10	were	be	AUX
aji-40	224	11	found	find	VERB
aji-40	224	12	to	to	PART
aji-40	224	13	be	be	AUX
aji-40	224	14	protective	protective	ADJ
aji-40	224	15	for	for	ADP
aji-40	224	16	women	woman	NOUN
aji-40	224	17	[	[	X
aji-40	224	18	26	26	NUM
aji-40	224	19	]	]	PUNCT
aji-40	224	20	.	.	PUNCT
aji-40	225	1	these	these	DET
aji-40	225	2	observations	observation	NOUN
aji-40	225	3	suggest	suggest	VERB
aji-40	225	4	that	that	SCONJ
aji-40	225	5	tnfr2	tnfr2	NOUN
aji-40	225	6	gene	gene	NOUN
aji-40	225	7	polymorphisms	polymorphism	NOUN
aji-40	225	8	churchill	churchill	VERB
aji-40	225	9	et	et	PROPN
aji-40	225	10	al	al	PROPN
aji-40	225	11	.	.	PROPN
aji-40	225	12	;	;	PUNCT
aji-40	225	13	aji	aji	PROPN
aji-40	225	14	,	,	PUNCT
aji-40	225	15	3(1	3(1	NUM
aji-40	225	16	):	):	PUNCT
aji-40	225	17	208	208	NUM
aji-40	225	18	-	-	SYM
aji-40	225	19	222	222	NUM
aji-40	225	20	,	,	PUNCT
aji-40	225	21	2020	2020	NUM
aji-40	225	22	;	;	PUNCT
aji-40	225	23	article	article	NOUN
aji-40	225	24	no.aji.57464	no.aji.57464	ADP
aji-40	225	25	213	213	NUM
aji-40	225	26	table	table	NOUN
aji-40	225	27	2	2	NUM
aji-40	225	28	.	.	PUNCT
aji-40	225	29	anti	anti	ADJ
aji-40	225	30	-	-	ADJ
aji-40	225	31	tnf	tnf	ADJ
aji-40	225	32	therapeutic	therapeutic	ADJ
aji-40	225	33	agents	agent	NOUN
aji-40	225	34	tnf	tnf	PROPN
aji-40	225	35	inhibitor	inhibitor	NOUN
aji-40	225	36	mechanism	mechanism	NOUN
aji-40	225	37	of	of	ADP
aji-40	225	38	action	action	NOUN
aji-40	225	39	specificity	specificity	NOUN
aji-40	225	40	dosage	dosage	NOUN
aji-40	225	41	schedule	schedule	NOUN
aji-40	225	42	approved	approve	VERB
aji-40	225	43	indications	indication	NOUN
aji-40	225	44	etanercept	etanercept	VERB
aji-40	225	45	fully	fully	ADV
aji-40	225	46	human	human	ADJ
aji-40	225	47	soluble	soluble	ADJ
aji-40	225	48	tnf	tnf	PROPN
aji-40	225	49	receptor	receptor	NOUN
aji-40	225	50	inhibitor	inhibitor	NOUN
aji-40	225	51	sol	sol	PROPN
aji-40	225	52	tnf	tnf	PROPN
aji-40	225	53	,	,	PUNCT
aji-40	225	54	tmtnf	tmtnf	VERB
aji-40	225	55	,	,	PUNCT
aji-40	225	56	subcutaneous	subcutaneous	ADJ
aji-40	225	57	injection	injection	NOUN
aji-40	225	58	weekly	weekly	NOUN
aji-40	225	59	ra	ra	PROPN
aji-40	225	60	,	,	PUNCT
aji-40	225	61	pa	pa	PROPN
aji-40	225	62	,	,	PUNCT
aji-40	225	63	jia	jia	PROPN
aji-40	225	64	,	,	PUNCT
aji-40	225	65	as	as	ADP
aji-40	225	66	lymphotoxin	lymphotoxin	PROPN
aji-40	225	67	a	a	DET
aji-40	225	68	infliximab	infliximab	PROPN
aji-40	225	69	mouse	mouse	NOUN
aji-40	225	70	chimeric	chimeric	ADJ
aji-40	225	71	monoclonal	monoclonal	NOUN
aji-40	225	72	antibody	antibody	NOUN
aji-40	225	73	to	to	ADP
aji-40	225	74	tnf	tnf	PROPN
aji-40	225	75	-	-	PUNCT
aji-40	225	76	α	α	PROPN
aji-40	225	77	sol	sol	PROPN
aji-40	225	78	tnf	tnf	PROPN
aji-40	225	79	,	,	PUNCT
aji-40	225	80	tmtnf	tmtnf	VERB
aji-40	225	81	intravenous	intravenous	ADJ
aji-40	225	82	injection	injection	NOUN
aji-40	225	83	every	every	DET
aji-40	225	84	6	6	NUM
aji-40	225	85	-	-	SYM
aji-40	225	86	8	8	NUM
aji-40	225	87	weeks	week	NOUN
aji-40	225	88	ra	ra	PROPN
aji-40	225	89	,	,	PUNCT
aji-40	225	90	pa	pa	PROPN
aji-40	225	91	,	,	PUNCT
aji-40	225	92	jia	jia	PROPN
aji-40	225	93	,	,	PUNCT
aji-40	225	94	as	as	ADP
aji-40	225	95	,	,	PUNCT
aji-40	225	96	cd	cd	PROPN
aji-40	225	97	,	,	PUNCT
aji-40	225	98	uc	uc	PROPN
aji-40	225	99	adalimumab	adalimumab	VERB
aji-40	225	100	fully	fully	ADV
aji-40	225	101	human	human	ADJ
aji-40	225	102	monoclonal	monoclonal	NOUN
aji-40	225	103	antibody	antibody	NOUN
aji-40	225	104	against	against	ADP
aji-40	225	105	tnf	tnf	PROPN
aji-40	225	106	-	-	PUNCT
aji-40	225	107	α	α	PROPN
aji-40	225	108	sol	sol	PROPN
aji-40	225	109	tnf	tnf	PROPN
aji-40	225	110	,	,	PUNCT
aji-40	225	111	tmtnf	tmtnf	VERB
aji-40	225	112	subcutaneous	subcutaneous	ADJ
aji-40	225	113	injection	injection	NOUN
aji-40	225	114	every	every	DET
aji-40	225	115	2	2	NUM
aji-40	225	116	weeks	week	NOUN
aji-40	225	117	ra	ra	PROPN
aji-40	225	118	,	,	PUNCT
aji-40	225	119	pa	pa	PROPN
aji-40	225	120	,	,	PUNCT
aji-40	225	121	jia	jia	PROPN
aji-40	225	122	,	,	PUNCT
aji-40	225	123	as	as	SCONJ
aji-40	225	124	,	,	PUNCT
aji-40	225	125	uc	uc	PROPN
aji-40	225	126	,	,	PUNCT
aji-40	225	127	cd	cd	PROPN
aji-40	225	128	certolizumab	certolizumab	PROPN
aji-40	225	129	human	human	PROPN
aji-40	225	130	fab	fab	PROPN
aji-40	225	131	fragment	fragment	NOUN
aji-40	225	132	against	against	ADP
aji-40	225	133	tnf	tnf	PROPN
aji-40	225	134	attached	attach	VERB
aji-40	225	135	to	to	ADP
aji-40	225	136	2	2	NUM
aji-40	225	137	polyethylene	polyethylene	NOUN
aji-40	225	138	glycol	glycol	NOUN
aji-40	225	139	molecules	molecule	NOUN
aji-40	225	140	sol	sol	PROPN
aji-40	225	141	tnf	tnf	PROPN
aji-40	225	142	,	,	PUNCT
aji-40	225	143	tmtnf	tmtnf	VERB
aji-40	225	144	subcutaneous	subcutaneous	ADJ
aji-40	225	145	injection	injection	NOUN
aji-40	225	146	every	every	DET
aji-40	225	147	4	4	NUM
aji-40	225	148	weeks	week	NOUN
aji-40	225	149	ra	ra	PROPN
aji-40	225	150	,	,	PUNCT
aji-40	225	151	pa	pa	PROPN
aji-40	225	152	,	,	PUNCT
aji-40	225	153	as	as	ADP
aji-40	225	154	,	,	PUNCT
aji-40	225	155	cd	cd	NOUN
aji-40	225	156	golimumab	golimumab	VERB
aji-40	225	157	fully	fully	ADV
aji-40	225	158	human	human	ADJ
aji-40	225	159	monoclonal	monoclonal	NOUN
aji-40	225	160	antibody	antibody	NOUN
aji-40	225	161	against	against	ADP
aji-40	225	162	tnf	tnf	PROPN
aji-40	225	163	-	-	PUNCT
aji-40	225	164	α	α	PROPN
aji-40	225	165	sol	sol	PROPN
aji-40	225	166	tnf	tnf	PROPN
aji-40	225	167	,	,	PUNCT
aji-40	225	168	tmtnf	tmtnf	VERB
aji-40	225	169	subcutaneous	subcutaneous	ADJ
aji-40	225	170	injection	injection	NOUN
aji-40	225	171	every	every	DET
aji-40	225	172	month	month	NOUN
aji-40	225	173	ra	ra	PROPN
aji-40	225	174	,	,	PUNCT
aji-40	225	175	as	as	ADP
aji-40	225	176	,	,	PUNCT
aji-40	225	177	pa	pa	PROPN
aji-40	225	178	,	,	PUNCT
aji-40	225	179	uc	uc	PROPN
aji-40	225	180	ra	ra	PROPN
aji-40	225	181	-	-	NOUN
aji-40	225	182	rheumatoid	rheumatoid	VERB
aji-40	225	183	arthritis	arthritis	NOUN
aji-40	225	184	;	;	PUNCT
aji-40	225	185	pa	pa	NOUN
aji-40	225	186	-	-	PUNCT
aji-40	225	187	psoriatic	psoriatic	ADJ
aji-40	225	188	arthritis	arthritis	NOUN
aji-40	225	189	;	;	PUNCT
aji-40	225	190	asankylosing	asankylose	VERB
aji-40	225	191	spondylitis	spondylitis	NOUN
aji-40	225	192	;	;	PUNCT
aji-40	225	193	jia	jia	ADJ
aji-40	225	194	-	-	ADJ
aji-40	225	195	juvenile	juvenile	ADJ
aji-40	225	196	inflammatory	inflammatory	ADJ
aji-40	225	197	arthritis	arthritis	NOUN
aji-40	225	198	;	;	PUNCT
aji-40	225	199	uc	uc	PRON
aji-40	225	200	ulcerative	ulcerative	ADJ
aji-40	225	201	colitis	colitis	NOUN
aji-40	225	202	;	;	PUNCT
aji-40	225	203	cdcrohn	cdcrohn	PROPN
aji-40	225	204	’s	’s	PART
aji-40	225	205	disease	disease	NOUN
aji-40	225	206	;	;	PUNCT
aji-40	225	207	sol	sol	NOUN
aji-40	225	208	tnfsoluble	tnfsoluble	ADJ
aji-40	225	209	tumor	tumor	NOUN
aji-40	225	210	necrosis	necrosis	NOUN
aji-40	225	211	factor	factor	NOUN
aji-40	225	212	;	;	PUNCT
aji-40	225	213	tm	tm	PRON
aji-40	225	214	tnftransmembrane	tnftransmembrane	NOUN
aji-40	225	215	tumor	tumor	NOUN
aji-40	225	216	necrosis	necrosis	NOUN
aji-40	225	217	factor	factor	NOUN
aji-40	225	218	have	have	VERB
aji-40	225	219	a	a	DET
aji-40	225	220	role	role	NOUN
aji-40	225	221	in	in	ADP
aji-40	225	222	determining	determine	VERB
aji-40	225	223	severity	severity	NOUN
aji-40	225	224	of	of	ADP
aji-40	225	225	schizophrenia	schizophrenia	NOUN
aji-40	225	226	.	.	PUNCT
aji-40	226	1	5.2	5.2	NUM
aji-40	226	2	coronary	coronary	ADJ
aji-40	226	3	artery	artery	NOUN
aji-40	226	4	disease	disease	NOUN
aji-40	226	5	v.h	v.h	NOUN
aji-40	226	6	sankar	sankar	NOUN
aji-40	226	7	,	,	PUNCT
aji-40	226	8	et	et	PROPN
aji-40	226	9	al	al	PROPN
aji-40	226	10	conducted	conduct	VERB
aji-40	226	11	a	a	DET
aji-40	226	12	study	study	NOUN
aji-40	226	13	to	to	PART
aji-40	226	14	evaluate	evaluate	VERB
aji-40	226	15	whether	whether	SCONJ
aji-40	226	16	polymorphism	polymorphism	NOUN
aji-40	226	17	at	at	ADP
aji-40	226	18	position	position	NOUN
aji-40	226	19	196	196	NUM
aji-40	226	20	in	in	ADP
aji-40	226	21	exon	exon	NOUN
aji-40	226	22	6	6	NUM
aji-40	226	23	of	of	ADP
aji-40	226	24	tumor	tumor	NOUN
aji-40	226	25	necrosis	necrosis	NOUN
aji-40	226	26	factor	factor	NOUN
aji-40	226	27	2	2	NUM
aji-40	226	28	(	(	PUNCT
aji-40	226	29	tnfr2	tnfr2	NOUN
aji-40	226	30	)	)	PUNCT
aji-40	226	31	gene	gene	NOUN
aji-40	226	32	is	be	AUX
aji-40	226	33	associated	associate	VERB
aji-40	226	34	with	with	ADP
aji-40	226	35	coronary	coronary	ADJ
aji-40	226	36	artery	artery	NOUN
aji-40	226	37	disease	disease	NOUN
aji-40	226	38	[	[	X
aji-40	226	39	27	27	NUM
aji-40	226	40	]	]	PUNCT
aji-40	226	41	.	.	PUNCT
aji-40	227	1	the	the	DET
aji-40	227	2	investigators	investigator	NOUN
aji-40	227	3	found	find	VERB
aji-40	227	4	that	that	SCONJ
aji-40	227	5	the	the	DET
aji-40	227	6	incidence	incidence	NOUN
aji-40	227	7	of	of	ADP
aji-40	227	8	coronary	coronary	ADJ
aji-40	227	9	artery	artery	NOUN
aji-40	227	10	disease	disease	NOUN
aji-40	227	11	in	in	ADP
aji-40	227	12	patients	patient	NOUN
aji-40	227	13	with	with	ADP
aji-40	227	14	mm	mm	PROPN
aji-40	227	15	genotype	genotype	NOUN
aji-40	227	16	was	be	AUX
aji-40	227	17	65	65	NUM
aji-40	227	18	%	%	NOUN
aji-40	227	19	and	and	CCONJ
aji-40	227	20	in	in	ADP
aji-40	227	21	those	those	PRON
aji-40	227	22	with	with	ADP
aji-40	227	23	rm	rm	NOUN
aji-40	227	24	genotype	genotype	NOUN
aji-40	227	25	was	be	AUX
aji-40	227	26	42	42	NUM
aji-40	227	27	%	%	NOUN
aji-40	227	28	[	[	X
aji-40	227	29	27	27	NUM
aji-40	227	30	]	]	PUNCT
aji-40	227	31	.	.	PUNCT
aji-40	228	1	the	the	DET
aji-40	228	2	investigators	investigator	NOUN
aji-40	228	3	concluded	conclude	VERB
aji-40	228	4	that	that	SCONJ
aji-40	228	5	mm	mm	PROPN
aji-40	228	6	genotype	genotype	NOUN
aji-40	228	7	of	of	ADP
aji-40	228	8	tnfr2	tnfr2	NOUN
aji-40	228	9	increases	increase	VERB
aji-40	228	10	the	the	DET
aji-40	228	11	risk	risk	NOUN
aji-40	228	12	of	of	ADP
aji-40	228	13	developing	develop	VERB
aji-40	228	14	coronary	coronary	ADJ
aji-40	228	15	artery	artery	NOUN
aji-40	228	16	disease	disease	NOUN
aji-40	228	17	,	,	PUNCT
aji-40	228	18	and	and	CCONJ
aji-40	228	19	the	the	DET
aji-40	228	20	rm	rm	PROPN
aji-40	228	21	genotype	genotype	NOUN
aji-40	228	22	has	have	VERB
aji-40	228	23	a	a	DET
aji-40	228	24	protective	protective	ADJ
aji-40	228	25	role	role	NOUN
aji-40	228	26	[	[	X
aji-40	228	27	27	27	NUM
aji-40	228	28	]	]	PUNCT
aji-40	228	29	.	.	PUNCT
aji-40	229	1	5.3	5.3	NUM
aji-40	229	2	chagas	chagas	PROPN
aji-40	229	3	disease	disease	PROPN
aji-40	229	4	libeth	libeth	PROPN
aji-40	229	5	criado	criado	X
aji-40	229	6	,	,	PUNCT
aji-40	229	7	et	et	PROPN
aji-40	229	8	al	al	PROPN
aji-40	229	9	included	include	VERB
aji-40	229	10	313	313	NUM
aji-40	229	11	chagas	chagas	NOUN
aji-40	229	12	disease	disease	NOUN
aji-40	229	13	patients	patient	NOUN
aji-40	229	14	from	from	ADP
aji-40	229	15	colombia	colombia	PROPN
aji-40	229	16	who	who	PRON
aji-40	229	17	were	be	AUX
aji-40	229	18	serologically	serologically	ADV
aji-40	229	19	positive	positive	ADJ
aji-40	229	20	for	for	ADP
aji-40	229	21	trypanosoma	trypanosoma	PROPN
aji-40	229	22	cruzi	cruzi	PROPN
aji-40	230	1	[	[	X
aji-40	230	2	28	28	NUM
aji-40	230	3	]	]	PUNCT
aji-40	230	4	.	.	PUNCT
aji-40	231	1	out	out	ADP
aji-40	231	2	of	of	ADP
aji-40	231	3	these	these	DET
aji-40	231	4	313	313	NUM
aji-40	231	5	patients	patient	NOUN
aji-40	231	6	,	,	PUNCT
aji-40	231	7	159	159	NUM
aji-40	231	8	had	have	VERB
aji-40	231	9	cardiomyopathy	cardiomyopathy	ADJ
aji-40	231	10	,	,	PUNCT
aji-40	231	11	and	and	CCONJ
aji-40	231	12	154	154	NUM
aji-40	231	13	were	be	AUX
aji-40	231	14	asymptomatic	asymptomatic	ADJ
aji-40	231	15	[	[	X
aji-40	231	16	28	28	NUM
aji-40	231	17	]	]	PUNCT
aji-40	231	18	.	.	PUNCT
aji-40	232	1	the	the	DET
aji-40	232	2	investigators	investigator	NOUN
aji-40	232	3	found	find	VERB
aji-40	232	4	that	that	SCONJ
aji-40	232	5	distribution	distribution	NOUN
aji-40	232	6	of	of	ADP
aji-40	232	7	the	the	DET
aji-40	232	8	tnfa	tnfa	ADJ
aji-40	232	9	-1031c	-1031c	NOUN
aji-40	232	10	and	and	CCONJ
aji-40	232	11	-308a	-308a	PROPN
aji-40	232	12	alleles	allele	NOUN
aji-40	232	13	between	between	ADP
aji-40	232	14	cardiomyopathic	cardiomyopathic	ADJ
aji-40	232	15	and	and	CCONJ
aji-40	232	16	asymptomatic	asymptomatic	ADJ
aji-40	232	17	subjects	subject	NOUN
aji-40	232	18	was	be	AUX
aji-40	232	19	significantly	significantly	ADV
aji-40	232	20	different	different	ADJ
aji-40	232	21	[	[	X
aji-40	232	22	28	28	NUM
aji-40	232	23	]	]	PUNCT
aji-40	232	24	.	.	PUNCT
aji-40	233	1	the	the	DET
aji-40	233	2	investigators	investigator	NOUN
aji-40	233	3	suggested	suggest	VERB
aji-40	233	4	that	that	SCONJ
aji-40	233	5	tnfa	tnfa	PRON
aji-40	233	6	1031c	1031c	NOUN
aji-40	233	7	and	and	CCONJ
aji-40	233	8	-308a	-308a	PROPN
aji-40	233	9	gene	gene	NOUN
aji-40	233	10	polymorphisms	polymorphism	NOUN
aji-40	233	11	may	may	AUX
aji-40	233	12	influence	influence	VERB
aji-40	233	13	susceptibility	susceptibility	NOUN
aji-40	233	14	to	to	PART
aji-40	233	15	develop	develop	VERB
aji-40	233	16	cardiomyopathy	cardiomyopathy	ADJ
aji-40	233	17	in	in	ADP
aji-40	233	18	chagas	chagas	NOUN
aji-40	233	19	disease	disease	NOUN
aji-40	233	20	[	[	X
aji-40	233	21	28	28	NUM
aji-40	233	22	]	]	SYM
aji-40	233	23	.	.	PUNCT
aji-40	234	1	6	6	NUM
aji-40	234	2	.	.	X
aji-40	234	3	anti	anti	ADJ
aji-40	234	4	-	-	ADJ
aji-40	234	5	tumor	tumor	ADJ
aji-40	234	6	necrosis	necrosis	NOUN
aji-40	234	7	factor	factor	NOUN
aji-40	234	8	therapeutic	therapeutic	ADJ
aji-40	234	9	agents	agent	NOUN
aji-40	234	10	tnf	tnf	PROPN
aji-40	234	11	-	-	PUNCT
aji-40	234	12	α	α	PROPN
aji-40	234	13	is	be	AUX
aji-40	234	14	involved	involve	VERB
aji-40	234	15	in	in	ADP
aji-40	234	16	pathogenesis	pathogenesis	NOUN
aji-40	234	17	of	of	ADP
aji-40	234	18	several	several	ADJ
aji-40	234	19	diseases	disease	NOUN
aji-40	234	20	including	include	VERB
aji-40	234	21	rheumatoid	rheumatoid	NOUN
aji-40	234	22	arthritis	arthritis	NOUN
aji-40	234	23	,	,	PUNCT
aji-40	234	24	systemic	systemic	ADJ
aji-40	234	25	lupus	lupus	PROPN
aji-40	234	26	erythematosus	erythematosus	NOUN
aji-40	234	27	,	,	PUNCT
aji-40	234	28	ulcerative	ulcerative	ADJ
aji-40	234	29	colitis	colitis	NOUN
aji-40	234	30	and	and	CCONJ
aji-40	234	31	crohn	crohn	PROPN
aji-40	234	32	’s	’s	PART
aji-40	234	33	disease	disease	NOUN
aji-40	234	34	[	[	X
aji-40	234	35	1,3	1,3	NUM
aji-40	234	36	]	]	PUNCT
aji-40	234	37	.	.	PUNCT
aji-40	235	1	anti	anti	ADJ
aji-40	235	2	-	-	ADJ
aji-40	235	3	tnf	tnf	ADJ
aji-40	235	4	therapeutic	therapeutic	ADJ
aji-40	235	5	agents	agent	NOUN
aji-40	235	6	are	be	AUX
aji-40	235	7	used	use	VERB
aji-40	235	8	for	for	ADP
aji-40	235	9	several	several	ADJ
aji-40	235	10	therapeutic	therapeutic	ADJ
aji-40	235	11	indications	indication	NOUN
aji-40	235	12	including	include	VERB
aji-40	235	13	rheumatoid	rheumatoid	NOUN
aji-40	235	14	arthritis	arthritis	NOUN
aji-40	235	15	(	(	PUNCT
aji-40	235	16	ra	ra	NOUN
aji-40	235	17	)	)	PUNCT
aji-40	235	18	,	,	PUNCT
aji-40	235	19	ankylosing	ankylose	VERB
aji-40	235	20	spondylitis	spondylitis	NOUN
aji-40	235	21	(	(	PUNCT
aji-40	235	22	as	as	ADP
aji-40	235	23	)	)	PUNCT
aji-40	235	24	,	,	PUNCT
aji-40	235	25	psoriatic	psoriatic	ADJ
aji-40	235	26	arthritis	arthritis	NOUN
aji-40	235	27	(	(	PUNCT
aji-40	235	28	pa	pa	PROPN
aji-40	235	29	)	)	PUNCT
aji-40	235	30	,	,	PUNCT
aji-40	235	31	juvenile	juvenile	ADJ
aji-40	235	32	inflammatory	inflammatory	ADJ
aji-40	235	33	arthritis	arthritis	NOUN
aji-40	235	34	(	(	PUNCT
aji-40	235	35	jia	jia	NOUN
aji-40	235	36	)	)	PUNCT
aji-40	235	37	,	,	PUNCT
aji-40	235	38	crohn	crohn	PROPN
aji-40	235	39	’s	’s	PART
aji-40	235	40	disease	disease	NOUN
aji-40	235	41	(	(	PUNCT
aji-40	235	42	cd	cd	PROPN
aji-40	235	43	)	)	PUNCT
aji-40	235	44	and	and	CCONJ
aji-40	235	45	ulcerative	ulcerative	ADJ
aji-40	235	46	colitis	colitis	NOUN
aji-40	235	47	(	(	PUNCT
aji-40	235	48	uc	uc	PROPN
aji-40	235	49	)	)	PUNCT
aji-40	236	1	[	[	X
aji-40	236	2	5	5	NUM
aji-40	236	3	-	-	SYM
aji-40	236	4	8	8	NUM
aji-40	236	5	]	]	PUNCT
aji-40	236	6	.	.	PUNCT
aji-40	237	1	table	table	NOUN
aji-40	237	2	2	2	NUM
aji-40	237	3	depicts	depict	VERB
aji-40	237	4	a	a	DET
aji-40	237	5	brief	brief	ADJ
aji-40	237	6	overview	overview	NOUN
aji-40	237	7	of	of	ADP
aji-40	237	8	these	these	DET
aji-40	237	9	agents	agent	NOUN
aji-40	237	10	[	[	X
aji-40	237	11	5	5	NUM
aji-40	237	12	-	-	SYM
aji-40	237	13	8,29	8,29	NUM
aji-40	237	14	]	]	PUNCT
aji-40	237	15	.	.	PUNCT
aji-40	238	1	7	7	X
aji-40	238	2	.	.	X
aji-40	238	3	impact	impact	NOUN
aji-40	238	4	of	of	ADP
aji-40	238	5	tnf	tnf	PROPN
aji-40	238	6	blockade	blockade	NOUN
aji-40	238	7	on	on	ADP
aji-40	238	8	different	different	ADJ
aji-40	238	9	organ	organ	NOUN
aji-40	238	10	systems	system	NOUN
aji-40	238	11	7.1	7.1	NUM
aji-40	238	12	immune	immune	ADJ
aji-40	238	13	system	system	NOUN
aji-40	238	14	and	and	CCONJ
aji-40	238	15	infections	infection	NOUN
aji-40	238	16	the	the	DET
aji-40	238	17	pro	pro	ADJ
aji-40	238	18	-	-	ADJ
aji-40	238	19	inflammatory	inflammatory	ADJ
aji-40	238	20	role	role	NOUN
aji-40	238	21	of	of	ADP
aji-40	238	22	tnf	tnf	PROPN
aji-40	238	23	-	-	PUNCT
aji-40	238	24	α	α	PROPN
aji-40	238	25	is	be	AUX
aji-40	238	26	a	a	DET
aji-40	238	27	vital	vital	ADJ
aji-40	238	28	component	component	NOUN
aji-40	238	29	of	of	ADP
aji-40	238	30	host	host	NOUN
aji-40	238	31	defense	defense	NOUN
aji-40	238	32	against	against	ADP
aji-40	238	33	infections	infection	NOUN
aji-40	238	34	[	[	X
aji-40	238	35	10	10	NUM
aji-40	238	36	]	]	PUNCT
aji-40	238	37	.	.	PUNCT
aji-40	239	1	tnf	tnf	PROPN
aji-40	239	2	-	-	PUNCT
aji-40	239	3	α	α	PROPN
aji-40	239	4	blockers	blocker	NOUN
aji-40	239	5	increase	increase	VERB
aji-40	239	6	the	the	DET
aji-40	239	7	risk	risk	NOUN
aji-40	239	8	of	of	ADP
aji-40	239	9	infections	infection	NOUN
aji-40	239	10	(	(	PUNCT
aji-40	239	11	bacterial	bacterial	ADJ
aji-40	239	12	,	,	PUNCT
aji-40	239	13	viral	viral	ADJ
aji-40	239	14	,	,	PUNCT
aji-40	239	15	and	and	CCONJ
aji-40	239	16	mycotic	mycotic	ADJ
aji-40	239	17	)	)	PUNCT
aji-40	239	18	,	,	PUNCT
aji-40	239	19	including	include	VERB
aji-40	239	20	tuberculosis	tuberculosis	NOUN
aji-40	239	21	,	,	PUNCT
aji-40	239	22	histoplasmosis	histoplasmosis	NOUN
aji-40	239	23	,	,	PUNCT
aji-40	239	24	candidiasis	candidiasis	NOUN
aji-40	239	25	,	,	PUNCT
aji-40	239	26	aspergillosis	aspergillosis	NOUN
aji-40	239	27	,	,	PUNCT
aji-40	239	28	listeriosis	listeriosis	NOUN
aji-40	239	29	,	,	PUNCT
aji-40	239	30	infection	infection	NOUN
aji-40	239	31	with	with	ADP
aji-40	239	32	atypical	atypical	ADJ
aji-40	239	33	mycobacterium	mycobacterium	NOUN
aji-40	239	34	,	,	PUNCT
aji-40	239	35	pneumocystis	pneumocystis	NOUN
aji-40	239	36	carinii	carinii	VERB
aji-40	240	1	[	[	X
aji-40	240	2	30,31	30,31	NOUN
aji-40	240	3	]	]	PUNCT
aji-40	240	4	.	.	PUNCT
aji-40	241	1	lymphoma	lymphoma	NOUN
aji-40	241	2	,	,	PUNCT
aji-40	241	3	neuropathy	neuropathy	ADJ
aji-40	241	4	and	and	CCONJ
aji-40	241	5	bowel	bowel	NOUN
aji-40	241	6	obstruction	obstruction	NOUN
aji-40	241	7	have	have	AUX
aji-40	241	8	also	also	ADV
aji-40	241	9	been	be	AUX
aji-40	241	10	noted	note	VERB
aji-40	241	11	with	with	ADP
aji-40	241	12	the	the	DET
aji-40	241	13	use	use	NOUN
aji-40	241	14	of	of	ADP
aji-40	241	15	anti	anti	ADJ
aji-40	241	16	tnf	tnf	PROPN
aji-40	241	17	-	-	PUNCT
aji-40	241	18	α	α	NOUN
aji-40	241	19	therapeutic	therapeutic	ADJ
aji-40	241	20	agents	agent	NOUN
aji-40	241	21	[	[	X
aji-40	241	22	31	31	NUM
aji-40	241	23	]	]	PUNCT
aji-40	241	24	.	.	PUNCT
aji-40	242	1	tnf	tnf	PROPN
aji-40	242	2	-	-	PUNCT
aji-40	242	3	α	α	PROPN
aji-40	242	4	together	together	ADV
aji-40	242	5	with	with	ADP
aji-40	242	6	other	other	ADJ
aji-40	242	7	cytokines	cytokine	NOUN
aji-40	242	8	including	include	VERB
aji-40	242	9	interferon	interferon	ADJ
aji-40	242	10	-	-	PUNCT
aji-40	242	11	delta	delta	NOUN
aji-40	242	12	(	(	PUNCT
aji-40	242	13	ifn	ifn	PROPN
aji-40	242	14	-	-	PUNCT
aji-40	242	15	δ	δ	NOUN
aji-40	242	16	)	)	PUNCT
aji-40	242	17	,	,	PUNCT
aji-40	242	18	generates	generate	VERB
aji-40	242	19	a	a	DET
aji-40	242	20	cellmediated	cellmediated	ADJ
aji-40	242	21	immune	immune	ADJ
aji-40	242	22	response	response	NOUN
aji-40	242	23	to	to	ADP
aji-40	242	24	intracellular	intracellular	ADJ
aji-40	242	25	pathogens	pathogen	NOUN
aji-40	242	26	including	include	VERB
aji-40	242	27	mycobacterium	mycobacterium	NOUN
aji-40	242	28	tuberculosis	tuberculosis	NOUN
aji-40	242	29	,	,	PUNCT
aji-40	242	30	listeria	listeria	NOUN
aji-40	242	31	and	and	CCONJ
aji-40	242	32	histoplasma	histoplasma	VERB
aji-40	242	33	species	specie	NOUN
aji-40	242	34	leading	lead	VERB
aji-40	242	35	to	to	ADP
aji-40	242	36	granuloma	granuloma	ADJ
aji-40	242	37	formation	formation	NOUN
aji-40	242	38	[	[	X
aji-40	242	39	10	10	NUM
aji-40	242	40	]	]	PUNCT
aji-40	242	41	.	.	PUNCT
aji-40	243	1	granuloma	granuloma	ADJ
aji-40	243	2	formation	formation	NOUN
aji-40	243	3	is	be	AUX
aji-40	243	4	required	require	VERB
aji-40	243	5	to	to	PART
aji-40	243	6	contain	contain	VERB
aji-40	243	7	the	the	DET
aji-40	243	8	growth	growth	NOUN
aji-40	243	9	of	of	ADP
aji-40	243	10	and	and	CCONJ
aji-40	243	11	for	for	ADP
aji-40	243	12	the	the	DET
aji-40	243	13	resolution	resolution	NOUN
aji-40	243	14	of	of	ADP
aji-40	243	15	these	these	DET
aji-40	243	16	infections	infection	NOUN
aji-40	243	17	[	[	X
aji-40	243	18	10	10	NUM
aji-40	243	19	]	]	PUNCT
aji-40	243	20	.	.	PUNCT
aji-40	244	1	use	use	NOUN
aji-40	244	2	of	of	ADP
aji-40	244	3	anttnf	anttnf	PROPN
aji-40	244	4	-	-	PUNCT
aji-40	244	5	α	α	PROPN
aji-40	244	6	therapeutic	therapeutic	ADJ
aji-40	244	7	agents	agent	NOUN
aji-40	244	8	inhibits	inhibit	VERB
aji-40	244	9	this	this	DET
aji-40	244	10	cell	cell	NOUN
aji-40	244	11	churchill	churchill	NOUN
aji-40	244	12	et	et	PROPN
aji-40	244	13	al	al	PROPN
aji-40	244	14	.	.	PROPN
aji-40	244	15	;	;	PUNCT
aji-40	244	16	aji	aji	PROPN
aji-40	244	17	,	,	PUNCT
aji-40	244	18	3(1	3(1	NUM
aji-40	244	19	):	):	PUNCT
aji-40	244	20	208	208	NUM
aji-40	244	21	-	-	SYM
aji-40	244	22	222	222	NUM
aji-40	244	23	,	,	PUNCT
aji-40	244	24	2020	2020	NUM
aji-40	244	25	;	;	PUNCT
aji-40	244	26	article	article	NOUN
aji-40	244	27	no.aji.57464	no.aji.57464	ADP
aji-40	244	28	214	214	NUM
aji-40	244	29	mediated	mediate	VERB
aji-40	244	30	immune	immune	ADJ
aji-40	244	31	response	response	NOUN
aji-40	244	32	and	and	CCONJ
aji-40	244	33	granuloma	granuloma	ADJ
aji-40	244	34	formation	formation	NOUN
aji-40	244	35	,	,	PUNCT
aji-40	244	36	hence	hence	ADV
aji-40	244	37	increasing	increase	VERB
aji-40	244	38	the	the	DET
aji-40	244	39	risk	risk	NOUN
aji-40	244	40	of	of	ADP
aji-40	244	41	granulomatous	granulomatous	ADJ
aji-40	244	42	diseases	disease	NOUN
aji-40	244	43	including	include	VERB
aji-40	244	44	tuberculosis	tuberculosis	NOUN
aji-40	244	45	.	.	PUNCT
aji-40	245	1	reactivation	reactivation	NOUN
aji-40	245	2	of	of	ADP
aji-40	245	3	infections	infection	NOUN
aji-40	245	4	may	may	AUX
aji-40	245	5	also	also	ADV
aji-40	245	6	occur	occur	VERB
aji-40	245	7	,	,	PUNCT
aji-40	245	8	including	include	VERB
aji-40	245	9	reactivation	reactivation	NOUN
aji-40	245	10	of	of	ADP
aji-40	245	11	latent	latent	NOUN
aji-40	245	12	tuberculosis	tuberculosis	NOUN
aji-40	245	13	and	and	CCONJ
aji-40	245	14	hepatitis	hepatitis	PROPN
aji-40	245	15	b	b	PROPN
aji-40	245	16	virus	virus	NOUN
aji-40	246	1	[	[	X
aji-40	246	2	30,31	30,31	NOUN
aji-40	246	3	]	]	PUNCT
aji-40	246	4	.	.	PUNCT
aji-40	247	1	use	use	NOUN
aji-40	247	2	of	of	ADP
aji-40	247	3	live	live	ADJ
aji-40	247	4	vaccines	vaccine	NOUN
aji-40	247	5	during	during	ADP
aji-40	247	6	anti	anti	ADJ
aji-40	247	7	-	-	ADJ
aji-40	247	8	tnf	tnf	ADJ
aji-40	247	9	therapy	therapy	NOUN
aji-40	247	10	is	be	AUX
aji-40	247	11	not	not	PART
aji-40	247	12	recommended	recommend	VERB
aji-40	247	13	,	,	PUNCT
aji-40	247	14	as	as	SCONJ
aji-40	247	15	this	this	PRON
aji-40	247	16	may	may	AUX
aji-40	247	17	cause	cause	VERB
aji-40	247	18	vaccine	vaccine	NOUN
aji-40	247	19	associated	associated	ADJ
aji-40	247	20	disease	disease	NOUN
aji-40	247	21	,	,	PUNCT
aji-40	247	22	including	include	VERB
aji-40	247	23	disseminated	disseminate	VERB
aji-40	247	24	infection	infection	NOUN
aji-40	247	25	[	[	X
aji-40	247	26	32	32	NUM
aji-40	247	27	]	]	PUNCT
aji-40	247	28	.	.	PUNCT
aji-40	248	1	the	the	DET
aji-40	248	2	risk	risk	NOUN
aji-40	248	3	of	of	ADP
aji-40	248	4	serious	serious	ADJ
aji-40	248	5	infections	infection	NOUN
aji-40	248	6	in	in	ADP
aji-40	248	7	highest	high	ADJ
aji-40	248	8	in	in	ADP
aji-40	248	9	the	the	DET
aji-40	248	10	first	first	ADJ
aji-40	248	11	few	few	ADJ
aji-40	248	12	months	month	NOUN
aji-40	248	13	.	.	PUNCT
aji-40	249	1	the	the	DET
aji-40	249	2	incidence	incidence	NOUN
aji-40	249	3	of	of	ADP
aji-40	249	4	infection	infection	NOUN
aji-40	249	5	declines	decline	VERB
aji-40	249	6	over	over	ADP
aji-40	249	7	time	time	NOUN
aji-40	249	8	.	.	PUNCT
aji-40	250	1	galloway	galloway	NOUN
aji-40	250	2	et	et	PROPN
aji-40	250	3	al	al	PROPN
aji-40	250	4	evaluated	evaluate	VERB
aji-40	250	5	and	and	CCONJ
aji-40	250	6	compared	compare	VERB
aji-40	250	7	data	datum	NOUN
aji-40	250	8	of	of	ADP
aji-40	250	9	11,798	11,798	NUM
aji-40	250	10	anti	anti	ADJ
aji-40	250	11	-	-	ADJ
aji-40	250	12	tnf	tnf	ADJ
aji-40	250	13	treated	treat	VERB
aji-40	250	14	patients	patient	NOUN
aji-40	250	15	and	and	CCONJ
aji-40	250	16	3,598	3,598	NUM
aji-40	250	17	non	non	PROPN
aji-40	250	18	biologic	biologic	NOUN
aji-40	250	19	diseasemodifying	diseasemodifye	VERB
aji-40	250	20	antirheumatic	antirheumatic	ADJ
aji-40	250	21	drugs	drug	NOUN
aji-40	250	22	(	(	PUNCT
aji-40	250	23	nbdmard	nbdmard	ADV
aji-40	250	24	)	)	PUNCT
aji-40	250	25	treated	treat	VERB
aji-40	250	26	rheumatoid	rheumatoid	NOUN
aji-40	250	27	arthritis	arthritis	NOUN
aji-40	250	28	patients	patient	NOUN
aji-40	250	29	.	.	PUNCT
aji-40	251	1	they	they	PRON
aji-40	251	2	observed	observe	VERB
aji-40	251	3	that	that	SCONJ
aji-40	251	4	the	the	DET
aji-40	251	5	incidence	incidence	NOUN
aji-40	251	6	rate	rate	NOUN
aji-40	251	7	of	of	ADP
aji-40	251	8	serious	serious	ADJ
aji-40	251	9	infections	infection	NOUN
aji-40	251	10	was	be	AUX
aji-40	251	11	42	42	NUM
aji-40	251	12	per	per	ADP
aji-40	251	13	1000	1000	NUM
aji-40	251	14	patient	patient	NOUN
aji-40	251	15	-	-	PUNCT
aji-40	251	16	years	year	NOUN
aji-40	251	17	in	in	ADP
aji-40	251	18	antitnf	antitnf	PROPN
aji-40	251	19	treated	treat	VERB
aji-40	251	20	patients	patient	NOUN
aji-40	251	21	,	,	PUNCT
aji-40	251	22	and	and	CCONJ
aji-40	251	23	32	32	NUM
aji-40	251	24	per	per	ADP
aji-40	251	25	1000	1000	NUM
aji-40	251	26	patientyears	patientyear	NOUN
aji-40	251	27	in	in	ADP
aji-40	251	28	nbdmard	nbdmard	NOUN
aji-40	251	29	treated	treat	VERB
aji-40	251	30	patients	patient	NOUN
aji-40	251	31	indicating	indicate	VERB
aji-40	251	32	a	a	DET
aji-40	251	33	significant	significant	ADJ
aji-40	251	34	increase	increase	NOUN
aji-40	251	35	in	in	ADP
aji-40	251	36	serious	serious	ADJ
aji-40	251	37	infection	infection	NOUN
aji-40	251	38	risk	risk	NOUN
aji-40	251	39	with	with	ADP
aji-40	251	40	the	the	DET
aji-40	251	41	use	use	NOUN
aji-40	251	42	of	of	ADP
aji-40	251	43	anti	anti	ADJ
aji-40	251	44	-	-	ADJ
aji-40	251	45	tnf	tnf	ADJ
aji-40	251	46	therapy	therapy	NOUN
aji-40	251	47	[	[	X
aji-40	251	48	33	33	NUM
aji-40	251	49	]	]	PUNCT
aji-40	251	50	.	.	PUNCT
aji-40	252	1	the	the	DET
aji-40	252	2	adjusted	adjust	VERB
aji-40	252	3	serious	serious	ADJ
aji-40	252	4	infection	infection	NOUN
aji-40	252	5	rate	rate	NOUN
aji-40	252	6	was	be	AUX
aji-40	252	7	20	20	NUM
aji-40	252	8	%	%	NOUN
aji-40	252	9	higher	high	ADJ
aji-40	252	10	in	in	ADP
aji-40	252	11	anti	anti	ADJ
aji-40	252	12	-	-	ADJ
aji-40	252	13	tnf	tnf	ADJ
aji-40	252	14	treated	treat	VERB
aji-40	252	15	individuals	individual	NOUN
aji-40	252	16	than	than	ADP
aji-40	252	17	nbdmard	nbdmard	NOUN
aji-40	252	18	treated	treat	VERB
aji-40	252	19	subjects	subject	NOUN
aji-40	252	20	[	[	X
aji-40	252	21	33	33	NUM
aji-40	252	22	]	]	PUNCT
aji-40	252	23	.	.	PUNCT
aji-40	253	1	this	this	DET
aji-40	253	2	risk	risk	NOUN
aji-40	253	3	was	be	AUX
aji-40	253	4	highest	high	ADJ
aji-40	253	5	in	in	ADP
aji-40	253	6	the	the	DET
aji-40	253	7	first	first	ADJ
aji-40	253	8	six	six	NUM
aji-40	253	9	months	month	NOUN
aji-40	253	10	of	of	ADP
aji-40	253	11	therapy	therapy	NOUN
aji-40	253	12	,	,	PUNCT
aji-40	253	13	and	and	CCONJ
aji-40	253	14	then	then	ADV
aji-40	253	15	started	start	VERB
aji-40	253	16	to	to	PART
aji-40	253	17	decline	decline	VERB
aji-40	253	18	[	[	X
aji-40	253	19	33	33	NUM
aji-40	253	20	]	]	PUNCT
aji-40	253	21	.	.	PUNCT
aji-40	254	1	liao	liao	PROPN
aji-40	254	2	et	et	PROPN
aji-40	254	3	al	al	PROPN
aji-40	254	4	conducted	conduct	VERB
aji-40	254	5	a	a	DET
aji-40	254	6	meta	meta	ADJ
aji-40	254	7	-	-	PUNCT
aji-40	254	8	analysis	analysis	NOUN
aji-40	254	9	and	and	CCONJ
aji-40	254	10	found	find	VERB
aji-40	254	11	that	that	SCONJ
aji-40	254	12	the	the	DET
aji-40	254	13	risk	risk	NOUN
aji-40	254	14	of	of	ADP
aji-40	254	15	serious	serious	ADJ
aji-40	254	16	infections	infection	NOUN
aji-40	254	17	defined	define	VERB
aji-40	254	18	as	as	ADP
aji-40	254	19	those	those	PRON
aji-40	254	20	that	that	PRON
aji-40	254	21	were	be	AUX
aji-40	254	22	life‐threatening	life‐threatene	VERB
aji-40	254	23	,	,	PUNCT
aji-40	254	24	requiring	require	VERB
aji-40	254	25	hospitalization	hospitalization	NOUN
aji-40	254	26	and/or	and/or	CCONJ
aji-40	254	27	intravenous	intravenous	ADJ
aji-40	254	28	antibiotic	antibiotic	ADJ
aji-40	254	29	therapy	therapy	NOUN
aji-40	254	30	,	,	PUNCT
aji-40	254	31	or	or	CCONJ
aji-40	254	32	leading	lead	VERB
aji-40	254	33	to	to	ADP
aji-40	254	34	significant	significant	ADJ
aji-40	254	35	disability	disability	NOUN
aji-40	254	36	/	/	SYM
aji-40	254	37	death	death	NOUN
aji-40	254	38	,	,	PUNCT
aji-40	254	39	and	and	CCONJ
aji-40	254	40	general	general	ADJ
aji-40	254	41	infections	infection	NOUN
aji-40	254	42	(	(	PUNCT
aji-40	254	43	infections	infection	NOUN
aji-40	254	44	regardless	regardless	ADV
aji-40	254	45	of	of	ADP
aji-40	254	46	severity	severity	NOUN
aji-40	254	47	and	and	CCONJ
aji-40	254	48	microorganisms	microorganism	NOUN
aji-40	254	49	)	)	PUNCT
aji-40	254	50	were	be	AUX
aji-40	254	51	lower	low	ADJ
aji-40	254	52	in	in	ADP
aji-40	254	53	etanercept	etanercept	NOUN
aji-40	254	54	(	(	PUNCT
aji-40	254	55	soluble	soluble	ADJ
aji-40	254	56	receptor	receptor	NOUN
aji-40	254	57	)	)	PUNCT
aji-40	254	58	treated	treat	VERB
aji-40	254	59	individuals	individual	NOUN
aji-40	254	60	,	,	PUNCT
aji-40	254	61	as	as	SCONJ
aji-40	254	62	compared	compare	VERB
aji-40	254	63	with	with	ADP
aji-40	254	64	the	the	DET
aji-40	254	65	monoclonal	monoclonal	NOUN
aji-40	254	66	antibodies	antibody	NOUN
aji-40	254	67	(	(	PUNCT
aji-40	254	68	adalimumab	adalimumab	NOUN
aji-40	254	69	and	and	CCONJ
aji-40	254	70	infliximab	infliximab	NOUN
aji-40	254	71	)	)	PUNCT
aji-40	255	1	[	[	X
aji-40	255	2	34	34	NUM
aji-40	255	3	]	]	PUNCT
aji-40	255	4	.	.	PUNCT
aji-40	256	1	the	the	DET
aji-40	256	2	risk	risk	NOUN
aji-40	256	3	of	of	ADP
aji-40	256	4	tuberculosis	tuberculosis	NOUN
aji-40	256	5	was	be	AUX
aji-40	256	6	also	also	ADV
aji-40	256	7	lower	low	ADJ
aji-40	256	8	in	in	ADP
aji-40	256	9	etanercept	etanercept	NOUN
aji-40	256	10	treated	treat	VERB
aji-40	256	11	individuals	individual	NOUN
aji-40	256	12	as	as	SCONJ
aji-40	256	13	compared	compare	VERB
aji-40	256	14	to	to	ADP
aji-40	256	15	the	the	DET
aji-40	256	16	individuals	individual	NOUN
aji-40	256	17	treated	treat	VERB
aji-40	256	18	with	with	ADP
aji-40	256	19	adalimumab	adalimumab	NOUN
aji-40	256	20	or	or	CCONJ
aji-40	256	21	infliximab	infliximab	NOUN
aji-40	256	22	[	[	X
aji-40	256	23	34	34	NUM
aji-40	256	24	]	]	PUNCT
aji-40	256	25	.	.	PUNCT
aji-40	257	1	7.1.1	7.1.1	NUM
aji-40	257	2	leprosy	leprosy	NOUN
aji-40	257	3	tnf	tnf	PROPN
aji-40	257	4	plays	play	VERB
aji-40	257	5	an	an	DET
aji-40	257	6	important	important	ADJ
aji-40	257	7	role	role	NOUN
aji-40	257	8	in	in	ADP
aji-40	257	9	pathogenesis	pathogenesis	NOUN
aji-40	257	10	of	of	ADP
aji-40	257	11	nerve	nerve	NOUN
aji-40	257	12	lesions	lesion	NOUN
aji-40	257	13	in	in	ADP
aji-40	257	14	leprosy	leprosy	NOUN
aji-40	257	15	.	.	PUNCT
aji-40	258	1	high	high	ADJ
aji-40	258	2	levels	level	NOUN
aji-40	258	3	of	of	ADP
aji-40	258	4	tnf	tnf	PROPN
aji-40	258	5	have	have	AUX
aji-40	258	6	been	be	AUX
aji-40	258	7	detected	detect	VERB
aji-40	258	8	in	in	ADP
aji-40	258	9	reactional	reactional	ADJ
aji-40	258	10	skin	skin	NOUN
aji-40	258	11	lesions	lesion	NOUN
aji-40	258	12	in	in	ADP
aji-40	258	13	leprosy	leprosy	NOUN
aji-40	258	14	[	[	X
aji-40	258	15	35	35	NUM
aji-40	258	16	]	]	PUNCT
aji-40	258	17	.	.	PUNCT
aji-40	259	1	tnf	tnf	PROPN
aji-40	259	2	may	may	AUX
aji-40	259	3	be	be	AUX
aji-40	259	4	involved	involve	VERB
aji-40	259	5	in	in	ADP
aji-40	259	6	early	early	ADJ
aji-40	259	7	stages	stage	NOUN
aji-40	259	8	of	of	ADP
aji-40	259	9	schwann	schwann	PROPN
aji-40	259	10	cell	cell	NOUN
aji-40	259	11	infection	infection	NOUN
aji-40	259	12	by	by	ADP
aji-40	259	13	mycobacterium	mycobacterium	NOUN
aji-40	259	14	leprae	leprae	NOUN
aji-40	259	15	[	[	X
aji-40	259	16	35	35	NUM
aji-40	259	17	]	]	PUNCT
aji-40	259	18	.	.	PUNCT
aji-40	260	1	tnf	tnf	PROPN
aji-40	260	2	induces	induce	VERB
aji-40	260	3	il-6	il-6	NUM
aji-40	260	4	and	and	CCONJ
aji-40	260	5	il-8	il-8	NOUN
aji-40	260	6	production	production	NOUN
aji-40	260	7	that	that	PRON
aji-40	260	8	contribute	contribute	VERB
aji-40	260	9	to	to	ADP
aji-40	260	10	neuroinflammation	neuroinflammation	NOUN
aji-40	260	11	[	[	X
aji-40	260	12	35	35	NUM
aji-40	260	13	]	]	PUNCT
aji-40	260	14	.	.	PUNCT
aji-40	261	1	mycobacterium	mycobacterium	NOUN
aji-40	261	2	leprae	leprae	NOUN
aji-40	261	3	also	also	ADV
aji-40	261	4	induces	induce	VERB
aji-40	261	5	il-23	il-23	DET
aji-40	261	6	production	production	NOUN
aji-40	261	7	in	in	ADP
aji-40	261	8	schwann	schwann	PROPN
aji-40	261	9	cells	cell	NOUN
aji-40	261	10	that	that	PRON
aji-40	261	11	contributes	contribute	VERB
aji-40	261	12	to	to	ADP
aji-40	261	13	demyelination	demyelination	NOUN
aji-40	261	14	[	[	X
aji-40	261	15	35	35	NUM
aji-40	261	16	]	]	PUNCT
aji-40	261	17	.	.	PUNCT
aji-40	262	1	more	more	ADJ
aji-40	262	2	studies	study	NOUN
aji-40	262	3	are	be	AUX
aji-40	262	4	required	require	VERB
aji-40	262	5	to	to	PART
aji-40	262	6	evaluate	evaluate	VERB
aji-40	262	7	the	the	DET
aji-40	262	8	effect	effect	NOUN
aji-40	262	9	of	of	ADP
aji-40	262	10	antitnf	antitnf	ADJ
aji-40	262	11	therapy	therapy	NOUN
aji-40	262	12	in	in	ADP
aji-40	262	13	patients	patient	NOUN
aji-40	262	14	with	with	ADP
aji-40	262	15	leprosy	leprosy	NOUN
aji-40	262	16	.	.	PUNCT
aji-40	263	1	7.1.2	7.1.2	NUM
aji-40	263	2	chagas	chagas	NOUN
aji-40	263	3	disease	disease	NOUN
aji-40	263	4	chagas	chagas	NOUN
aji-40	263	5	disease	disease	NOUN
aji-40	263	6	is	be	AUX
aji-40	263	7	caused	cause	VERB
aji-40	263	8	by	by	ADP
aji-40	263	9	protozoan	protozoan	NOUN
aji-40	263	10	parasite	parasite	NOUN
aji-40	263	11	trypanosoma	trypanosoma	NOUN
aji-40	263	12	cruzi	cruzi	PROPN
aji-40	264	1	[	[	X
aji-40	264	2	36	36	NUM
aji-40	264	3	]	]	PUNCT
aji-40	264	4	.	.	PUNCT
aji-40	265	1	chronic	chronic	ADJ
aji-40	265	2	chagas	chagas	NOUN
aji-40	265	3	disease	disease	NOUN
aji-40	265	4	cardiomyopathy	cardiomyopathy	ADJ
aji-40	265	5	(	(	PUNCT
aji-40	265	6	chronic	chronic	ADJ
aji-40	265	7	chagasic	chagasic	ADJ
aji-40	265	8	cardiomyopathy	cardiomyopathy	ADJ
aji-40	265	9	)	)	PUNCT
aji-40	265	10	,	,	PUNCT
aji-40	265	11	the	the	DET
aji-40	265	12	main	main	ADJ
aji-40	265	13	manifestation	manifestation	NOUN
aji-40	265	14	of	of	ADP
aji-40	265	15	chagas	chagas	PROPN
aji-40	265	16	disease	disease	NOUN
aji-40	265	17	,	,	PUNCT
aji-40	265	18	is	be	AUX
aji-40	265	19	associated	associate	VERB
aji-40	265	20	with	with	ADP
aji-40	265	21	heart	heart	NOUN
aji-40	265	22	failure	failure	NOUN
aji-40	265	23	[	[	X
aji-40	265	24	36,37	36,37	X
aji-40	265	25	]	]	PUNCT
aji-40	265	26	.	.	PUNCT
aji-40	266	1	elevated	elevated	ADJ
aji-40	266	2	levels	level	NOUN
aji-40	266	3	of	of	ADP
aji-40	266	4	tnf	tnf	PROPN
aji-40	266	5	-	-	PUNCT
aji-40	266	6	α	α	PROPN
aji-40	266	7	occur	occur	VERB
aji-40	266	8	in	in	ADP
aji-40	266	9	chronic	chronic	ADJ
aji-40	266	10	chagas	chagas	NOUN
aji-40	266	11	disease	disease	NOUN
aji-40	266	12	cardiomyopathy	cardiomyopathy	ADJ
aji-40	266	13	and	and	CCONJ
aji-40	266	14	are	be	AUX
aji-40	266	15	related	relate	VERB
aji-40	266	16	to	to	ADP
aji-40	266	17	the	the	DET
aji-40	266	18	severity	severity	NOUN
aji-40	266	19	of	of	ADP
aji-40	266	20	left	left	ADJ
aji-40	266	21	ventricular	ventricular	ADJ
aji-40	266	22	dysfunction	dysfunction	NOUN
aji-40	267	1	[	[	X
aji-40	267	2	36,37	36,37	X
aji-40	267	3	]	]	X
aji-40	267	4	.	.	PUNCT
aji-40	268	1	low	low	ADJ
aji-40	268	2	grade	grade	PROPN
aji-40	268	3	inflammation	inflammation	NOUN
aji-40	268	4	occurs	occur	VERB
aji-40	268	5	in	in	ADP
aji-40	268	6	cardiac	cardiac	ADJ
aji-40	268	7	tissue	tissue	NOUN
aji-40	268	8	in	in	ADP
aji-40	268	9	presence	presence	NOUN
aji-40	268	10	of	of	ADP
aji-40	268	11	elevated	elevated	ADJ
aji-40	268	12	tnf	tnf	PROPN
aji-40	268	13	and	and	CCONJ
aji-40	268	14	interferon	interferon	ADJ
aji-40	268	15	-	-	PUNCT
aji-40	268	16	γ	γ	NOUN
aji-40	268	17	levels	level	NOUN
aji-40	268	18	.	.	PUNCT
aji-40	269	1	pereira	pereira	PROPN
aji-40	269	2	i.r	i.r	PROPN
aji-40	269	3	found	find	VERB
aji-40	269	4	in	in	ADP
aji-40	269	5	their	their	PRON
aji-40	269	6	experimental	experimental	ADJ
aji-40	269	7	studies	study	NOUN
aji-40	269	8	in	in	ADP
aji-40	269	9	mice	mouse	NOUN
aji-40	269	10	that	that	SCONJ
aji-40	269	11	short	short	ADJ
aji-40	269	12	term	term	NOUN
aji-40	269	13	anti	anti	ADJ
aji-40	269	14	-	-	ADJ
aji-40	269	15	tnf	tnf	ADJ
aji-40	269	16	therapy	therapy	NOUN
aji-40	269	17	together	together	ADV
aji-40	269	18	with	with	ADP
aji-40	269	19	trypanocidal	trypanocidal	ADJ
aji-40	269	20	treatment	treatment	NOUN
aji-40	269	21	may	may	AUX
aji-40	269	22	have	have	VERB
aji-40	269	23	beneficial	beneficial	ADJ
aji-40	269	24	effect	effect	NOUN
aji-40	269	25	in	in	ADP
aji-40	269	26	chronic	chronic	ADJ
aji-40	269	27	chagasic	chagasic	ADJ
aji-40	269	28	cardiomyopathy	cardiomyopathy	ADJ
aji-40	270	1	[	[	X
aji-40	270	2	36	36	NUM
aji-40	270	3	]	]	PUNCT
aji-40	270	4	.	.	PUNCT
aji-40	271	1	however	however	ADV
aji-40	271	2	other	other	ADJ
aji-40	271	3	investigators	investigator	NOUN
aji-40	271	4	have	have	AUX
aji-40	271	5	observed	observe	VERB
aji-40	271	6	conflicting	conflicting	ADJ
aji-40	271	7	results	result	NOUN
aji-40	271	8	in	in	ADP
aji-40	271	9	animal	animal	NOUN
aji-40	271	10	studies	study	NOUN
aji-40	271	11	,	,	PUNCT
aji-40	271	12	and	and	CCONJ
aji-40	271	13	have	have	AUX
aji-40	271	14	noticed	notice	VERB
aji-40	271	15	that	that	SCONJ
aji-40	271	16	anti	anti	ADJ
aji-40	271	17	-	-	ADJ
aji-40	271	18	tnf	tnf	ADJ
aji-40	271	19	therapy	therapy	NOUN
aji-40	271	20	may	may	AUX
aji-40	271	21	actually	actually	ADV
aji-40	271	22	aggravate	aggravate	VERB
aji-40	271	23	the	the	DET
aji-40	271	24	cardiomyopathy	cardiomyopathy	ADJ
aji-40	271	25	[	[	X
aji-40	271	26	37	37	NUM
aji-40	271	27	]	]	PUNCT
aji-40	271	28	.	.	PUNCT
aji-40	272	1	more	more	ADJ
aji-40	272	2	studies	study	NOUN
aji-40	272	3	are	be	AUX
aji-40	272	4	required	require	VERB
aji-40	272	5	to	to	PART
aji-40	272	6	evaluate	evaluate	VERB
aji-40	272	7	the	the	DET
aji-40	272	8	effect	effect	NOUN
aji-40	272	9	of	of	ADP
aji-40	272	10	anti	anti	ADJ
aji-40	272	11	-	-	ADJ
aji-40	272	12	tnf	tnf	ADJ
aji-40	272	13	therapy	therapy	NOUN
aji-40	272	14	in	in	ADP
aji-40	272	15	chronic	chronic	ADJ
aji-40	272	16	chagasic	chagasic	ADJ
aji-40	272	17	cardiomyopathy	cardiomyopathy	ADJ
aji-40	272	18	.	.	PUNCT
aji-40	273	1	7.1.3	7.1.3	NUM
aji-40	273	2	covid-19	covid-19	PROPN
aji-40	273	3	high	high	ADJ
aji-40	273	4	mortality	mortality	NOUN
aji-40	273	5	associated	associate	VERB
aji-40	273	6	with	with	ADP
aji-40	273	7	coronavirus	coronavirus	NOUN
aji-40	273	8	disease	disease	NOUN
aji-40	273	9	2019	2019	NUM
aji-40	273	10	(	(	PUNCT
aji-40	273	11	covid-19	covid-19	PROPN
aji-40	273	12	)	)	PUNCT
aji-40	273	13	has	have	AUX
aji-40	273	14	prompted	prompt	VERB
aji-40	273	15	researchers	researcher	NOUN
aji-40	273	16	worldwide	worldwide	ADV
aji-40	273	17	to	to	PART
aji-40	273	18	accelerate	accelerate	VERB
aji-40	273	19	the	the	DET
aji-40	273	20	research	research	NOUN
aji-40	273	21	activities	activity	NOUN
aji-40	273	22	to	to	PART
aji-40	273	23	find	find	VERB
aji-40	273	24	possible	possible	ADJ
aji-40	273	25	safe	safe	ADJ
aji-40	273	26	and	and	CCONJ
aji-40	273	27	effective	effective	ADJ
aji-40	273	28	treatment	treatment	NOUN
aji-40	273	29	options	option	NOUN
aji-40	273	30	and	and	CCONJ
aji-40	273	31	preventive	preventive	ADJ
aji-40	273	32	measures	measure	NOUN
aji-40	273	33	including	include	VERB
aji-40	273	34	vaccines	vaccine	NOUN
aji-40	273	35	[	[	X
aji-40	273	36	38	38	NUM
aji-40	273	37	]	]	PUNCT
aji-40	273	38	.	.	PUNCT
aji-40	274	1	severe	severe	ADJ
aji-40	274	2	acute	acute	ADJ
aji-40	274	3	respiratory	respiratory	ADJ
aji-40	274	4	syndrome	syndrome	NOUN
aji-40	274	5	coronavirus	coronavirus	NOUN
aji-40	274	6	2	2	NUM
aji-40	274	7	(	(	PUNCT
aji-40	274	8	sars	sar	NOUN
aji-40	274	9	-	-	PUNCT
aji-40	274	10	cov-2	cov-2	NOUN
aji-40	274	11	)	)	PUNCT
aji-40	274	12	that	that	PRON
aji-40	274	13	causes	cause	VERB
aji-40	274	14	covid-19	covid-19	PROPN
aji-40	274	15	,	,	PUNCT
aji-40	274	16	enters	enter	VERB
aji-40	274	17	the	the	DET
aji-40	274	18	host	host	NOUN
aji-40	274	19	cells	cell	NOUN
aji-40	274	20	through	through	ADP
aji-40	274	21	angiotensin	angiotensin	NOUN
aji-40	274	22	converting	convert	VERB
aji-40	274	23	enzyme-2	enzyme-2	PRON
aji-40	274	24	expressed	express	VERB
aji-40	274	25	by	by	ADP
aji-40	274	26	type	type	NOUN
aji-40	274	27	ii	ii	PROPN
aji-40	274	28	surfactant	surfactant	NOUN
aji-40	274	29	-	-	PUNCT
aji-40	274	30	secreting	secrete	VERB
aji-40	274	31	alveolar	alveolar	ADJ
aji-40	274	32	cells	cell	NOUN
aji-40	274	33	in	in	ADP
aji-40	274	34	the	the	DET
aji-40	274	35	lungs	lung	NOUN
aji-40	274	36	[	[	X
aji-40	274	37	38	38	NUM
aji-40	274	38	]	]	PUNCT
aji-40	274	39	.	.	PUNCT
aji-40	275	1	the	the	DET
aji-40	275	2	most	most	ADV
aji-40	275	3	important	important	ADJ
aji-40	275	4	mediators	mediator	NOUN
aji-40	275	5	that	that	PRON
aji-40	275	6	drive	drive	VERB
aji-40	275	7	inflammatory	inflammatory	ADJ
aji-40	275	8	response	response	NOUN
aji-40	275	9	to	to	ADP
aji-40	275	10	covid-19	covid-19	PROPN
aji-40	275	11	are	be	AUX
aji-40	275	12	not	not	PART
aji-40	275	13	completely	completely	ADV
aji-40	275	14	known	know	VERB
aji-40	275	15	.	.	PUNCT
aji-40	276	1	upregulation	upregulation	NOUN
aji-40	276	2	of	of	ADP
aji-40	276	3	different	different	ADJ
aji-40	276	4	cytokines	cytokine	NOUN
aji-40	276	5	including	include	VERB
aji-40	276	6	interleukin-1	interleukin-1	NUM
aji-40	276	7	(	(	PUNCT
aji-40	276	8	il-1	il-1	NUM
aji-40	276	9	)	)	PUNCT
aji-40	276	10	,	,	PUNCT
aji-40	276	11	interleukin-6	interleukin-6	PROPN
aji-40	276	12	(	(	PUNCT
aji-40	276	13	il-6	il-6	NUM
aji-40	276	14	)	)	PUNCT
aji-40	276	15	,	,	PUNCT
aji-40	276	16	tnf	tnf	PROPN
aji-40	276	17	,	,	PUNCT
aji-40	276	18	and	and	CCONJ
aji-40	276	19	interferon	interferon	ADJ
aji-40	276	20	-	-	PUNCT
aji-40	276	21	γ	γ	NOUN
aji-40	276	22	occurs	occur	VERB
aji-40	276	23	in	in	ADP
aji-40	276	24	covid-19	covid-19	PROPN
aji-40	277	1	[	[	X
aji-40	277	2	38	38	NUM
aji-40	277	3	]	]	PUNCT
aji-40	277	4	.	.	PUNCT
aji-40	278	1	‘	'	PUNCT
aji-40	278	2	cytokine	cytokine	ADJ
aji-40	278	3	storm	storm	NOUN
aji-40	278	4	’	'	PUNCT
aji-40	278	5	,	,	PUNCT
aji-40	278	6	in	in	ADP
aji-40	278	7	which	which	PRON
aji-40	278	8	too	too	ADV
aji-40	278	9	many	many	ADJ
aji-40	278	10	cytokines	cytokine	NOUN
aji-40	278	11	are	be	AUX
aji-40	278	12	suddenly	suddenly	ADV
aji-40	278	13	released	release	VERB
aji-40	278	14	into	into	ADP
aji-40	278	15	circulation	circulation	NOUN
aji-40	278	16	,	,	PUNCT
aji-40	278	17	can	can	AUX
aji-40	278	18	cause	cause	VERB
aji-40	278	19	severe	severe	ADJ
aji-40	278	20	inflammatory	inflammatory	ADJ
aji-40	278	21	response	response	NOUN
aji-40	278	22	that	that	PRON
aji-40	278	23	causes	cause	VERB
aji-40	278	24	more	more	ADJ
aji-40	278	25	harm	harm	NOUN
aji-40	278	26	than	than	ADP
aji-40	278	27	good	good	ADJ
aji-40	278	28	.	.	PUNCT
aji-40	279	1	marc	marc	PROPN
aji-40	279	2	feldmann	feldmann	PROPN
aji-40	279	3	,	,	PUNCT
aji-40	279	4	et	et	PROPN
aji-40	279	5	al	al	PROPN
aji-40	279	6	have	have	AUX
aji-40	279	7	discussed	discuss	VERB
aji-40	279	8	this	this	DET
aji-40	279	9	topic	topic	NOUN
aji-40	279	10	in	in	ADP
aji-40	279	11	detail	detail	NOUN
aji-40	279	12	and	and	CCONJ
aji-40	279	13	have	have	AUX
aji-40	279	14	proposed	propose	VERB
aji-40	279	15	that	that	SCONJ
aji-40	279	16	clinical	clinical	ADJ
aji-40	279	17	trials	trial	NOUN
aji-40	279	18	are	be	AUX
aji-40	279	19	needed	need	VERB
aji-40	279	20	to	to	PART
aji-40	279	21	evaluate	evaluate	VERB
aji-40	279	22	safety	safety	NOUN
aji-40	279	23	and	and	CCONJ
aji-40	279	24	effectiveness	effectiveness	NOUN
aji-40	279	25	of	of	ADP
aji-40	279	26	anti	anti	ADJ
aji-40	279	27	-	-	ADJ
aji-40	279	28	tnf	tnf	ADJ
aji-40	279	29	therapies	therapy	NOUN
aji-40	279	30	,	,	PUNCT
aji-40	279	31	particularly	particularly	ADV
aji-40	279	32	infliximab	infliximab	NOUN
aji-40	279	33	and	and	CCONJ
aji-40	279	34	adalimumab	adalimumab	NOUN
aji-40	280	1	[	[	X
aji-40	280	2	38	38	NUM
aji-40	280	3	]	]	PUNCT
aji-40	280	4	.	.	PUNCT
aji-40	281	1	they	they	PRON
aji-40	281	2	speculate	speculate	VERB
aji-40	281	3	that	that	SCONJ
aji-40	281	4	these	these	DET
aji-40	281	5	antitnf	antitnf	ADJ
aji-40	281	6	agents	agent	NOUN
aji-40	281	7	may	may	AUX
aji-40	281	8	be	be	AUX
aji-40	281	9	beneficial	beneficial	ADJ
aji-40	281	10	in	in	ADP
aji-40	281	11	decreasing	decrease	VERB
aji-40	281	12	the	the	DET
aji-40	281	13	intensity	intensity	NOUN
aji-40	281	14	of	of	ADP
aji-40	281	15	the	the	DET
aji-40	281	16	‘	'	PUNCT
aji-40	281	17	cytokine	cytokine	ADJ
aji-40	281	18	storm	storm	NOUN
aji-40	281	19	’	'	PUNCT
aji-40	281	20	,	,	PUNCT
aji-40	281	21	reduce	reduce	VERB
aji-40	281	22	inflammation	inflammation	NOUN
aji-40	281	23	,	,	PUNCT
aji-40	281	24	and	and	CCONJ
aji-40	281	25	help	help	VERB
aji-40	281	26	in	in	ADP
aji-40	281	27	severe	severe	ADJ
aji-40	281	28	covid-19	covid-19	PROPN
aji-40	282	1	[	[	X
aji-40	282	2	38	38	NUM
aji-40	282	3	]	]	PUNCT
aji-40	282	4	.	.	PUNCT
aji-40	283	1	churchill	churchill	PROPN
aji-40	283	2	et	et	PROPN
aji-40	283	3	al	al	PROPN
aji-40	283	4	.	.	PROPN
aji-40	283	5	;	;	PUNCT
aji-40	283	6	aji	aji	PROPN
aji-40	283	7	,	,	PUNCT
aji-40	283	8	3(1	3(1	NUM
aji-40	283	9	):	):	PUNCT
aji-40	283	10	208	208	NUM
aji-40	283	11	-	-	SYM
aji-40	283	12	222	222	NUM
aji-40	283	13	,	,	PUNCT
aji-40	283	14	2020	2020	NUM
aji-40	283	15	;	;	PUNCT
aji-40	283	16	article	article	NOUN
aji-40	283	17	no.aji.57464	no.aji.57464	PRON
aji-40	283	18	215	215	NUM
aji-40	283	19	7.2	7.2	NUM
aji-40	283	20	autoimmune	autoimmune	ADJ
aji-40	283	21	disorders	disorder	NOUN
aji-40	283	22	the	the	DET
aji-40	283	23	mechanisms	mechanism	NOUN
aji-40	283	24	leading	lead	VERB
aji-40	283	25	to	to	ADP
aji-40	283	26	disease	disease	NOUN
aji-40	283	27	through	through	ADP
aji-40	283	28	tnf	tnf	PROPN
aji-40	283	29	-	-	PUNCT
aji-40	283	30	α	α	PROPN
aji-40	283	31	and	and	CCONJ
aji-40	283	32	tnf	tnf	PROPN
aji-40	283	33	receptors	receptor	NOUN
aji-40	283	34	pathway	pathway	NOUN
aji-40	283	35	are	be	AUX
aji-40	283	36	complex	complex	ADJ
aji-40	283	37	showing	show	VERB
aji-40	283	38	both	both	CCONJ
aji-40	283	39	positive	positive	ADJ
aji-40	283	40	and	and	CCONJ
aji-40	283	41	negative	negative	ADJ
aji-40	283	42	effects	effect	NOUN
aji-40	283	43	on	on	ADP
aji-40	283	44	autoimmune	autoimmune	ADJ
aji-40	283	45	disorders	disorder	NOUN
aji-40	283	46	.	.	PUNCT
aji-40	284	1	a	a	DET
aji-40	284	2	few	few	ADJ
aji-40	284	3	cases	case	NOUN
aji-40	284	4	have	have	AUX
aji-40	284	5	been	be	AUX
aji-40	284	6	reported	report	VERB
aji-40	284	7	of	of	ADP
aji-40	284	8	etanercept	etanercept	NOUN
aji-40	284	9	and	and	CCONJ
aji-40	284	10	adalimumab	adalimumab	NOUN
aji-40	284	11	inducing	induce	VERB
aji-40	284	12	systemic	systemic	ADJ
aji-40	284	13	lupus	lupus	NOUN
aji-40	284	14	erythematosus	erythematosus	NOUN
aji-40	284	15	and	and	CCONJ
aji-40	284	16	lupus	lupus	ADJ
aji-40	284	17	serositis	serositis	ADJ
aji-40	284	18	[	[	X
aji-40	284	19	39	39	NUM
aji-40	284	20	-	-	SYM
aji-40	284	21	43	43	NUM
aji-40	284	22	]	]	PUNCT
aji-40	284	23	.	.	PUNCT
aji-40	285	1	but	but	CCONJ
aji-40	285	2	there	there	PRON
aji-40	285	3	are	be	VERB
aji-40	285	4	other	other	ADJ
aji-40	285	5	reports	report	NOUN
aji-40	285	6	favoring	favor	VERB
aji-40	285	7	anti	anti	ADJ
aji-40	285	8	-	-	ADJ
aji-40	285	9	tnf	tnf	ADJ
aji-40	285	10	therapeutic	therapeutic	ADJ
aji-40	285	11	agents	agent	NOUN
aji-40	285	12	having	have	VERB
aji-40	285	13	beneficial	beneficial	ADJ
aji-40	285	14	effect	effect	NOUN
aji-40	285	15	on	on	ADP
aji-40	285	16	these	these	DET
aji-40	285	17	autoimmune	autoimmune	ADJ
aji-40	285	18	diseases	disease	NOUN
aji-40	285	19	.	.	PUNCT
aji-40	286	1	uppal	uppal	PROPN
aji-40	286	2	,	,	PUNCT
aji-40	286	3	et	et	PROPN
aji-40	286	4	al	al	PROPN
aji-40	286	5	investigated	investigate	VERB
aji-40	286	6	the	the	DET
aji-40	286	7	effect	effect	NOUN
aji-40	286	8	of	of	ADP
aji-40	286	9	infliximab	infliximab	NOUN
aji-40	286	10	in	in	ADP
aji-40	286	11	active	active	ADJ
aji-40	286	12	systemic	systemic	ADJ
aji-40	286	13	lupus	lupus	NOUN
aji-40	286	14	erythematosus	erythematosus	NOUN
aji-40	286	15	subjects	subject	NOUN
aji-40	286	16	and	and	CCONJ
aji-40	286	17	found	find	VERB
aji-40	286	18	that	that	SCONJ
aji-40	286	19	the	the	DET
aji-40	286	20	drug	drug	NOUN
aji-40	286	21	significantly	significantly	ADV
aji-40	286	22	decreases	decrease	VERB
aji-40	286	23	the	the	DET
aji-40	286	24	systemic	systemic	ADJ
aji-40	286	25	lupus	lupus	PROPN
aji-40	286	26	erythematosus	erythematosus	PROPN
aji-40	286	27	disease	disease	NOUN
aji-40	286	28	activity	activity	NOUN
aji-40	286	29	index	index	NOUN
aji-40	286	30	(	(	PUNCT
aji-40	286	31	sledai	sledai	NOUN
aji-40	286	32	)	)	PUNCT
aji-40	286	33	.	.	PUNCT
aji-40	287	1	they	they	PRON
aji-40	287	2	concluded	conclude	VERB
aji-40	287	3	that	that	SCONJ
aji-40	287	4	anti	anti	ADJ
aji-40	287	5	-	-	ADJ
aji-40	287	6	tnf	tnf	ADJ
aji-40	287	7	therapeutic	therapeutic	ADJ
aji-40	287	8	agents	agent	NOUN
aji-40	287	9	are	be	AUX
aji-40	287	10	interesting	interesting	ADJ
aji-40	287	11	candidates	candidate	NOUN
aji-40	287	12	that	that	PRON
aji-40	287	13	can	can	AUX
aji-40	287	14	be	be	AUX
aji-40	287	15	explored	explore	VERB
aji-40	287	16	further	far	ADV
aji-40	287	17	for	for	ADP
aji-40	287	18	treatment	treatment	NOUN
aji-40	287	19	of	of	ADP
aji-40	287	20	active	active	ADJ
aji-40	287	21	sle	sle	NOUN
aji-40	288	1	[	[	X
aji-40	288	2	44	44	NUM
aji-40	288	3	]	]	PUNCT
aji-40	288	4	.	.	PUNCT
aji-40	289	1	there	there	PRON
aji-40	289	2	are	be	VERB
aji-40	289	3	conflicting	conflicting	ADJ
aji-40	289	4	experiences	experience	NOUN
aji-40	289	5	with	with	ADP
aji-40	289	6	other	other	ADJ
aji-40	289	7	anti	anti	ADJ
aji-40	289	8	-	-	ADJ
aji-40	289	9	tnf	tnf	ADJ
aji-40	289	10	therapies	therapy	NOUN
aji-40	289	11	and	and	CCONJ
aji-40	289	12	autoimmune	autoimmune	ADJ
aji-40	289	13	diseases	disease	NOUN
aji-40	289	14	too	too	ADV
aji-40	289	15	.	.	PUNCT
aji-40	290	1	it	it	PRON
aji-40	290	2	is	be	AUX
aji-40	290	3	known	know	VERB
aji-40	290	4	that	that	SCONJ
aji-40	290	5	there	there	PRON
aji-40	290	6	is	be	VERB
aji-40	290	7	deficiency	deficiency	NOUN
aji-40	290	8	of	of	ADP
aji-40	290	9	tnfr2	tnfr2	NOUN
aji-40	290	10	in	in	ADP
aji-40	290	11	several	several	ADJ
aji-40	290	12	autoimmune	autoimmune	ADJ
aji-40	290	13	diseases	disease	NOUN
aji-40	290	14	that	that	PRON
aji-40	290	15	could	could	AUX
aji-40	290	16	result	result	VERB
aji-40	290	17	in	in	ADP
aji-40	290	18	uncontrolled	uncontrolled	ADJ
aji-40	290	19	inflammatory	inflammatory	ADJ
aji-40	290	20	activity	activity	NOUN
aji-40	290	21	through	through	ADP
aji-40	290	22	soluble	soluble	ADJ
aji-40	290	23	tnf	tnf	PROPN
aji-40	290	24	-	-	PUNCT
aji-40	290	25	α	α	PROPN
aji-40	290	26	,	,	PUNCT
aji-40	290	27	tnfr1	tnfr1	NOUN
aji-40	290	28	pathway	pathway	NOUN
aji-40	290	29	.	.	PUNCT
aji-40	291	1	instead	instead	ADV
aji-40	291	2	of	of	ADP
aji-40	291	3	using	use	VERB
aji-40	291	4	non	non	ADJ
aji-40	291	5	-	-	ADJ
aji-40	291	6	specific	specific	ADJ
aji-40	291	7	anti	anti	ADJ
aji-40	291	8	-	-	ADJ
aji-40	291	9	tnf	tnf	ADJ
aji-40	291	10	-	-	PUNCT
aji-40	291	11	α	α	NOUN
aji-40	291	12	therapeutic	therapeutic	ADJ
aji-40	291	13	agents	agent	NOUN
aji-40	291	14	that	that	PRON
aji-40	291	15	cause	cause	VERB
aji-40	291	16	varying	vary	VERB
aji-40	291	17	impact	impact	NOUN
aji-40	291	18	on	on	ADP
aji-40	291	19	both	both	DET
aji-40	291	20	tnfr1	tnfr1	NOUN
aji-40	291	21	and	and	CCONJ
aji-40	291	22	tnfr2	tnfr2	VERB
aji-40	291	23	pathways	pathway	NOUN
aji-40	291	24	resulting	result	VERB
aji-40	291	25	in	in	ADP
aji-40	291	26	unpredictable	unpredictable	ADJ
aji-40	291	27	consequences	consequence	NOUN
aji-40	291	28	,	,	PUNCT
aji-40	291	29	using	use	VERB
aji-40	291	30	specific	specific	ADJ
aji-40	291	31	agents	agent	NOUN
aji-40	291	32	to	to	PART
aji-40	291	33	target	target	VERB
aji-40	291	34	tnfr1	tnfr1	NOUN
aji-40	291	35	or	or	CCONJ
aji-40	291	36	tnfr2	tnfr2	NOUN
aji-40	291	37	pathways	pathway	NOUN
aji-40	291	38	may	may	AUX
aji-40	291	39	yield	yield	VERB
aji-40	291	40	better	well	ADJ
aji-40	291	41	and	and	CCONJ
aji-40	291	42	predictable	predictable	ADJ
aji-40	291	43	results	result	NOUN
aji-40	291	44	.	.	PUNCT
aji-40	292	1	yang	yang	PROPN
aji-40	292	2	et	et	PROPN
aji-40	292	3	al	al	PROPN
aji-40	292	4	have	have	AUX
aji-40	292	5	proposed	propose	VERB
aji-40	292	6	that	that	SCONJ
aji-40	292	7	either	either	CCONJ
aji-40	292	8	using	use	VERB
aji-40	292	9	agents	agent	NOUN
aji-40	292	10	that	that	SCONJ
aji-40	292	11	specifically	specifically	ADV
aji-40	292	12	block	block	VERB
aji-40	292	13	tnf	tnf	PROPN
aji-40	292	14	-	-	PUNCT
aji-40	292	15	α	α	PROPN
aji-40	292	16	or	or	CCONJ
aji-40	292	17	tnfr1	tnfr1	NOUN
aji-40	292	18	and	and	CCONJ
aji-40	292	19	preserve	preserve	VERB
aji-40	292	20	the	the	DET
aji-40	292	21	available	available	ADJ
aji-40	292	22	tnfr2	tnfr2	NOUN
aji-40	292	23	;	;	PUNCT
aji-40	292	24	or	or	CCONJ
aji-40	292	25	using	use	VERB
aji-40	292	26	tnfr2	tnfr2	NOUN
aji-40	292	27	agonists	agonist	NOUN
aji-40	292	28	to	to	PART
aji-40	292	29	increase	increase	VERB
aji-40	292	30	the	the	DET
aji-40	292	31	number	number	NOUN
aji-40	292	32	of	of	ADP
aji-40	292	33	tnfr2	tnfr2	NOUN
aji-40	292	34	and	and	CCONJ
aji-40	292	35	promote	promote	VERB
aji-40	292	36	tissue	tissue	NOUN
aji-40	292	37	regeneration	regeneration	NOUN
aji-40	292	38	may	may	AUX
aji-40	292	39	prove	prove	VERB
aji-40	292	40	to	to	PART
aji-40	292	41	be	be	AUX
aji-40	292	42	good	good	ADJ
aji-40	292	43	therapeutic	therapeutic	ADJ
aji-40	292	44	strategies	strategy	NOUN
aji-40	292	45	in	in	ADP
aji-40	292	46	autoimmune	autoimmune	ADJ
aji-40	292	47	diseases	disease	NOUN
aji-40	293	1	[	[	X
aji-40	293	2	3	3	NUM
aji-40	293	3	]	]	PUNCT
aji-40	293	4	.	.	PUNCT
aji-40	294	1	further	further	ADJ
aji-40	294	2	studies	study	NOUN
aji-40	294	3	are	be	AUX
aji-40	294	4	required	require	VERB
aji-40	294	5	to	to	PART
aji-40	294	6	evaluate	evaluate	VERB
aji-40	294	7	whether	whether	SCONJ
aji-40	294	8	these	these	DET
aji-40	294	9	strategies	strategy	NOUN
aji-40	294	10	are	be	AUX
aji-40	294	11	indeed	indeed	ADV
aji-40	294	12	beneficial	beneficial	ADJ
aji-40	294	13	and	and	CCONJ
aji-40	294	14	could	could	AUX
aji-40	294	15	be	be	AUX
aji-40	294	16	safely	safely	ADV
aji-40	294	17	implemented	implement	VERB
aji-40	294	18	.	.	PUNCT
aji-40	295	1	7.3	7.3	NUM
aji-40	295	2	cardiovascular	cardiovascular	ADJ
aji-40	295	3	system	system	NOUN
aji-40	295	4	tnf	tnf	PROPN
aji-40	295	5	-	-	PUNCT
aji-40	295	6	α	α	PROPN
aji-40	295	7	levels	level	NOUN
aji-40	295	8	have	have	VERB
aji-40	295	9	an	an	DET
aji-40	295	10	important	important	ADJ
aji-40	295	11	relationship	relationship	NOUN
aji-40	295	12	with	with	ADP
aji-40	295	13	cardiovascular	cardiovascular	ADJ
aji-40	295	14	diseases	disease	NOUN
aji-40	295	15	and	and	CCONJ
aji-40	295	16	events	event	NOUN
aji-40	295	17	including	include	VERB
aji-40	295	18	congestive	congestive	ADJ
aji-40	295	19	heart	heart	NOUN
aji-40	295	20	failure	failure	NOUN
aji-40	295	21	[	[	X
aji-40	295	22	30,31	30,31	NOUN
aji-40	295	23	]	]	PUNCT
aji-40	295	24	.	.	PUNCT
aji-40	296	1	the	the	DET
aji-40	296	2	level	level	NOUN
aji-40	296	3	of	of	ADP
aji-40	296	4	tnf	tnf	PROPN
aji-40	296	5	-	-	PUNCT
aji-40	296	6	α	α	PROPN
aji-40	296	7	has	have	AUX
aji-40	296	8	been	be	AUX
aji-40	296	9	shown	show	VERB
aji-40	296	10	to	to	PART
aji-40	296	11	be	be	AUX
aji-40	296	12	predictive	predictive	ADJ
aji-40	296	13	of	of	ADP
aji-40	296	14	recurrent	recurrent	ADJ
aji-40	296	15	myocardial	myocardial	ADJ
aji-40	296	16	infarction	infarction	NOUN
aji-40	297	1	[	[	X
aji-40	297	2	43	43	NUM
aji-40	297	3	]	]	PUNCT
aji-40	297	4	.	.	PUNCT
aji-40	298	1	also	also	ADV
aji-40	298	2	,	,	PUNCT
aji-40	298	3	tnf	tnf	PROPN
aji-40	298	4	-	-	PUNCT
aji-40	298	5	α	α	NOUN
aji-40	298	6	level	level	NOUN
aji-40	298	7	may	may	AUX
aji-40	298	8	play	play	VERB
aji-40	298	9	a	a	DET
aji-40	298	10	role	role	NOUN
aji-40	298	11	in	in	ADP
aji-40	298	12	hypertension	hypertension	NOUN
aji-40	298	13	,	,	PUNCT
aji-40	298	14	dyslipidemia	dyslipidemia	NOUN
aji-40	298	15	,	,	PUNCT
aji-40	298	16	and	and	CCONJ
aji-40	298	17	atherosclerosis	atherosclerosis	NOUN
aji-40	298	18	[	[	PUNCT
aji-40	298	19	45	45	NUM
aji-40	298	20	-	-	SYM
aji-40	298	21	48	48	NUM
aji-40	298	22	]	]	PUNCT
aji-40	298	23	.	.	PUNCT
aji-40	299	1	investigators	investigator	NOUN
aji-40	299	2	have	have	AUX
aji-40	299	3	proposed	propose	VERB
aji-40	299	4	that	that	SCONJ
aji-40	299	5	tnf	tnf	PROPN
aji-40	299	6	-	-	PUNCT
aji-40	299	7	α	α	PROPN
aji-40	299	8	induces	induce	NOUN
aji-40	299	9	atherogenesis	atherogenesis	NOUN
aji-40	299	10	by	by	ADP
aji-40	299	11	promoting	promote	VERB
aji-40	299	12	induction	induction	NOUN
aji-40	299	13	of	of	ADP
aji-40	299	14	vascular	vascular	ADJ
aji-40	299	15	cell	cell	NOUN
aji-40	299	16	adhesion	adhesion	NOUN
aji-40	299	17	molecule-1	molecule-1	PROPN
aji-40	299	18	(	(	PUNCT
aji-40	299	19	vcam-1	vcam-1	NOUN
aji-40	299	20	)	)	PUNCT
aji-40	299	21	and	and	CCONJ
aji-40	299	22	intercellular	intercellular	ADJ
aji-40	299	23	adhesion	adhesion	NOUN
aji-40	299	24	molecule-1	molecule-1	PROPN
aji-40	299	25	(	(	PUNCT
aji-40	299	26	icam-1	icam-1	NOUN
aji-40	299	27	)	)	PUNCT
aji-40	299	28	expression	expression	NOUN
aji-40	299	29	by	by	ADP
aji-40	299	30	endothelial	endothelial	ADJ
aji-40	299	31	cells	cell	NOUN
aji-40	299	32	and	and	CCONJ
aji-40	299	33	vascular	vascular	ADJ
aji-40	299	34	smooth	smooth	ADJ
aji-40	299	35	muscle	muscle	NOUN
aji-40	299	36	cells	cell	NOUN
aji-40	299	37	,	,	PUNCT
aji-40	299	38	endothelial	endothelial	ADJ
aji-40	299	39	cell	cell	NOUN
aji-40	299	40	apoptosis	apoptosis	NOUN
aji-40	299	41	,	,	PUNCT
aji-40	299	42	and	and	CCONJ
aji-40	299	43	smooth	smooth	ADJ
aji-40	299	44	muscle	muscle	NOUN
aji-40	299	45	cell	cell	NOUN
aji-40	299	46	migration	migration	NOUN
aji-40	299	47	and	and	CCONJ
aji-40	299	48	proliferation	proliferation	NOUN
aji-40	299	49	[	[	X
aji-40	299	50	45	45	NUM
aji-40	299	51	]	]	PUNCT
aji-40	299	52	.	.	PUNCT
aji-40	300	1	interestingly	interestingly	ADV
aji-40	300	2	,	,	PUNCT
aji-40	300	3	the	the	DET
aji-40	300	4	cellular	cellular	ADJ
aji-40	300	5	location	location	NOUN
aji-40	300	6	of	of	ADP
aji-40	300	7	tnfr1	tnfr1	NOUN
aji-40	300	8	may	may	AUX
aji-40	300	9	have	have	VERB
aji-40	300	10	effects	effect	NOUN
aji-40	300	11	on	on	ADP
aji-40	300	12	atherogenesis	atherogenesis	NOUN
aji-40	300	13	.	.	PUNCT
aji-40	301	1	as	as	ADP
aji-40	301	2	an	an	DET
aji-40	301	3	example	example	NOUN
aji-40	301	4	,	,	PUNCT
aji-40	301	5	tnfr1	tnfr1	NOUN
aji-40	301	6	in	in	ADP
aji-40	301	7	macrophages	macrophage	NOUN
aji-40	301	8	may	may	AUX
aji-40	301	9	decrease	decrease	VERB
aji-40	301	10	atherogenesis	atherogenesis	VERB
aji-40	301	11	,	,	PUNCT
aji-40	301	12	whereas	whereas	SCONJ
aji-40	301	13	the	the	DET
aji-40	301	14	tnfr1	tnfr1	NOUN
aji-40	301	15	in	in	ADP
aji-40	301	16	the	the	DET
aji-40	301	17	arterial	arterial	ADJ
aji-40	301	18	walls	wall	NOUN
aji-40	301	19	may	may	AUX
aji-40	301	20	promote	promote	VERB
aji-40	301	21	atherogenesis	atherogenesis	NOUN
aji-40	302	1	[	[	X
aji-40	302	2	45,48	45,48	X
aji-40	302	3	]	]	X
aji-40	302	4	.	.	PUNCT
aji-40	303	1	tnf	tnf	PROPN
aji-40	303	2	-	-	PUNCT
aji-40	303	3	α	α	PROPN
aji-40	303	4	might	might	AUX
aji-40	303	5	have	have	VERB
aji-40	303	6	a	a	DET
aji-40	303	7	role	role	NOUN
aji-40	303	8	in	in	ADP
aji-40	303	9	arterial	arterial	ADJ
aji-40	303	10	inflammation	inflammation	NOUN
aji-40	303	11	and	and	CCONJ
aji-40	303	12	intimal	intimal	ADJ
aji-40	303	13	hyperplasia	hyperplasia	NOUN
aji-40	304	1	[	[	X
aji-40	304	2	15	15	NUM
aji-40	304	3	]	]	PUNCT
aji-40	304	4	.	.	PUNCT
aji-40	305	1	kitagaki	kitagaki	PROPN
aji-40	305	2	et	et	PROPN
aji-40	305	3	al	al	PROPN
aji-40	305	4	showed	show	VERB
aji-40	305	5	that	that	SCONJ
aji-40	305	6	tnf	tnf	PROPN
aji-40	305	7	-	-	PUNCT
aji-40	305	8	α	α	PROPN
aji-40	305	9	is	be	AUX
aji-40	305	10	an	an	DET
aji-40	305	11	important	important	ADJ
aji-40	305	12	contributor	contributor	NOUN
aji-40	305	13	to	to	PART
aji-40	305	14	arterial	arterial	VERB
aji-40	305	15	inflammation	inflammation	NOUN
aji-40	305	16	in	in	ADP
aji-40	305	17	mice	mouse	NOUN
aji-40	305	18	and	and	CCONJ
aji-40	305	19	that	that	DET
aji-40	305	20	blockage	blockage	NOUN
aji-40	305	21	of	of	ADP
aji-40	305	22	tnfr1	tnfr1	PROPN
aji-40	305	23	inhibits	inhibit	VERB
aji-40	305	24	intimal	intimal	ADJ
aji-40	305	25	hyperplasia	hyperplasia	NOUN
aji-40	305	26	following	follow	VERB
aji-40	305	27	experimentally	experimentally	ADV
aji-40	305	28	induced	induce	VERB
aji-40	305	29	arterial	arterial	ADJ
aji-40	305	30	inflammation	inflammation	NOUN
aji-40	305	31	(	(	PUNCT
aji-40	305	32	post	post	NOUN
aji-40	305	33	injury	injury	NOUN
aji-40	305	34	)	)	PUNCT
aji-40	306	1	[	[	X
aji-40	306	2	15	15	NUM
aji-40	306	3	]	]	PUNCT
aji-40	306	4	.	.	PUNCT
aji-40	307	1	tnfr2	tnfr2	NOUN
aji-40	308	1	signaling	signal	VERB
aji-40	308	2	mediates	mediate	NOUN
aji-40	308	3	inhibition	inhibition	NOUN
aji-40	308	4	of	of	ADP
aji-40	308	5	neointimal	neointimal	ADJ
aji-40	308	6	formation	formation	NOUN
aji-40	308	7	by	by	ADP
aji-40	308	8	decreasing	decrease	VERB
aji-40	308	9	adherent	adherent	ADJ
aji-40	308	10	cells	cell	NOUN
aji-40	308	11	and	and	CCONJ
aji-40	308	12	apoptosis	apoptosis	NOUN
aji-40	308	13	of	of	ADP
aji-40	308	14	endothelial	endothelial	ADJ
aji-40	308	15	cells	cell	NOUN
aji-40	308	16	as	as	ADV
aji-40	308	17	well	well	ADV
aji-40	308	18	as	as	ADP
aji-40	308	19	the	the	DET
aji-40	308	20	activation	activation	NOUN
aji-40	308	21	,	,	PUNCT
aji-40	308	22	proliferation	proliferation	NOUN
aji-40	308	23	and	and	CCONJ
aji-40	308	24	migration	migration	NOUN
aji-40	308	25	of	of	ADP
aji-40	308	26	endothelial	endothelial	ADJ
aji-40	308	27	cells	cell	NOUN
aji-40	308	28	[	[	X
aji-40	308	29	15	15	NUM
aji-40	308	30	]	]	PUNCT
aji-40	308	31	.	.	PUNCT
aji-40	309	1	7.4	7.4	NUM
aji-40	309	2	malignancy	malignancy	NOUN
aji-40	309	3	tnf	tnf	PROPN
aji-40	309	4	-	-	PUNCT
aji-40	309	5	α	α	PROPN
aji-40	309	6	is	be	AUX
aji-40	309	7	an	an	DET
aji-40	309	8	important	important	ADJ
aji-40	309	9	cytokine	cytokine	NOUN
aji-40	309	10	that	that	PRON
aji-40	309	11	is	be	AUX
aji-40	309	12	involved	involve	VERB
aji-40	309	13	in	in	ADP
aji-40	309	14	tumor	tumor	NOUN
aji-40	309	15	surveillance	surveillance	NOUN
aji-40	309	16	and	and	CCONJ
aji-40	309	17	hence	hence	ADV
aji-40	309	18	anti	anti	ADJ
aji-40	309	19	-	-	ADJ
aji-40	309	20	tnf	tnf	ADJ
aji-40	309	21	therapy	therapy	NOUN
aji-40	309	22	theoretically	theoretically	ADV
aji-40	309	23	poses	pose	VERB
aji-40	309	24	a	a	DET
aji-40	309	25	risk	risk	NOUN
aji-40	309	26	for	for	ADP
aji-40	309	27	developing	develop	VERB
aji-40	309	28	malignancies	malignancy	NOUN
aji-40	309	29	.	.	PUNCT
aji-40	310	1	this	this	PRON
aji-40	310	2	has	have	AUX
aji-40	310	3	been	be	AUX
aji-40	310	4	substantiated	substantiate	VERB
aji-40	310	5	in	in	ADP
aji-40	310	6	several	several	ADJ
aji-40	310	7	studies	study	NOUN
aji-40	310	8	indicating	indicate	VERB
aji-40	310	9	that	that	SCONJ
aji-40	310	10	anti	anti	ADJ
aji-40	310	11	-	-	ADJ
aji-40	310	12	tnf	tnf	ADJ
aji-40	310	13	therapeutic	therapeutic	ADJ
aji-40	310	14	agents	agent	NOUN
aji-40	310	15	may	may	AUX
aji-40	310	16	be	be	AUX
aji-40	310	17	associated	associate	VERB
aji-40	310	18	with	with	ADP
aji-40	310	19	an	an	DET
aji-40	310	20	increased	increase	VERB
aji-40	310	21	risk	risk	NOUN
aji-40	310	22	of	of	ADP
aji-40	310	23	malignancies	malignancy	NOUN
aji-40	310	24	including	include	VERB
aji-40	310	25	lymphoma	lymphoma	NOUN
aji-40	310	26	,	,	PUNCT
aji-40	310	27	breast	breast	NOUN
aji-40	310	28	cancer	cancer	NOUN
aji-40	310	29	,	,	PUNCT
aji-40	310	30	colorectal	colorectal	ADJ
aji-40	310	31	cancer	cancer	NOUN
aji-40	310	32	,	,	PUNCT
aji-40	310	33	and	and	CCONJ
aji-40	310	34	melanoma	melanoma	NOUN
aji-40	310	35	[	[	X
aji-40	310	36	30,31,49	30,31,49	NUM
aji-40	310	37	]	]	X
aji-40	310	38	.	.	PUNCT
aji-40	311	1	berghen	berghen	ADV
aji-40	311	2	et	et	PROPN
aji-40	311	3	al	al	PROPN
aji-40	311	4	observed	observe	VERB
aji-40	311	5	incidence	incidence	NOUN
aji-40	311	6	of	of	ADP
aji-40	311	7	malignancy	malignancy	NOUN
aji-40	311	8	in	in	ADP
aji-40	311	9	365	365	NUM
aji-40	311	10	rheumatoid	rheumatoid	NOUN
aji-40	311	11	arthritis	arthritis	NOUN
aji-40	311	12	patients	patient	NOUN
aji-40	311	13	receiving	receive	VERB
aji-40	311	14	antitnf	antitnf	PROPN
aji-40	311	15	therapy	therapy	NOUN
aji-40	311	16	at	at	ADP
aji-40	311	17	a	a	DET
aji-40	311	18	single	single	ADJ
aji-40	311	19	center	center	NOUN
aji-40	311	20	from	from	ADP
aji-40	311	21	january	january	PROPN
aji-40	311	22	2000	2000	NUM
aji-40	311	23	until	until	ADP
aji-40	311	24	january	january	PROPN
aji-40	311	25	2012	2012	NUM
aji-40	311	26	that	that	PRON
aji-40	311	27	received	receive	VERB
aji-40	311	28	anti	anti	ADJ
aji-40	311	29	-	-	ADJ
aji-40	311	30	tnf	tnf	ADJ
aji-40	311	31	therapy	therapy	NOUN
aji-40	311	32	[	[	X
aji-40	311	33	49	49	NUM
aji-40	311	34	]	]	PUNCT
aji-40	311	35	.	.	PUNCT
aji-40	312	1	they	they	PRON
aji-40	312	2	observed	observe	VERB
aji-40	312	3	occurrence	occurrence	NOUN
aji-40	312	4	of	of	ADP
aji-40	312	5	34	34	NUM
aji-40	312	6	malignancies	malignancy	NOUN
aji-40	312	7	in	in	ADP
aji-40	312	8	30	30	NUM
aji-40	312	9	patients	patient	NOUN
aji-40	312	10	after	after	ADP
aji-40	312	11	the	the	DET
aji-40	312	12	start	start	NOUN
aji-40	312	13	of	of	ADP
aji-40	312	14	antitnf	antitnf	ADJ
aji-40	312	15	treatment	treatment	NOUN
aji-40	312	16	.	.	PUNCT
aji-40	313	1	among	among	ADP
aji-40	313	2	these	these	PRON
aji-40	313	3	,	,	PUNCT
aji-40	313	4	20	20	NUM
aji-40	313	5	patients	patient	NOUN
aji-40	313	6	developed	develop	VERB
aji-40	313	7	a	a	DET
aji-40	313	8	solid	solid	ADJ
aji-40	313	9	malignancy	malignancy	NOUN
aji-40	313	10	,	,	PUNCT
aji-40	313	11	6	6	NUM
aji-40	313	12	a	a	DET
aji-40	313	13	hematologic	hematologic	NOUN
aji-40	313	14	,	,	PUNCT
aji-40	313	15	2	2	NUM
aji-40	313	16	a	a	DET
aji-40	313	17	solid	solid	ADJ
aji-40	313	18	and	and	CCONJ
aji-40	313	19	a	a	DET
aji-40	313	20	hematologic	hematologic	NOUN
aji-40	313	21	malignancy	malignancy	NOUN
aji-40	313	22	,	,	PUNCT
aji-40	313	23	and	and	CCONJ
aji-40	313	24	2	2	NUM
aji-40	313	25	patients	patient	NOUN
aji-40	313	26	developed	develop	VERB
aji-40	313	27	multiple	multiple	ADJ
aji-40	313	28	(	(	PUNCT
aji-40	313	29	2	2	NUM
aji-40	313	30	solid	solid	ADJ
aji-40	313	31	)	)	PUNCT
aji-40	313	32	malignancies	malignancy	NOUN
aji-40	313	33	.	.	PUNCT
aji-40	314	1	they	they	PRON
aji-40	314	2	also	also	ADV
aji-40	314	3	observed	observe	VERB
aji-40	314	4	that	that	SCONJ
aji-40	314	5	some	some	DET
aji-40	314	6	immune	immune	ADJ
aji-40	314	7	modulation	modulation	NOUN
aji-40	314	8	-	-	PUNCT
aji-40	314	9	related	relate	VERB
aji-40	314	10	lymphoproliferative	lymphoproliferative	ADJ
aji-40	314	11	disorders	disorder	NOUN
aji-40	314	12	regressed	regress	VERB
aji-40	314	13	spontaneously	spontaneously	ADV
aji-40	314	14	after	after	ADP
aji-40	314	15	stopping	stop	VERB
aji-40	314	16	anti	anti	ADJ
aji-40	314	17	-	-	ADJ
aji-40	314	18	tnf	tnf	ADJ
aji-40	314	19	therapy	therapy	NOUN
aji-40	314	20	.	.	PUNCT
aji-40	315	1	they	they	PRON
aji-40	315	2	concluded	conclude	VERB
aji-40	315	3	that	that	SCONJ
aji-40	315	4	the	the	DET
aji-40	315	5	malignancy	malignancy	NOUN
aji-40	315	6	risk	risk	NOUN
aji-40	315	7	in	in	ADP
aji-40	315	8	rheumatoid	rheumatoid	NOUN
aji-40	315	9	arthritis	arthritis	NOUN
aji-40	315	10	patients	patient	NOUN
aji-40	315	11	treated	treat	VERB
aji-40	315	12	with	with	ADP
aji-40	315	13	anti	anti	ADJ
aji-40	315	14	-	-	ADJ
aji-40	315	15	tnf	tnf	ADJ
aji-40	315	16	therapy	therapy	NOUN
aji-40	315	17	was	be	AUX
aji-40	315	18	slightly	slightly	ADV
aji-40	315	19	higher	high	ADJ
aji-40	315	20	than	than	ADP
aji-40	315	21	in	in	ADP
aji-40	315	22	the	the	DET
aji-40	315	23	normal	normal	ADJ
aji-40	315	24	population	population	NOUN
aji-40	316	1	[	[	X
aji-40	316	2	49	49	NUM
aji-40	316	3	]	]	PUNCT
aji-40	316	4	.	.	PUNCT
aji-40	317	1	however	however	ADV
aji-40	317	2	,	,	PUNCT
aji-40	317	3	there	there	PRON
aji-40	317	4	are	be	VERB
aji-40	317	5	other	other	ADJ
aji-40	317	6	studies	study	NOUN
aji-40	317	7	that	that	PRON
aji-40	317	8	have	have	AUX
aji-40	317	9	shown	show	VERB
aji-40	317	10	conflicting	conflicting	ADJ
aji-40	317	11	results	result	NOUN
aji-40	317	12	.	.	PUNCT
aji-40	318	1	mercer	mercer	PROPN
aji-40	318	2	et	et	PROPN
aji-40	318	3	al	al	PROPN
aji-40	318	4	compared	compare	VERB
aji-40	318	5	the	the	DET
aji-40	318	6	rates	rate	NOUN
aji-40	318	7	of	of	ADP
aji-40	318	8	solid	solid	ADJ
aji-40	318	9	tumors	tumor	NOUN
aji-40	318	10	in	in	ADP
aji-40	318	11	11,767	11,767	NUM
aji-40	318	12	anti	anti	ADJ
aji-40	318	13	-	-	ADJ
aji-40	318	14	tnf	tnf	ADJ
aji-40	318	15	treated	treat	VERB
aji-40	318	16	patients	patient	NOUN
aji-40	318	17	with	with	ADP
aji-40	318	18	3,249	3,249	NUM
aji-40	318	19	non	non	ADJ
aji-40	318	20	-	-	ADJ
aji-40	318	21	biologic	biologic	ADJ
aji-40	318	22	or	or	CCONJ
aji-40	318	23	synthetic	synthetic	ADJ
aji-40	318	24	disease	disease	NOUN
aji-40	318	25	modifying	modify	VERB
aji-40	318	26	anti	anti	ADJ
aji-40	318	27	-	-	ADJ
aji-40	318	28	rheumatic	rheumatic	ADJ
aji-40	318	29	drugs	drug	NOUN
aji-40	318	30	(	(	PUNCT
aji-40	318	31	s	s	X
aji-40	318	32	-	-	PUNCT
aji-40	318	33	dmardsincluding	dmardsinclude	VERB
aji-40	318	34	methotrexate	methotrexate	NOUN
aji-40	318	35	,	,	PUNCT
aji-40	318	36	azathioprine	azathioprine	NOUN
aji-40	318	37	and	and	CCONJ
aji-40	318	38	cyclophosphamide	cyclophosphamide	NOUN
aji-40	318	39	)	)	PUNCT
aji-40	318	40	in	in	ADP
aji-40	318	41	5	5	NUM
aji-40	318	42	-	-	PUNCT
aji-40	318	43	year	year	NOUN
aji-40	318	44	data	datum	NOUN
aji-40	318	45	was	be	AUX
aji-40	318	46	obtained	obtain	VERB
aji-40	318	47	from	from	ADP
aji-40	318	48	british	british	ADJ
aji-40	318	49	society	society	NOUN
aji-40	318	50	for	for	ADP
aji-40	318	51	churchill	churchill	PROPN
aji-40	318	52	et	et	PROPN
aji-40	318	53	al	al	PROPN
aji-40	318	54	.	.	PROPN
aji-40	318	55	;	;	PUNCT
aji-40	318	56	aji	aji	PROPN
aji-40	318	57	,	,	PUNCT
aji-40	318	58	3(1	3(1	NUM
aji-40	318	59	):	):	PUNCT
aji-40	318	60	208	208	NUM
aji-40	318	61	-	-	SYM
aji-40	318	62	222	222	NUM
aji-40	318	63	,	,	PUNCT
aji-40	318	64	2020	2020	NUM
aji-40	318	65	;	;	PUNCT
aji-40	318	66	article	article	NOUN
aji-40	318	67	no.aji.57464	no.aji.57464	ADP
aji-40	318	68	216	216	NUM
aji-40	318	69	rheumatology	rheumatology	NOUN
aji-40	318	70	biologics	biologic	NOUN
aji-40	318	71	register	register	VERB
aji-40	318	72	[	[	X
aji-40	318	73	50	50	NUM
aji-40	318	74	]	]	PUNCT
aji-40	318	75	.	.	PUNCT
aji-40	319	1	none	none	NOUN
aji-40	319	2	of	of	ADP
aji-40	319	3	these	these	DET
aji-40	319	4	patients	patient	NOUN
aji-40	319	5	had	have	VERB
aji-40	319	6	prior	prior	ADJ
aji-40	319	7	history	history	NOUN
aji-40	319	8	of	of	ADP
aji-40	319	9	cancer	cancer	NOUN
aji-40	319	10	.	.	PUNCT
aji-40	320	1	they	they	PRON
aji-40	320	2	observed	observe	VERB
aji-40	320	3	that	that	SCONJ
aji-40	320	4	solid	solid	ADJ
aji-40	320	5	tumors	tumor	NOUN
aji-40	320	6	developed	develop	VERB
aji-40	320	7	in	in	ADP
aji-40	320	8	81	81	NUM
aji-40	320	9	per	per	ADP
aji-40	320	10	10,000	10,000	NUM
aji-40	320	11	patient	patient	NOUN
aji-40	320	12	-	-	PUNCT
aji-40	320	13	years	year	NOUN
aji-40	320	14	in	in	ADP
aji-40	320	15	anti	anti	ADJ
aji-40	320	16	-	-	ADJ
aji-40	320	17	tnf	tnf	ADJ
aji-40	320	18	treated	treat	VERB
aji-40	320	19	patients	patient	NOUN
aji-40	320	20	,	,	PUNCT
aji-40	320	21	and	and	CCONJ
aji-40	320	22	117	117	NUM
aji-40	320	23	per	per	ADP
aji-40	320	24	10,000	10,000	NUM
aji-40	320	25	patient	patient	NOUN
aji-40	320	26	-	-	PUNCT
aji-40	320	27	years	year	NOUN
aji-40	320	28	in	in	ADP
aji-40	320	29	s	s	NOUN
aji-40	320	30	-	-	PUNCT
aji-40	320	31	dmards	dmard	NOUN
aji-40	320	32	treated	treat	VERB
aji-40	320	33	patients	patient	NOUN
aji-40	320	34	.	.	PUNCT
aji-40	321	1	there	there	PRON
aji-40	321	2	was	be	VERB
aji-40	321	3	no	no	DET
aji-40	321	4	statistically	statistically	ADV
aji-40	321	5	significant	significant	ADJ
aji-40	321	6	difference	difference	NOUN
aji-40	321	7	in	in	ADP
aji-40	321	8	risk	risk	NOUN
aji-40	321	9	of	of	ADP
aji-40	321	10	solid	solid	ADJ
aji-40	321	11	cancer	cancer	NOUN
aji-40	321	12	for	for	ADP
aji-40	321	13	anti	anti	ADJ
aji-40	321	14	-	-	ADJ
aji-40	321	15	tnf	tnf	PROPN
aji-40	321	16	treated	treat	VERB
aji-40	321	17	versus	versus	ADP
aji-40	321	18	sdmard	sdmard	NOUN
aji-40	321	19	treated	treat	VERB
aji-40	321	20	patients	patient	NOUN
aji-40	321	21	[	[	X
aji-40	321	22	50	50	NUM
aji-40	321	23	]	]	PUNCT
aji-40	321	24	.	.	PUNCT
aji-40	322	1	another	another	DET
aji-40	322	2	study	study	NOUN
aji-40	322	3	by	by	ADP
aji-40	322	4	min	min	PROPN
aji-40	322	5	jung	jung	PROPN
aji-40	322	6	et	et	PROPN
aji-40	322	7	al	al	PROPN
aji-40	322	8	also	also	ADV
aji-40	322	9	showed	show	VERB
aji-40	322	10	similar	similar	ADJ
aji-40	322	11	results	result	NOUN
aji-40	322	12	[	[	X
aji-40	322	13	51	51	NUM
aji-40	322	14	]	]	PUNCT
aji-40	322	15	.	.	PUNCT
aji-40	323	1	the	the	DET
aji-40	323	2	investigators	investigator	NOUN
aji-40	323	3	collected	collect	VERB
aji-40	323	4	information	information	NOUN
aji-40	323	5	of	of	ADP
aji-40	323	6	45,423	45,423	NUM
aji-40	323	7	seropositive	seropositive	ADJ
aji-40	323	8	rheumatoid	rheumatoid	NOUN
aji-40	323	9	arthritis	arthritis	NOUN
aji-40	323	10	patients	patient	NOUN
aji-40	323	11	from	from	ADP
aji-40	323	12	korean	korean	PROPN
aji-40	323	13	nationwide	nationwide	PROPN
aji-40	323	14	health	health	NOUN
aji-40	323	15	insurance	insurance	NOUN
aji-40	323	16	claims	claim	VERB
aji-40	323	17	data	datum	NOUN
aji-40	323	18	.	.	PUNCT
aji-40	324	1	they	they	PRON
aji-40	324	2	compared	compare	VERB
aji-40	324	3	incidence	incidence	NOUN
aji-40	324	4	of	of	ADP
aji-40	324	5	tumor	tumor	NOUN
aji-40	324	6	in	in	ADP
aji-40	324	7	patients	patient	NOUN
aji-40	324	8	receiving	receive	VERB
aji-40	324	9	anti	anti	ADJ
aji-40	324	10	-	-	ADJ
aji-40	324	11	tnf	tnf	ADJ
aji-40	324	12	therapy	therapy	NOUN
aji-40	324	13	(	(	PUNCT
aji-40	324	14	2,337	2,337	NUM
aji-40	324	15	patients	patient	NOUN
aji-40	324	16	)	)	PUNCT
aji-40	324	17	,	,	PUNCT
aji-40	324	18	and	and	CCONJ
aji-40	324	19	those	those	PRON
aji-40	324	20	receiving	receive	VERB
aji-40	324	21	conventional	conventional	ADJ
aji-40	324	22	synthetic	synthetic	ADJ
aji-40	324	23	disease	disease	NOUN
aji-40	324	24	-	-	PUNCT
aji-40	324	25	modifying	modify	VERB
aji-40	324	26	anti	anti	ADJ
aji-40	324	27	-	-	ADJ
aji-40	324	28	rheumatic	rheumatic	ADJ
aji-40	324	29	drugs	drug	NOUN
aji-40	324	30	(	(	PUNCT
aji-40	324	31	csdmardsincluding	csdmardsinclude	VERB
aji-40	324	32	methotrexate	methotrexate	NOUN
aji-40	324	33	,	,	PUNCT
aji-40	324	34	leflunomide	leflunomide	ADJ
aji-40	324	35	,	,	PUNCT
aji-40	324	36	hydroxychloroquine	hydroxychloroquine	PROPN
aji-40	324	37	,	,	PUNCT
aji-40	324	38	sulfasalazine	sulfasalazine	NOUN
aji-40	324	39	,	,	PUNCT
aji-40	324	40	cyclosporine	cyclosporine	NOUN
aji-40	324	41	,	,	PUNCT
aji-40	324	42	tacrolimus	tacrolimus	NOUN
aji-40	324	43	,	,	PUNCT
aji-40	324	44	azathioprine	azathioprine	NOUN
aji-40	324	45	,	,	PUNCT
aji-40	324	46	mizoribine	mizoribine	NOUN
aji-40	324	47	,	,	PUNCT
aji-40	324	48	and	and	CCONJ
aji-40	324	49	bucillamine	bucillamine	VERB
aji-40	324	50	)	)	PUNCT
aji-40	324	51	(	(	PUNCT
aji-40	324	52	43,086	43,086	NUM
aji-40	324	53	patients	patient	NOUN
aji-40	324	54	)	)	PUNCT
aji-40	324	55	from	from	ADP
aji-40	324	56	the	the	DET
aji-40	324	57	5	5	NUM
aji-40	324	58	years	year	NOUN
aji-40	324	59	of	of	ADP
aji-40	324	60	data	datum	NOUN
aji-40	324	61	.	.	PUNCT
aji-40	325	1	they	they	PRON
aji-40	325	2	found	find	VERB
aji-40	325	3	that	that	SCONJ
aji-40	325	4	1732	1732	NUM
aji-40	325	5	patients	patient	NOUN
aji-40	325	6	in	in	ADP
aji-40	325	7	csdmard	csdmard	ADJ
aji-40	325	8	group	group	NOUN
aji-40	325	9	and	and	CCONJ
aji-40	325	10	49	49	NUM
aji-40	325	11	patients	patient	NOUN
aji-40	325	12	in	in	ADP
aji-40	325	13	anti	anti	ADJ
aji-40	325	14	-	-	ADJ
aji-40	325	15	tnf	tnf	ADJ
aji-40	325	16	group	group	NOUN
aji-40	325	17	developed	develop	VERB
aji-40	325	18	malignancy	malignancy	NOUN
aji-40	325	19	.	.	PUNCT
aji-40	326	1	on	on	ADP
aji-40	326	2	statistical	statistical	ADJ
aji-40	326	3	analysis	analysis	NOUN
aji-40	326	4	,	,	PUNCT
aji-40	326	5	the	the	DET
aji-40	326	6	investigators	investigator	NOUN
aji-40	326	7	found	find	VERB
aji-40	326	8	that	that	SCONJ
aji-40	326	9	incidence	incidence	NOUN
aji-40	326	10	of	of	ADP
aji-40	326	11	cancer	cancer	NOUN
aji-40	326	12	was	be	AUX
aji-40	326	13	similar	similar	ADJ
aji-40	326	14	in	in	ADP
aji-40	326	15	ra	ra	PROPN
aji-40	326	16	patients	patient	NOUN
aji-40	326	17	treated	treat	VERB
aji-40	326	18	with	with	ADP
aji-40	326	19	anti	anti	ADJ
aji-40	326	20	-	-	ADJ
aji-40	326	21	tnf	tnf	ADJ
aji-40	326	22	and	and	CCONJ
aji-40	326	23	csdmards	csdmard	NOUN
aji-40	326	24	[	[	X
aji-40	326	25	51	51	NUM
aji-40	326	26	]	]	PUNCT
aji-40	326	27	.	.	PUNCT
aji-40	327	1	7.5	7.5	NUM
aji-40	327	2	nervous	nervous	ADJ
aji-40	327	3	system	system	NOUN
aji-40	327	4	increased	increase	VERB
aji-40	327	5	production	production	NOUN
aji-40	327	6	of	of	ADP
aji-40	327	7	tnf	tnf	PROPN
aji-40	327	8	-	-	PUNCT
aji-40	327	9	α	α	PROPN
aji-40	327	10	has	have	AUX
aji-40	327	11	been	be	AUX
aji-40	327	12	noticed	notice	VERB
aji-40	327	13	in	in	ADP
aji-40	327	14	several	several	ADJ
aji-40	327	15	central	central	ADJ
aji-40	327	16	nervous	nervous	ADJ
aji-40	327	17	system	system	NOUN
aji-40	327	18	disorders	disorder	NOUN
aji-40	327	19	including	include	VERB
aji-40	327	20	multiple	multiple	ADJ
aji-40	327	21	sclerosis	sclerosis	NOUN
aji-40	327	22	,	,	PUNCT
aji-40	327	23	alzheimer	alzheimer	PROPN
aji-40	327	24	’s	’s	PART
aji-40	327	25	disease	disease	NOUN
aji-40	327	26	,	,	PUNCT
aji-40	327	27	parkinson	parkinson	NOUN
aji-40	327	28	’s	’s	PART
aji-40	327	29	disease	disease	NOUN
aji-40	327	30	,	,	PUNCT
aji-40	327	31	hiv	hiv	PROPN
aji-40	327	32	encephalopathy	encephalopathy	NOUN
aji-40	327	33	,	,	PUNCT
aji-40	327	34	meningitis	meningitis	NOUN
aji-40	327	35	,	,	PUNCT
aji-40	327	36	stroke	stroke	NOUN
aji-40	327	37	,	,	PUNCT
aji-40	327	38	demyelinating	demyelinate	VERB
aji-40	327	39	disorders	disorder	NOUN
aji-40	327	40	,	,	PUNCT
aji-40	327	41	neuropathy	neuropathy	ADJ
aji-40	327	42	,	,	PUNCT
aji-40	327	43	and	and	CCONJ
aji-40	327	44	myelosuppression	myelosuppression	NOUN
aji-40	328	1	[	[	X
aji-40	328	2	30,31,5256	30,31,5256	NUM
aji-40	328	3	]	]	X
aji-40	328	4	.	.	PUNCT
aji-40	329	1	high	high	ADJ
aji-40	329	2	levels	level	NOUN
aji-40	329	3	of	of	ADP
aji-40	329	4	tnf	tnf	PROPN
aji-40	329	5	in	in	ADP
aji-40	329	6	nervous	nervous	ADJ
aji-40	329	7	system	system	NOUN
aji-40	329	8	disorders	disorder	NOUN
aji-40	329	9	promote	promote	VERB
aji-40	329	10	demyelination	demyelination	NOUN
aji-40	329	11	,	,	PUNCT
aji-40	329	12	axonal	axonal	ADJ
aji-40	329	13	degeneration	degeneration	NOUN
aji-40	329	14	and	and	CCONJ
aji-40	329	15	increased	increase	VERB
aji-40	329	16	permeability	permeability	NOUN
aji-40	329	17	of	of	ADP
aji-40	329	18	blood	blood	NOUN
aji-40	329	19	brain	brain	NOUN
aji-40	329	20	barrier	barrier	NOUN
aji-40	329	21	[	[	X
aji-40	329	22	35	35	NUM
aji-40	329	23	]	]	PUNCT
aji-40	329	24	.	.	PUNCT
aji-40	330	1	tnfr2	tnfr2	NOUN
aji-40	330	2	has	have	VERB
aji-40	330	3	a	a	DET
aji-40	330	4	neuroprotective	neuroprotective	ADJ
aji-40	330	5	role	role	NOUN
aji-40	330	6	and	and	CCONJ
aji-40	330	7	serves	serve	VERB
aji-40	330	8	an	an	DET
aji-40	330	9	important	important	ADJ
aji-40	330	10	role	role	NOUN
aji-40	330	11	in	in	ADP
aji-40	330	12	oligodendrocyte	oligodendrocyte	ADJ
aji-40	330	13	regeneration	regeneration	NOUN
aji-40	330	14	and	and	CCONJ
aji-40	330	15	remyelination	remyelination	NOUN
aji-40	331	1	[	[	X
aji-40	331	2	3,53	3,53	NOUN
aji-40	331	3	]	]	X
aji-40	331	4	.	.	PUNCT
aji-40	332	1	fischer	fischer	PROPN
aji-40	332	2	et	et	PROPN
aji-40	332	3	al	al	PROPN
aji-40	332	4	synthesized	synthesize	VERB
aji-40	332	5	a	a	DET
aji-40	332	6	soluble	soluble	ADJ
aji-40	332	7	,	,	PUNCT
aji-40	332	8	human	human	ADJ
aji-40	332	9	tnfr2	tnfr2	NOUN
aji-40	332	10	agonist	agonist	NOUN
aji-40	332	11	(	(	PUNCT
aji-40	332	12	tnc	tnc	NOUN
aji-40	332	13	-	-	NOUN
aji-40	332	14	sctnfr2	sctnfr2	NOUN
aji-40	332	15	)	)	PUNCT
aji-40	332	16	by	by	ADP
aji-40	332	17	genetic	genetic	ADJ
aji-40	332	18	fusion	fusion	NOUN
aji-40	332	19	of	of	ADP
aji-40	332	20	tenascin	tenascin	VERB
aji-40	332	21	c	c	NOUN
aji-40	332	22	to	to	ADP
aji-40	332	23	a	a	DET
aji-40	332	24	tnfr2	tnfr2	ADJ
aji-40	332	25	-	-	ADJ
aji-40	332	26	selective	selective	ADJ
aji-40	332	27	single	single	ADJ
aji-40	332	28	-	-	PUNCT
aji-40	332	29	chain	chain	NOUN
aji-40	332	30	tnf	tnf	PROPN
aji-40	332	31	molecule	molecule	NOUN
aji-40	332	32	and	and	CCONJ
aji-40	332	33	showed	show	VERB
aji-40	332	34	that	that	SCONJ
aji-40	332	35	tnc	tnc	NOUN
aji-40	332	36	-	-	PUNCT
aji-40	332	37	sctnfr2	sctnfr2	NOUN
aji-40	332	38	rescues	rescue	NOUN
aji-40	332	39	human	human	ADJ
aji-40	332	40	differentiated	differentiated	ADJ
aji-40	332	41	neurons	neuron	NOUN
aji-40	332	42	from	from	ADP
aji-40	332	43	oxidative	oxidative	ADJ
aji-40	332	44	stress	stress	NOUN
aji-40	332	45	induced	induce	VERB
aji-40	332	46	cell	cell	NOUN
aji-40	332	47	death	death	NOUN
aji-40	333	1	[	[	X
aji-40	333	2	57	57	NUM
aji-40	333	3	]	]	PUNCT
aji-40	333	4	.	.	PUNCT
aji-40	334	1	they	they	PRON
aji-40	334	2	speculated	speculate	VERB
aji-40	334	3	that	that	SCONJ
aji-40	334	4	tnfr2	tnfr2	NOUN
aji-40	334	5	agonists	agonist	NOUN
aji-40	334	6	may	may	AUX
aji-40	334	7	be	be	AUX
aji-40	334	8	good	good	ADJ
aji-40	334	9	therapeutic	therapeutic	ADJ
aji-40	334	10	options	option	NOUN
aji-40	334	11	in	in	ADP
aji-40	334	12	several	several	ADJ
aji-40	334	13	diseases	disease	NOUN
aji-40	334	14	,	,	PUNCT
aji-40	334	15	including	include	VERB
aji-40	334	16	neurodegenerative	neurodegenerative	ADJ
aji-40	334	17	,	,	PUNCT
aji-40	334	18	cardiac	cardiac	ADJ
aji-40	334	19	and	and	CCONJ
aji-40	334	20	autoimmune	autoimmune	ADJ
aji-40	334	21	and	and	CCONJ
aji-40	334	22	diseases	disease	NOUN
aji-40	334	23	[	[	X
aji-40	334	24	57	57	NUM
aji-40	334	25	]	]	PUNCT
aji-40	334	26	.	.	PUNCT
aji-40	335	1	alzheimer	alzheimer	PROPN
aji-40	335	2	’s	’s	PART
aji-40	335	3	disease	disease	NOUN
aji-40	335	4	:	:	PUNCT
aji-40	335	5	tnf	tnf	PROPN
aji-40	335	6	-	-	PUNCT
aji-40	335	7	α	α	PROPN
aji-40	335	8	and	and	CCONJ
aji-40	335	9	tnfr1	tnfr1	NOUN
aji-40	335	10	levels	level	NOUN
aji-40	335	11	are	be	AUX
aji-40	335	12	increased	increase	VERB
aji-40	335	13	,	,	PUNCT
aji-40	335	14	and	and	CCONJ
aji-40	335	15	tnfr2	tnfr2	NOUN
aji-40	335	16	levels	level	NOUN
aji-40	335	17	are	be	AUX
aji-40	335	18	decreased	decrease	VERB
aji-40	335	19	in	in	ADP
aji-40	335	20	human	human	PROPN
aji-40	335	21	alzheimer	alzheimer	PROPN
aji-40	335	22	’s	’s	PART
aji-40	335	23	disease	disease	NOUN
aji-40	335	24	brain	brain	NOUN
aji-40	335	25	tissues	tissue	NOUN
aji-40	335	26	[	[	X
aji-40	335	27	30,53	30,53	NOUN
aji-40	335	28	]	]	PUNCT
aji-40	335	29	.	.	PUNCT
aji-40	336	1	though	though	SCONJ
aji-40	336	2	theoretically	theoretically	ADV
aji-40	336	3	it	it	PRON
aji-40	336	4	appears	appear	VERB
aji-40	336	5	that	that	SCONJ
aji-40	336	6	antitnf	antitnf	PROPN
aji-40	336	7	therapy	therapy	NOUN
aji-40	336	8	should	should	AUX
aji-40	336	9	be	be	AUX
aji-40	336	10	helpful	helpful	ADJ
aji-40	336	11	in	in	ADP
aji-40	336	12	alzheimer	alzheimer	PROPN
aji-40	336	13	’s	’s	PART
aji-40	336	14	disease	disease	NOUN
aji-40	336	15	,	,	PUNCT
aji-40	336	16	investigators	investigator	NOUN
aji-40	336	17	have	have	AUX
aji-40	336	18	observed	observe	VERB
aji-40	336	19	conflicting	conflicting	ADJ
aji-40	336	20	results	result	NOUN
aji-40	336	21	.	.	PUNCT
aji-40	337	1	as	as	ADP
aji-40	337	2	an	an	DET
aji-40	337	3	example	example	NOUN
aji-40	337	4	,	,	PUNCT
aji-40	337	5	experimental	experimental	ADJ
aji-40	337	6	studies	study	NOUN
aji-40	337	7	in	in	ADP
aji-40	337	8	animals	animal	NOUN
aji-40	337	9	have	have	AUX
aji-40	337	10	shown	show	VERB
aji-40	337	11	that	that	DET
aji-40	337	12	infliximab	infliximab	NOUN
aji-40	337	13	that	that	PRON
aji-40	337	14	binds	bind	VERB
aji-40	337	15	tnf	tnf	PROPN
aji-40	337	16	-	-	PUNCT
aji-40	337	17	α	α	PROPN
aji-40	337	18	(	(	PUNCT
aji-40	337	19	anti	anti	ADJ
aji-40	337	20	-	-	ADJ
aji-40	337	21	tnf	tnf	ADJ
aji-40	337	22	-	-	PUNCT
aji-40	337	23	α	α	NOUN
aji-40	337	24	therapy	therapy	NOUN
aji-40	337	25	)	)	PUNCT
aji-40	337	26	reduced	reduce	VERB
aji-40	337	27	amyloid	amyloid	NOUN
aji-40	337	28	plaques	plaque	NOUN
aji-40	337	29	and	and	CCONJ
aji-40	337	30	tau	tau	PROPN
aji-40	337	31	phosphorylation	phosphorylation	NOUN
aji-40	337	32	in	in	ADP
aji-40	337	33	alzheimer	alzheimer	PROPN
aji-40	337	34	’s	’s	PART
aji-40	337	35	disease	disease	NOUN
aji-40	337	36	in	in	ADP
aji-40	337	37	mice	mouse	NOUN
aji-40	337	38	as	as	ADV
aji-40	337	39	early	early	ADV
aji-40	337	40	as	as	ADP
aji-40	337	41	3	3	NUM
aji-40	337	42	days	day	NOUN
aji-40	337	43	after	after	ADP
aji-40	337	44	the	the	DET
aji-40	337	45	intracerebroventricular	intracerebroventricular	ADJ
aji-40	337	46	injection	injection	NOUN
aji-40	337	47	;	;	PUNCT
aji-40	337	48	and	and	CCONJ
aji-40	337	49	improves	improve	VERB
aji-40	337	50	object	object	NOUN
aji-40	337	51	recognition	recognition	NOUN
aji-40	337	52	memory	memory	NOUN
aji-40	337	53	impairment	impairment	NOUN
aji-40	338	1	[	[	X
aji-40	338	2	58,59	58,59	X
aji-40	338	3	]	]	PUNCT
aji-40	338	4	.	.	PUNCT
aji-40	339	1	shi	shi	PROPN
aji-40	339	2	et	et	PROPN
aji-40	339	3	al	al	PROPN
aji-40	339	4	reported	report	VERB
aji-40	339	5	that	that	SCONJ
aji-40	339	6	intrathecal	intrathecal	ADJ
aji-40	339	7	injection	injection	NOUN
aji-40	339	8	of	of	ADP
aji-40	339	9	infliximab	infliximab	NOUN
aji-40	339	10	improved	improve	VERB
aji-40	339	11	cognition	cognition	NOUN
aji-40	339	12	significantly	significantly	ADV
aji-40	339	13	in	in	ADP
aji-40	339	14	a	a	DET
aji-40	339	15	female	female	ADJ
aji-40	339	16	suffering	suffering	NOUN
aji-40	339	17	from	from	ADP
aji-40	339	18	alzheimer	alzheimer	PROPN
aji-40	339	19	’s	’s	PART
aji-40	339	20	disease	disease	NOUN
aji-40	340	1	[	[	X
aji-40	340	2	60	60	NUM
aji-40	340	3	]	]	PUNCT
aji-40	340	4	.	.	PUNCT
aji-40	341	1	peri	peri	NOUN
aji-40	341	2	-	-	PUNCT
aji-40	341	3	spinal	spinal	NOUN
aji-40	341	4	injection	injection	NOUN
aji-40	341	5	of	of	ADP
aji-40	341	6	etanercept	etanercept	NOUN
aji-40	341	7	has	have	AUX
aji-40	341	8	been	be	AUX
aji-40	341	9	shown	show	VERB
aji-40	341	10	to	to	PART
aji-40	341	11	improve	improve	VERB
aji-40	341	12	cognitive	cognitive	ADJ
aji-40	341	13	impairment	impairment	NOUN
aji-40	341	14	within	within	ADP
aji-40	341	15	minutes	minute	NOUN
aji-40	341	16	of	of	ADP
aji-40	341	17	administering	administer	VERB
aji-40	341	18	the	the	DET
aji-40	341	19	injection	injection	NOUN
aji-40	341	20	[	[	X
aji-40	341	21	61	61	NUM
aji-40	341	22	]	]	PUNCT
aji-40	341	23	.	.	PUNCT
aji-40	342	1	it	it	PRON
aji-40	342	2	is	be	AUX
aji-40	342	3	generally	generally	ADV
aji-40	342	4	accepted	accept	VERB
aji-40	342	5	that	that	SCONJ
aji-40	342	6	total	total	ADJ
aji-40	342	7	inhibition	inhibition	NOUN
aji-40	342	8	of	of	ADP
aji-40	342	9	tnf	tnf	PROPN
aji-40	342	10	(	(	PUNCT
aji-40	342	11	especially	especially	ADV
aji-40	342	12	inhibition	inhibition	NOUN
aji-40	342	13	of	of	ADP
aji-40	342	14	the	the	DET
aji-40	342	15	neuroprotective	neuroprotective	ADJ
aji-40	342	16	tnfr2	tnfr2	NOUN
aji-40	342	17	)	)	PUNCT
aji-40	342	18	may	may	AUX
aji-40	342	19	nullify	nullify	VERB
aji-40	342	20	the	the	DET
aji-40	342	21	positive	positive	ADJ
aji-40	342	22	effects	effect	NOUN
aji-40	342	23	of	of	ADP
aji-40	342	24	antitnf	antitnf	ADJ
aji-40	342	25	therapies	therapy	NOUN
aji-40	342	26	[	[	X
aji-40	342	27	53	53	NUM
aji-40	342	28	]	]	PUNCT
aji-40	342	29	.	.	PUNCT
aji-40	343	1	though	though	SCONJ
aji-40	343	2	there	there	PRON
aji-40	343	3	are	be	VERB
aji-40	343	4	case	case	NOUN
aji-40	343	5	reports	report	NOUN
aji-40	343	6	and	and	CCONJ
aji-40	343	7	experimental	experimental	ADJ
aji-40	343	8	data	datum	NOUN
aji-40	343	9	supporting	support	VERB
aji-40	343	10	a	a	DET
aji-40	343	11	beneficial	beneficial	ADJ
aji-40	343	12	role	role	NOUN
aji-40	343	13	[	[	X
aji-40	343	14	58	58	NUM
aji-40	343	15	-	-	SYM
aji-40	343	16	61	61	NUM
aji-40	343	17	]	]	PUNCT
aji-40	343	18	,	,	PUNCT
aji-40	343	19	more	more	ADJ
aji-40	343	20	studies	study	NOUN
aji-40	343	21	(	(	PUNCT
aji-40	343	22	large	large	ADJ
aji-40	343	23	scale	scale	NOUN
aji-40	343	24	,	,	PUNCT
aji-40	343	25	randomized	randomize	VERB
aji-40	343	26	controlled	control	VERB
aji-40	343	27	trials	trial	NOUN
aji-40	343	28	)	)	PUNCT
aji-40	343	29	are	be	AUX
aji-40	343	30	needed	need	VERB
aji-40	343	31	to	to	PART
aji-40	343	32	explore	explore	VERB
aji-40	343	33	the	the	DET
aji-40	343	34	safety	safety	NOUN
aji-40	343	35	and	and	CCONJ
aji-40	343	36	efficacy	efficacy	NOUN
aji-40	343	37	of	of	ADP
aji-40	343	38	anti	anti	ADJ
aji-40	343	39	-	-	ADJ
aji-40	343	40	tnf	tnf	ADJ
aji-40	343	41	therapies	therapy	NOUN
aji-40	343	42	in	in	ADP
aji-40	343	43	alzheimer	alzheimer	PROPN
aji-40	343	44	’s	’s	PART
aji-40	343	45	disease	disease	NOUN
aji-40	343	46	.	.	PUNCT
aji-40	344	1	multiple	multiple	ADJ
aji-40	344	2	sclerosis	sclerosis	NOUN
aji-40	344	3	:	:	PUNCT
aji-40	344	4	experimental	experimental	ADJ
aji-40	344	5	studies	study	NOUN
aji-40	344	6	in	in	ADP
aji-40	344	7	animals	animal	NOUN
aji-40	344	8	with	with	ADP
aji-40	344	9	multiple	multiple	ADJ
aji-40	344	10	sclerosis	sclerosis	NOUN
aji-40	344	11	has	have	AUX
aji-40	344	12	shown	show	VERB
aji-40	344	13	beneficial	beneficial	ADJ
aji-40	344	14	effect	effect	NOUN
aji-40	344	15	of	of	ADP
aji-40	344	16	anti	anti	ADJ
aji-40	344	17	-	-	ADJ
aji-40	344	18	tnf	tnf	ADJ
aji-40	344	19	therapies	therapy	NOUN
aji-40	344	20	.	.	PUNCT
aji-40	345	1	however	however	ADV
aji-40	345	2	,	,	PUNCT
aji-40	345	3	investigators	investigator	NOUN
aji-40	345	4	have	have	AUX
aji-40	345	5	also	also	ADV
aji-40	345	6	reported	report	VERB
aji-40	345	7	conflicting	conflicting	ADJ
aji-40	345	8	evidence	evidence	NOUN
aji-40	345	9	:	:	PUNCT
aji-40	345	10	several	several	ADJ
aji-40	345	11	cases	case	NOUN
aji-40	345	12	of	of	ADP
aji-40	345	13	development	development	NOUN
aji-40	345	14	of	of	ADP
aji-40	345	15	multiple	multiple	ADJ
aji-40	345	16	sclerosis	sclerosis	NOUN
aji-40	345	17	after	after	ADP
aji-40	345	18	initiating	initiate	VERB
aji-40	345	19	anti	anti	ADJ
aji-40	345	20	-	-	ADJ
aji-40	345	21	tnf	tnf	ADJ
aji-40	345	22	therapy	therapy	NOUN
aji-40	345	23	[	[	X
aji-40	345	24	54	54	NUM
aji-40	345	25	-	-	SYM
aji-40	345	26	56	56	NUM
aji-40	345	27	]	]	PUNCT
aji-40	345	28	.	.	PUNCT
aji-40	346	1	titelbaum	titelbaum	PROPN
aji-40	346	2	et	et	PROPN
aji-40	346	3	al	al	PROPN
aji-40	346	4	.	.	PROPN
aji-40	346	5	reported	report	VERB
aji-40	346	6	new	new	ADJ
aji-40	346	7	onset	onset	NOUN
aji-40	346	8	multiple	multiple	ADJ
aji-40	346	9	sclerosis	sclerosis	NOUN
aji-40	346	10	in	in	ADP
aji-40	346	11	a	a	DET
aji-40	346	12	rheumatoid	rheumatoid	NOUN
aji-40	346	13	arthritis	arthritis	NOUN
aji-40	346	14	patient	patient	NOUN
aji-40	346	15	who	who	PRON
aji-40	346	16	was	be	AUX
aji-40	346	17	on	on	ADP
aji-40	346	18	etanercept	etanercept	NOUN
aji-40	346	19	therapy	therapy	NOUN
aji-40	346	20	for	for	ADP
aji-40	346	21	two	two	NUM
aji-40	346	22	years	year	NOUN
aji-40	346	23	.	.	PUNCT
aji-40	347	1	on	on	ADP
aji-40	347	2	stopping	stop	VERB
aji-40	347	3	etanercept	etanercept	NOUN
aji-40	347	4	,	,	PUNCT
aji-40	347	5	there	there	PRON
aji-40	347	6	was	be	VERB
aji-40	347	7	radiological	radiological	ADJ
aji-40	347	8	resolution	resolution	NOUN
aji-40	347	9	of	of	ADP
aji-40	347	10	lesions	lesion	NOUN
aji-40	347	11	.	.	PUNCT
aji-40	348	1	however	however	ADV
aji-40	348	2	,	,	PUNCT
aji-40	348	3	after	after	ADP
aji-40	348	4	6	6	NUM
aji-40	348	5	months	month	NOUN
aji-40	348	6	,	,	PUNCT
aji-40	348	7	new	new	ADJ
aji-40	348	8	lesions	lesion	NOUN
aji-40	348	9	developed	develop	VERB
aji-40	348	10	[	[	PUNCT
aji-40	348	11	62	62	NUM
aji-40	348	12	]	]	PUNCT
aji-40	348	13	.	.	PUNCT
aji-40	349	1	these	these	DET
aji-40	349	2	conflicting	conflicting	ADJ
aji-40	349	3	evidences	evidence	NOUN
aji-40	349	4	suggest	suggest	VERB
aji-40	349	5	that	that	SCONJ
aji-40	349	6	more	more	ADJ
aji-40	349	7	studies	study	NOUN
aji-40	349	8	are	be	AUX
aji-40	349	9	required	require	VERB
aji-40	349	10	in	in	ADP
aji-40	349	11	this	this	DET
aji-40	349	12	therapeutic	therapeutic	ADJ
aji-40	349	13	area	area	NOUN
aji-40	349	14	to	to	PART
aji-40	349	15	get	get	VERB
aji-40	349	16	a	a	DET
aji-40	349	17	clearer	clear	ADJ
aji-40	349	18	picture	picture	NOUN
aji-40	349	19	regarding	regard	VERB
aji-40	349	20	whether	whether	SCONJ
aji-40	349	21	anti	anti	ADJ
aji-40	349	22	-	-	ADJ
aji-40	349	23	tnf	tnf	ADJ
aji-40	349	24	therapy	therapy	NOUN
aji-40	349	25	is	be	AUX
aji-40	349	26	beneficial	beneficial	ADJ
aji-40	349	27	in	in	ADP
aji-40	349	28	multiple	multiple	ADJ
aji-40	349	29	sclerosis	sclerosis	NOUN
aji-40	349	30	.	.	PUNCT
aji-40	350	1	7.6	7.6	NUM
aji-40	350	2	kidneys	kidney	NOUN
aji-40	350	3	tnf	tnf	PROPN
aji-40	350	4	-	-	PUNCT
aji-40	350	5	α	α	NOUN
aji-40	350	6	blockers	blocker	NOUN
aji-40	350	7	used	use	VERB
aji-40	350	8	in	in	ADP
aji-40	350	9	rheumatoid	rheumatoid	NOUN
aji-40	350	10	arthritis	arthritis	NOUN
aji-40	350	11	and	and	CCONJ
aji-40	350	12	crohn	crohn	PROPN
aji-40	350	13	’s	’s	PART
aji-40	350	14	disease	disease	NOUN
aji-40	350	15	occasionally	occasionally	ADV
aji-40	350	16	result	result	VERB
aji-40	350	17	in	in	ADP
aji-40	350	18	the	the	DET
aji-40	350	19	development	development	NOUN
aji-40	350	20	of	of	ADP
aji-40	350	21	autoantibodies	autoantibody	NOUN
aji-40	350	22	,	,	PUNCT
aji-40	350	23	lupus	lupus	NOUN
aji-40	350	24	-	-	PUNCT
aji-40	350	25	like	like	ADJ
aji-40	350	26	syndrome	syndrome	NOUN
aji-40	350	27	,	,	PUNCT
aji-40	350	28	and	and	CCONJ
aji-40	350	29	glomerulonephritis	glomerulonephritis	NOUN
aji-40	350	30	[	[	X
aji-40	350	31	63	63	NUM
aji-40	350	32	]	]	PUNCT
aji-40	350	33	.	.	PUNCT
aji-40	351	1	this	this	PRON
aji-40	351	2	has	have	AUX
aji-40	351	3	raised	raise	VERB
aji-40	351	4	a	a	DET
aji-40	351	5	concern	concern	NOUN
aji-40	351	6	regarding	regard	VERB
aji-40	351	7	the	the	DET
aji-40	351	8	use	use	NOUN
aji-40	351	9	of	of	ADP
aji-40	351	10	tnf	tnf	PROPN
aji-40	351	11	-	-	PUNCT
aji-40	351	12	α	α	PROPN
aji-40	351	13	blocking	block	VERB
aji-40	351	14	agents	agent	NOUN
aji-40	351	15	in	in	ADP
aji-40	351	16	patients	patient	NOUN
aji-40	351	17	who	who	PRON
aji-40	351	18	are	be	AUX
aji-40	351	19	at	at	ADP
aji-40	351	20	risk	risk	NOUN
aji-40	351	21	of	of	ADP
aji-40	351	22	developing	develop	VERB
aji-40	351	23	renal	renal	ADJ
aji-40	351	24	disease	disease	NOUN
aji-40	351	25	or	or	CCONJ
aji-40	351	26	who	who	PRON
aji-40	351	27	have	have	VERB
aji-40	351	28	underlying	underlie	VERB
aji-40	351	29	renal	renal	ADJ
aji-40	351	30	disease	disease	NOUN
aji-40	351	31	[	[	X
aji-40	351	32	63	63	NUM
aji-40	351	33	]	]	PUNCT
aji-40	351	34	.	.	PUNCT
aji-40	352	1	churchill	churchill	PROPN
aji-40	352	2	et	et	PROPN
aji-40	352	3	al	al	PROPN
aji-40	352	4	.	.	PROPN
aji-40	352	5	;	;	PUNCT
aji-40	352	6	aji	aji	PROPN
aji-40	352	7	,	,	PUNCT
aji-40	352	8	3(1	3(1	NUM
aji-40	352	9	):	):	PUNCT
aji-40	352	10	208	208	NUM
aji-40	352	11	-	-	SYM
aji-40	352	12	222	222	NUM
aji-40	352	13	,	,	PUNCT
aji-40	352	14	2020	2020	NUM
aji-40	352	15	;	;	PUNCT
aji-40	352	16	article	article	NOUN
aji-40	352	17	no.aji.57464	no.aji.57464	ADP
aji-40	352	18	217	217	NUM
aji-40	352	19	tnf	tnf	PROPN
aji-40	352	20	-	-	PUNCT
aji-40	352	21	α	α	PROPN
aji-40	352	22	may	may	AUX
aji-40	352	23	be	be	AUX
aji-40	352	24	produced	produce	VERB
aji-40	352	25	in	in	ADP
aji-40	352	26	inflamed	inflame	VERB
aji-40	352	27	kidneys	kidney	NOUN
aji-40	352	28	from	from	ADP
aji-40	352	29	infiltrating	infiltrate	VERB
aji-40	352	30	monocytes	monocyte	NOUN
aji-40	352	31	and	and	CCONJ
aji-40	352	32	macrophages	macrophage	NOUN
aji-40	352	33	,	,	PUNCT
aji-40	352	34	and	and	CCONJ
aji-40	352	35	intrinsically	intrinsically	ADV
aji-40	352	36	by	by	ADP
aji-40	352	37	renal	renal	ADJ
aji-40	352	38	tissue	tissue	NOUN
aji-40	352	39	including	include	VERB
aji-40	352	40	podocytes	podocyte	NOUN
aji-40	352	41	,	,	PUNCT
aji-40	352	42	mesangial	mesangial	ADJ
aji-40	352	43	cells	cell	NOUN
aji-40	352	44	,	,	PUNCT
aji-40	352	45	proximal	proximal	ADJ
aji-40	352	46	tubules	tubule	NOUN
aji-40	352	47	,	,	PUNCT
aji-40	352	48	thick	thick	ADJ
aji-40	352	49	ascending	ascend	VERB
aji-40	352	50	limb	limb	NOUN
aji-40	352	51	of	of	ADP
aji-40	352	52	loop	loop	NOUN
aji-40	352	53	of	of	ADP
aji-40	352	54	henle	henle	NOUN
aji-40	352	55	,	,	PUNCT
aji-40	352	56	and	and	CCONJ
aji-40	352	57	the	the	DET
aji-40	352	58	collecting	collect	VERB
aji-40	352	59	ducts	duct	NOUN
aji-40	352	60	[	[	X
aji-40	352	61	16,64	16,64	NUM
aji-40	352	62	]	]	X
aji-40	352	63	.	.	PUNCT
aji-40	353	1	tnf	tnf	PROPN
aji-40	353	2	-	-	PUNCT
aji-40	353	3	α	α	PROPN
aji-40	353	4	is	be	AUX
aji-40	353	5	cytotoxic	cytotoxic	ADJ
aji-40	353	6	to	to	ADP
aji-40	353	7	renal	renal	ADJ
aji-40	353	8	cells	cell	NOUN
aji-40	353	9	and	and	CCONJ
aji-40	353	10	is	be	AUX
aji-40	353	11	involved	involve	VERB
aji-40	353	12	in	in	ADP
aji-40	353	13	renal	renal	ADJ
aji-40	353	14	scarring	scarring	NOUN
aji-40	354	1	[	[	X
aji-40	354	2	6567	6567	NUM
aji-40	354	3	]	]	PUNCT
aji-40	354	4	.	.	PUNCT
aji-40	355	1	tnf	tnf	PROPN
aji-40	355	2	-	-	PUNCT
aji-40	355	3	α	α	PROPN
aji-40	355	4	induces	induce	VERB
aji-40	355	5	the	the	DET
aji-40	355	6	production	production	NOUN
aji-40	355	7	of	of	ADP
aji-40	355	8	reactive	reactive	ADJ
aji-40	355	9	oxygen	oxygen	NOUN
aji-40	355	10	species	specie	NOUN
aji-40	355	11	including	include	VERB
aji-40	355	12	superoxide	superoxide	NOUN
aji-40	355	13	.	.	PUNCT
aji-40	356	1	superoxide	superoxide	NOUN
aji-40	356	2	increases	increase	NOUN
aji-40	356	3	glomerular	glomerular	ADJ
aji-40	356	4	permeability	permeability	NOUN
aji-40	356	5	to	to	ADP
aji-40	356	6	albumin	albumin	NOUN
aji-40	356	7	[	[	X
aji-40	356	8	68	68	NUM
aji-40	356	9	]	]	PUNCT
aji-40	356	10	.	.	PUNCT
aji-40	357	1	animal	animal	NOUN
aji-40	357	2	studies	study	NOUN
aji-40	357	3	have	have	AUX
aji-40	357	4	shown	show	VERB
aji-40	357	5	that	that	SCONJ
aji-40	357	6	nitric	nitric	ADJ
aji-40	357	7	oxide	oxide	NOUN
aji-40	357	8	is	be	AUX
aji-40	357	9	also	also	ADV
aji-40	357	10	produced	produce	VERB
aji-40	357	11	in	in	ADP
aji-40	357	12	several	several	ADJ
aji-40	357	13	glomerular	glomerular	ADJ
aji-40	357	14	diseases	disease	NOUN
aji-40	357	15	.	.	PUNCT
aji-40	358	1	nitric	nitric	ADJ
aji-40	358	2	oxide	oxide	NOUN
aji-40	358	3	has	have	VERB
aji-40	358	4	a	a	DET
aji-40	358	5	protective	protective	ADJ
aji-40	358	6	effect	effect	NOUN
aji-40	358	7	and	and	CCONJ
aji-40	358	8	protects	protect	VERB
aji-40	358	9	the	the	DET
aji-40	358	10	kidneys	kidney	NOUN
aji-40	358	11	from	from	ADP
aji-40	358	12	the	the	DET
aji-40	358	13	injurious	injurious	ADJ
aji-40	358	14	effect	effect	NOUN
aji-40	358	15	of	of	ADP
aji-40	358	16	superoxide	superoxide	NOUN
aji-40	358	17	,	,	PUNCT
aji-40	358	18	and	and	CCONJ
aji-40	358	19	even	even	ADV
aji-40	358	20	reverses	reverse	VERB
aji-40	358	21	the	the	DET
aji-40	358	22	damage	damage	NOUN
aji-40	358	23	[	[	X
aji-40	358	24	68	68	NUM
aji-40	358	25	]	]	PUNCT
aji-40	358	26	.	.	PUNCT
aji-40	359	1	in	in	ADP
aji-40	359	2	kidneys	kidney	NOUN
aji-40	359	3	,	,	PUNCT
aji-40	359	4	tnfr1	tnfr1	NOUN
aji-40	359	5	is	be	AUX
aji-40	359	6	primarily	primarily	ADV
aji-40	359	7	present	present	ADJ
aji-40	359	8	in	in	ADP
aji-40	359	9	glomeruli	glomeruli	NOUN
aji-40	359	10	and	and	CCONJ
aji-40	359	11	peritubular	peritubular	ADJ
aji-40	359	12	endothelial	endothelial	ADJ
aji-40	359	13	cells	cell	NOUN
aji-40	359	14	[	[	X
aji-40	359	15	16	16	NUM
aji-40	359	16	]	]	PUNCT
aji-40	359	17	.	.	PUNCT
aji-40	360	1	tnfr2	tnfr2	NOUN
aji-40	360	2	is	be	AUX
aji-40	360	3	usually	usually	ADV
aji-40	360	4	absent	absent	ADJ
aji-40	360	5	in	in	ADP
aji-40	360	6	the	the	DET
aji-40	360	7	kidneys	kidney	NOUN
aji-40	360	8	in	in	ADP
aji-40	360	9	normal	normal	ADJ
aji-40	360	10	state	state	NOUN
aji-40	361	1	[	[	X
aji-40	361	2	16	16	NUM
aji-40	361	3	]	]	PUNCT
aji-40	361	4	.	.	PUNCT
aji-40	362	1	in	in	ADP
aji-40	362	2	several	several	ADJ
aji-40	362	3	renal	renal	ADJ
aji-40	362	4	diseases	disease	NOUN
aji-40	362	5	,	,	PUNCT
aji-40	362	6	tnfr2	tnfr2	NOUN
aji-40	362	7	levels	level	NOUN
aji-40	362	8	increase	increase	VERB
aji-40	362	9	in	in	ADP
aji-40	362	10	the	the	DET
aji-40	362	11	kidneys	kidney	NOUN
aji-40	362	12	especially	especially	ADV
aji-40	362	13	at	at	ADP
aji-40	362	14	the	the	DET
aji-40	362	15	site	site	NOUN
aji-40	362	16	of	of	ADP
aji-40	362	17	injury	injury	NOUN
aji-40	362	18	[	[	X
aji-40	362	19	16	16	NUM
aji-40	362	20	]	]	PUNCT
aji-40	362	21	.	.	PUNCT
aji-40	363	1	tnf	tnf	PROPN
aji-40	363	2	-	-	PUNCT
aji-40	363	3	α	α	PROPN
aji-40	363	4	has	have	AUX
aji-40	363	5	been	be	AUX
aji-40	363	6	implicated	implicate	VERB
aji-40	363	7	in	in	ADP
aji-40	363	8	acute	acute	ADJ
aji-40	363	9	kidney	kidney	NOUN
aji-40	363	10	injury	injury	NOUN
aji-40	363	11	(	(	PUNCT
aji-40	363	12	aki	aki	NOUN
aji-40	363	13	)	)	PUNCT
aji-40	363	14	and	and	CCONJ
aji-40	363	15	chronic	chronic	ADJ
aji-40	363	16	kidney	kidney	NOUN
aji-40	363	17	disease	disease	NOUN
aji-40	363	18	(	(	PUNCT
aji-40	363	19	ckd	ckd	NOUN
aji-40	363	20	)	)	PUNCT
aji-40	364	1	[	[	X
aji-40	364	2	69	69	NUM
aji-40	364	3	]	]	PUNCT
aji-40	364	4	.	.	PUNCT
aji-40	365	1	studies	study	NOUN
aji-40	365	2	in	in	ADP
aji-40	365	3	animal	animal	NOUN
aji-40	365	4	models	model	NOUN
aji-40	365	5	have	have	AUX
aji-40	365	6	shown	show	VERB
aji-40	365	7	that	that	SCONJ
aji-40	365	8	inflammatory	inflammatory	ADJ
aji-40	365	9	cytokines	cytokine	NOUN
aji-40	365	10	like	like	ADP
aji-40	365	11	tnf	tnf	PROPN
aji-40	365	12	-	-	PUNCT
aji-40	365	13	α	α	PROPN
aji-40	365	14	play	play	VERB
aji-40	365	15	a	a	DET
aji-40	365	16	role	role	NOUN
aji-40	365	17	in	in	ADP
aji-40	365	18	development	development	NOUN
aji-40	365	19	of	of	ADP
aji-40	365	20	aki	aki	NOUN
aji-40	365	21	and	and	CCONJ
aji-40	365	22	its	its	PRON
aji-40	365	23	inhibition	inhibition	NOUN
aji-40	365	24	may	may	AUX
aji-40	365	25	protect	protect	VERB
aji-40	365	26	kidneys	kidney	NOUN
aji-40	365	27	from	from	ADP
aji-40	365	28	the	the	DET
aji-40	365	29	damage	damage	NOUN
aji-40	365	30	[	[	X
aji-40	365	31	70,71	70,71	NOUN
aji-40	365	32	]	]	X
aji-40	365	33	.	.	PUNCT
aji-40	366	1	however	however	ADV
aji-40	366	2	,	,	PUNCT
aji-40	366	3	antitnf	antitnf	PROPN
aji-40	366	4	therapy	therapy	NOUN
aji-40	366	5	may	may	AUX
aji-40	366	6	also	also	ADV
aji-40	366	7	result	result	VERB
aji-40	366	8	in	in	ADP
aji-40	366	9	acute	acute	ADJ
aji-40	366	10	kidney	kidney	NOUN
aji-40	366	11	injury	injury	NOUN
aji-40	366	12	.	.	PUNCT
aji-40	367	1	michael	michael	PROPN
aji-40	367	2	b	b	PROPN
aji-40	367	3	stokes	stokes	PROPN
aji-40	367	4	et	et	PROPN
aji-40	367	5	al	al	PROPN
aji-40	367	6	reported	report	VERB
aji-40	367	7	5	5	NUM
aji-40	367	8	cases	case	NOUN
aji-40	367	9	of	of	ADP
aji-40	367	10	rheumatoid	rheumatoid	NOUN
aji-40	367	11	arthritis	arthritis	NOUN
aji-40	367	12	who	who	PRON
aji-40	367	13	developed	develop	VERB
aji-40	367	14	acute	acute	ADJ
aji-40	367	15	kidney	kidney	NOUN
aji-40	367	16	injury	injury	NOUN
aji-40	367	17	possibly	possibly	ADV
aji-40	367	18	due	due	ADP
aji-40	367	19	to	to	ADP
aji-40	367	20	anti	anti	ADJ
aji-40	367	21	-	-	ADJ
aji-40	367	22	tnf	tnf	ADJ
aji-40	367	23	therapy	therapy	NOUN
aji-40	367	24	[	[	X
aji-40	367	25	72	72	NUM
aji-40	367	26	]	]	PUNCT
aji-40	367	27	.	.	PUNCT
aji-40	368	1	tnf	tnf	PROPN
aji-40	368	2	-	-	PUNCT
aji-40	368	3	α	α	PROPN
aji-40	368	4	and	and	CCONJ
aji-40	368	5	tnfr1	tnfr1	NOUN
aji-40	368	6	and	and	CCONJ
aji-40	368	7	tnfr2	tnfr2	NOUN
aji-40	368	8	are	be	AUX
aji-40	368	9	higher	high	ADJ
aji-40	368	10	in	in	ADP
aji-40	368	11	chronic	chronic	ADJ
aji-40	368	12	kidney	kidney	NOUN
aji-40	368	13	disease	disease	NOUN
aji-40	368	14	[	[	X
aji-40	368	15	65,73	65,73	NOUN
aji-40	368	16	]	]	PUNCT
aji-40	368	17	.	.	PUNCT
aji-40	369	1	richard	richard	PROPN
aji-40	369	2	et	et	PROPN
aji-40	369	3	al	al	PROPN
aji-40	369	4	found	find	VERB
aji-40	369	5	that	that	SCONJ
aji-40	369	6	higher	high	ADJ
aji-40	369	7	levels	level	NOUN
aji-40	369	8	of	of	ADP
aji-40	369	9	tnf	tnf	PROPN
aji-40	369	10	-	-	PUNCT
aji-40	369	11	α	α	PROPN
aji-40	369	12	are	be	AUX
aji-40	369	13	associated	associate	VERB
aji-40	369	14	with	with	ADP
aji-40	369	15	more	more	ADV
aji-40	369	16	rapid	rapid	ADJ
aji-40	369	17	worsening	worsening	NOUN
aji-40	369	18	of	of	ADP
aji-40	369	19	renal	renal	ADJ
aji-40	369	20	functions	function	NOUN
aji-40	369	21	over	over	ADP
aji-40	369	22	time	time	NOUN
aji-40	369	23	in	in	ADP
aji-40	369	24	patients	patient	NOUN
aji-40	369	25	with	with	ADP
aji-40	369	26	chronic	chronic	ADJ
aji-40	369	27	kidney	kidney	NOUN
aji-40	369	28	disease	disease	NOUN
aji-40	369	29	[	[	X
aji-40	369	30	65	65	NUM
aji-40	369	31	]	]	PUNCT
aji-40	369	32	.	.	PUNCT
aji-40	370	1	it	it	PRON
aji-40	370	2	has	have	AUX
aji-40	370	3	also	also	ADV
aji-40	370	4	been	be	AUX
aji-40	370	5	observed	observe	VERB
aji-40	370	6	that	that	SCONJ
aji-40	370	7	high	high	ADJ
aji-40	370	8	levels	level	NOUN
aji-40	370	9	of	of	ADP
aji-40	370	10	tnfr	tnfr	NOUN
aji-40	370	11	1	1	NUM
aji-40	370	12	and	and	CCONJ
aji-40	370	13	tnfr2	tnfr2	NOUN
aji-40	370	14	in	in	ADP
aji-40	370	15	diabetes	diabetes	NOUN
aji-40	370	16	are	be	AUX
aji-40	370	17	associated	associate	VERB
aji-40	370	18	with	with	ADP
aji-40	370	19	progression	progression	NOUN
aji-40	370	20	of	of	ADP
aji-40	370	21	diabetic	diabetic	ADJ
aji-40	370	22	kidney	kidney	NOUN
aji-40	370	23	disease	disease	NOUN
aji-40	370	24	,	,	PUNCT
aji-40	370	25	and	and	CCONJ
aji-40	370	26	higher	high	ADJ
aji-40	370	27	mortality	mortality	NOUN
aji-40	371	1	[	[	X
aji-40	371	2	74	74	NUM
aji-40	371	3	]	]	PUNCT
aji-40	371	4	.	.	PUNCT
aji-40	372	1	tnf	tnf	PROPN
aji-40	372	2	-	-	PUNCT
aji-40	372	3	α	α	PROPN
aji-40	372	4	may	may	AUX
aji-40	372	5	play	play	VERB
aji-40	372	6	a	a	DET
aji-40	372	7	role	role	NOUN
aji-40	372	8	in	in	ADP
aji-40	372	9	renal	renal	ADJ
aji-40	372	10	ischemiareperfusion	ischemiareperfusion	NOUN
aji-40	372	11	injury	injury	NOUN
aji-40	372	12	post	post	NOUN
aji-40	372	13	kidney	kidney	NOUN
aji-40	372	14	transplantation	transplantation	NOUN
aji-40	372	15	[	[	X
aji-40	372	16	69	69	NUM
aji-40	372	17	]	]	PUNCT
aji-40	372	18	.	.	PUNCT
aji-40	373	1	in	in	ADP
aji-40	373	2	the	the	DET
aji-40	373	3	pathogenesis	pathogenesis	NOUN
aji-40	373	4	of	of	ADP
aji-40	373	5	renal	renal	ADJ
aji-40	373	6	ischemiareperfusion	ischemiareperfusion	NOUN
aji-40	373	7	injury	injury	NOUN
aji-40	373	8	,	,	PUNCT
aji-40	373	9	tnf	tnf	PROPN
aji-40	373	10	-	-	PUNCT
aji-40	373	11	α	α	PROPN
aji-40	373	12	induces	induce	VERB
aji-40	373	13	fibrin	fibrin	NOUN
aji-40	373	14	deposition	deposition	NOUN
aji-40	373	15	,	,	PUNCT
aji-40	373	16	cellular	cellular	ADJ
aji-40	373	17	infiltration	infiltration	NOUN
aji-40	373	18	,	,	PUNCT
aji-40	373	19	vasoconstriction	vasoconstriction	NOUN
aji-40	373	20	and	and	CCONJ
aji-40	373	21	apoptosis	apoptosis	NOUN
aji-40	373	22	[	[	X
aji-40	373	23	69	69	NUM
aji-40	373	24	]	]	PUNCT
aji-40	373	25	.	.	PUNCT
aji-40	374	1	investigators	investigator	NOUN
aji-40	374	2	have	have	AUX
aji-40	374	3	found	find	VERB
aji-40	374	4	that	that	SCONJ
aji-40	374	5	inhibition	inhibition	NOUN
aji-40	374	6	of	of	ADP
aji-40	374	7	tnfr2	tnfr2	NOUN
aji-40	374	8	pathway	pathway	NOUN
aji-40	374	9	may	may	AUX
aji-40	374	10	be	be	AUX
aji-40	374	11	helpful	helpful	ADJ
aji-40	374	12	in	in	ADP
aji-40	374	13	decreasing	decrease	VERB
aji-40	374	14	incidence	incidence	NOUN
aji-40	374	15	of	of	ADP
aji-40	374	16	glomerulonephritis	glomerulonephritis	NOUN
aji-40	374	17	.	.	PUNCT
aji-40	375	1	the	the	DET
aji-40	375	2	possible	possible	ADJ
aji-40	375	3	underlying	underlying	ADJ
aji-40	375	4	mechanisms	mechanism	NOUN
aji-40	375	5	that	that	PRON
aji-40	375	6	are	be	AUX
aji-40	375	7	involved	involve	VERB
aji-40	375	8	in	in	ADP
aji-40	375	9	this	this	PRON
aji-40	375	10	are	be	AUX
aji-40	375	11	not	not	PART
aji-40	375	12	completely	completely	ADV
aji-40	375	13	understood	understand	VERB
aji-40	375	14	.	.	PUNCT
aji-40	376	1	tnfr2	tnfr2	NOUN
aji-40	376	2	(	(	PUNCT
aji-40	376	3	but	but	CCONJ
aji-40	376	4	not	not	PART
aji-40	376	5	tnfr1	tnfr1	NOUN
aji-40	376	6	)	)	PUNCT
aji-40	376	7	is	be	AUX
aji-40	376	8	found	find	VERB
aji-40	376	9	in	in	ADP
aji-40	376	10	high	high	ADJ
aji-40	376	11	concentration	concentration	NOUN
aji-40	376	12	in	in	ADP
aji-40	376	13	renal	renal	ADJ
aji-40	376	14	tubular	tubular	ADJ
aji-40	376	15	epithelial	epithelial	ADJ
aji-40	376	16	cells	cell	NOUN
aji-40	376	17	in	in	ADP
aji-40	376	18	renal	renal	ADJ
aji-40	376	19	tubulointerstitial	tubulointerstitial	ADJ
aji-40	376	20	nephritis	nephritis	NOUN
aji-40	376	21	and	and	CCONJ
aji-40	376	22	interacts	interact	VERB
aji-40	376	23	with	with	ADP
aji-40	376	24	‘	'	PUNCT
aji-40	376	25	sef	sef	NOUN
aji-40	376	26	’	'	PUNCT
aji-40	376	27	or	or	CCONJ
aji-40	376	28	il-17rd	il-17rd	PROPN
aji-40	376	29	,	,	PUNCT
aji-40	376	30	causing	cause	VERB
aji-40	376	31	activation	activation	NOUN
aji-40	376	32	of	of	ADP
aji-40	376	33	nf	nf	ADJ
aji-40	376	34	-	-	PUNCT
aji-40	376	35	kb	kb	NOUN
aji-40	376	36	pathway	pathway	NOUN
aji-40	376	37	and	and	CCONJ
aji-40	376	38	inflammation	inflammation	NOUN
aji-40	376	39	[	[	X
aji-40	376	40	16,17	16,17	NUM
aji-40	376	41	]	]	PUNCT
aji-40	376	42	.	.	PUNCT
aji-40	377	1	tnf	tnf	PROPN
aji-40	377	2	-	-	PUNCT
aji-40	377	3	α	α	PROPN
aji-40	377	4	may	may	AUX
aji-40	377	5	enhance	enhance	VERB
aji-40	377	6	the	the	DET
aji-40	377	7	interaction	interaction	NOUN
aji-40	377	8	of	of	ADP
aji-40	377	9	tnfr2	tnfr2	NOUN
aji-40	377	10	and	and	CCONJ
aji-40	377	11	il-17rd	il-17rd	PROPN
aji-40	377	12	,	,	PUNCT
aji-40	377	13	but	but	CCONJ
aji-40	377	14	the	the	DET
aji-40	377	15	presence	presence	NOUN
aji-40	377	16	of	of	ADP
aji-40	377	17	tnf	tnf	PROPN
aji-40	377	18	-	-	PUNCT
aji-40	377	19	α	α	PROPN
aji-40	377	20	is	be	AUX
aji-40	377	21	not	not	PART
aji-40	377	22	absolutely	absolutely	ADV
aji-40	377	23	necessary	necessary	ADJ
aji-40	377	24	for	for	SCONJ
aji-40	377	25	the	the	DET
aji-40	377	26	interaction	interaction	NOUN
aji-40	377	27	to	to	PART
aji-40	377	28	occur	occur	VERB
aji-40	377	29	(	(	PUNCT
aji-40	377	30	upregulated	upregulated	ADJ
aji-40	377	31	tnfr2	tnfr2	NOUN
aji-40	377	32	may	may	AUX
aji-40	377	33	trigger	trigger	VERB
aji-40	377	34	interaction	interaction	NOUN
aji-40	377	35	with	with	ADP
aji-40	377	36	il-17rd	il-17rd	PROPN
aji-40	377	37	independent	independent	NOUN
aji-40	377	38	of	of	ADP
aji-40	377	39	tnf	tnf	PROPN
aji-40	377	40	-	-	PUNCT
aji-40	377	41	α	α	NOUN
aji-40	377	42	)	)	PUNCT
aji-40	378	1	[	[	X
aji-40	378	2	17	17	NUM
aji-40	378	3	]	]	PUNCT
aji-40	378	4	.	.	PUNCT
aji-40	379	1	this	this	PRON
aji-40	379	2	may	may	AUX
aji-40	379	3	be	be	AUX
aji-40	379	4	one	one	NUM
aji-40	379	5	of	of	ADP
aji-40	379	6	the	the	DET
aji-40	379	7	pathogenic	pathogenic	ADJ
aji-40	379	8	mechanisms	mechanism	NOUN
aji-40	379	9	explaining	explain	VERB
aji-40	379	10	the	the	DET
aji-40	379	11	role	role	NOUN
aji-40	379	12	of	of	ADP
aji-40	379	13	upregulated	upregulated	ADJ
aji-40	379	14	tnfr2	tnfr2	NOUN
aji-40	379	15	contributing	contribute	VERB
aji-40	379	16	to	to	ADP
aji-40	379	17	nephritis	nephritis	NOUN
aji-40	379	18	and	and	CCONJ
aji-40	379	19	tubulointerstitial	tubulointerstitial	ADJ
aji-40	379	20	renal	renal	ADJ
aji-40	379	21	diseases	disease	NOUN
aji-40	379	22	[	[	X
aji-40	379	23	17	17	NUM
aji-40	379	24	]	]	PUNCT
aji-40	379	25	.	.	PUNCT
aji-40	380	1	the	the	DET
aji-40	380	2	evidence	evidence	NOUN
aji-40	380	3	is	be	AUX
aji-40	380	4	helpful	helpful	ADJ
aji-40	380	5	,	,	PUNCT
aji-40	380	6	but	but	CCONJ
aji-40	380	7	more	more	ADJ
aji-40	380	8	studies	study	NOUN
aji-40	380	9	are	be	AUX
aji-40	380	10	needed	need	VERB
aji-40	380	11	to	to	PART
aji-40	380	12	understand	understand	VERB
aji-40	380	13	the	the	DET
aji-40	380	14	role	role	NOUN
aji-40	380	15	of	of	ADP
aji-40	380	16	tnf	tnf	PROPN
aji-40	380	17	-	-	PUNCT
aji-40	380	18	α	α	PROPN
aji-40	380	19	and	and	CCONJ
aji-40	380	20	tnf	tnf	PROPN
aji-40	380	21	receptors	receptor	NOUN
aji-40	380	22	in	in	ADP
aji-40	380	23	renal	renal	ADJ
aji-40	380	24	diseases	disease	NOUN
aji-40	380	25	.	.	PUNCT
aji-40	381	1	kidney	kidney	NOUN
aji-40	381	2	transplant	transplant	NOUN
aji-40	381	3	recipients	recipient	NOUN
aji-40	381	4	are	be	AUX
aji-40	381	5	on	on	ADP
aji-40	381	6	immunosuppressive	immunosuppressive	ADJ
aji-40	381	7	medications	medication	NOUN
aji-40	381	8	and	and	CCONJ
aji-40	381	9	are	be	AUX
aji-40	381	10	already	already	ADV
aji-40	381	11	at	at	ADP
aji-40	381	12	an	an	DET
aji-40	381	13	increased	increase	VERB
aji-40	381	14	risk	risk	NOUN
aji-40	381	15	of	of	ADP
aji-40	381	16	infections	infection	NOUN
aji-40	381	17	[	[	X
aji-40	381	18	75	75	NUM
aji-40	381	19	]	]	PUNCT
aji-40	381	20	.	.	PUNCT
aji-40	382	1	anti	anti	ADJ
aji-40	382	2	-	-	ADJ
aji-40	382	3	tnf	tnf	ADJ
aji-40	382	4	therapy	therapy	NOUN
aji-40	382	5	may	may	AUX
aji-40	382	6	increase	increase	VERB
aji-40	382	7	this	this	DET
aji-40	382	8	risk	risk	NOUN
aji-40	382	9	of	of	ADP
aji-40	382	10	infections	infection	NOUN
aji-40	382	11	and	and	CCONJ
aji-40	382	12	malignancy	malignancy	NOUN
aji-40	382	13	in	in	ADP
aji-40	382	14	kidney	kidney	NOUN
aji-40	382	15	transplant	transplant	NOUN
aji-40	382	16	recipients	recipient	NOUN
aji-40	382	17	and	and	CCONJ
aji-40	382	18	should	should	AUX
aji-40	382	19	be	be	AUX
aji-40	382	20	used	use	VERB
aji-40	382	21	with	with	ADP
aji-40	382	22	caution	caution	NOUN
aji-40	382	23	[	[	X
aji-40	382	24	76	76	NUM
aji-40	382	25	]	]	X
aji-40	382	26	.	.	PUNCT
aji-40	383	1	8	8	X
aji-40	383	2	.	.	X
aji-40	383	3	conclusion	conclusion	NOUN
aji-40	383	4	tnf	tnf	PROPN
aji-40	383	5	-	-	PUNCT
aji-40	383	6	α	α	PROPN
aji-40	383	7	,	,	PUNCT
aji-40	383	8	tnfr1	tnfr1	NOUN
aji-40	383	9	and	and	CCONJ
aji-40	383	10	tnfr2	tnfr2	NOUN
aji-40	383	11	systems	system	NOUN
aji-40	383	12	are	be	AUX
aji-40	383	13	complex	complex	ADJ
aji-40	383	14	.	.	PUNCT
aji-40	384	1	increased	increase	VERB
aji-40	384	2	concentration	concentration	NOUN
aji-40	384	3	of	of	ADP
aji-40	384	4	tnf	tnf	PROPN
aji-40	384	5	-	-	PUNCT
aji-40	384	6	α	α	PROPN
aji-40	384	7	is	be	AUX
aji-40	384	8	a	a	DET
aji-40	384	9	prominent	prominent	ADJ
aji-40	384	10	feature	feature	NOUN
aji-40	384	11	of	of	ADP
aji-40	384	12	many	many	ADJ
aji-40	384	13	diseases	disease	NOUN
aji-40	384	14	including	include	VERB
aji-40	384	15	rheumatoid	rheumatoid	NOUN
aji-40	384	16	arthritis	arthritis	NOUN
aji-40	384	17	,	,	PUNCT
aji-40	384	18	ankylosing	ankylose	VERB
aji-40	384	19	spondylitis	spondylitis	NOUN
aji-40	384	20	,	,	PUNCT
aji-40	384	21	juvenile	juvenile	ADJ
aji-40	384	22	inflammatory	inflammatory	ADJ
aji-40	384	23	arthritis	arthritis	NOUN
aji-40	384	24	,	,	PUNCT
aji-40	384	25	crohn	crohn	PROPN
aji-40	384	26	’s	’s	PART
aji-40	384	27	disease	disease	NOUN
aji-40	384	28	,	,	PUNCT
aji-40	384	29	ulcerative	ulcerative	ADJ
aji-40	384	30	colitis	colitis	NOUN
aji-40	384	31	and	and	CCONJ
aji-40	384	32	psoriatic	psoriatic	ADJ
aji-40	384	33	arthritis	arthritis	NOUN
aji-40	384	34	.	.	PUNCT
aji-40	385	1	the	the	DET
aji-40	385	2	beneficial	beneficial	ADJ
aji-40	385	3	effects	effect	NOUN
aji-40	385	4	of	of	ADP
aji-40	385	5	anti	anti	ADJ
aji-40	385	6	-	-	ADJ
aji-40	385	7	tnf	tnf	ADJ
aji-40	385	8	therapies	therapy	NOUN
aji-40	385	9	in	in	ADP
aji-40	385	10	these	these	DET
aji-40	385	11	diseases	disease	NOUN
aji-40	385	12	led	lead	VERB
aji-40	385	13	to	to	ADP
aji-40	385	14	the	the	DET
aji-40	385	15	speculation	speculation	NOUN
aji-40	385	16	that	that	SCONJ
aji-40	385	17	these	these	DET
aji-40	385	18	therapeutic	therapeutic	ADJ
aji-40	385	19	agents	agent	NOUN
aji-40	385	20	may	may	AUX
aji-40	385	21	be	be	AUX
aji-40	385	22	helpful	helpful	ADJ
aji-40	385	23	in	in	ADP
aji-40	385	24	other	other	ADJ
aji-40	385	25	ailments	ailment	NOUN
aji-40	385	26	that	that	PRON
aji-40	385	27	have	have	VERB
aji-40	385	28	abnormalities	abnormality	NOUN
aji-40	385	29	in	in	ADP
aji-40	385	30	concentration	concentration	NOUN
aji-40	385	31	of	of	ADP
aji-40	385	32	tnf	tnf	PROPN
aji-40	385	33	-	-	PUNCT
aji-40	385	34	α	α	PROPN
aji-40	385	35	and	and	CCONJ
aji-40	385	36	tnf	tnf	PROPN
aji-40	385	37	receptorsfor	receptorsfor	PROPN
aji-40	385	38	example	example	NOUN
aji-40	385	39	,	,	PUNCT
aji-40	385	40	in	in	ADP
aji-40	385	41	alzheimer	alzheimer	PROPN
aji-40	385	42	’s	’s	PART
aji-40	385	43	disease	disease	NOUN
aji-40	385	44	,	,	PUNCT
aji-40	385	45	parkinson	parkinson	NOUN
aji-40	385	46	’s	’s	PART
aji-40	385	47	disease	disease	NOUN
aji-40	385	48	,	,	PUNCT
aji-40	385	49	systemic	systemic	ADJ
aji-40	385	50	lupus	lupus	PROPN
aji-40	385	51	erythematosus	erythematosus	PROPN
aji-40	385	52	,	,	PUNCT
aji-40	385	53	tubulointerstitial	tubulointerstitial	ADJ
aji-40	385	54	nephritis	nephritis	NOUN
aji-40	385	55	,	,	PUNCT
aji-40	385	56	diabetic	diabetic	ADJ
aji-40	385	57	nephropathy	nephropathy	NOUN
aji-40	385	58	,	,	PUNCT
aji-40	385	59	chronic	chronic	ADJ
aji-40	385	60	kidney	kidney	NOUN
aji-40	385	61	disease	disease	NOUN
aji-40	385	62	,	,	PUNCT
aji-40	385	63	and	and	CCONJ
aji-40	385	64	cardiovascular	cardiovascular	ADJ
aji-40	385	65	diseases	disease	NOUN
aji-40	385	66	including	include	VERB
aji-40	385	67	hypertension	hypertension	NOUN
aji-40	385	68	and	and	CCONJ
aji-40	385	69	atherosclerosis	atherosclerosis	NOUN
aji-40	385	70	.	.	PUNCT
aji-40	386	1	however	however	ADV
aji-40	386	2	,	,	PUNCT
aji-40	386	3	investigators	investigator	NOUN
aji-40	386	4	have	have	AUX
aji-40	386	5	found	find	VERB
aji-40	386	6	that	that	SCONJ
aji-40	386	7	this	this	PRON
aji-40	386	8	is	be	AUX
aji-40	386	9	not	not	PART
aji-40	386	10	entirely	entirely	ADV
aji-40	386	11	true	true	ADJ
aji-40	386	12	.	.	PUNCT
aji-40	387	1	while	while	SCONJ
aji-40	387	2	some	some	DET
aji-40	387	3	studies	study	NOUN
aji-40	387	4	have	have	AUX
aji-40	387	5	shown	show	VERB
aji-40	387	6	beneficial	beneficial	ADJ
aji-40	387	7	effects	effect	NOUN
aji-40	387	8	of	of	ADP
aji-40	387	9	anti	anti	ADJ
aji-40	387	10	-	-	ADJ
aji-40	387	11	tnf	tnf	ADJ
aji-40	387	12	therapy	therapy	NOUN
aji-40	387	13	,	,	PUNCT
aji-40	387	14	other	other	ADJ
aji-40	387	15	studies	study	NOUN
aji-40	387	16	have	have	AUX
aji-40	387	17	shown	show	VERB
aji-40	387	18	conflicting	conflicting	ADJ
aji-40	387	19	results	result	NOUN
aji-40	387	20	that	that	PRON
aji-40	387	21	point	point	VERB
aji-40	387	22	towards	towards	ADP
aji-40	387	23	the	the	DET
aji-40	387	24	complex	complex	ADJ
aji-40	387	25	nature	nature	NOUN
aji-40	387	26	of	of	ADP
aji-40	387	27	tnf	tnf	PROPN
aji-40	387	28	-	-	PUNCT
aji-40	387	29	α	α	PROPN
aji-40	387	30	and	and	CCONJ
aji-40	387	31	tnf	tnf	PROPN
aji-40	387	32	receptors	receptor	NOUN
aji-40	387	33	pathway	pathway	NOUN
aji-40	387	34	.	.	PUNCT
aji-40	388	1	more	more	ADV
aji-40	388	2	extensive	extensive	ADJ
aji-40	388	3	research	research	NOUN
aji-40	388	4	is	be	AUX
aji-40	388	5	needed	need	VERB
aji-40	388	6	to	to	PART
aji-40	388	7	understand	understand	VERB
aji-40	388	8	this	this	DET
aji-40	388	9	system	system	NOUN
aji-40	388	10	,	,	PUNCT
aji-40	388	11	so	so	SCONJ
aji-40	388	12	that	that	SCONJ
aji-40	388	13	better	well	ADJ
aji-40	388	14	and	and	CCONJ
aji-40	388	15	more	more	ADV
aji-40	388	16	selective	selective	ADJ
aji-40	388	17	anti	anti	ADJ
aji-40	388	18	-	-	ADJ
aji-40	388	19	tnf	tnf	ADJ
aji-40	388	20	therapeutic	therapeutic	ADJ
aji-40	388	21	agents	agent	NOUN
aji-40	388	22	may	may	AUX
aji-40	388	23	be	be	AUX
aji-40	388	24	developed	develop	VERB
aji-40	388	25	to	to	PART
aji-40	388	26	help	help	VERB
aji-40	388	27	in	in	ADP
aji-40	388	28	diseases	disease	NOUN
aji-40	388	29	including	include	VERB
aji-40	388	30	alzheimer	alzheimer	PROPN
aji-40	388	31	’s	’s	PART
aji-40	388	32	disease	disease	NOUN
aji-40	388	33	,	,	PUNCT
aji-40	388	34	multiple	multiple	ADJ
aji-40	388	35	sclerosis	sclerosis	NOUN
aji-40	388	36	,	,	PUNCT
aji-40	388	37	parkinson	parkinson	NOUN
aji-40	388	38	’s	’s	PART
aji-40	388	39	disease	disease	NOUN
aji-40	388	40	,	,	PUNCT
aji-40	388	41	renal	renal	ADJ
aji-40	388	42	and	and	CCONJ
aji-40	388	43	cardiovascular	cardiovascular	ADJ
aji-40	388	44	diseases	disease	NOUN
aji-40	388	45	.	.	PUNCT
aji-40	389	1	declaration	declaration	NOUN
aji-40	389	2	we	we	PRON
aji-40	389	3	thank	thank	VERB
aji-40	389	4	iqvia	iqvia	NOUN
aji-40	389	5	(	(	PUNCT
aji-40	389	6	communications	communication	NOUN
aji-40	389	7	,	,	PUNCT
aji-40	389	8	branding	branding	NOUN
aji-40	389	9	,	,	PUNCT
aji-40	389	10	and	and	CCONJ
aji-40	389	11	legal	legal	ADJ
aji-40	389	12	units	unit	NOUN
aji-40	389	13	)	)	PUNCT
aji-40	389	14	for	for	ADP
aji-40	389	15	giving	give	VERB
aji-40	389	16	us	we	PRON
aji-40	389	17	permission	permission	NOUN
aji-40	389	18	,	,	PUNCT
aji-40	389	19	and	and	CCONJ
aji-40	389	20	‘	'	PUNCT
aji-40	389	21	no	no	DET
aji-40	389	22	churchill	churchill	NOUN
aji-40	389	23	et	et	PROPN
aji-40	389	24	al	al	PROPN
aji-40	389	25	.	.	PROPN
aji-40	389	26	;	;	PUNCT
aji-40	389	27	aji	aji	PROPN
aji-40	389	28	,	,	PUNCT
aji-40	389	29	3(1	3(1	NUM
aji-40	389	30	):	):	PUNCT
aji-40	389	31	208	208	NUM
aji-40	389	32	-	-	SYM
aji-40	389	33	222	222	NUM
aji-40	389	34	,	,	PUNCT
aji-40	389	35	2020	2020	NUM
aji-40	389	36	;	;	PUNCT
aji-40	389	37	article	article	NOUN
aji-40	389	38	no.aji.57464	no.aji.57464	NOUN
aji-40	389	39	218	218	NUM
aji-40	389	40	objection	objection	NOUN
aji-40	389	41	’	'	PUNCT
aji-40	389	42	note	note	NOUN
aji-40	389	43	for	for	ADP
aji-40	389	44	publication	publication	NOUN
aji-40	389	45	of	of	ADP
aji-40	389	46	this	this	DET
aji-40	389	47	paper	paper	NOUN
aji-40	389	48	.	.	PUNCT
aji-40	390	1	we	we	PRON
aji-40	390	2	thank	thank	VERB
aji-40	390	3	iqvia	iqvia	NOUN
aji-40	390	4	for	for	ADP
aji-40	390	5	providing	provide	VERB
aji-40	390	6	us	we	PRON
aji-40	390	7	the	the	DET
aji-40	390	8	support	support	NOUN
aji-40	390	9	and	and	CCONJ
aji-40	390	10	infrastructure	infrastructure	NOUN
aji-40	390	11	needed	need	VERB
aji-40	390	12	to	to	PART
aji-40	390	13	complete	complete	VERB
aji-40	390	14	this	this	DET
aji-40	390	15	paper	paper	NOUN
aji-40	390	16	,	,	PUNCT
aji-40	390	17	including	include	VERB
aji-40	390	18	giving	give	VERB
aji-40	390	19	us	we	PRON
aji-40	390	20	the	the	DET
aji-40	390	21	opportunity	opportunity	NOUN
aji-40	390	22	to	to	PART
aji-40	390	23	form	form	VERB
aji-40	390	24	this	this	DET
aji-40	390	25	great	great	ADJ
aji-40	390	26	team	team	NOUN
aji-40	390	27	that	that	PRON
aji-40	390	28	was	be	AUX
aji-40	390	29	instrumental	instrumental	ADJ
aji-40	390	30	in	in	ADP
aji-40	390	31	bringing	bring	VERB
aji-40	390	32	this	this	DET
aji-40	390	33	paper	paper	NOUN
aji-40	390	34	to	to	ADP
aji-40	390	35	conclusion	conclusion	NOUN
aji-40	390	36	.	.	PUNCT
aji-40	391	1	consent	consent	NOUN
aji-40	391	2	it	it	PRON
aji-40	391	3	is	be	AUX
aji-40	391	4	not	not	PART
aji-40	391	5	applicable	applicable	ADJ
aji-40	391	6	.	.	PUNCT
aji-40	392	1	ethical	ethical	ADJ
aji-40	392	2	approval	approval	NOUN
aji-40	392	3	it	it	PRON
aji-40	392	4	is	be	AUX
aji-40	392	5	not	not	PART
aji-40	392	6	applicable	applicable	ADJ
aji-40	392	7	.	.	PUNCT
aji-40	393	1	competing	compete	VERB
aji-40	393	2	interests	interest	NOUN
aji-40	393	3	authors	author	NOUN
aji-40	393	4	have	have	AUX
aji-40	393	5	declared	declare	VERB
aji-40	393	6	that	that	SCONJ
aji-40	393	7	no	no	DET
aji-40	393	8	competing	compete	VERB
aji-40	393	9	interests	interest	NOUN
aji-40	393	10	exist	exist	VERB
aji-40	393	11	.	.	PUNCT
aji-40	394	1	references	reference	NOUN
aji-40	394	2	1	1	NUM
aji-40	394	3	.	.	PUNCT
aji-40	395	1	chen	chen	PROPN
aji-40	395	2	x	x	PROPN
aji-40	395	3	,	,	PUNCT
aji-40	395	4	li	li	PROPN
aji-40	395	5	p	p	PROPN
aji-40	395	6	,	,	PUNCT
aji-40	395	7	yang	yang	PROPN
aji-40	395	8	x	x	PROPN
aji-40	395	9	,	,	PUNCT
aji-40	395	10	miao	miao	PROPN
aji-40	395	11	x	x	PROPN
aji-40	395	12	,	,	PUNCT
aji-40	395	13	luo	luo	PROPN
aji-40	395	14	h.	h.	PROPN
aji-40	395	15	tumor	tumor	PROPN
aji-40	395	16	necrosis	necrosis	NOUN
aji-40	395	17	factor	factor	NOUN
aji-40	395	18	receptor	receptor	NOUN
aji-40	395	19	ii	ii	PROPN
aji-40	395	20	(	(	PUNCT
aji-40	395	21	tnfr2	tnfr2	NOUN
aji-40	395	22	)	)	PUNCT
aji-40	395	23	promotes	promote	VERB
aji-40	395	24	the	the	DET
aji-40	395	25	growth	growth	NOUN
aji-40	395	26	of	of	ADP
aji-40	395	27	mouse	mouse	NOUN
aji-40	395	28	ct26	ct26	PROPN
aji-40	395	29	colon	colon	NOUN
aji-40	395	30	cancer	cancer	NOUN
aji-40	395	31	.	.	PUNCT
aji-40	396	1	j	j	PROPN
aji-40	396	2	immunol	immunol	NOUN
aji-40	396	3	.	.	PUNCT
aji-40	397	1	2018;200(1	2018;200(1	NUM
aji-40	398	1	supplement):178.7	supplement):178.7	X
aji-40	398	2	.	.	NOUN
aji-40	398	3	2	2	NUM
aji-40	398	4	.	.	X
aji-40	398	5	idriss	idriss	PROPN
aji-40	398	6	ht	ht	PROPN
aji-40	398	7	,	,	PUNCT
aji-40	398	8	naismith	naismith	PROPN
aji-40	398	9	jh	jh	PROPN
aji-40	398	10	.	.	PUNCT
aji-40	399	1	tnf	tnf	PROPN
aji-40	399	2	alpha	alpha	NOUN
aji-40	399	3	and	and	CCONJ
aji-40	399	4	the	the	DET
aji-40	399	5	tnf	tnf	PROPN
aji-40	399	6	receptor	receptor	NOUN
aji-40	399	7	superfamily	superfamily	NOUN
aji-40	399	8	:	:	PUNCT
aji-40	399	9	structurefunction	structurefunction	NOUN
aji-40	399	10	relationship(s	relationship(s	NOUN
aji-40	399	11	)	)	PUNCT
aji-40	399	12	.	.	PUNCT
aji-40	400	1	microsc	microsc	PROPN
aji-40	400	2	res	re	NOUN
aji-40	400	3	tech	tech	NOUN
aji-40	400	4	.	.	PUNCT
aji-40	401	1	[	[	X
aji-40	401	2	internet	internet	NOUN
aji-40	401	3	]	]	PUNCT
aji-40	401	4	.	.	PUNCT
aji-40	402	1	2000;50(3):184	2000;50(3):184	NUM
aji-40	402	2	-	-	SYM
aji-40	402	3	95	95	NUM
aji-40	402	4	.	.	PUNCT
aji-40	403	1	available	available	ADJ
aji-40	403	2	:	:	PUNCT
aji-40	403	3	https://www.ncbi.nlm.nih.gov	https://www.ncbi.nlm.nih.gov	ADJ
aji-40	403	4	/	/	SYM
aji-40	403	5	pub	pub	NOUN
aji-40	403	6	med/10891884	med/10891884	NOUN
aji-40	403	7	(	(	PUNCT
aji-40	403	8	accessed	access	VERB
aji-40	403	9	on	on	ADP
aji-40	403	10	27	27	NUM
aji-40	403	11	may	may	NOUN
aji-40	403	12	2020	2020	NUM
aji-40	403	13	)	)	PUNCT
aji-40	404	1	3	3	NUM
aji-40	404	2	.	.	X
aji-40	404	3	yang	yang	PROPN
aji-40	404	4	s	s	PROPN
aji-40	404	5	,	,	PUNCT
aji-40	404	6	wang	wang	PROPN
aji-40	404	7	j	j	PROPN
aji-40	404	8	,	,	PUNCT
aji-40	404	9	brand	brand	PROPN
aji-40	404	10	dd	dd	PROPN
aji-40	404	11	,	,	PUNCT
aji-40	404	12	zheng	zheng	PROPN
aji-40	404	13	sg	sg	PROPN
aji-40	404	14	.	.	PUNCT
aji-40	405	1	role	role	NOUN
aji-40	405	2	of	of	ADP
aji-40	405	3	tnf	tnf	PROPN
aji-40	405	4	-	-	PUNCT
aji-40	405	5	tnf	tnf	PROPN
aji-40	405	6	receptor	receptor	NOUN
aji-40	405	7	2	2	NUM
aji-40	405	8	signal	signal	NOUN
aji-40	405	9	in	in	ADP
aji-40	405	10	regulatory	regulatory	ADJ
aji-40	405	11	t	t	NOUN
aji-40	405	12	cells	cell	NOUN
aji-40	405	13	and	and	CCONJ
aji-40	405	14	its	its	PRON
aji-40	405	15	therapeutic	therapeutic	ADJ
aji-40	405	16	implications	implication	NOUN
aji-40	405	17	.	.	PUNCT
aji-40	406	1	front	front	ADJ
aji-40	406	2	immunol	immunol	NOUN
aji-40	406	3	.	.	PUNCT
aji-40	407	1	2018;9:784	2018;9:784	ADJ
aji-40	407	2	.	.	PUNCT
aji-40	408	1	available	available	ADJ
aji-40	408	2	:	:	PUNCT
aji-40	408	3	https://doi.org/10.3389	https://doi.org/10.3389	NOUN
aji-40	408	4	/	/	SYM
aji-40	408	5	fimmu.20	fimmu.20	NOUN
aji-40	408	6	18.00784	18.00784	NUM
aji-40	408	7	4	4	NUM
aji-40	408	8	.	.	PUNCT
aji-40	408	9	horiuchi	horiuchi	PROPN
aji-40	408	10	t	t	PROPN
aji-40	408	11	,	,	PUNCT
aji-40	408	12	mitoma	mitoma	VERB
aji-40	408	13	h	h	NOUN
aji-40	408	14	,	,	PUNCT
aji-40	408	15	harashima	harashima	PROPN
aji-40	408	16	s	s	PROPN
aji-40	408	17	,	,	PUNCT
aji-40	408	18	tsukamoto	tsukamoto	NOUN
aji-40	408	19	h	h	PROPN
aji-40	408	20	,	,	PUNCT
aji-40	408	21	shimoda	shimoda	PROPN
aji-40	408	22	t.	t.	PROPN
aji-40	408	23	transmembrane	transmembrane	PROPN
aji-40	408	24	tnf	tnf	PROPN
aji-40	408	25	-	-	PUNCT
aji-40	408	26	α	α	PROPN
aji-40	408	27	:	:	PUNCT
aji-40	408	28	structure	structure	NOUN
aji-40	408	29	,	,	PUNCT
aji-40	408	30	function	function	NOUN
aji-40	408	31	and	and	CCONJ
aji-40	408	32	interaction	interaction	NOUN
aji-40	408	33	with	with	ADP
aji-40	408	34	anti	anti	ADJ
aji-40	408	35	-	-	ADJ
aji-40	408	36	tnf	tnf	ADJ
aji-40	408	37	agents	agent	NOUN
aji-40	408	38	.	.	PUNCT
aji-40	409	1	rheumatology	rheumatology	NOUN
aji-40	409	2	.	.	PUNCT
aji-40	410	1	2010;49(7):1215–1228	2010;49(7):1215–1228	NUM
aji-40	410	2	.	.	PUNCT
aji-40	411	1	available	available	ADJ
aji-40	411	2	:	:	PUNCT
aji-40	411	3	https://doi.org/10.1093	https://doi.org/10.1093	NOUN
aji-40	411	4	/	/	SYM
aji-40	411	5	rheumatol	rheumatol	ADJ
aji-40	411	6	ogy	ogy	NOUN
aji-40	411	7	/	/	SYM
aji-40	411	8	keq031	keq031	PROPN
aji-40	411	9	5	5	NUM
aji-40	411	10	.	.	PUNCT
aji-40	411	11	kalliolias	kalliolias	PROPN
aji-40	411	12	gd	gd	PROPN
aji-40	411	13	,	,	PUNCT
aji-40	411	14	ivashkiv	ivashkiv	ADV
aji-40	411	15	lb	lb	PROPN
aji-40	411	16	.	.	PUNCT
aji-40	412	1	tnf	tnf	PROPN
aji-40	412	2	biology	biology	NOUN
aji-40	412	3	,	,	PUNCT
aji-40	412	4	pathogenic	pathogenic	ADJ
aji-40	412	5	mechanisms	mechanism	NOUN
aji-40	412	6	and	and	CCONJ
aji-40	412	7	emerging	emerge	VERB
aji-40	412	8	therapeutic	therapeutic	ADJ
aji-40	412	9	strategies	strategy	NOUN
aji-40	412	10	.	.	PUNCT
aji-40	413	1	nat	nat	PROPN
aji-40	413	2	rev	rev	PROPN
aji-40	413	3	rheumatol	rheumatol	NOUN
aji-40	413	4	.	.	PUNCT
aji-40	414	1	2016;12(1):49‐62	2016;12(1):49‐62	X
aji-40	414	2	.	.	PUNCT
aji-40	415	1	doi	doi	NOUN
aji-40	415	2	:	:	PUNCT
aji-40	415	3	10.1038	10.1038	NUM
aji-40	415	4	/	/	SYM
aji-40	415	5	nrrheum.2015.169	nrrheum.2015.169	PROPN
aji-40	415	6	6	6	NUM
aji-40	415	7	.	.	PUNCT
aji-40	415	8	astrakhantseva	astrakhantseva	PROPN
aji-40	415	9	iv	iv	PROPN
aji-40	415	10	,	,	PUNCT
aji-40	415	11	efimov	efimov	PROPN
aji-40	415	12	ga	ga	PROPN
aji-40	415	13	,	,	PUNCT
aji-40	415	14	drutskaya	drutskaya	PROPN
aji-40	415	15	ms	ms	PROPN
aji-40	415	16	,	,	PUNCT
aji-40	415	17	kruglov	kruglov	ADJ
aji-40	415	18	aa	aa	PROPN
aji-40	415	19	,	,	PUNCT
aji-40	415	20	nedospasov	nedospasov	PROPN
aji-40	415	21	sa	sa	PROPN
aji-40	415	22	.	.	PUNCT
aji-40	416	1	modern	modern	ADJ
aji-40	416	2	anti	anti	ADJ
aji-40	416	3	-	-	ADJ
aji-40	416	4	cytokine	cytokine	ADJ
aji-40	416	5	therapy	therapy	NOUN
aji-40	416	6	of	of	ADP
aji-40	416	7	autoimmune	autoimmune	ADJ
aji-40	416	8	diseases	disease	NOUN
aji-40	416	9	.	.	PUNCT
aji-40	417	1	biochemistry	biochemistry	NOUN
aji-40	417	2	(	(	PUNCT
aji-40	417	3	moscow	moscow	PROPN
aji-40	417	4	)	)	PUNCT
aji-40	417	5	.	.	PUNCT
aji-40	418	1	2014	2014	NUM
aji-40	418	2	;	;	PUNCT
aji-40	418	3	79(12):1308	79(12):1308	X
aji-40	418	4	-	-	SYM
aji-40	418	5	1321	1321	NUM
aji-40	418	6	.	.	PUNCT
aji-40	419	1	available	available	ADJ
aji-40	419	2	:	:	PUNCT
aji-40	419	3	https://doi.org/10.1134	https://doi.org/10.1134	ADJ
aji-40	419	4	/	/	SYM
aji-40	419	5	s0006297	s0006297	NOUN
aji-40	419	6	914120049	914120049	NUM
aji-40	419	7	7	7	NUM
aji-40	419	8	.	.	PUNCT
aji-40	420	1	porter	porter	PROPN
aji-40	420	2	c	c	PROPN
aji-40	420	3	,	,	PUNCT
aji-40	420	4	armstrong	armstrong	PROPN
aji-40	420	5	-	-	PUNCT
aji-40	420	6	fisher	fisher	PROPN
aji-40	420	7	s	s	PROPN
aji-40	420	8	,	,	PUNCT
aji-40	420	9	kopotsha	kopotsha	PROPN
aji-40	420	10	t	t	PROPN
aji-40	420	11	,	,	PUNCT
aji-40	420	12	smith	smith	PROPN
aji-40	420	13	b	b	PROPN
aji-40	420	14	,	,	PUNCT
aji-40	420	15	baker	baker	PROPN
aji-40	420	16	t	t	PROPN
aji-40	420	17	,	,	PUNCT
aji-40	420	18	kevorkian	kevorkian	PROPN
aji-40	420	19	l	l	PROPN
aji-40	420	20	,	,	PUNCT
aji-40	420	21	et	et	PROPN
aji-40	420	22	al	al	PROPN
aji-40	420	23	.	.	PUNCT
aji-40	421	1	certolizumab	certolizumab	PROPN
aji-40	421	2	pegol	pegol	PROPN
aji-40	421	3	does	do	AUX
aji-40	421	4	not	not	PART
aji-40	421	5	bind	bind	VERB
aji-40	421	6	the	the	DET
aji-40	421	7	neonatal	neonatal	ADJ
aji-40	421	8	fc	fc	PROPN
aji-40	421	9	receptor	receptor	NOUN
aji-40	421	10	(	(	PUNCT
aji-40	421	11	fcrn	fcrn	NOUN
aji-40	421	12	):	):	PUNCT
aji-40	421	13	consequences	consequence	NOUN
aji-40	421	14	for	for	ADP
aji-40	421	15	fcrn	fcrn	NOUN
aji-40	421	16	-	-	PUNCT
aji-40	421	17	mediated	mediate	VERB
aji-40	421	18	in	in	ADP
aji-40	421	19	vitro	vitro	X
aji-40	421	20	transcytosis	transcytosis	NOUN
aji-40	421	21	and	and	CCONJ
aji-40	421	22	ex	ex	PRON
aji-40	421	23	vivohuman	vivohuman	NOUN
aji-40	421	24	placental	placental	NOUN
aji-40	421	25	transfer	transfer	NOUN
aji-40	421	26	.	.	PUNCT
aji-40	422	1	journal	journal	NOUN
aji-40	422	2	of	of	ADP
aji-40	422	3	reproductive	reproductive	ADJ
aji-40	422	4	immunology	immunology	NOUN
aji-40	422	5	.	.	PUNCT
aji-40	423	1	2016;116:7–12	2016;116:7–12	X
aji-40	423	2	.	.	PUNCT
aji-40	424	1	available	available	ADJ
aji-40	424	2	:	:	PUNCT
aji-40	424	3	http://dx.doi.org/10.1016	http://dx.doi.org/10.1016	PROPN
aji-40	424	4	/	/	SYM
aji-40	424	5	j.jri.201	j.jri.201	ADJ
aji-40	424	6	6.04.284	6.04.284	NOUN
aji-40	424	7	8	8	NUM
aji-40	424	8	.	.	PUNCT
aji-40	425	1	geiler	geiler	PROPN
aji-40	425	2	j	j	PROPN
aji-40	425	3	,	,	PUNCT
aji-40	425	4	buch	buch	PROPN
aji-40	425	5	m	m	PROPN
aji-40	425	6	,	,	PUNCT
aji-40	425	7	mcdermott	mcdermott	PROPN
aji-40	425	8	m.f	m.f	PROPN
aji-40	425	9	.	.	PROPN
aji-40	425	10	antitnf	antitnf	PROPN
aji-40	425	11	treatment	treatment	NOUN
aji-40	425	12	in	in	ADP
aji-40	425	13	rheumatoid	rheumatoid	NOUN
aji-40	425	14	arthritis	arthritis	NOUN
aji-40	425	15	.	.	PUNCT
aji-40	426	1	current	current	ADJ
aji-40	426	2	pharmaceutical	pharmaceutical	ADJ
aji-40	426	3	design	design	NOUN
aji-40	426	4	.	.	PUNCT
aji-40	427	1	2011;17	2011;17	NUM
aji-40	427	2	(	(	PUNCT
aji-40	427	3	29):3141	29):3141	NUM
aji-40	427	4	-	-	SYM
aji-40	427	5	54	54	NUM
aji-40	427	6	.	.	PUNCT
aji-40	428	1	available	available	ADJ
aji-40	428	2	:	:	PUNCT
aji-40	428	3	http://dx.doi.org/10.2174/138161	http://dx.doi.org/10.2174/138161	ADJ
aji-40	428	4	211798157658	211798157658	NUM
aji-40	428	5	9	9	NUM
aji-40	428	6	.	.	PUNCT
aji-40	428	7	smyth	smyth	NOUN
aji-40	428	8	,	,	PUNCT
aji-40	428	9	m.	m.	NOUN
aji-40	428	10	lloyd	lloyd	PROPN
aji-40	428	11	john	john	PROPN
aji-40	428	12	old	old	PROPN
aji-40	428	13	1933–2011	1933–2011	NUM
aji-40	428	14	.	.	PUNCT
aji-40	429	1	nat	nat	PROPN
aji-40	429	2	immunol	immunol	NOUN
aji-40	429	3	.	.	PUNCT
aji-40	430	1	2012;13:103	2012;13:103	NOUN
aji-40	430	2	.	.	PUNCT
aji-40	431	1	available	available	ADJ
aji-40	431	2	:	:	PUNCT
aji-40	431	3	https://doi.org/10.1038	https://doi.org/10.1038	PROPN
aji-40	431	4	/	/	SYM
aji-40	431	5	ni.2209	ni.2209	PROPN
aji-40	431	6	10	10	NUM
aji-40	431	7	.	.	PUNCT
aji-40	432	1	johnston	johnston	PROPN
aji-40	432	2	b	b	PROPN
aji-40	432	3	,	,	PUNCT
aji-40	432	4	conly	conly	ADJ
aji-40	432	5	j.	j.	PROPN
aji-40	432	6	tumour	tumour	NOUN
aji-40	432	7	necrosis	necrosis	NOUN
aji-40	432	8	factor	factor	NOUN
aji-40	432	9	inhibitors	inhibitor	NOUN
aji-40	432	10	and	and	CCONJ
aji-40	432	11	infection	infection	NOUN
aji-40	432	12	:	:	PUNCT
aji-40	432	13	what	what	PRON
aji-40	432	14	is	be	AUX
aji-40	432	15	there	there	ADV
aji-40	432	16	to	to	PART
aji-40	432	17	know	know	VERB
aji-40	432	18	for	for	ADP
aji-40	432	19	infectious	infectious	ADJ
aji-40	432	20	diseases	disease	NOUN
aji-40	432	21	physicians	physician	NOUN
aji-40	432	22	?	?	PUNCT
aji-40	433	1	can	can	AUX
aji-40	433	2	j	j	PROPN
aji-40	433	3	infect	infect	VERB
aji-40	433	4	dis	dis	PROPN
aji-40	433	5	med	med	PROPN
aji-40	433	6	microbiol	microbiol	PROPN
aji-40	433	7	.	.	PUNCT
aji-40	434	1	2006;17(4):209–212	2006;17(4):209–212	NUM
aji-40	434	2	.	.	PUNCT
aji-40	434	3	available	available	ADJ
aji-40	434	4	:	:	PUNCT
aji-40	434	5	https://doi.org/10.1155/2006/385	https://doi.org/10.1155/2006/385	PROPN
aji-40	434	6	789	789	NUM
aji-40	434	7	11	11	NUM
aji-40	434	8	.	.	PUNCT
aji-40	435	1	vasanthi	vasanthi	PROPN
aji-40	435	2	p	p	PROPN
aji-40	435	3	,	,	PUNCT
aji-40	435	4	nalini	nalini	PROPN
aji-40	435	5	g	g	PROPN
aji-40	435	6	,	,	PUNCT
aji-40	435	7	rajasekhar	rajasekhar	PROPN
aji-40	435	8	g.	g.	NOUN
aji-40	435	9	role	role	NOUN
aji-40	435	10	of	of	ADP
aji-40	435	11	tumor	tumor	NOUN
aji-40	435	12	necrosis	necrosis	NOUN
aji-40	435	13	factor	factor	NOUN
aji-40	435	14	-	-	PUNCT
aji-40	435	15	alpha	alpha	NOUN
aji-40	435	16	in	in	ADP
aji-40	435	17	rheumatoid	rheumatoid	NOUN
aji-40	435	18	arthritis	arthritis	NOUN
aji-40	435	19	:	:	PUNCT
aji-40	435	20	a	a	DET
aji-40	435	21	review	review	NOUN
aji-40	435	22	.	.	PUNCT
aji-40	436	1	aplar	aplar	ADJ
aji-40	436	2	journal	journal	PROPN
aji-40	436	3	of	of	ADP
aji-40	436	4	rheumatology	rheumatology	NOUN
aji-40	436	5	.	.	PUNCT
aji-40	437	1	2007;10:270	2007;10:270	NUM
aji-40	437	2	–	–	PUNCT
aji-40	437	3	274	274	NUM
aji-40	437	4	.	.	NOUN
aji-40	437	5	12	12	NUM
aji-40	437	6	.	.	PUNCT
aji-40	438	1	inoko	inoko	PROPN
aji-40	438	2	h	h	PROPN
aji-40	438	3	,	,	PUNCT
aji-40	438	4	trowsdale	trowsdale	PROPN
aji-40	438	5	j.	j.	PROPN
aji-40	438	6	linkage	linkage	PROPN
aji-40	438	7	of	of	ADP
aji-40	438	8	tnf	tnf	PROPN
aji-40	438	9	genes	gene	NOUN
aji-40	438	10	to	to	ADP
aji-40	438	11	the	the	DET
aji-40	438	12	hla	hla	PROPN
aji-40	438	13	-	-	PUNCT
aji-40	438	14	b	b	NOUN
aji-40	438	15	locus	locus	NOUN
aji-40	438	16	.	.	PUNCT
aji-40	439	1	nucleic	nucleic	ADJ
aji-40	439	2	acids	acid	NOUN
aji-40	439	3	res	re	NOUN
aji-40	439	4	.	.	PUNCT
aji-40	440	1	1987;15(21):8957‐8962	1987;15(21):8957‐8962	X
aji-40	440	2	.	.	PUNCT
aji-40	441	1	doi	doi	NOUN
aji-40	441	2	:	:	PUNCT
aji-40	441	3	10.1093	10.1093	NUM
aji-40	441	4	/	/	SYM
aji-40	441	5	nar/15.21.8957	nar/15.21.8957	NOUN
aji-40	441	6	13	13	NUM
aji-40	441	7	.	.	PUNCT
aji-40	442	1	churchill	churchill	PROPN
aji-40	442	2	b.m	b.m	PROPN
aji-40	442	3	,	,	PUNCT
aji-40	442	4	kossi	kossi	PROPN
aji-40	442	5	m.e	m.e	PROPN
aji-40	442	6	,	,	PUNCT
aji-40	442	7	jin	jin	PROPN
aji-40	442	8	j.k	j.k	PROPN
aji-40	442	9	,	,	PUNCT
aji-40	442	10	sharma	sharma	PROPN
aji-40	442	11	a	a	X
aji-40	442	12	,	,	PUNCT
aji-40	442	13	halawa	halawa	PROPN
aji-40	442	14	a.	a.	NOUN
aji-40	442	15	understanding	understand	VERB
aji-40	442	16	human	human	ADJ
aji-40	442	17	leukocyte	leukocyte	NOUN
aji-40	442	18	antigen	antigen	NOUN
aji-40	442	19	typing	typing	NOUN
aji-40	442	20	and	and	CCONJ
aji-40	442	21	crossmatch	crossmatch	VERB
aji-40	442	22	techniques	technique	NOUN
aji-40	442	23	in	in	ADP
aji-40	442	24	renal	renal	ADJ
aji-40	442	25	transplantation	transplantation	NOUN
aji-40	442	26	.	.	PUNCT
aji-40	443	1	british	british	ADJ
aji-40	443	2	journal	journal	PROPN
aji-40	443	3	of	of	ADP
aji-40	443	4	renal	renal	ADJ
aji-40	443	5	medicine	medicine	NOUN
aji-40	443	6	(	(	PUNCT
aji-40	443	7	bjrm	bjrm	NOUN
aji-40	443	8	)	)	PUNCT
aji-40	443	9	.	.	PUNCT
aji-40	444	1	winter	winter	NOUN
aji-40	444	2	;	;	PUNCT
aji-40	444	3	2017;22(4):115–121	2017;22(4):115–121	NUM
aji-40	444	4	.	.	NOUN
aji-40	444	5	14	14	NUM
aji-40	444	6	.	.	PUNCT
aji-40	445	1	holbrook	holbrook	PROPN
aji-40	445	2	j	j	PROPN
aji-40	445	3	,	,	PUNCT
aji-40	445	4	lara	lara	NOUN
aji-40	445	5	-	-	PUNCT
aji-40	445	6	reyna	reyna	NOUN
aji-40	445	7	s	s	PROPN
aji-40	445	8	,	,	PUNCT
aji-40	445	9	jarosz	jarosz	NOUN
aji-40	445	10	-	-	PUNCT
aji-40	445	11	griffiths	griffiths	PROPN
aji-40	445	12	h	h	PROPN
aji-40	445	13	,	,	PUNCT
aji-40	445	14	mcdermott	mcdermott	PROPN
aji-40	445	15	m.	m.	PROPN
aji-40	445	16	tumour	tumour	NOUN
aji-40	445	17	necrosis	necrosis	NOUN
aji-40	445	18	factor	factor	NOUN
aji-40	445	19	signalling	signal	VERB
aji-40	445	20	in	in	ADP
aji-40	445	21	health	health	NOUN
aji-40	445	22	and	and	CCONJ
aji-40	445	23	disease	disease	NOUN
aji-40	445	24	.	.	PUNCT
aji-40	446	1	f1000res	f1000res	PROPN
aji-40	446	2	.	.	PUNCT
aji-40	446	3	2019;8	2019;8	NOUN
aji-40	446	4	:	:	PUNCT
aji-40	447	1	f1000	f1000	PROPN
aji-40	447	2	.	.	PROPN
aji-40	447	3	available	available	ADJ
aji-40	447	4	:	:	PUNCT
aji-40	447	5	https://doi.org/10.12688	https://doi.org/10.12688	NOUN
aji-40	447	6	/	/	SYM
aji-40	447	7	f1000res	f1000re	NOUN
aji-40	447	8	earch.17023.1	earch.17023.1	PROPN
aji-40	447	9	15	15	NUM
aji-40	447	10	.	.	PUNCT
aji-40	448	1	kitagaki	kitagaki	PROPN
aji-40	448	2	m	m	PROPN
aji-40	448	3	,	,	PUNCT
aji-40	448	4	isoda	isoda	PROPN
aji-40	448	5	k	k	PROPN
aji-40	448	6	,	,	PUNCT
aji-40	448	7	kamada	kamada	PROPN
aji-40	448	8	h	h	PROPN
aji-40	448	9	,	,	PUNCT
aji-40	448	10	kobayashi	kobayashi	PROPN
aji-40	448	11	t	t	PROPN
aji-40	448	12	,	,	PUNCT
aji-40	448	13	tsunoda	tsunoda	PROPN
aji-40	448	14	s	s	PART
aji-40	448	15	,	,	PUNCT
aji-40	448	16	tsutsumi	tsutsumi	PROPN
aji-40	448	17	y	y	PROPN
aji-40	448	18	,	,	PUNCT
aji-40	448	19	et	et	PROPN
aji-40	448	20	al	al	PROPN
aji-40	448	21	.	.	PROPN
aji-40	448	22	novel	novel	PROPN
aji-40	448	23	tnf	tnf	PROPN
aji-40	448	24	-	-	PUNCT
aji-40	448	25	α	α	PROPN
aji-40	448	26	receptor	receptor	NOUN
aji-40	448	27	1	1	NUM
aji-40	448	28	antagonist	antagonist	NOUN
aji-40	448	29	treatment	treatment	NOUN
aji-40	448	30	attenuates	attenuate	VERB
aji-40	448	31	arterial	arterial	ADJ
aji-40	448	32	inflammation	inflammation	NOUN
aji-40	448	33	and	and	CCONJ
aji-40	448	34	intimal	intimal	ADJ
aji-40	448	35	hyperplasia	hyperplasia	NOUN
aji-40	448	36	in	in	ADP
aji-40	448	37	mice	mouse	NOUN
aji-40	448	38	.	.	PUNCT
aji-40	449	1	journal	journal	NOUN
aji-40	449	2	of	of	ADP
aji-40	449	3	atherosclerosis	atherosclerosis	NOUN
aji-40	449	4	and	and	CCONJ
aji-40	449	5	thrombosis	thrombosis	NOUN
aji-40	449	6	.	.	PUNCT
aji-40	450	1	2012	2012	NUM
aji-40	450	2	;	;	PUNCT
aji-40	450	3	19(1):36	19(1):36	NUM
aji-40	450	4	-	-	SYM
aji-40	450	5	46	46	NUM
aji-40	450	6	.	.	PUNCT
aji-40	451	1	https://www.ncbi.nlm.nih.gov/pubmed/10891884	https://www.ncbi.nlm.nih.gov/pubmed/10891884	PRON
aji-40	451	2	https://www.ncbi.nlm.nih.gov/pubmed/10891884	https://www.ncbi.nlm.nih.gov/pubmed/10891884	NUM
aji-40	451	3	https://doi.org/10.3389/fimmu.2018.00784	https://doi.org/10.3389/fimmu.2018.00784	PROPN
aji-40	451	4	https://doi.org/10.3389/fimmu.2018.00784	https://doi.org/10.3389/fimmu.2018.00784	PROPN
aji-40	451	5	https://doi.org/10.1093/rheumatology/keq031	https://doi.org/10.1093/rheumatology/keq031	NOUN
aji-40	451	6	https://doi.org/10.1093/rheumatology/keq031	https://doi.org/10.1093/rheumatology/keq031	NOUN
aji-40	451	7	https://doi.org/10.1134/s0006297914120049	https://doi.org/10.1134/s0006297914120049	PROPN
aji-40	451	8	https://doi.org/10.1134/s0006297914120049	https://doi.org/10.1134/s0006297914120049	PROPN
aji-40	451	9	http://dx.doi.org/10.1016/j.jri.2016.04.284	http://dx.doi.org/10.1016/j.jri.2016.04.284	PROPN
aji-40	451	10	http://dx.doi.org/10.1016/j.jri.2016.04.284	http://dx.doi.org/10.1016/j.jri.2016.04.284	NOUN
aji-40	451	11	http://dx.doi.org/10.2174/138161211798157658	http://dx.doi.org/10.2174/138161211798157658	NOUN
aji-40	451	12	http://dx.doi.org/10.2174/138161211798157658	http://dx.doi.org/10.2174/138161211798157658	NOUN
aji-40	451	13	https://doi.org/10.1038/ni.2209	https://doi.org/10.1038/ni.2209	ADV
aji-40	451	14	https://doi.org/10.1155/2006/385789	https://doi.org/10.1155/2006/385789	ADV
aji-40	451	15	https://doi.org/10.1155/2006/385789	https://doi.org/10.1155/2006/385789	ADV
aji-40	451	16	https://doi.org/10.12688/f1000research.17023.1	https://doi.org/10.12688/f1000research.17023.1	PROPN
aji-40	451	17	https://doi.org/10.12688/f1000research.17023.1	https://doi.org/10.12688/f1000research.17023.1	PROPN
aji-40	451	18	churchill	churchill	NOUN
aji-40	451	19	et	et	PROPN
aji-40	451	20	al	al	PROPN
aji-40	451	21	.	.	PROPN
aji-40	451	22	;	;	PUNCT
aji-40	451	23	aji	aji	PROPN
aji-40	451	24	,	,	PUNCT
aji-40	451	25	3(1	3(1	NUM
aji-40	451	26	):	):	PUNCT
aji-40	451	27	208	208	NUM
aji-40	451	28	-	-	SYM
aji-40	451	29	222	222	NUM
aji-40	451	30	,	,	PUNCT
aji-40	451	31	2020	2020	NUM
aji-40	451	32	;	;	PUNCT
aji-40	451	33	article	article	NOUN
aji-40	451	34	no.aji.57464	no.aji.57464	ADP
aji-40	451	35	219	219	NUM
aji-40	451	36	16	16	NUM
aji-40	451	37	.	.	PUNCT
aji-40	452	1	al	al	PROPN
aji-40	452	2	-	-	PUNCT
aji-40	452	3	lamki	lamki	ADJ
aji-40	452	4	rs	rs	NOUN
aji-40	452	5	,	,	PUNCT
aji-40	452	6	mayadas	mayadas	PROPN
aji-40	452	7	tn	tn	PROPN
aji-40	452	8	.	.	PUNCT
aji-40	453	1	tnf	tnf	PROPN
aji-40	453	2	receptors	receptor	NOUN
aji-40	453	3	:	:	PUNCT
aji-40	453	4	signaling	signal	VERB
aji-40	453	5	pathways	pathway	NOUN
aji-40	453	6	and	and	CCONJ
aji-40	453	7	contribution	contribution	NOUN
aji-40	453	8	to	to	ADP
aji-40	453	9	renal	renal	ADJ
aji-40	453	10	dysfunction	dysfunction	NOUN
aji-40	453	11	.	.	PUNCT
aji-40	454	1	kidney	kidney	PROPN
aji-40	454	2	international	international	PROPN
aji-40	454	3	.	.	PUNCT
aji-40	455	1	2015;87(2):281–296	2015;87(2):281–296	X
aji-40	455	2	.	.	PUNCT
aji-40	456	1	available	available	ADJ
aji-40	456	2	:	:	PUNCT
aji-40	456	3	https://doi.org/10.1038	https://doi.org/10.1038	PROPN
aji-40	456	4	/	/	SYM
aji-40	456	5	ki.2014.2	ki.2014.2	PROPN
aji-40	456	6	85	85	NUM
aji-40	456	7	17	17	NUM
aji-40	456	8	.	.	PUNCT
aji-40	457	1	yang	yang	PROPN
aji-40	457	2	s	s	PROPN
aji-40	457	3	,	,	PUNCT
aji-40	457	4	wang	wang	PROPN
aji-40	457	5	y	y	PROPN
aji-40	457	6	,	,	PUNCT
aji-40	457	7	mei	mei	PROPN
aji-40	457	8	k	k	PROPN
aji-40	457	9	,	,	PUNCT
aji-40	457	10	zhang	zhang	PROPN
aji-40	457	11	s	s	PROPN
aji-40	457	12	,	,	PUNCT
aji-40	457	13	sun	sun	PROPN
aji-40	457	14	x	x	NOUN
aji-40	457	15	,	,	PUNCT
aji-40	457	16	ren	ren	PROPN
aji-40	457	17	f	f	AUX
aji-40	457	18	,	,	PUNCT
aji-40	457	19	et	et	PROPN
aji-40	457	20	al	al	PROPN
aji-40	457	21	.	.	PROPN
aji-40	457	22	tumor	tumor	PROPN
aji-40	457	23	necrosis	necrosis	NOUN
aji-40	457	24	factor	factor	NOUN
aji-40	457	25	receptor	receptor	NOUN
aji-40	457	26	2	2	NUM
aji-40	457	27	(	(	PUNCT
aji-40	457	28	tnfr2)interleukin-17	tnfr2)interleukin-17	NOUN
aji-40	457	29	receptor	receptor	NOUN
aji-40	457	30	d	d	NOUN
aji-40	457	31	(	(	PUNCT
aji-40	457	32	il-17rd	il-17rd	PROPN
aji-40	457	33	)	)	PUNCT
aji-40	457	34	heteromerization	heteromerization	NOUN
aji-40	457	35	reveals	reveal	VERB
aji-40	457	36	a	a	DET
aji-40	457	37	novel	novel	ADJ
aji-40	457	38	mechanism	mechanism	NOUN
aji-40	457	39	for	for	ADP
aji-40	457	40	nf	nf	ADJ
aji-40	457	41	-	-	PUNCT
aji-40	457	42	b	b	NOUN
aji-40	457	43	activation	activation	NOUN
aji-40	457	44	.	.	PUNCT
aji-40	458	1	j	j	PROPN
aji-40	458	2	biol	biol	PROPN
aji-40	458	3	chem	chem	NOUN
aji-40	458	4	.	.	PUNCT
aji-40	459	1	2015;290(2):86171	2015;290(2):86171	X
aji-40	459	2	.	.	PUNCT
aji-40	460	1	available	available	ADJ
aji-40	460	2	:	:	PUNCT
aji-40	461	1	https://doi.org/10.1074	https://doi.org/10.1074	PROPN
aji-40	461	2	/	/	SYM
aji-40	461	3	jbc.m114	jbc.m114	PROPN
aji-40	461	4	.	.	PUNCT
aji-40	461	5	586560	586560	NUM
aji-40	461	6	18	18	NUM
aji-40	461	7	.	.	PUNCT
aji-40	462	1	das	das	PROPN
aji-40	462	2	s	s	PROPN
aji-40	462	3	,	,	PUNCT
aji-40	462	4	baruah	baruah	NOUN
aji-40	462	5	c	c	PROPN
aji-40	462	6	,	,	PUNCT
aji-40	462	7	saikia	saikia	PROPN
aji-40	462	8	a.k	a.k	PROPN
aji-40	462	9	,	,	PUNCT
aji-40	462	10	tiwari	tiwari	ADJ
aji-40	462	11	d	d	NOUN
aji-40	462	12	,	,	PUNCT
aji-40	462	13	bose	bose	PROPN
aji-40	462	14	s.	s.	PROPN
aji-40	462	15	genetic	genetic	ADJ
aji-40	462	16	and	and	CCONJ
aji-40	462	17	expression	expression	NOUN
aji-40	462	18	changes	change	NOUN
aji-40	462	19	in	in	ADP
aji-40	462	20	tnf	tnf	PROPN
aji-40	462	21	-	-	PUNCT
aji-40	462	22	α	α	PROPN
aji-40	462	23	as	as	ADP
aji-40	462	24	a	a	DET
aji-40	462	25	risk	risk	NOUN
aji-40	462	26	factor	factor	NOUN
aji-40	462	27	for	for	ADP
aji-40	462	28	rheumatoid	rheumatoid	VERB
aji-40	462	29	arthritis	arthritis	NOUN
aji-40	462	30	pathogenesis	pathogenesis	NOUN
aji-40	462	31	in	in	ADP
aji-40	462	32	northeast	northeast	PROPN
aji-40	462	33	india	india	PROPN
aji-40	462	34	.	.	PUNCT
aji-40	463	1	j	j	PROPN
aji-40	463	2	genet	genet	PROPN
aji-40	463	3	.	.	PUNCT
aji-40	464	1	2019	2019	NUM
aji-40	464	2	mar;98:3	mar;98:3	PROPN
aji-40	464	3	.	.	PROPN
aji-40	465	1	19	19	NUM
aji-40	465	2	.	.	PUNCT
aji-40	466	1	lin	lin	PROPN
aji-40	466	2	yj	yj	PROPN
aji-40	466	3	,	,	PUNCT
aji-40	466	4	chen	chen	PROPN
aji-40	466	5	rh	rh	PROPN
aji-40	466	6	,	,	PUNCT
aji-40	466	7	wan	wan	PROPN
aji-40	466	8	l	l	PROPN
aji-40	466	9	,	,	PUNCT
aji-40	466	10	et	et	PROPN
aji-40	466	11	al	al	PROPN
aji-40	466	12	.	.	PROPN
aji-40	466	13	association	association	PROPN
aji-40	466	14	of	of	ADP
aji-40	466	15	tnf	tnf	PROPN
aji-40	466	16	-	-	PUNCT
aji-40	466	17	alpha	alpha	NOUN
aji-40	466	18	gene	gene	NOUN
aji-40	466	19	polymorphisms	polymorphism	NOUN
aji-40	466	20	with	with	ADP
aji-40	466	21	systemic	systemic	ADJ
aji-40	466	22	lupus	lupus	NOUN
aji-40	466	23	erythematosus	erythematosus	NOUN
aji-40	466	24	in	in	ADP
aji-40	466	25	taiwanese	taiwanese	ADJ
aji-40	466	26	patients	patient	NOUN
aji-40	466	27	.	.	PUNCT
aji-40	467	1	lupus	lupus	NOUN
aji-40	467	2	.	.	PUNCT
aji-40	468	1	2009;18(11	2009;18(11	NUM
aji-40	468	2	):	):	PUNCT
aji-40	468	3	974	974	NUM
aji-40	468	4	-	-	SYM
aji-40	468	5	9	9	NUM
aji-40	468	6	.	.	PUNCT
aji-40	468	7	doi	doi	NOUN
aji-40	468	8	:	:	PUNCT
aji-40	468	9	10.1177/0961203309105361	10.1177/0961203309105361	NUM
aji-40	468	10	20	20	NUM
aji-40	468	11	.	.	PUNCT
aji-40	469	1	ramírez	ramírez	NOUN
aji-40	469	2	-	-	PUNCT
aji-40	469	3	bello	bello	PROPN
aji-40	469	4	j	j	PROPN
aji-40	469	5	,	,	PUNCT
aji-40	469	6	cadena	cadena	PROPN
aji-40	469	7	-	-	PUNCT
aji-40	469	8	sandoval	sandoval	PROPN
aji-40	469	9	d	d	PROPN
aji-40	469	10	,	,	PUNCT
aji-40	469	11	mendoza	mendoza	PROPN
aji-40	469	12	-	-	PUNCT
aji-40	469	13	rincón	rincón	PROPN
aji-40	469	14	jf	jf	PROPN
aji-40	469	15	,	,	PUNCT
aji-40	469	16	barbosa	barbosa	PROPN
aji-40	469	17	-	-	PUNCT
aji-40	469	18	cobos	cobos	PROPN
aji-40	469	19	re	re	PROPN
aji-40	469	20	,	,	PUNCT
aji-40	469	21	sánchez	sánchez	PROPN
aji-40	469	22	-	-	PUNCT
aji-40	469	23	muñoz	muñoz	PROPN
aji-40	469	24	f	f	PROPN
aji-40	469	25	,	,	PUNCT
aji-40	469	26	amezcua	amezcua	NOUN
aji-40	469	27	-	-	PUNCT
aji-40	469	28	guerra	guerra	NOUN
aji-40	469	29	lm	lm	PROPN
aji-40	469	30	,	,	PUNCT
aji-40	469	31	sierra	sierra	PROPN
aji-40	469	32	-	-	PUNCT
aji-40	469	33	martínez	martínez	PROPN
aji-40	469	34	m	m	PROPN
aji-40	469	35	,	,	PUNCT
aji-40	469	36	jiménez	jiménez	PROPN
aji-40	469	37	-	-	PUNCT
aji-40	469	38	morales	morales	PROPN
aji-40	469	39	s.	s.	PROPN
aji-40	469	40	tumor	tumor	PROPN
aji-40	469	41	necrosis	necrosis	NOUN
aji-40	469	42	factor	factor	NOUN
aji-40	469	43	gene	gene	NOUN
aji-40	469	44	polymorphisms	polymorphism	NOUN
aji-40	469	45	are	be	AUX
aji-40	469	46	associated	associate	VERB
aji-40	469	47	with	with	ADP
aji-40	469	48	systemic	systemic	ADJ
aji-40	469	49	lupus	lupus	NOUN
aji-40	469	50	erythematosus	erythematosus	NOUN
aji-40	469	51	susceptibility	susceptibility	NOUN
aji-40	469	52	or	or	CCONJ
aji-40	469	53	lupus	lupus	NOUN
aji-40	469	54	nephritis	nephritis	NOUN
aji-40	469	55	in	in	ADP
aji-40	469	56	mexican	mexican	ADJ
aji-40	469	57	patients	patient	NOUN
aji-40	469	58	.	.	PUNCT
aji-40	470	1	immunol	immunol	NOUN
aji-40	470	2	res	re	NOUN
aji-40	470	3	.	.	PUNCT
aji-40	471	1	2018;66(3):348354	2018;66(3):348354	X
aji-40	471	2	.	.	PUNCT
aji-40	471	3	doi	doi	NOUN
aji-40	471	4	:	:	PUNCT
aji-40	471	5	10.1007	10.1007	NUM
aji-40	471	6	/	/	SYM
aji-40	471	7	s12026	s12026	NUM
aji-40	471	8	-	-	PUNCT
aji-40	471	9	018	018	NUM
aji-40	471	10	-	-	PUNCT
aji-40	471	11	8993	8993	NUM
aji-40	471	12	-	-	SYM
aji-40	471	13	8	8	NUM
aji-40	471	14	21	21	NUM
aji-40	471	15	.	.	PUNCT
aji-40	472	1	santana	santana	PROPN
aji-40	472	2	g	g	PROPN
aji-40	472	3	,	,	PUNCT
aji-40	472	4	bendicho	bendicho	PROPN
aji-40	472	5	mt	mt	PROPN
aji-40	472	6	,	,	PUNCT
aji-40	472	7	santana	santana	PROPN
aji-40	472	8	tc	tc	PROPN
aji-40	472	9	,	,	PUNCT
aji-40	472	10	dos	do	VERB
aji-40	472	11	reis	reis	NOUN
aji-40	472	12	lb	lb	NOUN
aji-40	472	13	,	,	PUNCT
aji-40	472	14	lemaire	lemaire	PROPN
aji-40	472	15	d	d	PROPN
aji-40	472	16	,	,	PUNCT
aji-40	472	17	lyra	lyra	PROPN
aji-40	472	18	ac	ac	PROPN
aji-40	472	19	.	.	PUNCT
aji-40	473	1	the	the	DET
aji-40	473	2	tnf	tnf	PROPN
aji-40	473	3	-	-	PUNCT
aji-40	473	4	α	α	NOUN
aji-40	473	5	-308	-308	NOUN
aji-40	473	6	polymorphism	polymorphism	NOUN
aji-40	473	7	may	may	AUX
aji-40	473	8	affect	affect	VERB
aji-40	473	9	the	the	DET
aji-40	473	10	severity	severity	NOUN
aji-40	473	11	of	of	ADP
aji-40	473	12	crohn	crohn	PROPN
aji-40	473	13	's	's	PART
aji-40	473	14	disease	disease	NOUN
aji-40	473	15	.	.	PUNCT
aji-40	474	1	clinics	clinic	NOUN
aji-40	474	2	vol.66	vol.66	ADP
aji-40	474	3	no.8	no.8	PROPN
aji-40	474	4	são	são	PROPN
aji-40	474	5	paulo	paulo	PROPN
aji-40	474	6	;	;	PUNCT
aji-40	474	7	2011	2011	NUM
aji-40	474	8	.	.	PUNCT
aji-40	475	1	available	available	ADJ
aji-40	475	2	:	:	PUNCT
aji-40	475	3	https://doi.org/10.1590	https://doi.org/10.1590	NOUN
aji-40	475	4	/	/	SYM
aji-40	475	5	s180759322011000800011	s180759322011000800011	PRON
aji-40	475	6	22	22	NUM
aji-40	475	7	.	.	PUNCT
aji-40	476	1	fischer	fischer	PROPN
aji-40	476	2	r	r	PROPN
aji-40	476	3	,	,	PUNCT
aji-40	476	4	kontermann	kontermann	PROPN
aji-40	476	5	re	re	PROPN
aji-40	476	6	,	,	PUNCT
aji-40	476	7	maier	maier	PROPN
aji-40	476	8	o.	o.	NOUN
aji-40	476	9	targeting	target	VERB
aji-40	476	10	stnf	stnf	PROPN
aji-40	476	11	/	/	SYM
aji-40	476	12	tnfr1	tnfr1	NOUN
aji-40	476	13	signaling	signal	VERB
aji-40	476	14	as	as	ADP
aji-40	476	15	a	a	DET
aji-40	476	16	new	new	ADJ
aji-40	476	17	therapeutic	therapeutic	ADJ
aji-40	476	18	strategy	strategy	NOUN
aji-40	476	19	.	.	PUNCT
aji-40	476	20	antibodies	antibodie	VERB
aji-40	476	21	.	.	PUNCT
aji-40	477	1	2015;4	2015;4	NUM
aji-40	477	2	:	:	PUNCT
aji-40	477	3	48	48	NUM
aji-40	477	4	-	-	SYM
aji-40	477	5	70	70	NUM
aji-40	477	6	.	.	PUNCT
aji-40	478	1	available	available	ADJ
aji-40	478	2	:	:	PUNCT
aji-40	478	3	https://doi.org/10.3390	https://doi.org/10.3390	NOUN
aji-40	478	4	/	/	SYM
aji-40	478	5	antib4010	antib4010	PROPN
aji-40	478	6	048	048	NUM
aji-40	478	7	23	23	NUM
aji-40	478	8	.	.	PUNCT
aji-40	479	1	kimberley	kimberley	PROPN
aji-40	479	2	fc	fc	PROPN
aji-40	479	3	,	,	PUNCT
aji-40	479	4	lobito	lobito	PROPN
aji-40	479	5	aa	aa	PROPN
aji-40	479	6	,	,	PUNCT
aji-40	479	7	siegel	siegel	PROPN
aji-40	479	8	rm	rm	PROPN
aji-40	479	9	,	,	PUNCT
aji-40	479	10	screaton	screaton	PROPN
aji-40	479	11	gr	gr	PRON
aji-40	479	12	.	.	PUNCT
aji-40	480	1	falling	fall	VERB
aji-40	480	2	into	into	ADP
aji-40	480	3	traps	trap	NOUN
aji-40	480	4	--	--	PUNCT
aji-40	480	5	receptor	receptor	NOUN
aji-40	480	6	misfolding	misfolde	VERB
aji-40	480	7	in	in	ADP
aji-40	480	8	the	the	DET
aji-40	480	9	tnf	tnf	PROPN
aji-40	480	10	receptor	receptor	NOUN
aji-40	480	11	1associated	1associated	NUM
aji-40	480	12	periodic	periodic	ADJ
aji-40	480	13	fever	fever	NOUN
aji-40	480	14	syndrome	syndrome	NOUN
aji-40	480	15	.	.	PUNCT
aji-40	481	1	arthritis	arthritis	NOUN
aji-40	481	2	res	re	NOUN
aji-40	481	3	ther	ther	ADV
aji-40	481	4	.	.	PUNCT
aji-40	482	1	2007;9(4	2007;9(4	NUM
aji-40	482	2	):	):	PUNCT
aji-40	482	3	217	217	NUM
aji-40	482	4	.	.	PUNCT
aji-40	483	1	available	available	ADJ
aji-40	483	2	:	:	PUNCT
aji-40	483	3	https://doi.org/10.1186	https://doi.org/10.1186	PROPN
aji-40	483	4	/	/	SYM
aji-40	483	5	ar2197	ar2197	PROPN
aji-40	483	6	24	24	NUM
aji-40	483	7	.	.	PUNCT
aji-40	484	1	sainz	sainz	PROPN
aji-40	484	2	j	j	PROPN
aji-40	484	3	,	,	PUNCT
aji-40	484	4	salas	salas	PROPN
aji-40	484	5	-	-	PUNCT
aji-40	484	6	alvarado	alvarado	PROPN
aji-40	484	7	i	i	PROPN
aji-40	484	8	,	,	PUNCT
aji-40	484	9	lopezfernandez	lopezfernandez	PROPN
aji-40	484	10	e	e	PROPN
aji-40	484	11	,	,	PUNCT
aji-40	484	12	olmedo	olmedo	PROPN
aji-40	484	13	c	c	NOUN
aji-40	484	14	,	,	PUNCT
aji-40	484	15	comino	comino	PROPN
aji-40	484	16	a	a	PRON
aji-40	484	17	,	,	PUNCT
aji-40	484	18	garcia	garcia	PROPN
aji-40	484	19	f	f	AUX
aji-40	484	20	,	,	PUNCT
aji-40	484	21	et	et	PROPN
aji-40	484	22	al	al	PROPN
aji-40	484	23	.	.	PROPN
aji-40	485	1	tnfri	tnfri	PROPN
aji-40	485	2	mrna	mrna	PROPN
aji-40	485	3	expression	expression	NOUN
aji-40	485	4	level	level	NOUN
aji-40	485	5	and	and	CCONJ
aji-40	485	6	tnfri	tnfri	ADJ
aji-40	485	7	gene	gene	NOUN
aji-40	485	8	polymorphisms	polymorphism	NOUN
aji-40	485	9	are	be	AUX
aji-40	485	10	predictive	predictive	ADJ
aji-40	485	11	markers	marker	NOUN
aji-40	485	12	for	for	ADP
aji-40	485	13	susceptibility	susceptibility	NOUN
aji-40	485	14	to	to	PART
aji-40	485	15	develop	develop	VERB
aji-40	485	16	invasive	invasive	ADJ
aji-40	485	17	pulmonary	pulmonary	ADJ
aji-40	485	18	aspergillosis	aspergillosis	NOUN
aji-40	485	19	.	.	PUNCT
aji-40	486	1	international	international	ADJ
aji-40	486	2	journal	journal	PROPN
aji-40	486	3	of	of	ADP
aji-40	486	4	immunopathology	immunopathology	NOUN
aji-40	486	5	and	and	CCONJ
aji-40	486	6	pharmacology	pharmacology	NOUN
aji-40	486	7	.	.	PUNCT
aji-40	487	1	2010;23(2):423	2010;23(2):423	NUM
aji-40	487	2	-	-	SYM
aji-40	487	3	436	436	NUM
aji-40	487	4	.	.	PUNCT
aji-40	487	5	25	25	NUM
aji-40	487	6	.	.	PUNCT
aji-40	488	1	sainz	sainz	PROPN
aji-40	488	2	j	j	PROPN
aji-40	488	3	,	,	PUNCT
aji-40	488	4	pérez	pérez	NOUN
aji-40	488	5	e	e	PROPN
aji-40	488	6	,	,	PUNCT
aji-40	488	7	hassan	hassan	PROPN
aji-40	488	8	l	l	PROPN
aji-40	488	9	,	,	PUNCT
aji-40	488	10	moratalla	moratalla	PROPN
aji-40	488	11	a	a	PRON
aji-40	488	12	,	,	PUNCT
aji-40	488	13	romero	romero	PROPN
aji-40	488	14	a	a	PROPN
aji-40	488	15	,	,	PUNCT
aji-40	488	16	collado	collado	PROPN
aji-40	488	17	md	md	PROPN
aji-40	488	18	,	,	PUNCT
aji-40	488	19	et	et	PROPN
aji-40	488	20	al	al	PROPN
aji-40	488	21	.	.	PROPN
aji-40	488	22	vntr	vntr	PROPN
aji-40	488	23	of	of	ADP
aji-40	488	24	tnf	tnf	PROPN
aji-40	488	25	receptor	receptor	NOUN
aji-40	488	26	2	2	NUM
aji-40	488	27	promoter	promoter	NOUN
aji-40	488	28	as	as	ADP
aji-40	488	29	genetic	genetic	ADJ
aji-40	488	30	biomarker	biomarker	NOUN
aji-40	488	31	of	of	ADP
aji-40	488	32	susceptibility	susceptibility	NOUN
aji-40	488	33	to	to	PART
aji-40	488	34	develop	develop	VERB
aji-40	488	35	invasive	invasive	ADJ
aji-40	488	36	pulmonary	pulmonary	ADJ
aji-40	488	37	aspergilosis	aspergilosis	NOUN
aji-40	488	38	.	.	PUNCT
aji-40	489	1	human	human	ADJ
aji-40	489	2	immunology	immunology	NOUN
aji-40	489	3	.	.	PUNCT
aji-40	490	1	2007;68:41	2007;68:41	NUM
aji-40	490	2	-	-	SYM
aji-40	490	3	50	50	NUM
aji-40	490	4	.	.	NOUN
aji-40	491	1	26	26	NUM
aji-40	491	2	.	.	PUNCT
aji-40	492	1	suchanek	suchanek	ADJ
aji-40	492	2	-	-	PUNCT
aji-40	492	3	raif	raif	NOUN
aji-40	492	4	r	r	NOUN
aji-40	492	5	,	,	PUNCT
aji-40	492	6	raif	raif	PROPN
aji-40	492	7	p	p	PROPN
aji-40	492	8	,	,	PUNCT
aji-40	492	9	kowalczyk	kowalczyk	PROPN
aji-40	492	10	m	m	PROPN
aji-40	492	11	,	,	PUNCT
aji-40	492	12	et	et	PROPN
aji-40	492	13	al	al	PROPN
aji-40	492	14	.	.	PUNCT
aji-40	493	1	polymorphic	polymorphic	ADJ
aji-40	493	2	variants	variant	NOUN
aji-40	493	3	of	of	ADP
aji-40	493	4	tnfr2	tnfr2	ADJ
aji-40	493	5	gene	gene	NOUN
aji-40	493	6	in	in	ADP
aji-40	493	7	schizophrenia	schizophrenia	NOUN
aji-40	493	8	and	and	CCONJ
aji-40	493	9	its	its	PRON
aji-40	493	10	interaction	interaction	NOUN
aji-40	493	11	with	with	ADP
aji-40	493	12	308g	308g	PROPN
aji-40	493	13	/	/	SYM
aji-40	493	14	a	a	DET
aji-40	493	15	tnf	tnf	PROPN
aji-40	493	16	-	-	PUNCT
aji-40	493	17	α	α	PROPN
aji-40	493	18	gene	gene	NOUN
aji-40	493	19	polymorphism	polymorphism	NOUN
aji-40	493	20	.	.	PUNCT
aji-40	494	1	mediators	mediator	NOUN
aji-40	494	2	inflamm	inflamm	NOUN
aji-40	494	3	.	.	PUNCT
aji-40	495	1	2018;2018:8741249	2018;2018:8741249	NUM
aji-40	495	2	.	.	PUNCT
aji-40	496	1	doi	doi	NOUN
aji-40	496	2	:	:	PUNCT
aji-40	496	3	10.1155/2018/8741249	10.1155/2018/8741249	NUM
aji-40	496	4	27	27	NUM
aji-40	496	5	.	.	PUNCT
aji-40	497	1	sankar	sankar	PROPN
aji-40	497	2	vh	vh	PROPN
aji-40	497	3	,	,	PUNCT
aji-40	497	4	girisha	girisha	PROPN
aji-40	497	5	km	km	PROPN
aji-40	497	6	,	,	PUNCT
aji-40	497	7	gilmour	gilmour	NOUN
aji-40	497	8	a	a	PRON
aji-40	497	9	,	,	PUNCT
aji-40	497	10	singh	singh	PROPN
aji-40	497	11	vp	vp	PROPN
aji-40	497	12	,	,	PUNCT
aji-40	497	13	sinha	sinha	PROPN
aji-40	497	14	n	n	PRON
aji-40	497	15	,	,	PUNCT
aji-40	497	16	tewari	tewari	PROPN
aji-40	497	17	s	s	PROPN
aji-40	497	18	,	,	PUNCT
aji-40	497	19	ramesh	ramesh	PROPN
aji-40	497	20	v	v	PROPN
aji-40	497	21	,	,	PUNCT
aji-40	497	22	mastana	mastana	PROPN
aji-40	497	23	s	s	PART
aji-40	497	24	,	,	PUNCT
aji-40	497	25	agrawal	agrawal	PROPN
aji-40	497	26	s.	s.	PROPN
aji-40	497	27	tnfr2	tnfr2	PROPN
aji-40	497	28	gene	gene	NOUN
aji-40	497	29	polymorphism	polymorphism	NOUN
aji-40	497	30	in	in	ADP
aji-40	497	31	coronary	coronary	ADJ
aji-40	497	32	artery	artery	NOUN
aji-40	497	33	disease	disease	NOUN
aji-40	497	34	.	.	PUNCT
aji-40	498	1	indian	indian	PROPN
aji-40	498	2	j	j	PROPN
aji-40	498	3	med	med	PROPN
aji-40	498	4	sci	sci	PROPN
aji-40	498	5	.	.	PUNCT
aji-40	499	1	2005;59(3):104	2005;59(3):104	NUM
aji-40	499	2	-	-	PUNCT
aji-40	499	3	8	8	NUM
aji-40	499	4	.	.	PUNCT
aji-40	500	1	doi	doi	NOUN
aji-40	500	2	:	:	PUNCT
aji-40	500	3	10.4103/0019	10.4103/0019	NUM
aji-40	500	4	-	-	SYM
aji-40	500	5	5359.15086	5359.15086	NUM
aji-40	500	6	.	.	PUNCT
aji-40	501	1	28	28	NUM
aji-40	501	2	.	.	PUNCT
aji-40	502	1	criado	criado	PROPN
aji-40	502	2	l	l	NOUN
aji-40	502	3	,	,	PUNCT
aji-40	502	4	flórez	flórez	NOUN
aji-40	502	5	o	o	NOUN
aji-40	502	6	,	,	PUNCT
aji-40	502	7	martín	martín	PROPN
aji-40	502	8	j	j	PROPN
aji-40	502	9	,	,	PUNCT
aji-40	502	10	gonzález	gonzález	PROPN
aji-40	502	11	c.i	c.i	PROPN
aji-40	502	12	.	.	PUNCT
aji-40	502	13	genetic	genetic	ADJ
aji-40	502	14	polymorphisms	polymorphism	NOUN
aji-40	502	15	in	in	ADP
aji-40	502	16	tnfa	tnfa	ADJ
aji-40	502	17	/	/	SYM
aji-40	502	18	tnfr2	tnfr2	NOUN
aji-40	502	19	genes	gene	NOUN
aji-40	502	20	and	and	CCONJ
aji-40	502	21	chagas	chagas	NOUN
aji-40	502	22	disease	disease	NOUN
aji-40	502	23	in	in	ADP
aji-40	502	24	a	a	DET
aji-40	502	25	colombian	colombian	ADJ
aji-40	502	26	endemic	endemic	ADJ
aji-40	502	27	population	population	NOUN
aji-40	502	28	.	.	PUNCT
aji-40	503	1	cytokine	cytokine	NOUN
aji-40	503	2	.	.	PUNCT
aji-40	504	1	march	march	PROPN
aji-40	504	2	2012;57(3):398	2012;57(3):398	PROPN
aji-40	504	3	-	-	PUNCT
aji-40	504	4	401	401	NUM
aji-40	504	5	.	.	PUNCT
aji-40	505	1	doi	doi	NOUN
aji-40	505	2	:	:	PUNCT
aji-40	505	3	https://doi.org/10.1016	https://doi.org/10.1016	PROPN
aji-40	505	4	/	/	SYM
aji-40	505	5	j.cyto.2011.12	j.cyto.2011.12	NOUN
aji-40	505	6	.	.	NOUN
aji-40	506	1	007	007	NUM
aji-40	506	2	29	29	NUM
aji-40	506	3	.	.	PUNCT
aji-40	507	1	gerriets	gerriet	NOUN
aji-40	507	2	v	v	ADP
aji-40	507	3	,	,	PUNCT
aji-40	507	4	bansal	bansal	NOUN
aji-40	507	5	p	p	PROPN
aji-40	507	6	,	,	PUNCT
aji-40	507	7	khaddour	khaddour	PROPN
aji-40	507	8	k.	k.	PROPN
aji-40	507	9	tumor	tumor	PROPN
aji-40	507	10	necrosis	necrosis	NOUN
aji-40	507	11	factor	factor	NOUN
aji-40	507	12	(	(	PUNCT
aji-40	507	13	tnf	tnf	PROPN
aji-40	507	14	)	)	PUNCT
aji-40	507	15	inhibitors	inhibitor	NOUN
aji-40	507	16	.	.	PUNCT
aji-40	508	1	bethesda	bethesda	PROPN
aji-40	508	2	md	md	PROPN
aji-40	508	3	:	:	PUNCT
aji-40	508	4	statpearls	statpearls	PROPN
aji-40	508	5	publishing	publishing	NOUN
aji-40	508	6	;	;	PUNCT
aji-40	508	7	2019	2019	NUM
aji-40	508	8	.	.	PUNCT
aji-40	509	1	available	available	ADJ
aji-40	509	2	:	:	PUNCT
aji-40	509	3	https://www.ncbi.nlm.nih.gov	https://www.ncbi.nlm.nih.gov	ADJ
aji-40	509	4	/	/	SYM
aji-40	509	5	boo	boo	NOUN
aji-40	509	6	ks	ks	PROPN
aji-40	509	7	/	/	SYM
aji-40	509	8	nbk482425/	nbk482425/	PROPN
aji-40	509	9	(	(	PUNCT
aji-40	509	10	accessed	access	VERB
aji-40	509	11	on	on	ADP
aji-40	509	12	27	27	NUM
aji-40	509	13	march	march	NOUN
aji-40	509	14	2020	2020	NUM
aji-40	509	15	)	)	PUNCT
aji-40	509	16	30	30	NUM
aji-40	509	17	.	.	PUNCT
aji-40	510	1	antoni	antoni	PROPN
aji-40	510	2	c	c	PROPN
aji-40	510	3	,	,	PUNCT
aji-40	510	4	braun	braun	PROPN
aji-40	510	5	j.	j.	PROPN
aji-40	510	6	side	side	PROPN
aji-40	510	7	effects	effect	NOUN
aji-40	510	8	of	of	ADP
aji-40	510	9	anti	anti	ADJ
aji-40	510	10	-	-	ADJ
aji-40	510	11	tnf	tnf	ADJ
aji-40	510	12	therapy	therapy	NOUN
aji-40	510	13	:	:	PUNCT
aji-40	510	14	current	current	ADJ
aji-40	510	15	knowledge	knowledge	NOUN
aji-40	510	16	.	.	PUNCT
aji-40	511	1	clin	clin	PROPN
aji-40	511	2	exp	exp	NOUN
aji-40	511	3	rheumatol	rheumatol	NOUN
aji-40	511	4	.	.	PUNCT
aji-40	512	1	2002;20(suppl	2002;20(suppl	PROPN
aji-40	512	2	.	.	PUNCT
aji-40	513	1	28):s152s157	28):s152s157	PROPN
aji-40	513	2	.	.	PROPN
aji-40	514	1	31	31	NUM
aji-40	514	2	.	.	PUNCT
aji-40	515	1	hansen	hansen	PROPN
aji-40	515	2	ra	ra	PROPN
aji-40	515	3	,	,	PUNCT
aji-40	515	4	gartlehner	gartlehner	NOUN
aji-40	515	5	g	g	PROPN
aji-40	515	6	,	,	PUNCT
aji-40	515	7	powell	powell	PROPN
aji-40	515	8	ge	ge	PROPN
aji-40	515	9	,	,	PUNCT
aji-40	515	10	sandler	sandler	PROPN
aji-40	515	11	rs	rs	PROPN
aji-40	515	12	.	.	PUNCT
aji-40	516	1	serious	serious	ADJ
aji-40	516	2	adverse	adverse	ADJ
aji-40	516	3	events	event	NOUN
aji-40	516	4	with	with	ADP
aji-40	516	5	infliximab	infliximab	NOUN
aji-40	516	6	:	:	PUNCT
aji-40	516	7	analysis	analysis	NOUN
aji-40	516	8	of	of	ADP
aji-40	516	9	spontaneously	spontaneously	ADV
aji-40	516	10	reported	report	VERB
aji-40	516	11	adverse	adverse	ADJ
aji-40	516	12	events	event	NOUN
aji-40	516	13	.	.	PUNCT
aji-40	517	1	clin	clin	PROPN
aji-40	517	2	gastroenterol	gastroenterol	PROPN
aji-40	517	3	hepatol	hepatol	ADV
aji-40	517	4	.	.	PUNCT
aji-40	518	1	2007;5(6):729	2007;5(6):729	X
aji-40	518	2	-	-	SYM
aji-40	518	3	35	35	NUM
aji-40	518	4	.	.	PUNCT
aji-40	519	1	32	32	NUM
aji-40	519	2	.	.	PUNCT
aji-40	520	1	badsha	badsha	PROPN
aji-40	520	2	h	h	PROPN
aji-40	520	3	,	,	PUNCT
aji-40	520	4	daher	daher	PROPN
aji-40	520	5	m	m	PROPN
aji-40	520	6	,	,	PUNCT
aji-40	520	7	edwards	edwards	PROPN
aji-40	520	8	cj	cj	PROPN
aji-40	520	9	.	.	PUNCT
aji-40	521	1	live	live	ADJ
aji-40	521	2	polio	polio	NOUN
aji-40	521	3	vaccine	vaccine	NOUN
aji-40	521	4	exposure	exposure	NOUN
aji-40	521	5	while	while	SCONJ
aji-40	521	6	receiving	receive	VERB
aji-40	521	7	anti	anti	ADJ
aji-40	521	8	-	-	ADJ
aji-40	521	9	tnf	tnf	ADJ
aji-40	521	10	therapy	therapy	NOUN
aji-40	521	11	for	for	ADP
aji-40	521	12	reactive	reactive	ADJ
aji-40	521	13	arthritis.int	arthritis.int	NOUN
aji-40	521	14	j	j	PROPN
aji-40	521	15	rheum	rheum	PROPN
aji-40	521	16	dis	dis	PROPN
aji-40	521	17	.	.	PUNCT
aji-40	522	1	2010;13(2):184	2010;13(2):184	NUM
aji-40	522	2	-	-	SYM
aji-40	522	3	6	6	NUM
aji-40	522	4	.	.	PUNCT
aji-40	523	1	available	available	ADJ
aji-40	523	2	:	:	PUNCT
aji-40	523	3	https://doi.org/10.1111	https://doi.org/10.1111	PROPN
aji-40	523	4	/	/	SYM
aji-40	523	5	j.1756185x.2010.01466.x	j.1756185x.2010.01466.x	PROPN
aji-40	523	6	33	33	NUM
aji-40	523	7	.	.	PUNCT
aji-40	524	1	galloway	galloway	PROPN
aji-40	524	2	jb	jb	PROPN
aji-40	524	3	,	,	PUNCT
aji-40	524	4	hyrich	hyrich	PROPN
aji-40	524	5	kl	kl	PROPN
aji-40	524	6	,	,	PUNCT
aji-40	524	7	mercer	mercer	PROPN
aji-40	524	8	lk	lk	PROPN
aji-40	524	9	,	,	PUNCT
aji-40	524	10	dixon	dixon	PROPN
aji-40	524	11	wg	wg	PROPN
aji-40	524	12	,	,	PUNCT
aji-40	524	13	fu	fu	PROPN
aji-40	524	14	b	b	PROPN
aji-40	524	15	,	,	PUNCT
aji-40	524	16	ustianowski	ustianowski	PROPN
aji-40	524	17	ap	ap	PROPN
aji-40	524	18	,	,	PUNCT
aji-40	524	19	et	et	PROPN
aji-40	524	20	al	al	PROPN
aji-40	524	21	,	,	PUNCT
aji-40	524	22	on	on	ADP
aji-40	524	23	behalf	behalf	NOUN
aji-40	524	24	of	of	ADP
aji-40	524	25	the	the	DET
aji-40	524	26	british	british	ADJ
aji-40	524	27	society	society	NOUN
aji-40	524	28	for	for	ADP
aji-40	524	29	rheumatology	rheumatology	NOUN
aji-40	524	30	https://doi.org/10.1038/ki.2014.285	https://doi.org/10.1038/ki.2014.285	PROPN
aji-40	524	31	https://doi.org/10.1038/ki.2014.285	https://doi.org/10.1038/ki.2014.285	PROPN
aji-40	525	1	https://doi.org/10.1074/jbc.m114.586560	https://doi.org/10.1074/jbc.m114.586560	PROPN
aji-40	525	2	https://doi.org/10.1074/jbc.m114.586560	https://doi.org/10.1074/jbc.m114.586560	PROPN
aji-40	525	3	https://doi.org/10.1590/s1807-59322011000800011	https://doi.org/10.1590/s1807-59322011000800011	PROPN
aji-40	525	4	https://doi.org/10.1590/s1807-59322011000800011	https://doi.org/10.1590/s1807-59322011000800011	PROPN
aji-40	525	5	https://doi.org/10.3390/antib4010048	https://doi.org/10.3390/antib4010048	PROPN
aji-40	525	6	https://doi.org/10.3390/antib4010048	https://doi.org/10.3390/antib4010048	NOUN
aji-40	525	7	https://doi.org/10.1186/ar2197	https://doi.org/10.1186/ar2197	NOUN
aji-40	525	8	https://www.ncbi.nlm.nih.gov/books/nbk482425/	https://www.ncbi.nlm.nih.gov/books/nbk482425/	PROPN
aji-40	525	9	https://www.ncbi.nlm.nih.gov/books/nbk482425/	https://www.ncbi.nlm.nih.gov/books/nbk482425/	PROPN
aji-40	525	10	https://doi.org/10.1111/j.1756-185x.2010.01466.x	https://doi.org/10.1111/j.1756-185x.2010.01466.x	CCONJ
aji-40	525	11	https://doi.org/10.1111/j.1756-185x.2010.01466.x	https://doi.org/10.1111/j.1756-185x.2010.01466.x	PROPN
aji-40	525	12	churchill	churchill	PROPN
aji-40	525	13	et	et	PROPN
aji-40	525	14	al	al	PROPN
aji-40	525	15	.	.	PROPN
aji-40	525	16	;	;	PUNCT
aji-40	526	1	aji	aji	PROPN
aji-40	526	2	,	,	PUNCT
aji-40	526	3	3(1	3(1	NUM
aji-40	526	4	):	):	PUNCT
aji-40	526	5	208	208	NUM
aji-40	526	6	-	-	SYM
aji-40	526	7	222	222	NUM
aji-40	526	8	,	,	PUNCT
aji-40	526	9	2020	2020	NUM
aji-40	526	10	;	;	PUNCT
aji-40	526	11	article	article	NOUN
aji-40	526	12	no.aji.57464	no.aji.57464	ADP
aji-40	526	13	220	220	NUM
aji-40	526	14	biologics	biologic	NOUN
aji-40	526	15	register	register	VERB
aji-40	526	16	.	.	PUNCT
aji-40	527	1	anti	anti	ADJ
aji-40	527	2	-	-	ADJ
aji-40	527	3	tnf	tnf	ADJ
aji-40	527	4	therapy	therapy	NOUN
aji-40	527	5	is	be	AUX
aji-40	527	6	associated	associate	VERB
aji-40	527	7	with	with	ADP
aji-40	527	8	an	an	DET
aji-40	527	9	increased	increase	VERB
aji-40	527	10	risk	risk	NOUN
aji-40	527	11	of	of	ADP
aji-40	527	12	serious	serious	ADJ
aji-40	527	13	infections	infection	NOUN
aji-40	527	14	in	in	ADP
aji-40	527	15	patients	patient	NOUN
aji-40	527	16	with	with	ADP
aji-40	527	17	rheumatoid	rheumatoid	NOUN
aji-40	527	18	arthritis	arthritis	NOUN
aji-40	527	19	especially	especially	ADV
aji-40	527	20	in	in	ADP
aji-40	527	21	the	the	DET
aji-40	527	22	first	first	ADJ
aji-40	527	23	6	6	NUM
aji-40	527	24	months	month	NOUN
aji-40	527	25	of	of	ADP
aji-40	527	26	treatment	treatment	NOUN
aji-40	527	27	:	:	PUNCT
aji-40	527	28	updated	update	VERB
aji-40	527	29	results	result	NOUN
aji-40	527	30	from	from	ADP
aji-40	527	31	the	the	DET
aji-40	527	32	british	british	ADJ
aji-40	527	33	society	society	NOUN
aji-40	527	34	for	for	ADP
aji-40	527	35	rheumatology	rheumatology	NOUN
aji-40	527	36	biologics	biologic	NOUN
aji-40	527	37	register	register	VERB
aji-40	527	38	with	with	ADP
aji-40	527	39	special	special	ADJ
aji-40	527	40	emphasis	emphasis	NOUN
aji-40	527	41	on	on	ADP
aji-40	527	42	risks	risk	NOUN
aji-40	527	43	in	in	ADP
aji-40	527	44	the	the	DET
aji-40	527	45	elderly	elderly	ADJ
aji-40	527	46	.	.	PUNCT
aji-40	528	1	rheumatology	rheumatology	NOUN
aji-40	528	2	.	.	PUNCT
aji-40	529	1	2011;50(1):124–131	2011;50(1):124–131	X
aji-40	529	2	.	.	PUNCT
aji-40	529	3	available	available	ADJ
aji-40	529	4	:	:	PUNCT
aji-40	529	5	https://doi.org/10.1093	https://doi.org/10.1093	NOUN
aji-40	529	6	/	/	SYM
aji-40	529	7	rheumatol	rheumatol	ADJ
aji-40	529	8	ogy	ogy	NOUN
aji-40	529	9	/	/	SYM
aji-40	529	10	keq242	keq242	PROPN
aji-40	529	11	34	34	NUM
aji-40	529	12	.	.	PUNCT
aji-40	530	1	liao	liao	PROPN
aji-40	530	2	h	h	PROPN
aji-40	530	3	,	,	PUNCT
aji-40	530	4	zhong	zhong	PROPN
aji-40	530	5	z	z	PROPN
aji-40	530	6	,	,	PUNCT
aji-40	530	7	liu	liu	PROPN
aji-40	530	8	z	z	PROPN
aji-40	530	9	,	,	PUNCT
aji-40	530	10	zou	zou	PROPN
aji-40	530	11	x.	x.	NOUN
aji-40	530	12	comparison	comparison	NOUN
aji-40	530	13	of	of	ADP
aji-40	530	14	the	the	DET
aji-40	530	15	risk	risk	NOUN
aji-40	530	16	of	of	ADP
aji-40	530	17	infections	infection	NOUN
aji-40	530	18	in	in	ADP
aji-40	530	19	different	different	ADJ
aji-40	530	20	anti‐tnf	anti‐tnf	ADJ
aji-40	530	21	agents	agent	NOUN
aji-40	530	22	:	:	PUNCT
aji-40	530	23	a	a	DET
aji-40	530	24	meta‐analysis	meta‐analysis	NOUN
aji-40	530	25	.	.	PUNCT
aji-40	531	1	international	international	ADJ
aji-40	531	2	journal	journal	PROPN
aji-40	531	3	of	of	ADP
aji-40	531	4	rheumatic	rheumatic	ADJ
aji-40	531	5	diseases	disease	NOUN
aji-40	531	6	.	.	PUNCT
aji-40	532	1	2017;20(2	2017;20(2	NUM
aji-40	532	2	):	):	PUNCT
aji-40	532	3	161	161	NUM
aji-40	532	4	-	-	SYM
aji-40	532	5	168	168	NUM
aji-40	532	6	.	.	PUNCT
aji-40	533	1	available	available	ADJ
aji-40	533	2	:	:	PUNCT
aji-40	534	1	https://doi.org/10.1111/1756185x.12970	https://doi.org/10.1111/1756185x.12970	PROPN
aji-40	534	2	35	35	NUM
aji-40	534	3	.	.	PUNCT
aji-40	535	1	andrade	andrade	PROPN
aji-40	535	2	pr	pr	PROPN
aji-40	535	3	,	,	PUNCT
aji-40	535	4	jardim	jardim	PROPN
aji-40	535	5	mr	mr	PROPN
aji-40	535	6	,	,	PUNCT
aji-40	535	7	costa	costa	PROPN
aji-40	535	8	da	da	PROPN
aji-40	535	9	silva	silva	PROPN
aji-40	535	10	ac	ac	PROPN
aji-40	535	11	,	,	PUNCT
aji-40	535	12	et	et	PROPN
aji-40	535	13	al	al	PROPN
aji-40	535	14	.	.	PUNCT
aji-40	536	1	inflammatory	inflammatory	ADJ
aji-40	536	2	cytokines	cytokine	NOUN
aji-40	536	3	are	be	AUX
aji-40	536	4	involved	involve	VERB
aji-40	536	5	in	in	ADP
aji-40	536	6	focal	focal	ADJ
aji-40	536	7	demyelination	demyelination	NOUN
aji-40	536	8	in	in	ADP
aji-40	536	9	leprosy	leprosy	NOUN
aji-40	536	10	neuritis	neuritis	NOUN
aji-40	536	11	.	.	PUNCT
aji-40	537	1	journal	journal	PROPN
aji-40	537	2	of	of	ADP
aji-40	537	3	neuropathology	neuropathology	NOUN
aji-40	537	4	&	&	CCONJ
aji-40	537	5	experimental	experimental	ADJ
aji-40	537	6	neurology	neurology	NOUN
aji-40	537	7	.	.	PUNCT
aji-40	538	1	march	march	PROPN
aji-40	538	2	2016;75	2016;75	NUM
aji-40	538	3	(	(	PUNCT
aji-40	538	4	3):272–283	3):272–283	NUM
aji-40	538	5	.	.	PUNCT
aji-40	539	1	doi	doi	NOUN
aji-40	539	2	:	:	PUNCT
aji-40	539	3	https://doi.org/10.1093/jnen/nlv027	https://doi.org/10.1093/jnen/nlv027	PROPN
aji-40	539	4	36	36	NUM
aji-40	539	5	.	.	PUNCT
aji-40	540	1	pereira	pereira	PROPN
aji-40	540	2	ir	ir	PROPN
aji-40	540	3	,	,	PUNCT
aji-40	540	4	vilar	vilar	PROPN
aji-40	540	5	-	-	PUNCT
aji-40	540	6	pereira	pereira	PROPN
aji-40	540	7	g	g	PROPN
aji-40	540	8	,	,	PUNCT
aji-40	540	9	silva	silva	PROPN
aji-40	540	10	aa	aa	PROPN
aji-40	540	11	,	,	PUNCT
aji-40	540	12	moreira	moreira	PROPN
aji-40	540	13	oc	oc	PROPN
aji-40	540	14	,	,	PUNCT
aji-40	540	15	britto	britto	PROPN
aji-40	540	16	c	c	PROPN
aji-40	540	17	,	,	PUNCT
aji-40	540	18	sarmento	sarmento	PROPN
aji-40	540	19	edm	edm	PROPN
aji-40	540	20	,	,	PUNCT
aji-40	540	21	lannes	lannes	PROPN
aji-40	540	22	-	-	PUNCT
aji-40	540	23	vieira	vieira	PROPN
aji-40	540	24	j.	j.	PROPN
aji-40	540	25	tumor	tumor	PROPN
aji-40	540	26	necrosis	necrosis	NOUN
aji-40	540	27	factor	factor	NOUN
aji-40	540	28	is	be	AUX
aji-40	540	29	a	a	DET
aji-40	540	30	therapeutic	therapeutic	ADJ
aji-40	540	31	target	target	NOUN
aji-40	540	32	for	for	ADP
aji-40	540	33	immunological	immunological	ADJ
aji-40	540	34	unbalance	unbalance	NOUN
aji-40	540	35	and	and	CCONJ
aji-40	540	36	cardiac	cardiac	ADJ
aji-40	540	37	abnormalities	abnormality	NOUN
aji-40	540	38	in	in	ADP
aji-40	540	39	chronic	chronic	ADJ
aji-40	540	40	experimental	experimental	ADJ
aji-40	540	41	chagas	chagas	NOUN
aji-40	540	42	’	'	PUNCT
aji-40	540	43	heart	heart	NOUN
aji-40	540	44	disease	disease	NOUN
aji-40	540	45	.	.	PUNCT
aji-40	541	1	mediators	mediator	NOUN
aji-40	541	2	of	of	ADP
aji-40	541	3	inflammation	inflammation	NOUN
aji-40	541	4	.	.	PUNCT
aji-40	542	1	2014;16	2014;16	X
aji-40	542	2	.	.	PUNCT
aji-40	543	1	doi	doi	NOUN
aji-40	543	2	:	:	PUNCT
aji-40	543	3	https://doi.org/10.1155/2014/798078	https://doi.org/10.1155/2014/798078	PROPN
aji-40	543	4	37	37	NUM
aji-40	543	5	.	.	PUNCT
aji-40	544	1	bilate	bilate	PROPN
aji-40	544	2	am	am	PROPN
aji-40	544	3	,	,	PUNCT
aji-40	544	4	salemi	salemi	PROPN
aji-40	544	5	vm	vm	PROPN
aji-40	544	6	,	,	PUNCT
aji-40	544	7	ramires	ramires	PROPN
aji-40	544	8	fj	fj	PROPN
aji-40	544	9	,	,	PUNCT
aji-40	544	10	de	de	PROPN
aji-40	544	11	brito	brito	PROPN
aji-40	544	12	t	t	PROPN
aji-40	544	13	,	,	PUNCT
aji-40	544	14	russo	russo	PROPN
aji-40	544	15	m	m	PROPN
aji-40	544	16	,	,	PUNCT
aji-40	544	17	fonseca	fonseca	PROPN
aji-40	544	18	sg	sg	PROPN
aji-40	544	19	,	,	PUNCT
aji-40	544	20	faé	faé	PROPN
aji-40	544	21	kc	kc	PROPN
aji-40	544	22	,	,	PUNCT
aji-40	544	23	martins	martin	VERB
aji-40	544	24	dg	dg	PROPN
aji-40	544	25	,	,	PUNCT
aji-40	544	26	silva	silva	PROPN
aji-40	544	27	am	am	PROPN
aji-40	544	28	,	,	PUNCT
aji-40	544	29	mady	mady	PROPN
aji-40	544	30	c	c	PROPN
aji-40	544	31	,	,	PUNCT
aji-40	544	32	kalil	kalil	PROPN
aji-40	544	33	j	j	PROPN
aji-40	544	34	,	,	PUNCT
aji-40	544	35	cunha	cunha	PROPN
aji-40	544	36	-	-	PUNCT
aji-40	544	37	neto	neto	PROPN
aji-40	544	38	e.	e.	PROPN
aji-40	544	39	tnf	tnf	PROPN
aji-40	544	40	blockade	blockade	NOUN
aji-40	544	41	aggravates	aggravate	VERB
aji-40	544	42	experimental	experimental	ADJ
aji-40	544	43	chronic	chronic	ADJ
aji-40	544	44	chagas	chagas	NOUN
aji-40	544	45	disease	disease	NOUN
aji-40	544	46	cardiomyopathy	cardiomyopathy	ADJ
aji-40	544	47	.	.	PUNCT
aji-40	545	1	microbes	microbe	NOUN
aji-40	545	2	and	and	CCONJ
aji-40	545	3	infection	infection	NOUN
aji-40	545	4	.	.	PUNCT
aji-40	546	1	2007;9(9):1104	2007;9(9):1104	X
aji-40	546	2	-	-	SYM
aji-40	546	3	1113	1113	NUM
aji-40	546	4	.	.	PUNCT
aji-40	547	1	doi	doi	NOUN
aji-40	547	2	:	:	PUNCT
aji-40	547	3	10.1016	10.1016	NUM
aji-40	547	4	/	/	SYM
aji-40	547	5	j.micinf.2007.05.014	j.micinf.2007.05.014	PROPN
aji-40	547	6	38	38	NUM
aji-40	547	7	.	.	PUNCT
aji-40	548	1	feldmann	feldmann	PROPN
aji-40	548	2	m	m	PROPN
aji-40	548	3	,	,	PUNCT
aji-40	548	4	maini	maini	PROPN
aji-40	548	5	rn	rn	PROPN
aji-40	548	6	,	,	PUNCT
aji-40	548	7	woody	woody	PROPN
aji-40	548	8	jn	jn	PROPN
aji-40	548	9	,	,	PUNCT
aji-40	548	10	holgate	holgate	PROPN
aji-40	548	11	st	st	PROPN
aji-40	548	12	,	,	PUNCT
aji-40	548	13	winter	winter	NOUN
aji-40	548	14	g	g	PROPN
aji-40	548	15	,	,	PUNCT
aji-40	548	16	rowland	rowland	PROPN
aji-40	548	17	m	m	PROPN
aji-40	548	18	,	,	PUNCT
aji-40	548	19	richards	richards	PROPN
aji-40	548	20	d	d	NOUN
aji-40	548	21	,	,	PUNCT
aji-40	548	22	hussell	hussell	ADJ
aji-40	548	23	t.	t.	ADJ
aji-40	548	24	trials	trial	NOUN
aji-40	548	25	of	of	ADP
aji-40	548	26	anti	anti	ADJ
aji-40	548	27	-	-	ADJ
aji-40	548	28	tumour	tumour	ADJ
aji-40	548	29	necrosis	necrosis	NOUN
aji-40	548	30	factor	factor	NOUN
aji-40	548	31	therapy	therapy	NOUN
aji-40	548	32	for	for	ADP
aji-40	548	33	covid-19	covid-19	PROPN
aji-40	548	34	are	be	AUX
aji-40	548	35	urgently	urgently	ADV
aji-40	548	36	needed	need	VERB
aji-40	548	37	.	.	PUNCT
aji-40	549	1	the	the	DET
aji-40	549	2	lancet	lancet	PROPN
aji-40	549	3	.	.	PUNCT
aji-40	550	1	2020;395	2020;395	NUM
aji-40	550	2	(	(	PUNCT
aji-40	550	3	10234):1407	10234):1407	NUM
aji-40	550	4	-	-	PUNCT
aji-40	550	5	1409	1409	NUM
aji-40	550	6	.	.	PUNCT
aji-40	551	1	doi	doi	NOUN
aji-40	551	2	:	:	PUNCT
aji-40	551	3	https://doi.org/10.1016	https://doi.org/10.1016	NOUN
aji-40	551	4	/	/	SYM
aji-40	551	5	s01406736(20)30858	s01406736(20)30858	NOUN
aji-40	551	6	-	-	PUNCT
aji-40	551	7	8	8	NUM
aji-40	551	8	39	39	NUM
aji-40	551	9	.	.	PUNCT
aji-40	552	1	swale	swale	PROPN
aji-40	552	2	vj	vj	PROPN
aji-40	552	3	,	,	PUNCT
aji-40	552	4	perrett	perrett	NOUN
aji-40	552	5	cm	cm	PROPN
aji-40	552	6	,	,	PUNCT
aji-40	552	7	denton	denton	PROPN
aji-40	552	8	cp	cp	PROPN
aji-40	552	9	,	,	PUNCT
aji-40	552	10	black	black	ADJ
aji-40	552	11	cm	cm	NOUN
aji-40	552	12	,	,	PUNCT
aji-40	552	13	rustin	rustin	PROPN
aji-40	552	14	mh	mh	PROPN
aji-40	552	15	.	.	PUNCT
aji-40	552	16	etanercept	etanercept	NOUN
aji-40	552	17	-	-	PUNCT
aji-40	552	18	induced	induce	VERB
aji-40	552	19	systemic	systemic	ADJ
aji-40	552	20	lupus	lupus	PROPN
aji-40	552	21	erythematosus	erythematosus	PROPN
aji-40	552	22	.	.	PUNCT
aji-40	553	1	clin	clin	PROPN
aji-40	553	2	exp	exp	NOUN
aji-40	553	3	dermatol	dermatol	NOUN
aji-40	553	4	.	.	PUNCT
aji-40	554	1	2003;28(6):604	2003;28(6):604	NUM
aji-40	554	2	-	-	SYM
aji-40	554	3	7	7	NUM
aji-40	554	4	.	.	NUM
aji-40	554	5	40	40	NUM
aji-40	554	6	.	.	PUNCT
aji-40	555	1	kang	kang	PROPN
aji-40	555	2	mj	mj	PROPN
aji-40	555	3	,	,	PUNCT
aji-40	555	4	lee	lee	PROPN
aji-40	555	5	yh	yh	PROPN
aji-40	555	6	,	,	PUNCT
aji-40	555	7	lee	lee	PROPN
aji-40	555	8	j.	j.	PROPN
aji-40	555	9	etanerceptinduced	etanerceptinduce	VERB
aji-40	555	10	systemic	systemic	ADJ
aji-40	555	11	lupus	lupus	PROPN
aji-40	555	12	erythematosus	erythematosus	NOUN
aji-40	555	13	in	in	ADP
aji-40	555	14	a	a	DET
aji-40	555	15	patient	patient	NOUN
aji-40	555	16	with	with	ADP
aji-40	555	17	rheumatoid	rheumatoid	NOUN
aji-40	555	18	arthritis	arthritis	NOUN
aji-40	555	19	.	.	PUNCT
aji-40	556	1	j	j	PROPN
aji-40	556	2	korean	korean	PROPN
aji-40	556	3	med	med	PROPN
aji-40	556	4	sci	sci	PROPN
aji-40	556	5	.	.	PUNCT
aji-40	557	1	2006;21(5):946–949	2006;21(5):946–949	NUM
aji-40	557	2	.	.	PUNCT
aji-40	558	1	available	available	ADJ
aji-40	558	2	:	:	PUNCT
aji-40	559	1	https://doi.org/10.3346	https://doi.org/10.3346	ADJ
aji-40	559	2	/	/	SYM
aji-40	559	3	jkms.2006	jkms.2006	PROPN
aji-40	559	4	.21.5.946	.21.5.946	PROPN
aji-40	559	5	41	41	NUM
aji-40	559	6	.	.	PUNCT
aji-40	560	1	cairns	cairns	PROPN
aji-40	560	2	ap	ap	PROPN
aji-40	560	3	,	,	PUNCT
aji-40	560	4	duncan	duncan	PROPN
aji-40	560	5	mkj	mkj	NOUN
aji-40	560	6	,	,	PUNCT
aji-40	560	7	hinder	hinder	PROPN
aji-40	560	8	ae	ae	PROPN
aji-40	560	9	,	,	PUNCT
aji-40	560	10	taggart	taggart	PROPN
aji-40	560	11	aj	aj	PROPN
aji-40	560	12	.	.	PUNCT
aji-40	561	1	new	new	ADJ
aji-40	561	2	onset	onset	VERB
aji-40	561	3	systemic	systemic	ADJ
aji-40	561	4	lupus	lupus	NOUN
aji-40	561	5	erythematosus	erythematosus	NOUN
aji-40	561	6	in	in	ADP
aji-40	561	7	a	a	DET
aji-40	561	8	patient	patient	NOUN
aji-40	561	9	receiving	receive	VERB
aji-40	561	10	etanercept	etanercept	NOUN
aji-40	561	11	for	for	ADP
aji-40	561	12	rheumatoid	rheumatoid	NOUN
aji-40	561	13	arthritis	arthritis	NOUN
aji-40	561	14	.	.	PUNCT
aji-40	562	1	annals	annal	NOUN
aji-40	562	2	of	of	ADP
aji-40	562	3	the	the	DET
aji-40	562	4	rheumatic	rheumatic	ADJ
aji-40	562	5	diseases	disease	NOUN
aji-40	562	6	.	.	PUNCT
aji-40	563	1	2002;61:10311032	2002;61:10311032	X
aji-40	563	2	.	.	PUNCT
aji-40	563	3	available	available	ADJ
aji-40	563	4	:	:	PUNCT
aji-40	563	5	http://dx.doi.org/10.1136	http://dx.doi.org/10.1136	NOUN
aji-40	563	6	/	/	SYM
aji-40	563	7	ard.61.1	ard.61.1	NOUN
aji-40	563	8	1.1031	1.1031	NUM
aji-40	563	9	42	42	NUM
aji-40	563	10	.	.	PUNCT
aji-40	564	1	vannucchi	vannucchi	PROPN
aji-40	564	2	v	v	PROPN
aji-40	564	3	,	,	PUNCT
aji-40	564	4	grazzini	grazzini	PROPN
aji-40	564	5	m	m	PROPN
aji-40	564	6	,	,	PUNCT
aji-40	564	7	pieralli	pieralli	PROPN
aji-40	564	8	f	f	AUX
aji-40	564	9	,	,	PUNCT
aji-40	564	10	giannotta	giannotta	NOUN
aji-40	564	11	m	m	NOUN
aji-40	564	12	,	,	PUNCT
aji-40	564	13	biagioni	biagioni	NOUN
aji-40	564	14	c	c	NOUN
aji-40	564	15	,	,	PUNCT
aji-40	564	16	nozzoli	nozzoli	ADJ
aji-40	564	17	c.	c.	PROPN
aji-40	564	18	adalimumab	adalimumab	PROPN
aji-40	564	19	-	-	PUNCT
aji-40	564	20	induced	induce	VERB
aji-40	564	21	lupus	lupus	NOUN
aji-40	564	22	erythematosus	erythematosus	NOUN
aji-40	564	23	with	with	ADP
aji-40	564	24	central	central	ADJ
aji-40	564	25	nervous	nervous	ADJ
aji-40	564	26	system	system	NOUN
aji-40	564	27	involvement	involvement	NOUN
aji-40	564	28	in	in	ADP
aji-40	564	29	a	a	DET
aji-40	564	30	patient	patient	NOUN
aji-40	564	31	with	with	ADP
aji-40	564	32	crohn	crohn	PROPN
aji-40	564	33	's	's	PART
aji-40	564	34	disease	disease	NOUN
aji-40	564	35	.	.	PUNCT
aji-40	565	1	j	j	PROPN
aji-40	565	2	gastrointestin	gastrointestin	PROPN
aji-40	565	3	liver	liver	PROPN
aji-40	565	4	dis	dis	PROPN
aji-40	565	5	.	.	PUNCT
aji-40	566	1	201;20(2):201	201;20(2):201	NUM
aji-40	566	2	-	-	PUNCT
aji-40	566	3	3	3	NUM
aji-40	566	4	.	.	NOUN
aji-40	566	5	43	43	NUM
aji-40	566	6	.	.	PUNCT
aji-40	567	1	kelly	kelly	PROPN
aji-40	567	2	d	d	PROPN
aji-40	567	3	,	,	PUNCT
aji-40	567	4	o'connell	o'connell	PROPN
aji-40	567	5	o	o	PROPN
aji-40	567	6	,	,	PUNCT
aji-40	567	7	henry	henry	PROPN
aji-40	567	8	m.	m.	PROPN
aji-40	567	9	adalimumab	adalimumab	PROPN
aji-40	567	10	-	-	PUNCT
aji-40	567	11	induced	induce	VERB
aji-40	567	12	lupus	lupus	NOUN
aji-40	567	13	serositis	serositis	NOUN
aji-40	567	14	.	.	PUNCT
aji-40	568	1	bmj	bmj	PROPN
aji-40	568	2	case	case	NOUN
aji-40	568	3	rep	rep	PROPN
aji-40	568	4	.	.	PROPN
aji-40	568	5	2015	2015	NUM
aji-40	568	6	:	:	PUNCT
aji-40	568	7	bcr2014207323	bcr2014207323	ADJ
aji-40	568	8	.	.	PUNCT
aji-40	569	1	available	available	ADJ
aji-40	569	2	:	:	PUNCT
aji-40	569	3	https://doi.org/10.1136	https://doi.org/10.1136	ADJ
aji-40	569	4	/	/	SYM
aji-40	569	5	bcr-2014207323	bcr-2014207323	NOUN
aji-40	569	6	44	44	NUM
aji-40	569	7	.	.	PUNCT
aji-40	570	1	uppal	uppal	PROPN
aji-40	570	2	ss	ss	PROPN
aji-40	570	3	,	,	PUNCT
aji-40	570	4	hayat	hayat	PROPN
aji-40	570	5	sj	sj	PROPN
aji-40	570	6	,	,	PUNCT
aji-40	570	7	raghupathy	raghupathy	PROPN
aji-40	570	8	r.	r.	PROPN
aji-40	570	9	efficacy	efficacy	PROPN
aji-40	570	10	and	and	CCONJ
aji-40	570	11	safety	safety	NOUN
aji-40	570	12	of	of	ADP
aji-40	570	13	infliximab	infliximab	NOUN
aji-40	570	14	in	in	ADP
aji-40	570	15	active	active	ADJ
aji-40	570	16	sle	sle	NOUN
aji-40	570	17	:	:	PUNCT
aji-40	570	18	a	a	DET
aji-40	570	19	pilot	pilot	NOUN
aji-40	570	20	study	study	NOUN
aji-40	570	21	.	.	PUNCT
aji-40	571	1	lupus	lupus	NOUN
aji-40	571	2	.	.	PUNCT
aji-40	572	1	2009;18(8):6907	2009;18(8):6907	NUM
aji-40	572	2	.	.	PUNCT
aji-40	573	1	available	available	ADJ
aji-40	573	2	:	:	PUNCT
aji-40	573	3	https://doi.org/10.1177/09612033	https://doi.org/10.1177/09612033	PROPN
aji-40	573	4	09102557	09102557	NUM
aji-40	573	5	45	45	NUM
aji-40	573	6	.	.	PUNCT
aji-40	574	1	zhang	zhang	PROPN
aji-40	574	2	l	l	PROPN
aji-40	574	3	,	,	PUNCT
aji-40	574	4	peppel	peppel	PROPN
aji-40	574	5	k	k	NOUN
aji-40	574	6	,	,	PUNCT
aji-40	574	7	sivashanmugam	sivashanmugam	NOUN
aji-40	574	8	p	p	NOUN
aji-40	574	9	,	,	PUNCT
aji-40	574	10	orman	orman	PROPN
aji-40	574	11	es	es	PROPN
aji-40	574	12	,	,	PUNCT
aji-40	574	13	brian	brian	PROPN
aji-40	574	14	l	l	PROPN
aji-40	574	15	,	,	PUNCT
aji-40	574	16	exum	exum	PROPN
aji-40	574	17	st	st	PROPN
aji-40	574	18	,	,	PUNCT
aji-40	574	19	et	et	PROPN
aji-40	574	20	al	al	PROPN
aji-40	574	21	.	.	PUNCT
aji-40	574	22	expression	expression	NOUN
aji-40	574	23	of	of	ADP
aji-40	574	24	tumor	tumor	NOUN
aji-40	574	25	necrosis	necrosis	NOUN
aji-40	574	26	factor	factor	NOUN
aji-40	574	27	receptor-1	receptor-1	NUM
aji-40	574	28	in	in	ADP
aji-40	574	29	arterial	arterial	ADJ
aji-40	574	30	wall	wall	NOUN
aji-40	574	31	cells	cell	NOUN
aji-40	574	32	promotes	promote	VERB
aji-40	574	33	atherosclerosis	atherosclerosis	NOUN
aji-40	574	34	.	.	PUNCT
aji-40	575	1	arterioscler	arterioscler	PROPN
aji-40	575	2	thromb	thromb	PROPN
aji-40	575	3	vasc	vasc	PROPN
aji-40	575	4	biol	biol	PROPN
aji-40	575	5	.	.	PUNCT
aji-40	576	1	2007;27(5):1087–1094	2007;27(5):1087–1094	X
aji-40	576	2	.	.	PUNCT
aji-40	577	1	46	46	NUM
aji-40	577	2	.	.	PUNCT
aji-40	578	1	ersozlu	ersozlu	PROPN
aji-40	578	2	bozkirli	bozkirli	PROPN
aji-40	578	3	ed	ed	NOUN
aji-40	578	4	,	,	PUNCT
aji-40	578	5	bozkirli	bozkirli	ADJ
aji-40	578	6	e	e	NOUN
aji-40	578	7	,	,	PUNCT
aji-40	578	8	yucel	yucel	PROPN
aji-40	578	9	ae	ae	PROPN
aji-40	578	10	.	.	PUNCT
aji-40	579	1	effects	effect	NOUN
aji-40	579	2	of	of	ADP
aji-40	579	3	infliximab	infliximab	NOUN
aji-40	579	4	treatment	treatment	NOUN
aji-40	579	5	in	in	ADP
aji-40	579	6	terms	term	NOUN
aji-40	579	7	of	of	ADP
aji-40	579	8	cardiovascular	cardiovascular	ADJ
aji-40	579	9	risk	risk	NOUN
aji-40	579	10	and	and	CCONJ
aji-40	579	11	insulin	insulin	NOUN
aji-40	579	12	resistance	resistance	NOUN
aji-40	579	13	in	in	ADP
aji-40	579	14	ankylosing	ankylose	VERB
aji-40	579	15	spondylitis	spondylitis	ADJ
aji-40	579	16	patients	patient	NOUN
aji-40	579	17	.	.	PUNCT
aji-40	580	1	mod	mod	PROPN
aji-40	580	2	rheumatol	rheumatol	NOUN
aji-40	580	3	.	.	PUNCT
aji-40	581	1	2014;24(2):335	2014;24(2):335	NUM
aji-40	581	2	-	-	SYM
aji-40	581	3	9	9	NUM
aji-40	581	4	.	.	PUNCT
aji-40	581	5	available	available	ADJ
aji-40	581	6	:	:	PUNCT
aji-40	581	7	https://doi.org/10.3109/14397595	https://doi.org/10.3109/14397595	NOUN
aji-40	581	8	.2013.843752	.2013.843752	PROPN
aji-40	582	1	47	47	NUM
aji-40	582	2	.	.	PUNCT
aji-40	583	1	wong	wong	PROPN
aji-40	583	2	m	m	PROPN
aji-40	583	3	,	,	PUNCT
aji-40	583	4	oakley	oakley	PROPN
aji-40	583	5	sp	sp	PROPN
aji-40	583	6	,	,	PUNCT
aji-40	583	7	young	young	ADJ
aji-40	583	8	l	l	NOUN
aji-40	583	9	,	,	PUNCT
aji-40	583	10	jiang	jiang	PROPN
aji-40	583	11	by	by	ADP
aji-40	583	12	,	,	PUNCT
aji-40	583	13	wierzbicki	wierzbicki	PROPN
aji-40	583	14	a	a	PRON
aji-40	583	15	,	,	PUNCT
aji-40	583	16	panayi	panayi	NOUN
aji-40	583	17	g	g	PROPN
aji-40	583	18	,	,	PUNCT
aji-40	583	19	et	et	PROPN
aji-40	583	20	al	al	PROPN
aji-40	583	21	.	.	PROPN
aji-40	583	22	infliximab	infliximab	PROPN
aji-40	583	23	improves	improve	VERB
aji-40	583	24	vascular	vascular	ADJ
aji-40	583	25	stiffness	stiffness	NOUN
aji-40	583	26	in	in	ADP
aji-40	583	27	patients	patient	NOUN
aji-40	583	28	with	with	ADP
aji-40	583	29	rheumatoid	rheumatoid	NOUN
aji-40	583	30	arthritis	arthritis	NOUN
aji-40	583	31	.	.	PUNCT
aji-40	584	1	ann	ann	PROPN
aji-40	584	2	rheum	rheum	PROPN
aji-40	584	3	dis	dis	PROPN
aji-40	584	4	.	.	PUNCT
aji-40	585	1	2009;68(8):1277	2009;68(8):1277	NUM
aji-40	585	2	-	-	PUNCT
aji-40	585	3	84	84	NUM
aji-40	585	4	.	.	PUNCT
aji-40	586	1	available	available	ADJ
aji-40	586	2	:	:	PUNCT
aji-40	586	3	https://doi.org/10.1136	https://doi.org/10.1136	NOUN
aji-40	586	4	/	/	SYM
aji-40	586	5	ard.2007	ard.2007	NOUN
aji-40	586	6	.	.	PUNCT
aji-40	586	7	086157	086157	NUM
aji-40	586	8	48	48	NUM
aji-40	586	9	.	.	PUNCT
aji-40	587	1	zhang	zhang	PROPN
aji-40	587	2	l	l	PROPN
aji-40	587	3	,	,	PUNCT
aji-40	587	4	connelly	connelly	PROPN
aji-40	587	5	jj	jj	PROPN
aji-40	587	6	,	,	PUNCT
aji-40	587	7	peppel	peppel	PROPN
aji-40	587	8	k	k	PROPN
aji-40	587	9	,	,	PUNCT
aji-40	587	10	brian	brian	PROPN
aji-40	587	11	l	l	PROPN
aji-40	587	12	,	,	PUNCT
aji-40	587	13	shah	shah	PROPN
aji-40	587	14	sh	sh	PROPN
aji-40	587	15	,	,	PUNCT
aji-40	587	16	nelson	nelson	PROPN
aji-40	587	17	s	s	PROPN
aji-40	587	18	,	,	PUNCT
aji-40	587	19	et	et	PROPN
aji-40	587	20	al	al	PROPN
aji-40	587	21	.	.	PUNCT
aji-40	587	22	aging	age	VERB
aji-40	587	23	-	-	PUNCT
aji-40	587	24	related	relate	VERB
aji-40	587	25	atherosclerosis	atherosclerosis	NOUN
aji-40	587	26	is	be	AUX
aji-40	587	27	exacerbated	exacerbate	VERB
aji-40	587	28	by	by	ADP
aji-40	587	29	arterial	arterial	ADJ
aji-40	587	30	expression	expression	NOUN
aji-40	587	31	of	of	ADP
aji-40	587	32	tumor	tumor	NOUN
aji-40	587	33	necrosis	necrosis	NOUN
aji-40	587	34	factor	factor	NOUN
aji-40	587	35	receptor-1	receptor-1	NUM
aji-40	587	36	:	:	PUNCT
aji-40	587	37	evidence	evidence	NOUN
aji-40	587	38	from	from	ADP
aji-40	587	39	mouse	mouse	NOUN
aji-40	587	40	models	model	NOUN
aji-40	587	41	and	and	CCONJ
aji-40	587	42	human	human	ADJ
aji-40	587	43	association	association	NOUN
aji-40	587	44	studies	study	NOUN
aji-40	587	45	.	.	PUNCT
aji-40	588	1	hum	hum	PROPN
aji-40	588	2	mol	mol	ADP
aji-40	588	3	genet	genet	NOUN
aji-40	588	4	.	.	PUNCT
aji-40	589	1	2010;19(14):2754–2766	2010;19(14):2754–2766	X
aji-40	589	2	.	.	PUNCT
aji-40	589	3	https://doi.org/10.1093/rheumatology/keq242	https://doi.org/10.1093/rheumatology/keq242	NOUN
aji-40	589	4	https://doi.org/10.1093/rheumatology/keq242	https://doi.org/10.1093/rheumatology/keq242	VERB
aji-40	589	5	https://doi.org/10.1111/1756-185x.12970	https://doi.org/10.1111/1756-185x.12970	PROPN
aji-40	589	6	https://doi.org/10.1111/1756-185x.12970	https://doi.org/10.1111/1756-185x.12970	PROPN
aji-40	589	7	https://doi.org/10.1093/jnen/nlv027	https://doi.org/10.1093/jnen/nlv027	ADJ
aji-40	589	8	https://doi.org/10.1155/2014/798078	https://doi.org/10.1155/2014/798078	PROPN
aji-40	589	9	https://doi.org/10.3346/jkms.2006.21.5.946	https://doi.org/10.3346/jkms.2006.21.5.946	PROPN
aji-40	589	10	https://doi.org/10.3346/jkms.2006.21.5.946	https://doi.org/10.3346/jkms.2006.21.5.946	PROPN
aji-40	589	11	http://dx.doi.org/10.1136/ard.61.11.1031	http://dx.doi.org/10.1136/ard.61.11.1031	PROPN
aji-40	589	12	http://dx.doi.org/10.1136/ard.61.11.1031	http://dx.doi.org/10.1136/ard.61.11.1031	PROPN
aji-40	589	13	https://doi.org/10.1136/bcr-2014-207323	https://doi.org/10.1136/bcr-2014-207323	PROPN
aji-40	589	14	https://doi.org/10.1136/bcr-2014-207323	https://doi.org/10.1136/bcr-2014-207323	PROPN
aji-40	589	15	https://doi.org/10.1177/0961203309102557	https://doi.org/10.1177/0961203309102557	PROPN
aji-40	589	16	https://doi.org/10.1177/0961203309102557	https://doi.org/10.1177/0961203309102557	PROPN
aji-40	589	17	https://doi.org/10.3109/14397595.2013.843752	https://doi.org/10.3109/14397595.2013.843752	PROPN
aji-40	589	18	https://doi.org/10.3109/14397595.2013.843752	https://doi.org/10.3109/14397595.2013.843752	PROPN
aji-40	590	1	https://doi.org/10.1136/ard.2007.086157	https://doi.org/10.1136/ard.2007.086157	VERB
aji-40	590	2	https://doi.org/10.1136/ard.2007.086157	https://doi.org/10.1136/ard.2007.086157	PROPN
aji-40	590	3	churchill	churchill	PROPN
aji-40	590	4	et	et	PROPN
aji-40	590	5	al	al	PROPN
aji-40	590	6	.	.	PROPN
aji-40	590	7	;	;	PUNCT
aji-40	590	8	aji	aji	PROPN
aji-40	590	9	,	,	PUNCT
aji-40	590	10	3(1	3(1	NUM
aji-40	590	11	):	):	PUNCT
aji-40	590	12	208	208	NUM
aji-40	590	13	-	-	SYM
aji-40	590	14	222	222	NUM
aji-40	590	15	,	,	PUNCT
aji-40	590	16	2020	2020	NUM
aji-40	590	17	;	;	PUNCT
aji-40	590	18	article	article	NOUN
aji-40	590	19	no.aji.57464	no.aji.57464	ADP
aji-40	590	20	221	221	NUM
aji-40	590	21	available	available	ADJ
aji-40	590	22	:	:	PUNCT
aji-40	590	23	https://doi.org/10.1093	https://doi.org/10.1093	NOUN
aji-40	590	24	/	/	SYM
aji-40	590	25	hmg	hmg	NOUN
aji-40	590	26	/	/	SYM
aji-40	590	27	ddq1	ddq1	PROPN
aji-40	590	28	72	72	NUM
aji-40	590	29	49	49	NUM
aji-40	590	30	.	.	PUNCT
aji-40	591	1	berghen	berghen	ADJ
aji-40	591	2	n	n	CCONJ
aji-40	591	3	,	,	PUNCT
aji-40	591	4	teuwen	teuwen	NOUN
aji-40	591	5	la	la	PROPN
aji-40	591	6	,	,	PUNCT
aji-40	591	7	westhovens	westhoven	NOUN
aji-40	591	8	r	r	NOUN
aji-40	591	9	,	,	PUNCT
aji-40	591	10	verschueren	verschueren	ADJ
aji-40	591	11	p.	p.	NOUN
aji-40	591	12	malignancies	malignancy	NOUN
aji-40	591	13	and	and	CCONJ
aji-40	591	14	antitnf	antitnf	VERB
aji-40	591	15	therapy	therapy	NOUN
aji-40	591	16	in	in	ADP
aji-40	591	17	rheumatoid	rheumatoid	NOUN
aji-40	591	18	arthritis	arthritis	NOUN
aji-40	591	19	:	:	PUNCT
aji-40	591	20	a	a	DET
aji-40	591	21	single	single	ADJ
aji-40	591	22	-	-	PUNCT
aji-40	591	23	center	center	NOUN
aji-40	591	24	observational	observational	ADJ
aji-40	591	25	cohort	cohort	NOUN
aji-40	591	26	study	study	NOUN
aji-40	591	27	.	.	PUNCT
aji-40	592	1	clin	clin	PROPN
aji-40	592	2	rheumatol	rheumatol	PROPN
aji-40	592	3	.	.	PUNCT
aji-40	593	1	2015;34(10):168795	2015;34(10):168795	X
aji-40	593	2	.	.	PUNCT
aji-40	593	3	available	available	ADJ
aji-40	593	4	:	:	PUNCT
aji-40	593	5	https://doi.org/10.1007	https://doi.org/10.1007	ADJ
aji-40	593	6	/	/	SYM
aji-40	593	7	s10067015	s10067015	PROPN
aji-40	593	8	-	-	PUNCT
aji-40	593	9	3026	3026	NUM
aji-40	593	10	-	-	SYM
aji-40	593	11	7	7	NUM
aji-40	593	12	50	50	NUM
aji-40	593	13	.	.	PUNCT
aji-40	594	1	mercer	mercer	PROPN
aji-40	594	2	lk	lk	PROPN
aji-40	594	3	,	,	PUNCT
aji-40	594	4	lunt	lunt	PROPN
aji-40	594	5	m	m	PROPN
aji-40	594	6	,	,	PUNCT
aji-40	594	7	low	low	ADJ
aji-40	594	8	als	al	NOUN
aji-40	594	9	,	,	PUNCT
aji-40	594	10	dixon	dixon	PROPN
aji-40	594	11	wg	wg	PROPN
aji-40	594	12	,	,	PUNCT
aji-40	594	13	watson	watson	PROPN
aji-40	594	14	kd	kd	PROPN
aji-40	594	15	,	,	PUNCT
aji-40	594	16	symmons	symmons	PROPN
aji-40	594	17	dpm	dpm	PROPN
aji-40	594	18	,	,	PUNCT
aji-40	594	19	et	et	PROPN
aji-40	594	20	al	al	PROPN
aji-40	594	21	,	,	PUNCT
aji-40	594	22	bsrbr	bsrbr	PROPN
aji-40	594	23	control	control	PROPN
aji-40	594	24	centre	centre	PROPN
aji-40	594	25	consortium	consortium	NOUN
aji-40	594	26	.	.	PUNCT
aji-40	595	1	risk	risk	NOUN
aji-40	595	2	of	of	ADP
aji-40	595	3	solid	solid	ADJ
aji-40	595	4	cancer	cancer	NOUN
aji-40	595	5	in	in	ADP
aji-40	595	6	patients	patient	NOUN
aji-40	595	7	exposed	expose	VERB
aji-40	595	8	to	to	ADP
aji-40	595	9	anti	anti	ADJ
aji-40	595	10	-	-	ADJ
aji-40	595	11	tumour	tumour	ADJ
aji-40	595	12	necrosis	necrosis	NOUN
aji-40	595	13	factor	factor	NOUN
aji-40	595	14	therapy	therapy	NOUN
aji-40	595	15	:	:	PUNCT
aji-40	595	16	results	result	NOUN
aji-40	595	17	from	from	ADP
aji-40	595	18	the	the	DET
aji-40	595	19	british	british	ADJ
aji-40	595	20	society	society	NOUN
aji-40	595	21	for	for	ADP
aji-40	595	22	rheumatology	rheumatology	NOUN
aji-40	595	23	biologics	biologic	NOUN
aji-40	595	24	register	register	VERB
aji-40	595	25	for	for	ADP
aji-40	595	26	rheumatoid	rheumatoid	NOUN
aji-40	595	27	arthritis	arthritis	NOUN
aji-40	595	28	.	.	PUNCT
aji-40	596	1	annals	annal	NOUN
aji-40	596	2	of	of	ADP
aji-40	596	3	the	the	DET
aji-40	596	4	rheumatic	rheumatic	ADJ
aji-40	596	5	diseases	disease	NOUN
aji-40	596	6	.	.	PUNCT
aji-40	597	1	2015;74:10871093	2015;74:10871093	NUM
aji-40	597	2	.	.	PUNCT
aji-40	597	3	51	51	NUM
aji-40	597	4	.	.	PUNCT
aji-40	597	5	jung	jung	PROPN
aji-40	597	6	sm	sm	PROPN
aji-40	597	7	,	,	PUNCT
aji-40	597	8	kwok	kwok	PROPN
aji-40	597	9	sk	sk	PROPN
aji-40	597	10	,	,	PUNCT
aji-40	597	11	ju	ju	PROPN
aji-40	597	12	jh	jh	PROPN
aji-40	597	13	,	,	PUNCT
aji-40	597	14	park	park	NOUN
aji-40	597	15	yb	yb	PROPN
aji-40	597	16	,	,	PUNCT
aji-40	597	17	park	park	PROPN
aji-40	597	18	sh	sh	PROPN
aji-40	597	19	.	.	PROPN
aji-40	597	20	risk	risk	NOUN
aji-40	597	21	of	of	ADP
aji-40	597	22	malignancy	malignancy	NOUN
aji-40	597	23	in	in	ADP
aji-40	597	24	patients	patient	NOUN
aji-40	597	25	with	with	ADP
aji-40	597	26	rheumatoid	rheumatoid	NOUN
aji-40	597	27	arthritis	arthritis	NOUN
aji-40	597	28	after	after	ADP
aji-40	597	29	anti	anti	ADJ
aji-40	597	30	-	-	ADJ
aji-40	597	31	tumor	tumor	ADJ
aji-40	597	32	necrosis	necrosis	NOUN
aji-40	597	33	factor	factor	NOUN
aji-40	597	34	therapy	therapy	NOUN
aji-40	597	35	:	:	PUNCT
aji-40	597	36	results	result	NOUN
aji-40	597	37	from	from	ADP
aji-40	597	38	korean	korean	ADJ
aji-40	597	39	national	national	PROPN
aji-40	597	40	health	health	PROPN
aji-40	597	41	insurance	insurance	PROPN
aji-40	597	42	claims	claim	VERB
aji-40	597	43	data	datum	NOUN
aji-40	597	44	.	.	PUNCT
aji-40	598	1	korean	korean	PROPN
aji-40	598	2	j	j	PROPN
aji-40	598	3	intern	intern	PROPN
aji-40	598	4	med	me	VERB
aji-40	598	5	.	.	PUNCT
aji-40	599	1	2019;34(3	2019;34(3	NUM
aji-40	599	2	):	):	PUNCT
aji-40	599	3	669	669	NUM
aji-40	599	4	-	-	SYM
aji-40	599	5	677	677	NUM
aji-40	599	6	.	.	PUNCT
aji-40	600	1	available	available	ADJ
aji-40	600	2	:	:	PUNCT
aji-40	600	3	https://doi.org/10.3904	https://doi.org/10.3904	NOUN
aji-40	600	4	/	/	SYM
aji-40	600	5	kjim.2016	kjim.2016	PROPN
aji-40	600	6	.374	.374	NUM
aji-40	600	7	52	52	NUM
aji-40	600	8	.	.	PUNCT
aji-40	601	1	probert	probert	PROPN
aji-40	601	2	l.	l.	PROPN
aji-40	601	3	tnf	tnf	PROPN
aji-40	601	4	and	and	CCONJ
aji-40	601	5	its	its	PRON
aji-40	601	6	receptors	receptor	NOUN
aji-40	601	7	in	in	ADP
aji-40	601	8	the	the	DET
aji-40	601	9	cns	cns	NOUN
aji-40	601	10	:	:	PUNCT
aji-40	601	11	the	the	DET
aji-40	601	12	essential	essential	ADJ
aji-40	601	13	,	,	PUNCT
aji-40	601	14	the	the	DET
aji-40	601	15	desirable	desirable	ADJ
aji-40	601	16	and	and	CCONJ
aji-40	601	17	the	the	DET
aji-40	601	18	deleterious	deleterious	ADJ
aji-40	601	19	effects	effect	NOUN
aji-40	601	20	.	.	PUNCT
aji-40	602	1	neuroscience	neuroscience	NOUN
aji-40	602	2	.	.	PUNCT
aji-40	603	1	2015	2015	NUM
aji-40	603	2	;	;	PUNCT
aji-40	603	3	302:2	302:2	NUM
aji-40	603	4	-	-	SYM
aji-40	603	5	22	22	NUM
aji-40	603	6	.	.	PUNCT
aji-40	604	1	available	available	ADJ
aji-40	604	2	:	:	PUNCT
aji-40	604	3	https://doi.org/10.1016	https://doi.org/10.1016	NOUN
aji-40	604	4	/	/	SYM
aji-40	604	5	j.neurosci	j.neurosci	X
aji-40	604	6	ence.2015.06.038	ence.2015.06.038	X
aji-40	605	1	53	53	NUM
aji-40	605	2	.	.	PUNCT
aji-40	605	3	ortí	ortí	NOUN
aji-40	605	4	-	-	PUNCT
aji-40	605	5	casañ	casañ	PROPN
aji-40	605	6	n	n	CCONJ
aji-40	605	7	,	,	PUNCT
aji-40	605	8	wu	wu	PROPN
aji-40	605	9	y	y	PROPN
aji-40	605	10	,	,	PUNCT
aji-40	605	11	naudé	naudé	ADP
aji-40	605	12	pjw	pjw	PROPN
aji-40	605	13	,	,	PUNCT
aji-40	605	14	de	de	X
aji-40	605	15	deyn	deyn	NOUN
aji-40	605	16	pp	pp	ADV
aji-40	605	17	,	,	PUNCT
aji-40	605	18	zuhorn	zuhorn	PROPN
aji-40	605	19	is	be	AUX
aji-40	605	20	,	,	PUNCT
aji-40	605	21	eisel	eisel	NOUN
aji-40	605	22	ulm	ulm	PROPN
aji-40	605	23	.	.	PUNCT
aji-40	606	1	targeting	target	VERB
aji-40	606	2	tnfr2	tnfr2	NOUN
aji-40	606	3	as	as	ADP
aji-40	606	4	a	a	DET
aji-40	606	5	novel	novel	ADJ
aji-40	606	6	therapeutic	therapeutic	ADJ
aji-40	606	7	strategy	strategy	NOUN
aji-40	606	8	for	for	ADP
aji-40	606	9	alzheimer	alzheimer	PROPN
aji-40	606	10	's	's	PART
aji-40	606	11	disease	disease	NOUN
aji-40	606	12	.	.	PUNCT
aji-40	607	1	front	front	ADJ
aji-40	607	2	neurosci	neurosci	PROPN
aji-40	607	3	.	.	PUNCT
aji-40	608	1	2019;13:49	2019;13:49	NUM
aji-40	608	2	.	.	PUNCT
aji-40	609	1	available	available	ADJ
aji-40	609	2	:	:	PUNCT
aji-40	609	3	https://doi.org/10.3389	https://doi.org/10.3389	NOUN
aji-40	609	4	/	/	SYM
aji-40	609	5	fnins.201	fnins.201	VERB
aji-40	609	6	9.00049	9.00049	NUM
aji-40	609	7	54	54	NUM
aji-40	609	8	.	.	PUNCT
aji-40	610	1	kemanetzoglou	kemanetzoglou	PROPN
aji-40	610	2	e	e	NOUN
aji-40	610	3	,	,	PUNCT
aji-40	610	4	andreadou	andreadou	ADJ
aji-40	610	5	e.	e.	PROPN
aji-40	610	6	cns	cns	PROPN
aji-40	610	7	demyelination	demyelination	NOUN
aji-40	610	8	with	with	ADP
aji-40	610	9	tnf	tnf	PROPN
aji-40	610	10	-	-	PUNCT
aji-40	610	11	α	α	NUM
aji-40	610	12	blockers	blocker	NOUN
aji-40	610	13	.	.	PUNCT
aji-40	611	1	curr	curr	PROPN
aji-40	611	2	neurol	neurol	PROPN
aji-40	611	3	neurosci	neurosci	PROPN
aji-40	611	4	rep	rep	PROPN
aji-40	611	5	.	.	PROPN
aji-40	612	1	2017;17(4):36	2017;17(4):36	PROPN
aji-40	612	2	.	.	PUNCT
aji-40	613	1	available	available	ADJ
aji-40	613	2	:	:	PUNCT
aji-40	613	3	https://doi.org/10.1007	https://doi.org/10.1007	ADJ
aji-40	613	4	/	/	SYM
aji-40	613	5	s11910017	s11910017	NOUN
aji-40	613	6	-	-	PUNCT
aji-40	613	7	0742	0742	NUM
aji-40	613	8	-	-	SYM
aji-40	613	9	1	1	NUM
aji-40	613	10	55	55	NUM
aji-40	613	11	.	.	PUNCT
aji-40	614	1	no	no	DET
aji-40	614	2	authors	author	NOUN
aji-40	614	3	listed	list	VERB
aji-40	614	4	.	.	PUNCT
aji-40	615	1	tnf	tnf	PROPN
aji-40	615	2	neutralization	neutralization	NOUN
aji-40	615	3	in	in	ADP
aji-40	615	4	ms	ms	NOUN
aji-40	615	5	:	:	PUNCT
aji-40	615	6	results	result	NOUN
aji-40	615	7	of	of	ADP
aji-40	615	8	a	a	DET
aji-40	615	9	randomized	randomized	ADJ
aji-40	615	10	,	,	PUNCT
aji-40	615	11	placebocontrolled	placebocontrolle	VERB
aji-40	615	12	multicenter	multicenter	ADJ
aji-40	615	13	study	study	NOUN
aji-40	615	14	.	.	PUNCT
aji-40	616	1	the	the	DET
aji-40	616	2	lenercept	lenercept	ADJ
aji-40	616	3	multiple	multiple	ADJ
aji-40	616	4	sclerosis	sclerosis	NOUN
aji-40	616	5	study	study	NOUN
aji-40	616	6	group	group	NOUN
aji-40	616	7	and	and	CCONJ
aji-40	616	8	the	the	DET
aji-40	616	9	university	university	PROPN
aji-40	616	10	of	of	ADP
aji-40	616	11	british	british	PROPN
aji-40	616	12	columbia	columbia	PROPN
aji-40	616	13	ms	ms	PROPN
aji-40	616	14	/	/	SYM
aji-40	616	15	mri	mri	NOUN
aji-40	616	16	analysis	analysis	NOUN
aji-40	616	17	group	group	NOUN
aji-40	616	18	.	.	PUNCT
aji-40	617	1	neurology	neurology	PROPN
aji-40	617	2	.	.	PUNCT
aji-40	618	1	1999	1999	NUM
aji-40	618	2	;	;	PUNCT
aji-40	618	3	53(3):457	53(3):457	PROPN
aji-40	618	4	-	-	SYM
aji-40	618	5	65	65	NUM
aji-40	618	6	.	.	PUNCT
aji-40	619	1	available	available	ADJ
aji-40	619	2	:	:	PUNCT
aji-40	619	3	https://www.ncbi.nlm.nih.gov	https://www.ncbi.nlm.nih.gov	ADJ
aji-40	619	4	/	/	SYM
aji-40	619	5	pub	pub	NOUN
aji-40	619	6	med/10449104	med/10449104	NOUN
aji-40	619	7	(	(	PUNCT
aji-40	619	8	accessed	access	VERB
aji-40	619	9	on	on	ADP
aji-40	619	10	:	:	PUNCT
aji-40	619	11	9	9	NUM
aji-40	619	12	dec	dec	PROPN
aji-40	619	13	2019	2019	NUM
aji-40	619	14	)	)	PUNCT
aji-40	619	15	56	56	NUM
aji-40	619	16	.	.	PUNCT
aji-40	620	1	sicotte	sicotte	PROPN
aji-40	620	2	nl	nl	PROPN
aji-40	620	3	,	,	PUNCT
aji-40	620	4	voskuhl	voskuhl	PROPN
aji-40	620	5	rr	rr	PROPN
aji-40	620	6	.	.	PROPN
aji-40	620	7	onset	onset	PROPN
aji-40	620	8	of	of	ADP
aji-40	620	9	multiple	multiple	ADJ
aji-40	620	10	sclerosis	sclerosis	NOUN
aji-40	620	11	associated	associate	VERB
aji-40	620	12	with	with	ADP
aji-40	620	13	anti	anti	ADJ
aji-40	620	14	-	-	ADJ
aji-40	620	15	tnf	tnf	ADJ
aji-40	620	16	therapy	therapy	NOUN
aji-40	620	17	.	.	PUNCT
aji-40	621	1	neurology	neurology	NOUN
aji-40	621	2	.	.	PUNCT
aji-40	622	1	2001;57(10):1885	2001;57(10):1885	NUM
aji-40	622	2	-	-	SYM
aji-40	622	3	1888	1888	NUM
aji-40	622	4	.	.	PUNCT
aji-40	623	1	available	available	ADJ
aji-40	623	2	:	:	PUNCT
aji-40	623	3	https://doi.org/10.1212	https://doi.org/10.1212	ADJ
aji-40	623	4	/	/	SYM
aji-40	623	5	wnl.57.10	wnl.57.10	NOUN
aji-40	623	6	.	.	PUNCT
aji-40	624	1	1885	1885	NUM
aji-40	624	2	57	57	NUM
aji-40	624	3	.	.	PUNCT
aji-40	625	1	fischer	fischer	PROPN
aji-40	625	2	r	r	PROPN
aji-40	625	3	,	,	PUNCT
aji-40	625	4	maier	maier	PROPN
aji-40	625	5	o	o	NOUN
aji-40	625	6	,	,	PUNCT
aji-40	625	7	siegemund	siegemund	PROPN
aji-40	625	8	m	m	PROPN
aji-40	625	9	,	,	PUNCT
aji-40	625	10	wajant	wajant	NOUN
aji-40	625	11	h	h	NOUN
aji-40	625	12	,	,	PUNCT
aji-40	625	13	scheurich	scheurich	VERB
aji-40	625	14	p	p	NOUN
aji-40	625	15	,	,	PUNCT
aji-40	625	16	pfizenmaier	pfizenmaier	NOUN
aji-40	625	17	k.	k.	PROPN
aji-40	626	1	a	a	DET
aji-40	626	2	tnf	tnf	PROPN
aji-40	626	3	receptor	receptor	NOUN
aji-40	626	4	2	2	NUM
aji-40	626	5	selective	selective	ADJ
aji-40	626	6	agonist	agonist	NOUN
aji-40	626	7	rescues	rescue	VERB
aji-40	626	8	human	human	ADJ
aji-40	626	9	neurons	neuron	NOUN
aji-40	626	10	from	from	ADP
aji-40	626	11	oxidative	oxidative	ADJ
aji-40	626	12	stressinduced	stressinduce	VERB
aji-40	626	13	cell	cell	NOUN
aji-40	626	14	death	death	NOUN
aji-40	626	15	.	.	PUNCT
aji-40	627	1	plos	plos	PROPN
aji-40	627	2	one	one	NUM
aji-40	627	3	.	.	PUNCT
aji-40	628	1	2011;6(11):e27621	2011;6(11):e27621	NUM
aji-40	628	2	.	.	PUNCT
aji-40	629	1	available	available	ADJ
aji-40	629	2	:	:	PUNCT
aji-40	629	3	https://doi.org/10.1371	https://doi.org/10.1371	ADJ
aji-40	629	4	/	/	SYM
aji-40	629	5	journal.po	journal.po	PROPN
aji-40	629	6	ne.0027621	ne.0027621	PROPN
aji-40	629	7	58	58	NUM
aji-40	629	8	.	.	PUNCT
aji-40	630	1	shi	shi	PROPN
aji-40	630	2	jq	jq	PROPN
aji-40	630	3	,	,	PUNCT
aji-40	630	4	shen	shen	PROPN
aji-40	630	5	w	w	PROPN
aji-40	630	6	,	,	PUNCT
aji-40	630	7	chen	chen	PROPN
aji-40	630	8	j	j	PROPN
aji-40	630	9	,	,	PUNCT
aji-40	630	10	wang	wang	PROPN
aji-40	630	11	br	br	PROPN
aji-40	630	12	,	,	PUNCT
aji-40	630	13	zhong	zhong	PROPN
aji-40	630	14	ll	ll	AUX
aji-40	630	15	,	,	PUNCT
aji-40	630	16	zhu	zhu	PROPN
aji-40	630	17	yw	yw	PROPN
aji-40	630	18	,	,	PUNCT
aji-40	630	19	et	et	PROPN
aji-40	630	20	al	al	PROPN
aji-40	630	21	.	.	PUNCT
aji-40	630	22	anti	anti	PROPN
aji-40	630	23	-	-	ADJ
aji-40	630	24	tnf	tnf	ADJ
aji-40	630	25	-	-	PUNCT
aji-40	630	26	α	α	NOUN
aji-40	630	27	reduces	reduce	VERB
aji-40	630	28	amyloid	amyloid	NOUN
aji-40	630	29	plaques	plaque	NOUN
aji-40	630	30	and	and	CCONJ
aji-40	630	31	tau	tau	PROPN
aji-40	630	32	phosphorylation	phosphorylation	NOUN
aji-40	630	33	and	and	CCONJ
aji-40	630	34	induces	induce	VERB
aji-40	630	35	cd11c	cd11c	NOUN
aji-40	630	36	-	-	PUNCT
aji-40	630	37	positive	positive	ADJ
aji-40	630	38	dendritic	dendritic	ADJ
aji-40	630	39	-	-	PUNCT
aji-40	630	40	like	like	ADJ
aji-40	630	41	cell	cell	NOUN
aji-40	630	42	in	in	ADP
aji-40	630	43	the	the	DET
aji-40	630	44	app	app	PROPN
aji-40	630	45	/	/	SYM
aji-40	630	46	ps1	ps1	NOUN
aji-40	630	47	transgenic	transgenic	NOUN
aji-40	630	48	mouse	mouse	NOUN
aji-40	630	49	brains	brain	NOUN
aji-40	630	50	.	.	PUNCT
aji-40	631	1	brain	brain	NOUN
aji-40	631	2	res	re	NOUN
aji-40	631	3	.	.	PUNCT
aji-40	632	1	2011;1368:239	2011;1368:239	NUM
aji-40	632	2	-	-	SYM
aji-40	632	3	47	47	NUM
aji-40	632	4	.	.	PUNCT
aji-40	633	1	available	available	ADJ
aji-40	633	2	:	:	PUNCT
aji-40	633	3	https://doi.org/10.1016	https://doi.org/10.1016	NOUN
aji-40	633	4	/	/	SYM
aji-40	633	5	j.brainres	j.brainre	NOUN
aji-40	633	6	.	.	PUNCT
aji-40	634	1	2010.10.053	2010.10.053	NUM
aji-40	634	2	59	59	NUM
aji-40	634	3	.	.	PUNCT
aji-40	635	1	kim	kim	PROPN
aji-40	635	2	dh	dh	PROPN
aji-40	635	3	,	,	PUNCT
aji-40	635	4	choi	choi	PROPN
aji-40	635	5	sm	sm	PROPN
aji-40	635	6	,	,	PUNCT
aji-40	635	7	jho	jho	PROPN
aji-40	635	8	j	j	PROPN
aji-40	635	9	,	,	PUNCT
aji-40	635	10	park	park	PROPN
aji-40	635	11	ms	ms	PROPN
aji-40	635	12	,	,	PUNCT
aji-40	635	13	kang	kang	PROPN
aji-40	635	14	j	j	PROPN
aji-40	635	15	,	,	PUNCT
aji-40	635	16	park	park	NOUN
aji-40	635	17	sj	sj	PROPN
aji-40	635	18	,	,	PUNCT
aji-40	635	19	et	et	PROPN
aji-40	635	20	al	al	PROPN
aji-40	635	21	.	.	PROPN
aji-40	635	22	infliximab	infliximab	PROPN
aji-40	635	23	ameliorates	ameliorate	VERB
aji-40	635	24	adassociated	adassociate	VERB
aji-40	635	25	object	object	NOUN
aji-40	635	26	recognition	recognition	NOUN
aji-40	635	27	memory	memory	NOUN
aji-40	635	28	impairment	impairment	NOUN
aji-40	635	29	.	.	PUNCT
aji-40	636	1	behav	behav	NOUN
aji-40	636	2	brain	brain	NOUN
aji-40	636	3	res	re	NOUN
aji-40	636	4	.	.	PROPN
aji-40	636	5	2016	2016	NUM
aji-40	636	6	;	;	PUNCT
aji-40	636	7	311:384	311:384	PROPN
aji-40	636	8	-	-	SYM
aji-40	636	9	391	391	NUM
aji-40	636	10	.	.	PUNCT
aji-40	637	1	available	available	ADJ
aji-40	637	2	:	:	PUNCT
aji-40	637	3	https://doi.org/10.1016	https://doi.org/10.1016	NOUN
aji-40	637	4	/	/	SYM
aji-40	637	5	j.bbr.2016	j.bbr.2016	PROPN
aji-40	637	6	.06.001	.06.001	PUNCT
aji-40	638	1	60	60	NUM
aji-40	638	2	.	.	PUNCT
aji-40	639	1	shi	shi	PROPN
aji-40	639	2	jq	jq	PROPN
aji-40	639	3	,	,	PUNCT
aji-40	639	4	wang	wang	PROPN
aji-40	639	5	br	br	PROPN
aji-40	639	6	,	,	PUNCT
aji-40	639	7	jiang	jiang	PROPN
aji-40	639	8	ww	ww	PROPN
aji-40	639	9	,	,	PUNCT
aji-40	639	10	chen	chen	PROPN
aji-40	639	11	j	j	PROPN
aji-40	639	12	,	,	PUNCT
aji-40	639	13	zhu	zhu	PROPN
aji-40	639	14	yw	yw	PROPN
aji-40	639	15	,	,	PUNCT
aji-40	639	16	zhong	zhong	PROPN
aji-40	639	17	ll	ll	AUX
aji-40	639	18	,	,	PUNCT
aji-40	639	19	et	et	PROPN
aji-40	639	20	al	al	PROPN
aji-40	639	21	.	.	PUNCT
aji-40	639	22	cognitive	cognitive	ADJ
aji-40	639	23	improvement	improvement	NOUN
aji-40	639	24	with	with	ADP
aji-40	639	25	intrathecal	intrathecal	ADJ
aji-40	639	26	administration	administration	NOUN
aji-40	639	27	of	of	ADP
aji-40	639	28	infliximab	infliximab	NOUN
aji-40	639	29	in	in	ADP
aji-40	639	30	a	a	DET
aji-40	639	31	woman	woman	NOUN
aji-40	639	32	with	with	ADP
aji-40	639	33	alzheimer	alzheimer	PROPN
aji-40	639	34	's	's	PART
aji-40	639	35	disease	disease	NOUN
aji-40	639	36	.	.	PUNCT
aji-40	640	1	j	j	PROPN
aji-40	640	2	am	be	AUX
aji-40	640	3	geriatr	geriatr	ADJ
aji-40	640	4	soc	soc	NOUN
aji-40	640	5	.	.	PUNCT
aji-40	641	1	2011;59(6):1142	2011;59(6):1142	NUM
aji-40	641	2	-	-	SYM
aji-40	641	3	4	4	NUM
aji-40	641	4	.	.	PUNCT
aji-40	642	1	available	available	ADJ
aji-40	642	2	:	:	PUNCT
aji-40	643	1	https://doi.org/10.1111	https://doi.org/10.1111	PROPN
aji-40	643	2	/	/	SYM
aji-40	643	3	j.15325415.2011.03445.x	j.15325415.2011.03445.x	NOUN
aji-40	643	4	61	61	NUM
aji-40	643	5	.	.	PUNCT
aji-40	643	6	tobinick	tobinick	PROPN
aji-40	643	7	el	el	PROPN
aji-40	643	8	,	,	PUNCT
aji-40	643	9	chen	chen	PROPN
aji-40	643	10	k	k	PROPN
aji-40	643	11	,	,	PUNCT
aji-40	643	12	chen	chen	PROPN
aji-40	643	13	x.	x.	PROPN
aji-40	643	14	rapid	rapid	ADJ
aji-40	643	15	intracerebroventricular	intracerebroventricular	ADJ
aji-40	643	16	delivery	delivery	NOUN
aji-40	643	17	of	of	ADP
aji-40	643	18	cudota	cudota	NOUN
aji-40	643	19	-	-	PUNCT
aji-40	643	20	etanercept	etanercept	NOUN
aji-40	643	21	after	after	SCONJ
aji-40	643	22	peripheral	peripheral	ADJ
aji-40	643	23	administration	administration	NOUN
aji-40	643	24	demonstrated	demonstrate	VERB
aji-40	643	25	by	by	ADP
aji-40	643	26	pet	pet	ADJ
aji-40	643	27	imaging	imaging	NOUN
aji-40	643	28	.	.	PUNCT
aji-40	644	1	bmc	bmc	ADJ
aji-40	644	2	res	re	NOUN
aji-40	644	3	notes	note	NOUN
aji-40	644	4	.	.	PUNCT
aji-40	645	1	2009;2:28	2009;2:28	NOUN
aji-40	645	2	.	.	PUNCT
aji-40	646	1	available	available	ADJ
aji-40	646	2	:	:	PUNCT
aji-40	646	3	https://doi.org/10.1186/17560500	https://doi.org/10.1186/17560500	NUM
aji-40	646	4	-	-	PUNCT
aji-40	646	5	2	2	NUM
aji-40	646	6	-	-	SYM
aji-40	646	7	28	28	NUM
aji-40	646	8	62	62	NUM
aji-40	646	9	.	.	PUNCT
aji-40	647	1	titelbaum	titelbaum	PROPN
aji-40	647	2	ds	ds	PROPN
aji-40	647	3	,	,	PUNCT
aji-40	647	4	degenhardt	degenhardt	ADJ
aji-40	647	5	a	a	PRON
aji-40	647	6	,	,	PUNCT
aji-40	647	7	kinkel	kinkel	PROPN
aji-40	647	8	rp	rp	NOUN
aji-40	647	9	.	.	PUNCT
aji-40	648	1	anti	anti	ADJ
aji-40	648	2	-	-	ADJ
aji-40	648	3	tumor	tumor	ADJ
aji-40	648	4	necrosis	necrosis	NOUN
aji-40	648	5	factor	factor	NOUN
aji-40	648	6	alphaassociated	alphaassociate	VERB
aji-40	648	7	multiple	multiple	ADJ
aji-40	648	8	sclerosis	sclerosis	NOUN
aji-40	648	9	.	.	PUNCT
aji-40	649	1	american	american	PROPN
aji-40	649	2	journal	journal	PROPN
aji-40	649	3	of	of	ADP
aji-40	649	4	neuroradiology	neuroradiology	NOUN
aji-40	649	5	.	.	PUNCT
aji-40	650	1	2005;26(6	2005;26(6	NUM
aji-40	650	2	):	):	PUNCT
aji-40	650	3	1548	1548	NUM
aji-40	650	4	-	-	SYM
aji-40	650	5	1550	1550	NUM
aji-40	650	6	.	.	PUNCT
aji-40	651	1	63	63	NUM
aji-40	651	2	.	.	PUNCT
aji-40	651	3	vielhauer	vielhauer	PROPN
aji-40	651	4	v	v	PROPN
aji-40	651	5	,	,	PUNCT
aji-40	651	6	mayadas	mayadas	PROPN
aji-40	651	7	tn	tn	PROPN
aji-40	651	8	.	.	PUNCT
aji-40	651	9	functions	function	NOUN
aji-40	651	10	of	of	ADP
aji-40	651	11	tnf	tnf	PROPN
aji-40	651	12	and	and	CCONJ
aji-40	651	13	its	its	PRON
aji-40	651	14	receptors	receptor	NOUN
aji-40	651	15	in	in	ADP
aji-40	651	16	renal	renal	ADJ
aji-40	651	17	disease	disease	NOUN
aji-40	651	18	:	:	PUNCT
aji-40	651	19	distinct	distinct	ADJ
aji-40	651	20	roles	role	NOUN
aji-40	651	21	in	in	ADP
aji-40	651	22	inflammatory	inflammatory	ADJ
aji-40	651	23	tissue	tissue	NOUN
aji-40	651	24	injury	injury	NOUN
aji-40	651	25	and	and	CCONJ
aji-40	651	26	immune	immune	ADJ
aji-40	651	27	regulation	regulation	NOUN
aji-40	651	28	.	.	PUNCT
aji-40	652	1	seminnephrol	seminnephrol	NOUN
aji-40	652	2	.	.	PUNCT
aji-40	653	1	2007;27(3):286	2007;27(3):286	NUM
aji-40	653	2	-	-	SYM
aji-40	653	3	308	308	NUM
aji-40	653	4	.	.	PUNCT
aji-40	654	1	available	available	ADJ
aji-40	654	2	:	:	PUNCT
aji-40	654	3	https://doi.org/10.1016	https://doi.org/10.1016	NOUN
aji-40	654	4	/	/	SYM
aji-40	654	5	j.semnep	j.semnep	NOUN
aji-40	654	6	hrol.2007.02.004	hrol.2007.02.004	PUNCT
aji-40	654	7	64	64	NUM
aji-40	654	8	.	.	PUNCT
aji-40	655	1	ernandez	ernandez	PROPN
aji-40	655	2	t	t	PROPN
aji-40	655	3	,	,	PUNCT
aji-40	655	4	mayadas	mayadas	PROPN
aji-40	655	5	t.	t.	PROPN
aji-40	655	6	immunoregulatory	immunoregulatory	ADJ
aji-40	655	7	role	role	NOUN
aji-40	655	8	of	of	ADP
aji-40	655	9	tnfα	tnfα	NOUN
aji-40	655	10	in	in	ADP
aji-40	655	11	https://doi.org/10.1093/hmg/ddq172	https://doi.org/10.1093/hmg/ddq172	PROPN
aji-40	655	12	https://doi.org/10.1093/hmg/ddq172	https://doi.org/10.1093/hmg/ddq172	PROPN
aji-40	655	13	https://doi.org/10.1007/s10067-015-3026-7	https://doi.org/10.1007/s10067-015-3026-7	NUM
aji-40	655	14	https://doi.org/10.1007/s10067-015-3026-7	https://doi.org/10.1007/s10067-015-3026-7	NUM
aji-40	655	15	https://doi.org/10.3904/kjim.2016.374	https://doi.org/10.3904/kjim.2016.374	PROPN
aji-40	655	16	https://doi.org/10.3904/kjim.2016.374	https://doi.org/10.3904/kjim.2016.374	PROPN
aji-40	655	17	https://doi.org/10.1016/j.neuroscience.2015.06.038	https://doi.org/10.1016/j.neuroscience.2015.06.038	VERB
aji-40	655	18	https://doi.org/10.1016/j.neuroscience.2015.06.038	https://doi.org/10.1016/j.neuroscience.2015.06.038	PROPN
aji-40	655	19	https://doi.org/10.3389/fnins.2019.00049	https://doi.org/10.3389/fnins.2019.00049	PROPN
aji-40	655	20	https://doi.org/10.3389/fnins.2019.00049	https://doi.org/10.3389/fnins.2019.00049	PROPN
aji-40	655	21	https://doi.org/10.1007/s11910-017-0742-1	https://doi.org/10.1007/s11910-017-0742-1	NUM
aji-40	655	22	https://doi.org/10.1007/s11910-017-0742-1	https://doi.org/10.1007/s11910-017-0742-1	NUM
aji-40	656	1	https://www.ncbi.nlm.nih.gov/pubmed/10449104	https://www.ncbi.nlm.nih.gov/pubmed/10449104	NUM
aji-40	657	1	https://www.ncbi.nlm.nih.gov/pubmed/10449104	https://www.ncbi.nlm.nih.gov/pubmed/10449104	NUM
aji-40	658	1	https://doi.org/10.1212/wnl.57.10.1885	https://doi.org/10.1212/wnl.57.10.1885	PROPN
aji-40	658	2	https://doi.org/10.1212/wnl.57.10.1885	https://doi.org/10.1212/wnl.57.10.1885	PROPN
aji-40	658	3	https://doi.org/10.1371/journal.pone.0027621	https://doi.org/10.1371/journal.pone.0027621	PROPN
aji-40	659	1	https://doi.org/10.1371/journal.pone.0027621	https://doi.org/10.1371/journal.pone.0027621	PROPN
aji-40	659	2	https://doi.org/10.1016/j.brainres.2010.10.053	https://doi.org/10.1016/j.brainres.2010.10.053	PROPN
aji-40	659	3	https://doi.org/10.1016/j.brainres.2010.10.053	https://doi.org/10.1016/j.brainres.2010.10.053	NOUN
aji-40	659	4	https://doi.org/10.1016/j.bbr.2016.06.001	https://doi.org/10.1016/j.bbr.2016.06.001	PROPN
aji-40	659	5	https://doi.org/10.1016/j.bbr.2016.06.001	https://doi.org/10.1016/j.bbr.2016.06.001	PROPN
aji-40	659	6	https://doi.org/10.1111/j.1532-5415.2011.03445.x	https://doi.org/10.1111/j.1532-5415.2011.03445.x	PROPN
aji-40	659	7	https://doi.org/10.1111/j.1532-5415.2011.03445.x	https://doi.org/10.1111/j.1532-5415.2011.03445.x	PROPN
aji-40	659	8	https://doi.org/10.1186/1756-0500-2-28	https://doi.org/10.1186/1756-0500-2-28	VERB
aji-40	659	9	https://doi.org/10.1186/1756-0500-2-28	https://doi.org/10.1186/1756-0500-2-28	VERB
aji-40	659	10	https://doi.org/10.1016/j.semnephrol.2007.02.004	https://doi.org/10.1016/j.semnephrol.2007.02.004	PROPN
aji-40	659	11	https://doi.org/10.1016/j.semnephrol.2007.02.004	https://doi.org/10.1016/j.semnephrol.2007.02.004	PROPN
aji-40	659	12	churchill	churchill	PROPN
aji-40	659	13	et	et	PROPN
aji-40	659	14	al	al	PROPN
aji-40	659	15	.	.	PROPN
aji-40	659	16	;	;	PUNCT
aji-40	659	17	aji	aji	PROPN
aji-40	659	18	,	,	PUNCT
aji-40	659	19	3(1	3(1	NUM
aji-40	659	20	):	):	PUNCT
aji-40	659	21	208	208	NUM
aji-40	659	22	-	-	SYM
aji-40	659	23	222	222	NUM
aji-40	659	24	,	,	PUNCT
aji-40	659	25	2020	2020	NUM
aji-40	659	26	;	;	PUNCT
aji-40	659	27	article	article	NOUN
aji-40	659	28	no.aji.57464	no.aji.57464	ADP
aji-40	659	29	222	222	NUM
aji-40	659	30	inflammatory	inflammatory	ADJ
aji-40	659	31	kidney	kidney	NOUN
aji-40	659	32	diseases	disease	NOUN
aji-40	659	33	.	.	PUNCT
aji-40	660	1	kidney	kidney	PROPN
aji-40	660	2	international	international	PROPN
aji-40	660	3	.	.	PUNCT
aji-40	661	1	august	august	PROPN
aji-40	661	2	2009;76(3):262	2009;76(3):262	PROPN
aji-40	661	3	-	-	PUNCT
aji-40	661	4	276	276	NUM
aji-40	661	5	.	.	PUNCT
aji-40	661	6	available	available	ADJ
aji-40	661	7	:	:	PUNCT
aji-40	661	8	https://doi.org/10.1038	https://doi.org/10.1038	PROPN
aji-40	661	9	/	/	SYM
aji-40	661	10	ki.2009.1	ki.2009.1	PROPN
aji-40	661	11	42	42	NUM
aji-40	661	12	65	65	NUM
aji-40	661	13	.	.	PUNCT
aji-40	662	1	amdur	amdur	PROPN
aji-40	662	2	rl	rl	PROPN
aji-40	662	3	,	,	PUNCT
aji-40	662	4	feldman	feldman	PROPN
aji-40	662	5	hi	hi	PROPN
aji-40	662	6	,	,	PUNCT
aji-40	662	7	gupta	gupta	PROPN
aji-40	662	8	j	j	PROPN
aji-40	662	9	,	,	PUNCT
aji-40	662	10	yang	yang	PROPN
aji-40	662	11	w	w	PROPN
aji-40	662	12	,	,	PUNCT
aji-40	662	13	kanetsky	kanetsky	NOUN
aji-40	662	14	p	p	NOUN
aji-40	662	15	,	,	PUNCT
aji-40	662	16	shlipak	shlipak	NOUN
aji-40	662	17	m	m	PROPN
aji-40	662	18	,	,	PUNCT
aji-40	662	19	et	et	PROPN
aji-40	662	20	al	al	PROPN
aji-40	662	21	.	.	PROPN
aji-40	662	22	inflammation	inflammation	NOUN
aji-40	662	23	and	and	CCONJ
aji-40	662	24	progression	progression	NOUN
aji-40	662	25	of	of	ADP
aji-40	662	26	ckd	ckd	PROPN
aji-40	662	27	:	:	PUNCT
aji-40	662	28	the	the	DET
aji-40	662	29	cric	cric	PROPN
aji-40	662	30	study	study	NOUN
aji-40	662	31	.	.	PUNCT
aji-40	663	1	cjasn	cjasn	VERB
aji-40	663	2	.	.	PUNCT
aji-40	664	1	september	september	PROPN
aji-40	664	2	2016;11(9):15461556	2016;11(9):15461556	NUM
aji-40	664	3	.	.	PUNCT
aji-40	664	4	available	available	ADJ
aji-40	664	5	:	:	PUNCT
aji-40	664	6	https://doi.org/10.2215	https://doi.org/10.2215	VERB
aji-40	664	7	/	/	SYM
aji-40	664	8	cjn.1312	cjn.1312	NUM
aji-40	664	9	1215	1215	NUM
aji-40	664	10	66	66	NUM
aji-40	664	11	.	.	PUNCT
aji-40	665	1	donate	donate	PROPN
aji-40	665	2	-	-	PUNCT
aji-40	665	3	correa	correa	PROPN
aji-40	665	4	j	j	PROPN
aji-40	665	5	,	,	PUNCT
aji-40	665	6	martín	martín	PROPN
aji-40	665	7	-	-	PUNCT
aji-40	665	8	núñez	núñez	PROPN
aji-40	665	9	e	e	NOUN
aji-40	665	10	,	,	PUNCT
aji-40	665	11	murosde	murosde	PROPN
aji-40	665	12	-	-	PUNCT
aji-40	665	13	fuentes	fuentes	PROPN
aji-40	665	14	m	m	PROPN
aji-40	665	15	,	,	PUNCT
aji-40	665	16	mora	mora	PROPN
aji-40	665	17	-	-	PUNCT
aji-40	665	18	fernández	fernández	PROPN
aji-40	665	19	c	c	PROPN
aji-40	665	20	,	,	PUNCT
aji-40	665	21	navarro	navarro	PROPN
aji-40	665	22	-	-	PUNCT
aji-40	665	23	gonzález	gonzález	PROPN
aji-40	665	24	jf	jf	PROPN
aji-40	665	25	.	.	PUNCT
aji-40	666	1	inflammatory	inflammatory	ADJ
aji-40	666	2	cytokines	cytokine	NOUN
aji-40	666	3	in	in	ADP
aji-40	666	4	diabetic	diabetic	ADJ
aji-40	666	5	nephropathy	nephropathy	NOUN
aji-40	666	6	.	.	PUNCT
aji-40	667	1	j	j	NOUN
aji-40	667	2	diabetes	diabetes	NOUN
aji-40	667	3	res	re	NOUN
aji-40	667	4	.	.	PUNCT
aji-40	668	1	2015:948417	2015:948417	NUM
aji-40	668	2	.	.	PUNCT
aji-40	668	3	available	available	ADJ
aji-40	668	4	:	:	PUNCT
aji-40	668	5	https://doi.org/10.1155/2015/948	https://doi.org/10.1155/2015/948	NOUN
aji-40	668	6	417	417	NUM
aji-40	668	7	67	67	NUM
aji-40	668	8	.	.	PUNCT
aji-40	669	1	navarro	navarro	PROPN
aji-40	669	2	-	-	PUNCT
aji-40	669	3	gonzález	gonzález	PROPN
aji-40	669	4	jf	jf	PROPN
aji-40	669	5	,	,	PUNCT
aji-40	669	6	mora	mora	PROPN
aji-40	669	7	-	-	PUNCT
aji-40	669	8	fernández	fernández	PROPN
aji-40	669	9	c.	c.	PROPN
aji-40	669	10	the	the	DET
aji-40	669	11	role	role	NOUN
aji-40	669	12	of	of	ADP
aji-40	669	13	inflammatory	inflammatory	ADJ
aji-40	669	14	cytokines	cytokine	NOUN
aji-40	669	15	in	in	ADP
aji-40	669	16	diabetic	diabetic	ADJ
aji-40	669	17	nephropathy	nephropathy	NOUN
aji-40	669	18	.	.	PUNCT
aji-40	670	1	jasn	jasn	NOUN
aji-40	670	2	.	.	PUNCT
aji-40	671	1	march	march	PROPN
aji-40	671	2	2008	2008	NUM
aji-40	671	3	;	;	PUNCT
aji-40	671	4	19(3):433	19(3):433	NUM
aji-40	671	5	-	-	SYM
aji-40	671	6	442	442	NUM
aji-40	671	7	.	.	PUNCT
aji-40	672	1	available	available	ADJ
aji-40	672	2	:	:	PUNCT
aji-40	672	3	https://doi.org/10.1681	https://doi.org/10.1681	NOUN
aji-40	672	4	/	/	SYM
aji-40	672	5	asn.2007	asn.2007	NOUN
aji-40	672	6	091048	091048	NUM
aji-40	672	7	68	68	NUM
aji-40	672	8	.	.	PUNCT
aji-40	673	1	sharma	sharma	PROPN
aji-40	673	2	m	m	PROPN
aji-40	673	3	,	,	PUNCT
aji-40	673	4	mccarthy	mccarthy	PROPN
aji-40	673	5	et	et	PROPN
aji-40	673	6	,	,	PUNCT
aji-40	673	7	savin	savin	PROPN
aji-40	673	8	vj	vj	PROPN
aji-40	673	9	,	,	PUNCT
aji-40	673	10	lianos	lianos	PROPN
aji-40	673	11	ea	ea	PROPN
aji-40	673	12	.	.	PROPN
aji-40	673	13	nitric	nitric	ADJ
aji-40	673	14	oxide	oxide	NOUN
aji-40	673	15	preserves	preserve	VERB
aji-40	673	16	the	the	DET
aji-40	673	17	glomerular	glomerular	ADJ
aji-40	673	18	protein	protein	NOUN
aji-40	673	19	permeability	permeability	NOUN
aji-40	673	20	barrier	barrier	NOUN
aji-40	673	21	by	by	ADP
aji-40	673	22	antagonizing	antagonize	VERB
aji-40	673	23	superoxide	superoxide	NOUN
aji-40	673	24	.	.	PUNCT
aji-40	674	1	kidney	kidney	NOUN
aji-40	674	2	int	int	NOUN
aji-40	674	3	.	.	PUNCT
aji-40	675	1	2005	2005	NUM
aji-40	675	2	;	;	PUNCT
aji-40	675	3	68(6):2735	68(6):2735	NUM
aji-40	675	4	-	-	SYM
aji-40	675	5	2744	2744	NUM
aji-40	675	6	.	.	PUNCT
aji-40	676	1	https://doi.org/10.1111/j.15231755.2005.00744.x	https://doi.org/10.1111/j.15231755.2005.00744.x	X
aji-40	677	1	69	69	NUM
aji-40	677	2	.	.	PUNCT
aji-40	678	1	donnahoo	donnahoo	PROPN
aji-40	678	2	kk	kk	PROPN
aji-40	678	3	,	,	PUNCT
aji-40	678	4	shames	shame	VERB
aji-40	678	5	bd	bd	PROPN
aji-40	678	6	,	,	PUNCT
aji-40	678	7	harken	harken	ADJ
aji-40	678	8	ah	ah	INTJ
aji-40	678	9	,	,	PUNCT
aji-40	678	10	meldrum	meldrum	PROPN
aji-40	678	11	dr	dr	PROPN
aji-40	678	12	.	.	PROPN
aji-40	678	13	review	review	PROPN
aji-40	678	14	article	article	NOUN
aji-40	678	15	:	:	PUNCT
aji-40	678	16	the	the	DET
aji-40	678	17	role	role	NOUN
aji-40	678	18	of	of	ADP
aji-40	678	19	tumor	tumor	NOUN
aji-40	678	20	necrosis	necrosis	NOUN
aji-40	678	21	factor	factor	NOUN
aji-40	678	22	in	in	ADP
aji-40	678	23	renal	renal	ADJ
aji-40	678	24	ischemiareperfusion	ischemiareperfusion	NOUN
aji-40	678	25	injury	injury	NOUN
aji-40	678	26	.	.	PUNCT
aji-40	679	1	journal	journal	PROPN
aji-40	679	2	of	of	ADP
aji-40	679	3	urology	urology	NOUN
aji-40	679	4	.	.	PUNCT
aji-40	680	1	1999;162(1):196	1999;162(1):196	NUM
aji-40	680	2	-	-	SYM
aji-40	680	3	203	203	NUM
aji-40	680	4	.	.	PUNCT
aji-40	681	1	available	available	ADJ
aji-40	681	2	:	:	PUNCT
aji-40	681	3	https://doi.org/10.1097/00005392	https://doi.org/10.1097/00005392	X
aji-40	681	4	-199907000	-199907000	PROPN
aji-40	681	5	-	-	PUNCT
aji-40	681	6	00068	00068	NUM
aji-40	681	7	70	70	NUM
aji-40	681	8	.	.	PUNCT
aji-40	682	1	akcay	akcay	PROPN
aji-40	682	2	a	a	PRON
aji-40	682	3	,	,	PUNCT
aji-40	682	4	nguyen	nguyen	PROPN
aji-40	682	5	q	q	X
aji-40	682	6	,	,	PUNCT
aji-40	682	7	edelstein	edelstein	PROPN
aji-40	682	8	cl	cl	NOUN
aji-40	682	9	.	.	PUNCT
aji-40	683	1	mediators	mediator	NOUN
aji-40	683	2	of	of	ADP
aji-40	683	3	inflammation	inflammation	NOUN
aji-40	683	4	in	in	ADP
aji-40	683	5	acute	acute	ADJ
aji-40	683	6	kidney	kidney	NOUN
aji-40	683	7	injury	injury	NOUN
aji-40	683	8	.	.	PUNCT
aji-40	684	1	mediators	mediator	NOUN
aji-40	684	2	of	of	ADP
aji-40	684	3	inflammation	inflammation	NOUN
aji-40	684	4	.	.	PUNCT
aji-40	685	1	2009:12	2009:12	NUM
aji-40	685	2	.	.	PUNCT
aji-40	686	1	available	available	ADJ
aji-40	686	2	:	:	PUNCT
aji-40	686	3	https://doi.org/10.1155/2009/137	https://doi.org/10.1155/2009/137	PROPN
aji-40	686	4	072	072	NUM
aji-40	686	5	.	.	PUNCT
aji-40	687	1	71	71	NUM
aji-40	687	2	.	.	PUNCT
aji-40	688	1	gao	gao	PROPN
aji-40	688	2	g	g	PROPN
aji-40	688	3	,	,	PUNCT
aji-40	688	4	zhang	zhang	PROPN
aji-40	688	5	b	b	PROPN
aji-40	688	6	,	,	PUNCT
aji-40	688	7	ramesh	ramesh	PROPN
aji-40	688	8	g	g	PROPN
aji-40	688	9	,	,	PUNCT
aji-40	688	10	betterly	betterly	ADV
aji-40	688	11	d	d	NOUN
aji-40	688	12	,	,	PUNCT
aji-40	688	13	tadagavadi	tadagavadi	PROPN
aji-40	688	14	rk	rk	NOUN
aji-40	688	15	,	,	PUNCT
aji-40	688	16	wang	wang	PROPN
aji-40	688	17	w	w	PROPN
aji-40	688	18	,	,	PUNCT
aji-40	688	19	et	et	PROPN
aji-40	688	20	al	al	PROPN
aji-40	688	21	.	.	PUNCT
aji-40	689	1	tnf	tnf	PROPN
aji-40	689	2	-	-	PUNCT
aji-40	689	3	α	α	PROPN
aji-40	689	4	mediates	mediate	NOUN
aji-40	689	5	increased	increase	VERB
aji-40	689	6	susceptibility	susceptibility	NOUN
aji-40	689	7	to	to	ADP
aji-40	689	8	ischemic	ischemic	ADJ
aji-40	689	9	aki	aki	NOUN
aji-40	689	10	in	in	ADP
aji-40	689	11	diabetes	diabetes	NOUN
aji-40	689	12	.	.	PUNCT
aji-40	690	1	am	be	AUX
aji-40	690	2	j	j	PROPN
aji-40	690	3	physiol	physiol	PROPN
aji-40	690	4	renal	renal	PROPN
aji-40	690	5	physiol	physiol	PROPN
aji-40	690	6	.	.	PUNCT
aji-40	691	1	2013;304(5):f515	2013;304(5):f515	NUM
aji-40	691	2	–	–	PUNCT
aji-40	691	3	f521	f521	PROPN
aji-40	691	4	.	.	PUNCT
aji-40	691	5	available	available	ADJ
aji-40	691	6	:	:	PUNCT
aji-40	692	1	https://doi.org/10.1152	https://doi.org/10.1152	PROPN
aji-40	692	2	/	/	SYM
aji-40	692	3	ajprenal.0	ajprenal.0	PROPN
aji-40	692	4	0533.2012	0533.2012	ADP
aji-40	692	5	72	72	NUM
aji-40	692	6	.	.	PUNCT
aji-40	693	1	stokes	stokes	PROPN
aji-40	693	2	mb	mb	PROPN
aji-40	693	3	,	,	PUNCT
aji-40	693	4	foster	foster	ADJ
aji-40	693	5	k	k	PROPN
aji-40	693	6	,	,	PUNCT
aji-40	693	7	markowitz	markowitz	PROPN
aji-40	693	8	gs	gs	PROPN
aji-40	693	9	.	.	PUNCT
aji-40	694	1	development	development	NOUN
aji-40	694	2	of	of	ADP
aji-40	694	3	glomerulonephritis	glomerulonephritis	NOUN
aji-40	694	4	during	during	ADP
aji-40	694	5	anti	anti	ADJ
aji-40	694	6	-	-	ADJ
aji-40	694	7	tnf	tnf	ADJ
aji-40	694	8	-	-	PUNCT
aji-40	694	9	α	α	NOUN
aji-40	694	10	therapy	therapy	NOUN
aji-40	694	11	for	for	ADP
aji-40	694	12	rheumatoid	rheumatoid	NOUN
aji-40	694	13	arthritis	arthritis	NOUN
aji-40	694	14	.	.	PUNCT
aji-40	695	1	nephrology	nephrology	NOUN
aji-40	695	2	dialysis	dialysis	NOUN
aji-40	695	3	transplantation	transplantation	NOUN
aji-40	695	4	.	.	PUNCT
aji-40	696	1	july	july	PROPN
aji-40	696	2	2005;20(7):1400–1406	2005;20(7):1400–1406	PROPN
aji-40	696	3	.	.	PUNCT
aji-40	697	1	available	available	ADJ
aji-40	697	2	:	:	PUNCT
aji-40	697	3	https://doi.org/10.1093	https://doi.org/10.1093	NOUN
aji-40	697	4	/	/	SYM
aji-40	697	5	ndt	ndt	NOUN
aji-40	697	6	/	/	SYM
aji-40	697	7	gfh83	gfh83	PROPN
aji-40	697	8	2	2	NUM
aji-40	697	9	73	73	NUM
aji-40	697	10	.	.	PUNCT
aji-40	698	1	gupta	gupta	PROPN
aji-40	698	2	j	j	PROPN
aji-40	698	3	,	,	PUNCT
aji-40	698	4	mitra	mitra	PROPN
aji-40	698	5	n	n	CCONJ
aji-40	698	6	,	,	PUNCT
aji-40	698	7	kanetsky	kanetsky	PROPN
aji-40	698	8	pa	pa	PROPN
aji-40	698	9	,	,	PUNCT
aji-40	698	10	devaney	devaney	PROPN
aji-40	698	11	j	j	PROPN
aji-40	698	12	,	,	PUNCT
aji-40	698	13	wing	wing	NOUN
aji-40	698	14	mr	mr	PROPN
aji-40	698	15	,	,	PUNCT
aji-40	698	16	reilly	reilly	PROPN
aji-40	698	17	m	m	PROPN
aji-40	698	18	,	,	PUNCT
aji-40	698	19	et	et	PROPN
aji-40	698	20	al	al	PROPN
aji-40	698	21	.	.	PROPN
aji-40	698	22	association	association	PROPN
aji-40	698	23	between	between	ADP
aji-40	698	24	albuminuria	albuminuria	PROPN
aji-40	698	25	,	,	PUNCT
aji-40	698	26	kidney	kidney	NOUN
aji-40	698	27	function	function	NOUN
aji-40	698	28	,	,	PUNCT
aji-40	698	29	and	and	CCONJ
aji-40	698	30	inflammatory	inflammatory	ADJ
aji-40	698	31	biomarker	biomarker	NOUN
aji-40	698	32	profile	profile	NOUN
aji-40	698	33	in	in	ADP
aji-40	698	34	ckd	ckd	PROPN
aji-40	698	35	in	in	ADP
aji-40	698	36	cric	cric	PROPN
aji-40	698	37	.	.	PUNCT
aji-40	699	1	cjasn	cjasn	PROPN
aji-40	699	2	.	.	PUNCT
aji-40	700	1	2012;7(12):19381946	2012;7(12):19381946	NUM
aji-40	700	2	.	.	PUNCT
aji-40	701	1	available	available	ADJ
aji-40	701	2	:	:	PUNCT
aji-40	701	3	https://doi.org/10.2215	https://doi.org/10.2215	VERB
aji-40	701	4	/	/	SYM
aji-40	701	5	cjn.0350	cjn.0350	NUM
aji-40	701	6	0412	0412	NUM
aji-40	701	7	74	74	NUM
aji-40	701	8	.	.	PUNCT
aji-40	702	1	gohda	gohda	PROPN
aji-40	702	2	t	t	PROPN
aji-40	702	3	,	,	PUNCT
aji-40	702	4	maruyama	maruyama	PROPN
aji-40	702	5	s	s	PART
aji-40	702	6	,	,	PUNCT
aji-40	702	7	kamei	kamei	PROPN
aji-40	702	8	n	n	AUX
aji-40	702	9	,	,	PUNCT
aji-40	702	10	yamaguchi	yamaguchi	PROPN
aji-40	702	11	s	s	PROPN
aji-40	702	12	,	,	PUNCT
aji-40	702	13	shibata	shibata	PROPN
aji-40	702	14	t	t	PROPN
aji-40	702	15	,	,	PUNCT
aji-40	702	16	murakoshi	murakoshi	PROPN
aji-40	702	17	m	m	PROPN
aji-40	702	18	,	,	PUNCT
aji-40	702	19	et	et	PROPN
aji-40	702	20	al	al	PROPN
aji-40	702	21	.	.	PROPN
aji-40	702	22	circulating	circulate	VERB
aji-40	702	23	tnf	tnf	PROPN
aji-40	702	24	receptors	receptor	NOUN
aji-40	702	25	1	1	NUM
aji-40	702	26	and	and	CCONJ
aji-40	702	27	2	2	NUM
aji-40	702	28	predict	predict	VERB
aji-40	702	29	mortality	mortality	NOUN
aji-40	702	30	in	in	ADP
aji-40	702	31	patients	patient	NOUN
aji-40	702	32	with	with	ADP
aji-40	702	33	end	end	NOUN
aji-40	702	34	-	-	PUNCT
aji-40	702	35	stage	stage	NOUN
aji-40	702	36	renal	renal	ADJ
aji-40	702	37	disease	disease	NOUN
aji-40	702	38	undergoing	undergo	VERB
aji-40	702	39	dialysis	dialysis	NOUN
aji-40	702	40	.	.	PUNCT
aji-40	703	1	sci	sci	PROPN
aji-40	703	2	rep	rep	PROPN
aji-40	703	3	.	.	PROPN
aji-40	703	4	2017;7:43520	2017;7:43520	PROPN
aji-40	703	5	.	.	PUNCT
aji-40	704	1	available	available	ADJ
aji-40	704	2	:	:	PUNCT
aji-40	704	3	https://doi.org/10.1038	https://doi.org/10.1038	NOUN
aji-40	704	4	/	/	SYM
aji-40	704	5	srep4352	srep4352	PROPN
aji-40	704	6	0	0	NUM
aji-40	704	7	75	75	NUM
aji-40	704	8	.	.	PUNCT
aji-40	705	1	patri	patri	PROPN
aji-40	705	2	p	p	PROPN
aji-40	705	3	,	,	PUNCT
aji-40	705	4	churchill	churchill	PROPN
aji-40	705	5	b.m	b.m	PROPN
aji-40	705	6	,	,	PUNCT
aji-40	705	7	ghosh	ghosh	PROPN
aji-40	705	8	r.p	r.p	PROPN
aji-40	705	9	.	.	PROPN
aji-40	705	10	vaccines	vaccine	NOUN
aji-40	705	11	for	for	ADP
aji-40	705	12	kidney	kidney	NOUN
aji-40	705	13	transplant	transplant	NOUN
aji-40	705	14	recipients	recipient	NOUN
aji-40	705	15	:	:	PUNCT
aji-40	705	16	efficacy	efficacy	NOUN
aji-40	705	17	considerations	consideration	NOUN
aji-40	705	18	and	and	CCONJ
aji-40	705	19	recommendations	recommendation	NOUN
aji-40	705	20	.	.	PUNCT
aji-40	706	1	british	british	ADJ
aji-40	706	2	journal	journal	PROPN
aji-40	706	3	of	of	ADP
aji-40	706	4	renal	renal	ADJ
aji-40	706	5	medicine	medicine	NOUN
aji-40	706	6	.	.	PUNCT
aji-40	707	1	2019;24(1):21	2019;24(1):21	NUM
aji-40	707	2	-	-	SYM
aji-40	707	3	27	27	NUM
aji-40	707	4	.	.	PUNCT
aji-40	708	1	76	76	NUM
aji-40	708	2	.	.	PUNCT
aji-40	709	1	garrouste	garrouste	PROPN
aji-40	709	2	c	c	PROPN
aji-40	709	3	,	,	PUNCT
aji-40	709	4	anglicheau	anglicheau	NOUN
aji-40	709	5	d	d	NOUN
aji-40	709	6	,	,	PUNCT
aji-40	709	7	kamar	kamar	PROPN
aji-40	709	8	n	n	CCONJ
aji-40	709	9	,	,	PUNCT
aji-40	709	10	et	et	PROPN
aji-40	709	11	al	al	PROPN
aji-40	709	12	.	.	PUNCT
aji-40	710	1	anti	anti	ADJ
aji-40	710	2	-	-	ADJ
aji-40	710	3	tnfα	tnfα	ADJ
aji-40	710	4	therapy	therapy	NOUN
aji-40	710	5	for	for	ADP
aji-40	710	6	chronic	chronic	ADJ
aji-40	710	7	inflammatory	inflammatory	ADJ
aji-40	710	8	disease	disease	NOUN
aji-40	710	9	in	in	ADP
aji-40	710	10	kidney	kidney	NOUN
aji-40	710	11	transplant	transplant	NOUN
aji-40	710	12	recipients	recipient	NOUN
aji-40	710	13	:	:	PUNCT
aji-40	710	14	clinical	clinical	ADJ
aji-40	710	15	outcomes	outcome	NOUN
aji-40	710	16	.	.	PUNCT
aji-40	711	1	medicine	medicine	NOUN
aji-40	711	2	(	(	PUNCT
aji-40	711	3	baltimore	baltimore	PROPN
aji-40	711	4	)	)	PUNCT
aji-40	711	5	.	.	PUNCT
aji-40	712	1	2016;95(41):e5108	2016;95(41):e5108	NOUN
aji-40	712	2	.	.	PUNCT
aji-40	713	1	available	available	ADJ
aji-40	713	2	:	:	PUNCT
aji-40	713	3	https://doi.org/10.1097	https://doi.org/10.1097	NOUN
aji-40	713	4	/	/	SYM
aji-40	713	5	md.0000	md.0000	NUM
aji-40	713	6	000000005108	000000005108	NUM
aji-40	714	1	_	_	PUNCT
aji-40	715	1	_	_	PUNCT
aji-40	716	1	_	_	PUNCT
aji-40	717	1	_	_	PUNCT
aji-40	718	1	_	_	PUNCT
aji-40	719	1	_	_	PUNCT
aji-40	720	1	_	_	PUNCT
aji-40	721	1	_	_	PUNCT
aji-40	722	1	_	_	PUNCT
aji-40	723	1	_	_	PUNCT
aji-40	724	1	_	_	PUNCT
aji-40	725	1	_	_	PUNCT
aji-40	726	1	_	_	PUNCT
aji-40	727	1	_	_	PUNCT
aji-40	728	1	_	_	PUNCT
aji-40	729	1	_	_	PUNCT
aji-40	730	1	_	_	PUNCT
aji-40	731	1	_	_	PUNCT
aji-40	732	1	_	_	PUNCT
aji-40	733	1	_	_	PUNCT
aji-40	734	1	_	_	PUNCT
aji-40	735	1	_	_	PUNCT
aji-40	736	1	_	_	PUNCT
aji-40	737	1	_	_	PUNCT
aji-40	738	1	_	_	PUNCT
aji-40	739	1	_	_	PUNCT
aji-40	740	1	_	_	PUNCT
aji-40	741	1	_	_	PUNCT
aji-40	742	1	_	_	PUNCT
aji-40	743	1	_	_	PUNCT
aji-40	744	1	_	_	PUNCT
aji-40	745	1	_	_	PUNCT
aji-40	746	1	_	_	PUNCT
aji-40	747	1	_	_	PUNCT
aji-40	748	1	_	_	PUNCT
aji-40	749	1	_	_	PUNCT
aji-40	750	1	_	_	PUNCT
aji-40	751	1	_	_	PUNCT
aji-40	752	1	_	_	PUNCT
aji-40	753	1	_	_	PUNCT
aji-40	754	1	_	_	PUNCT
aji-40	755	1	_	_	PUNCT
aji-40	756	1	_	_	PUNCT
aji-40	757	1	_	_	PUNCT
aji-40	758	1	_	_	PUNCT
aji-40	759	1	_	_	PUNCT
aji-40	760	1	_	_	PUNCT
aji-40	761	1	_	_	PUNCT
aji-40	762	1	_	_	PUNCT
aji-40	763	1	_	_	PUNCT
aji-40	764	1	_	_	PUNCT
aji-40	765	1	_	_	PUNCT
aji-40	766	1	_	_	PUNCT
aji-40	767	1	_	_	PUNCT
aji-40	768	1	_	_	PUNCT
aji-40	769	1	_	_	PUNCT
aji-40	770	1	_	_	PUNCT
aji-40	771	1	_	_	PUNCT
aji-40	772	1	_	_	PUNCT
aji-40	773	1	_	_	PUNCT
aji-40	774	1	_	_	PUNCT
aji-40	775	1	_	_	PUNCT
aji-40	776	1	_	_	PUNCT
aji-40	777	1	_	_	PUNCT
aji-40	778	1	_	_	PUNCT
aji-40	779	1	_	_	PUNCT
aji-40	780	1	_	_	PUNCT
aji-40	781	1	_	_	PUNCT
aji-40	782	1	_	_	PUNCT
aji-40	783	1	_	_	PUNCT
aji-40	784	1	_	_	PUNCT
aji-40	785	1	_	_	PUNCT
aji-40	786	1	_	_	PUNCT
aji-40	787	1	_	_	PUNCT
aji-40	788	1	_	_	PUNCT
aji-40	789	1	_	_	PUNCT
aji-40	790	1	_	_	PUNCT
aji-40	791	1	_	_	PUNCT
aji-40	792	1	_	_	PUNCT
aji-40	793	1	_	_	PUNCT
aji-40	794	1	_	_	PUNCT
aji-40	795	1	©	©	PROPN
aji-40	795	2	2020	2020	NUM
aji-40	795	3	churchill	churchill	PROPN
aji-40	795	4	et	et	PROPN
aji-40	795	5	al	al	PROPN
aji-40	795	6	.	.	PROPN
aji-40	795	7	;	;	PUNCT
aji-40	795	8	this	this	PRON
aji-40	795	9	is	be	AUX
aji-40	795	10	an	an	DET
aji-40	795	11	open	open	ADJ
aji-40	795	12	access	access	NOUN
aji-40	795	13	article	article	NOUN
aji-40	795	14	distributed	distribute	VERB
aji-40	795	15	under	under	ADP
aji-40	795	16	the	the	DET
aji-40	795	17	terms	term	NOUN
aji-40	795	18	of	of	ADP
aji-40	795	19	the	the	DET
aji-40	795	20	creative	creative	ADJ
aji-40	795	21	commons	common	NOUN
aji-40	795	22	attribution	attribution	NOUN
aji-40	795	23	license	license	NOUN
aji-40	795	24	(	(	PUNCT
aji-40	795	25	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	NOUN
aji-40	795	26	)	)	PUNCT
aji-40	795	27	,	,	PUNCT
aji-40	795	28	which	which	PRON
aji-40	795	29	permits	permit	VERB
aji-40	795	30	unrestricted	unrestricted	ADJ
aji-40	795	31	use	use	NOUN
aji-40	795	32	,	,	PUNCT
aji-40	795	33	distribution	distribution	NOUN
aji-40	795	34	,	,	PUNCT
aji-40	795	35	and	and	CCONJ
aji-40	795	36	reproduction	reproduction	NOUN
aji-40	795	37	in	in	ADP
aji-40	795	38	any	any	DET
aji-40	795	39	medium	medium	NOUN
aji-40	795	40	,	,	PUNCT
aji-40	795	41	provided	provide	VERB
aji-40	795	42	the	the	DET
aji-40	795	43	original	original	ADJ
aji-40	795	44	work	work	NOUN
aji-40	795	45	is	be	AUX
aji-40	795	46	properly	properly	ADV
aji-40	795	47	cited	cite	VERB
aji-40	795	48	.	.	PUNCT
aji-40	796	1	peer	peer	NOUN
aji-40	796	2	-	-	PUNCT
aji-40	796	3	review	review	NOUN
aji-40	796	4	history	history	NOUN
aji-40	796	5	:	:	PUNCT
aji-40	796	6	the	the	DET
aji-40	796	7	peer	peer	NOUN
aji-40	796	8	review	review	NOUN
aji-40	796	9	history	history	NOUN
aji-40	796	10	for	for	ADP
aji-40	796	11	this	this	DET
aji-40	796	12	paper	paper	NOUN
aji-40	796	13	can	can	AUX
aji-40	796	14	be	be	AUX
aji-40	796	15	accessed	access	VERB
aji-40	796	16	here	here	ADV
aji-40	796	17	:	:	PUNCT
aji-40	796	18	http://www.sdiarticle4.com/review-history/57464	http://www.sdiarticle4.com/review-history/57464	PROPN
aji-40	796	19	https://doi.org/10.1038/ki.2009.142	https://doi.org/10.1038/ki.2009.142	INTJ
aji-40	796	20	https://doi.org/10.1038/ki.2009.142	https://doi.org/10.1038/ki.2009.142	INTJ
aji-40	797	1	https://doi.org/10.2215/cjn.13121215	https://doi.org/10.2215/cjn.13121215	PROPN
aji-40	797	2	https://doi.org/10.2215/cjn.13121215	https://doi.org/10.2215/cjn.13121215	PROPN
aji-40	797	3	https://doi.org/10.1155/2015/948417	https://doi.org/10.1155/2015/948417	PROPN
aji-40	797	4	https://doi.org/10.1155/2015/948417	https://doi.org/10.1155/2015/948417	PROPN
aji-40	797	5	https://doi.org/10.1681/asn.2007091048	https://doi.org/10.1681/asn.2007091048	PROPN
aji-40	797	6	https://doi.org/10.1681/asn.2007091048	https://doi.org/10.1681/asn.2007091048	PROPN
aji-40	797	7	https://doi.org/10.1111/j.1523-1755.2005.00744.x	https://doi.org/10.1111/j.1523-1755.2005.00744.x	VERB
aji-40	797	8	https://doi.org/10.1111/j.1523-1755.2005.00744.x	https://doi.org/10.1111/j.1523-1755.2005.00744.x	VERB
aji-40	797	9	https://doi.org/10.1097/00005392-199907000-00068	https://doi.org/10.1097/00005392-199907000-00068	NOUN
aji-40	797	10	https://doi.org/10.1097/00005392-199907000-00068	https://doi.org/10.1097/00005392-199907000-00068	NOUN
aji-40	797	11	https://doi.org/10.1155/2009/137072	https://doi.org/10.1155/2009/137072	NOUN
aji-40	797	12	https://doi.org/10.1155/2009/137072	https://doi.org/10.1155/2009/137072	PROPN
aji-40	797	13	https://doi.org/10.1152/ajprenal.00533.2012	https://doi.org/10.1152/ajprenal.00533.2012	PROPN
aji-40	797	14	https://doi.org/10.1152/ajprenal.00533.2012	https://doi.org/10.1152/ajprenal.00533.2012	PROPN
aji-40	797	15	https://doi.org/10.1093/ndt/gfh832	https://doi.org/10.1093/ndt/gfh832	PROPN
aji-40	797	16	https://doi.org/10.1093/ndt/gfh832	https://doi.org/10.1093/ndt/gfh832	PROPN
aji-40	797	17	https://doi.org/10.2215/cjn.03500412	https://doi.org/10.2215/cjn.03500412	PROPN
aji-40	797	18	https://doi.org/10.2215/cjn.03500412	https://doi.org/10.2215/cjn.03500412	PROPN
aji-40	797	19	https://doi.org/10.1038/srep43520	https://doi.org/10.1038/srep43520	PROPN
aji-40	797	20	https://doi.org/10.1038/srep43520	https://doi.org/10.1038/srep43520	PROPN
aji-40	797	21	https://doi.org/10.1097/md.0000000000005108	https://doi.org/10.1097/md.0000000000005108	PRON
aji-40	797	22	https://doi.org/10.1097/md.0000000000005108	https://doi.org/10.1097/md.0000000000005108	PROPN
aji-40	797	23	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	X